

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 June 2006 (15.06.2006)

PCT

(10) International Publication Number
WO 2006/062716 A2

(51) International Patent Classification: **Not classified**

(21) International Application Number:
PCT/US2005/041664

(22) International Filing Date:
18 November 2005 (18.11.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/629,363 18 November 2004 (18.11.2004) US
60/649,479 2 February 2005 (02.02.2005) US
60/672,346 18 April 2005 (18.04.2005) US

(71) Applicant (for all designated States except US): **YALE UNIVERSITY** [US/US]; Two Whitney Avenue, New Haven, CT 06511 (US).

(72) Inventor: and

(75) Inventor/Applicant (for US only): **HOH, Josephine** [US/US]; Apartment 506, 152 Temple Street, New Haven, CT 06510 (US).

(74) Agent: **GRANAHAN, Patricia**; Fish & Neave IP Group, Ropes & Gray LLP, One International Place, Boston, MA 02110-2624 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BI, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS

(57) Abstract: The present invention relates to identification of a human gene, Complement Factor H (CFH), associated with the occurrence for developing age related macular degeneration (AMD), which is useful for identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD.



WO 2006/062716 A2

METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS

FUNDING

This invention was made with United States government support under grants NIH-K25HG000060 and NIH-R01EY015771, awarded by the National Institutes of Health.

- 5 The United States government has certain rights in the invention.

CROSS-REFERENCE TO RELATED APPLICATIONS

- This application claims the benefit of U.S. Provisional Application No. 60/629,363, filed November 18, 2004; U.S. Provisional Application No. 60/649,479, filed February 2, 2005; and U.S. Provisional Application No. 60/672,346, filed April 18, 2005. The
- 10 teachings of each of these referenced provisional applications are incorporated by reference herein in their entirety.

BACKGROUND OF THE INVENTION

- Age-related macular degeneration (AMD) is the leading cause of age-related blindness in the developed world. Its incidence is increasing as lifespan lengthens and the
- 15 elderly population expands (D.S. Friedman et al., Arch Ophthalmol 122, 564 (2004)). It is a chronic disease characterized by progressive destruction of the retina's central region (macula), causing central field visual loss (J. Tuo, C. M. Bojanowski, C. C. Chan, Prog Retin Eye Res 23, 229 (2004)). One key characteristic of AMD is the formation of extracellular deposits called drusen that are concentrated in and around the macula behind
- 20 the retina between the retina pigment epithelium (RPE) and choroid. To date, no therapy for this disease has proven to be broadly effective, especially in more advanced forms. Several risk factors have been linked to AMD, including age, smoking, and family history (AREDS Research Group, Ophthalmology 107, 2224 (2000)). Candidate gene association studies and genome-wide linkage scans have been performed to identify genetic risk
- 25 factors for AMD. A variety of candidate genes have been proposed based on their association with other retinal diseases or their known function. While some rare variants of some of these genes are associated with disease phenotype, no genetic differences have been observed that can account for a large proportion of the overall prevalence (J. Tuo, C.

M. Bojanowski, C. C. Chan, *Prog Retin Eye Res* 23, 229 (2004)). Additional information about genetic determinants of AMD is badly needed.

SUMMARY OF THE INVENTION

The present invention relates to identification of variations in a human gene correlated with a predisposition to AMD, which is useful in identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD. It also relates to methods for identifying or aiding in identifying individuals at risk for developing AMD, methods for diagnosing or aiding in the diagnosis of AMD, polynucleotides (e.g., probes, primers) useful in the methods, diagnostic kits containing probes or primers, methods of treating an individual at risk for or suffering from AMD and compositions useful for treating an individual at risk for or suffering from AMD.

In one embodiment, the present invention provides polynucleotides useful for the detection or aiding in the detection of a CFH gene that is correlated with the occurrence of AMD in humans and, in specific embodiments, variations in the CFH gene that are correlated with AMD in humans. In another embodiment, the present invention provides methods and compositions useful for identifying or aiding in identifying individuals at risk for developing AMD. In a further embodiment, the methods and compositions of the invention may be used for the treatment of an individual suffering from AMD or at risk for developing AMD. The disclosure also provides diagnostic kits for detecting a variant CFH gene in a sample from an individual. Such kits are useful in identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD in an individual.

In one embodiment, the invention provides an isolated polynucleotide for the detection of a variant CFH gene; the isolated polynucleotide comprises a nucleic acid molecule that specifically detects a variation in the CFH gene that is correlated with the occurrence of AMD in humans. Isolated polynucleotides are useful for detecting, in a sample from an individual, a variant CFH gene that is correlated with AMD in humans. The polynucleotides of the invention may further be used in allele-specific assays (e.g., allele-specific hybridization, primer extension, or ligation assays known in the art) to detect a variation in the CFH gene that is correlated with the occurrence of AMD. Allele-specific probes and primers are able to specifically hybridize to one or more alleles of a gene and

will not hybridize to other alleles of the same gene. For example, an allele-specific polynucleotide probe of the invention may hybridize to a variant CFH gene but will not hybridize to a wildtype CFH gene. In certain embodiments, the isolated polynucleotide is a probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of AMD in humans. In particular embodiments, an isolated polynucleotide probe of the invention hybridizes, under stringent conditions, to a nucleic acid molecule comprising all or a portion of a CFH gene, or allelic variants thereof, wherein the nucleic acid molecule comprises a variation that is correlated with the occurrence of AMD in humans. In other embodiments, an isolated polynucleotide probe of the invention hybridizes, under stringent conditions, to a nucleic acid molecule comprising at least 10 contiguous nucleotides of a CFH gene, or allelic variants thereof, wherein the nucleic acid molecule comprises a variation that is correlated with the occurrence of AMD in humans. In further embodiments, the isolated polynucleotide is a primer that hybridizes, under stringent conditions, adjacent, upstream, or downstream to a variation in the CFH gene that is correlated with the occurrence of AMD in humans. In certain embodiments, an isolated polynucleotide primer of the invention is at least 10 nucleotides long and hybridizes to one side or another of a variation in the CFH gene that is correlated with the occurrence of AMD in humans. The subject polynucleotides may contain alterations, such as one or more nucleotide substitutions, additions or deletions, provided they hybridize to their target variant CFH gene with the same degree of specificity. As used herein, the term "isolated" when used in relation to a nucleic acid, refers to a nucleic acid sequence that is identified and separated from at least one contaminant nucleic acid with which it is ordinarily associated in its natural source. By contrast, non-isolated nucleic acids are nucleic acids such as DNA and RNA found in the state they exist in nature.

The polynucleotides described herein (e.g., a polynucleotide probe or a polynucleotide primer) may be DNA or RNA. The subject polynucleotide may be single-stranded or double-stranded. Polynucleotide probes and primers of the invention may be from about 5 nucleotides to about 3000 nucleotides. In some embodiments, the polynucleotide probes and primers of the invention are from about 8 nucleotides to about 500 nucleotides. In other embodiments, the polynucleotide probes and primers of the invention are from about 10 nucleotides to about 250 nucleotides. In certain embodiments, the subject polynucleotide probes and primers are about 20 nucleotides (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides). In other embodiments, the

subject polynucleotide probes and primers are from about 50 to about 100 nucleotides (e.g., 45, 50, 55, 60, 65, 75, 85, or 100 nucleotides). The subject polynucleotides may comprise one or more non-natural or modified nucleotides. Non-natural or modified nucleotides include, without limitation, radioactively, fluorescently, or chemically labeled nucleotides.

5 In certain embodiments, the polynucleotide primer of the invention hybridizes upstream or downstream from a variation in the CFH gene that is correlated with the occurrence of AMD in humans. In one embodiment, the polynucleotide hybridizes vicinal to a variation in the CFH gene that is correlated with the occurrence of AMD in humans. For example, hybridization may occur in such a manner that fewer than 10 nucleotides
10 separate the variation and the end of the hybridized primer proximal to the variation. In another embodiment, hybridization occurs in such a manner that 1-3 nucleotides separate the variation and the end of the hybridized primer proximal to the variation. In certain other embodiments, the polynucleotide primer hybridizes immediately adjacent to the variation. In another embodiment, the polynucleotide primer of the invention hybridizes a
15 distance (e.g., at least 10 nucleotides) from a variation in the CFH gene that is correlated with the occurrence of AMD in humans. For example, hybridization may occur in such a manner that the end of the hybridized primer proximal to the variation is 10, 25, 50, 100, 250, 1000, 5000, or up to 10,000 nucleotides from the variation in the CFH gene. The invention described herein also relates to a pair of polynucleotide primers that specifically
20 detect a variation in the CFH gene that is correlated with the occurrence of AMD in humans, wherein the first polynucleotide primer hybridizes to one side of the variation and the second polynucleotide primer hybridizes to the other side of the variation. A pair of polynucleotide primers that hybridize to a region of DNA that comprises a variation in the CFH gene that is correlated with the occurrence of AMD in humans may hybridize to the
25 region in such a manner that the ends of the hybridized primers proximal to the variation are from about 20 to about 10,000 nucleotides apart. Alternatively, the pair of polynucleotide primers that hybridize to a region of DNA that comprises a variation in the CFH gene that is correlated with the occurrence of AMD in humans may hybridize to the
30 region in such a manner that the ends of the hybridized primers proximal to the variation are from about 100 to about 7,500 nucleotides apart, or from about 200 to about 5,000 nucleotides apart.

In another embodiment, the invention described herein provides three or more polynucleotide primers useful for distinguishing between two alleles of the CFH gene (for example, a wildtype allele and an allele that is correlated with the occurrence of AMD in humans). The first primer hybridizes to a nucleotide sequence that is common to both
5 alleles, such as a non-allelic nucleotide sequence that is upstream or downstream of the variation in the CFH gene that is correlated with the occurrence of AMD. A second primer specifically hybridizes to a sequence that is unique to a first allele (e.g., a variation in the CFH gene that is correlated with the occurrence of AMD in humans). A third primer specifically hybridizes to a nucleotide sequence that is unique to the second allele (e.g., a
10 wildtype CFH gene). The set of three primers result in the amplification of a region of DNA that is dependent on which CFH allele is present in the sample. For instance, one region of DNA is amplified if the CFH gene has a variation in the CFH gene that is correlated with the occurrence of AMD, and another region is amplified if a wildtype CFH gene is present in the sample. Alternatively, two primers out of the set may hybridize to a
15 nucleotide sequence that is common to two alleles of the CFH gene, such as non-allelic nucleotide sequences that are upstream and downstream of a variation in the CFH gene that is correlated with the occurrence of AMD in humans, and a third primer specifically hybridizes to one of the two alleles of the CFH gene (such as a wildtype allele or an allele that is correlated with the occurrence of AMD in humans).

20 A variety of variations in the CFH gene that predispose an individual to AMD may be detected by the methods and compositions described herein. In a particular embodiment, the variation encodes an amino acid other than histidine at position 402 of the CFH protein. In a specific embodiment, the variation encodes tyrosine at position 402 of the CFH protein. In another embodiment, the variation encodes an amino acid other than
25 valine at position 62 of the CFH protein. In a specific embodiment, the variation encodes isoleucine at position 62 of the CFH protein. In other embodiments, the methods and compositions described herein may be used to detect variations in the CFH gene that predispose an individual to AMD, such as those listed in Tables 4, 5 and 7. For example, other variant genes, such as those in which the variation is in a coding region (e.g.,
30 variations that encode: an amino acid other than serine, such as alanine, at position 58 of the CFH protein; an amino acid other than arginine, such as histidine, at position 127 of the CFH protein; an amino acid other than glutamine, such as lysine, at position 400 of the CFH protein; an amino acid other than valine, such as isoleucine, at position 609 of the

CFH protein; an amino acid other than serine, such as isoleucine, at position 890 of the CFH protein; an amino acid other than glutamic acid, such as aspartic acid, at position 936 of the CFH protein; an amino acid other than valine, such as leucine, at position 1007 of the CFH protein; an amino acid other than asparagine, such as tyrosine, at position 1050 of the CFH protein; an amino acid other than proline, such as glutamine, at position 1166 of the CFH protein; or an amino acid other than arginine, such as cysteine, at position 1210 of the CFH protein. See Tables 4, 5 and 7) can be detected using the methods and compositions described herein. Alternatively, variant genes in which the variation is in a noncoding region, such as those listed in Tables 4, 5 and 7, may be detected using the methods and compositions described herein. As used herein, the term "variant CFH gene" refers to DNA that includes a variation in the CFH gene that is correlated with the occurrence of AMD. As used herein, the terms "wildtype CFH DNA" and "wildtype CFH gene" refer to DNA that does not include a variation in the CFH gene that is correlated with AMD.

The present invention also relates to a method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of AMD in humans. Such a method may comprise: (a) combining the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with AMD in humans, but not to a wildtype CFH gene (wildtype CFH DNA is the term used above); and (b) determining whether hybridization occurs. The occurrence of hybridization indicates that a variant CFH gene that is correlated with age related macular degeneration is present in the sample. Samples used in the methods described herein may comprise cells from the eye, ear, nose, teeth, tongue, epidermis, epithelium, blood, tears, saliva, mucus, urinary tract, urine, muscle, cartilage, skin, or any other tissue or bodily fluid from which sufficient DNA or RNA can be obtained. Samples may be collected by a variety of means for collecting cells, such as for example, a buccal swab. The sample is processed, if necessary, to render the DNA or RNA that is present available for assaying in the methods described herein. For example, samples may be processed such that DNA from the sample is available for amplification or for hybridization to another polynucleotide. The processed samples may be crude lysates where available DNA or RNA is not purified from other cellular material, or may be purified to isolate available DNA or RNA. Samples may be processed by any means known in the art that renders DNA or RNA available for assaying in the methods described herein. Methods for

processing samples include, but are not limited to, mechanical, chemical, or molecular means of lysing and/or purifying cells and cell lysates. Processing methods may include, for example, chromatographic methods such as ion exchange (e.g., cation and anion), size exclusion, gel filtration, affinity, and hydrophobic interaction chromatography, or
5 ultrafiltration, electrophoresis, and immunoaffinity purification with antibodies specific for particular epitopes of the polypeptide.

In other embodiments, the invention provides a method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of age related macular degeneration in humans, comprising: (a) combining the sample
10 (referred to as a test sample) with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of AMD in humans, thereby producing a combination; (b) maintaining the combination produced in step (a) under stringent hybridization conditions; and (c) comparing hybridization that occurs in the combination with hybridization in a control. The occurrence of hybridization
15 in the combination but not in the control indicates that a variant CFH gene that correlates with AMD is present in the sample. In a further embodiment, the extent of hybridization is determined when comparing hybridization that occurs in the combination with hybridization in a control. The control is the same as the test sample and is treated the same as the test sample except that the polynucleotide probe is one that does not bind to a
20 variation in the CFH gene that is correlated with the occurrence of AMD in humans. Alternatively, the polynucleotide probe is one that binds only to a wildtype CFH gene. The control can be assayed serially or simultaneously with the combination described above. Alternatively, results from a control may be established in a reference assay previously or subsequent to the combination described above. The sample used in the control is typically
25 the same type of sample as the test sample and is treated the same as the test sample except that it is combined with a polynucleotide that does not hybridize to a variant CFH gene that is correlated with the occurrence of AMD in humans.

In another embodiment, the invention provides a method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of
30 AMD in humans, comprising: (a) combining a first portion of the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of AMD in humans; (b) combining a second

portion of the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a wildtype CFH gene; and (c) determining whether hybridization occurs. The occurrence of hybridization in the first portion, but not in the second portion, indicates that a variant CFH gene that is correlated with AMD is present in the sample.

5 In another embodiment, the invention provides a method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of AMD in humans, comprising: (a) combining the sample with a pair of polynucleotide primers, wherein the first polynucleotide primer hybridizes to one side of DNA encoding amino acid 402 of the CFH protein and the second polynucleotide primer hybridizes to the
10 other side of DNA encoding amino acid 402 of the CFH protein; (b) amplifying DNA in the sample, thereby producing amplified DNA; (c) sequencing amplified DNA; and (d) detecting in the DNA the presence of a variation that encodes an amino acid other than histidine at position 402 of the CFH protein. The presence of the variation indicates that a variant CFH gene that is correlated with the occurrence of AMD in humans is detected in
15 the sample.

In another embodiment, the invention provides a method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of AMD in humans, comprising: (a) combining the sample with a pair of polynucleotide primers, wherein the first polynucleotide primer hybridizes to one side of DNA encoding
20 amino acid 62 of the CFH protein and the second polynucleotide primer hybridizes to the other side of DNA encoding amino acid 62 of the CFH protein; (b) amplifying DNA in the sample, thereby producing amplified DNA; (c) sequencing amplified DNA; and (d) detecting in the DNA the presence of a variation that encodes an amino acid other than histidine at position 62 of the CFH protein. The presence of the variation indicates that a
25 variant CFH gene that is correlated with the occurrence of AMD in humans is detected in the sample.

Any method known in the art for amplifying nucleic acids may be used for the methods described herein. For example, DNA in a sample may be amplified using polymerase chain reaction (PCR), RT-PCR, quantitative PCR, real time PCR, Rapid
30 Amplified Polymorphic DNA Analysis, Rapid Amplification of cDNA Ends (RACE), or rolling circle amplification.

In other embodiments, the invention provides methods of identifying or aiding in identifying an individual at risk for developing AMD. In one specific embodiment, such a method comprises assaying a sample obtained from the individual for the presence of a variant CFH gene that is correlated with the occurrence of AMD in humans. The presence
5 of a variant CFH gene indicates that the individual is at risk for developing AMD.

In another embodiment, a method of identifying or aiding in identifying an individual at risk for developing AMD comprises: (a) combining a sample obtained from the individual with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with AMD in humans, but does not hybridize
10 to a wildtype CFH gene; and (b) determining whether hybridization occurs. The occurrence of hybridization indicates that the individual is at risk for developing AMD.

In another embodiment, a method of identifying or aiding in identifying an individual at risk for developing AMD, comprises: (a) obtaining DNA from an individual; (b) sequencing a region of the DNA that comprises the nucleotides that encode amino acid
15 402 of the CFH protein; and (c) determining whether a variation that encodes an amino acid other than histidine at position 402 of the CFH protein is present in the DNA. The presence of the variation indicates that the individual is at risk for developing AMD.

In another embodiment, a method of identifying or aiding in identifying an individual at risk for developing AMD, comprises: (a) obtaining DNA from an individual;
20 (b) sequencing a region of the DNA that comprises the nucleotides that encode amino acid 62 of the CFH protein; and (c) determining whether a variation that encodes an amino acid other than valine at position 62 of the CFH protein is present in the DNA. The presence of the variation indicates that the individual is at risk for developing AMD.

In another embodiment, the invention provides a method of detecting, in a sample
25 obtained from an individual, a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans. Such a method comprises: (a) combining the sample with an antibody that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and (b) determining whether binding occurs. The occurrence of binding indicates that a variant
30 CFH polypeptide that is correlated with the occurrence of age related macular degeneration is present in the sample.

In another embodiment, the invention provides diagnostic kits useful for detecting a variant CFH gene in a sample from an individual. A diagnostic kit may comprise, for example: (a) at least one container means having disposed therein a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated
5 with the occurrence of AMD in humans; and (b) a label and/or instructions for the use of the diagnostic kit in the detection of a variant CFH gene in a sample.

In another embodiment, a diagnostic kit useful for detecting a variant CFH gene in a sample from an individual may comprise, for example: (a) at least one container means having disposed therein a polynucleotide primer that hybridizes, under stringent conditions,
10 adjacent to one side of a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans; and (b) a label and/or instructions for the use of the diagnostic kit in the detection of CFH in a sample. Optionally, the diagnostic kit additionally comprises a second polynucleotide primer that hybridizes, under stringent conditions, to the other side of the variation in the CFH gene that is correlated with the
15 occurrence of age related macular degeneration in humans.

The present invention also relates to compositions for treating a subject suffering from AMD. In a particular embodiment, a composition for treating a subject suffering from AMD comprises an effective amount of an isolated or recombinantly produced CFH polypeptide, or a fragment thereof, and a pharmaceutically acceptable carrier. In a
20 particular embodiment, the CFH polypeptide, or the fragment thereof, inhibits the activation of C3. In another embodiment, the invention provides a method of treating a subject suffering from AMD, comprising administering to the subject an effective amount of an isolated or recombinantly produced CFH polypeptide, or a fragment thereof, and a pharmaceutically acceptable carrier.

25 In another embodiment, the invention provides a composition for treating a subject suffering from AMD, comprising an effective amount of an isolated or recombinantly produced nucleic acid molecule coding for a CFH polypeptide, or a fragment thereof, and a pharmaceutically acceptable carrier. As used herein, the term "effective amount" refers to the amount of an isolated or recombinantly produced CFH nucleic acid or polypeptide, or a
30 composition comprising a CFH nucleic acid or polypeptide, that is in sufficient quantities to treat a subject or to treat the disorder itself. For example, an effective amount is sufficient to delay, slow, or prevent the onset or progression of AMD or related symptoms.

In other embodiments, the invention provides a method of treating a subject suffering from AMD, comprising administering to the subject an effective amount of an isolated or recombinantly produced nucleic acid molecule coding for a CFH polypeptide, or a fragment thereof, and a pharmaceutically acceptable carrier.

5 In another embodiment, the invention provides a composition for treating a subject suffering from or at risk for age related macular degeneration, comprising: (a) a nucleic acid molecule comprising an antisense sequence that hybridizes to a variant CFH gene or mRNA that is correlated with the occurrence of age related macular degeneration in humans; and (b) a pharmaceutically acceptable carrier. In certain embodiments,
10 hybridization of the antisense sequence to the variant CFH gene reduces the amount of RNA transcribed from the variant CFH gene. In certain other embodiments, hybridization of the antisense sequence to the variant CFH mRNA reduces the amount of protein translated from the variant CFH mRNA, and/or alters the splicing of the variant CFH mRNA. A nucleic acid molecule comprising an antisense sequence that hybridizes to a
15 variant CFH gene or mRNA may comprise one or more modified nucleotides or nucleosides that enhance in vivo stability, transport across the cell membrane, or hybridization to a variant CFH gene or mRNA. In other embodiments, the invention provides a method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of a nucleic acid
20 molecule comprising an antisense sequence that hybridizes to a variant CFH gene or mRNA that is correlated with the occurrence of age related macular degeneration in humans, and a pharmaceutically acceptable carrier.

In another embodiment, the invention provides a composition for treating a subject suffering from or at risk for age related macular degeneration, comprising: (a) a nucleic
25 acid molecule comprising a siRNA or miRNA sequence, or a precursor thereof, that hybridizes to a variant CFH gene or mRNA that is correlated with the occurrence of age related macular degeneration in humans; and (b) a pharmaceutically acceptable carrier. In certain embodiments, hybridization of a nucleic acid molecule comprising a siRNA or miRNA sequence, or a precursor thereof to the variant CFH gene reduces the amount of
30 RNA transcribed from the variant CFH gene. In other embodiments, hybridization of a nucleic acid molecule comprising a siRNA or miRNA sequence, or a precursor thereof to the variant CFH mRNA reduces the amount of protein translated from the variant CFH

mRNA, and/or alters the splicing of the variant CFH mRNA. A nucleic acid molecule comprising an antisense sequence that hybridizes to a variant CFH gene or mRNA may comprise one or more modified nucleotides or nucleosides that enhance in vivo stability, transport across the cell membrane, or hybridization to a variant CFH gene or mRNA. In other embodiments, the invention provides a method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of a nucleic acid molecule comprising a siRNA or miRNA sequence, or a precursor thereof, that hybridizes to a variant CFH gene or mRNA that is correlated with the occurrence of age related macular degeneration in humans and a pharmaceutically acceptable carrier

In another embodiment, the invention provides a composition for treating a subject suffering from or at risk for age related macular degeneration, comprising: (a) an aptamer that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and (b) a pharmaceutically acceptable carrier, wherein binding of the aptamer to the variant CFH polypeptide reduces the activity of the variant CFH polypeptide. In other embodiments, the invention provides a method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of an aptamer that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans and a pharmaceutically acceptable carrier.

In another embodiment, the invention provides a composition for treating a subject suffering from or at risk for age related macular degeneration, comprising: (a) a small molecule that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and (b) a pharmaceutically acceptable carrier. In certain embodiments, binding of the small molecule to the variant CFH polypeptide reduces the activity of the variant CFH polypeptide. In another embodiment, the invention provides a method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of a small molecule that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans and a pharmaceutically acceptable carrier.

In another embodiment, the invention provides a composition for treating a subject suffering from or at risk for age related macular degeneration, comprising: (a) an antibody

that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and (b) a pharmaceutically acceptable carrier. In certain embodiments, binding of the antibody to the variant CFH polypeptide reduces the activity of the variant CFH polypeptide. In another embodiment, the invention also provides a method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of an antibody that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans and a pharmaceutically acceptable carrier.

The methods and compositions described herein for treating a subject suffering from AMD may be used for the prophylactic treatment of individuals who have been diagnosed or predicted to be at risk for developing AMD. For instance, the composition is administered in an amount and dose that is sufficient to delay, slow, or prevent the onset of AMD or related symptoms. Alternatively, the methods and compositions described herein may be used for the therapeutic treatment of individuals who suffer from AMD. For example, the composition is administered in an amount and dose that is sufficient to delay or slow the progression of the condition, totally or partially, or in an amount and dose that is sufficient to reverse the condition.

As described herein for CFH, variations in CFH-like genes in humans (e.g., CFHL1, CFHL3, and CFHL4) are also useful for identifying or aiding in identifying individuals at risk for developing AMD. Variations in CFHL1, CFHL3, and CFHL4 may also be useful for diagnosing or aiding in the diagnosis of AMD, identifying or aiding in identifying individuals at risk for developing AMD, methods for diagnosing or aiding in the diagnosis of AMD, polynucleotides (e.g., probes, primers) useful in the methods, diagnostic kits containing probes or primers, methods of treating an individual at risk for or suffering from AMD and compositions useful for treating an individual at risk for or suffering from AMD. Examples of variations in CFHL1, CFHL3, and CFHL4 that may be correlated with the occurrence of AMD are found in Tables 8-10. Such variations, which can be in a coding or noncoding region of a CFHL gene (e.g., CFHL1, CFHL3, and CFHL4) can be useful in the methods and compositions described herein.

In one embodiment, the present invention provides polynucleotides useful for the detection or aiding in the detection of a CFHL gene (e.g., CFHL1, CFHL3, or CFHL4) that is correlated with the occurrence of AMD in humans and, in specific embodiments,

variations in a CFHL gene that are correlated with AMD in humans. The disclosure also provides diagnostic kits for detecting a variant CFHL gene in a sample from an individual. Such kits are useful in identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD in an individual.

5 In another embodiment, the invention provides an isolated polynucleotide for the detection of a variant CFHL gene, such as CFHL1, CFHL3, or CFHL4, in a sample from an individual, comprising a nucleic acid molecule that specifically detects a variation in the CFHL gene that is correlated with the occurrence of age related macular degeneration in humans.

10 In another embodiment, the invention provides a polynucleotide primer that hybridizes, under stringent conditions, adjacent to a variation in a CFHL gene that is correlated with the occurrence of age related macular degeneration in humans. In certain embodiments, the invention provides a pair of polynucleotide primers that specifically detect a variation in a CFHL gene that is correlated with the occurrence of age related
15 macular degeneration in humans, wherein the first polynucleotide primer hybridizes to one side of the variation and the second polynucleotide primer hybridizes to the other side of the variation. The pair of polynucleotide primers may hybridize to a region of a CFHL gene in such a manner that the ends of the hybridized primers proximal to the variation are from about 100 to about 10,000 nucleotides apart.

20 The present invention also relates to a method of detecting, in a sample obtained from an individual, a variant CFHL gene that is correlated with the occurrence of AMD in humans. Such a method may comprise: (a) combining the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFHL gene that is correlated with AMD in humans, but not to a wildtype CFHL gene; and (b) determining
25 whether hybridization occurs. The occurrence of hybridization indicates that a variant CFHL gene that is correlated with age related macular degeneration is present in the sample. As used herein, the term "wildtype CFHL gene" refers to a CFHL gene, such as CFHL1, CFHL3, or CFHL4, that is not correlated with the occurrence of AMD.

 In other embodiments, the invention provides a method of detecting, in a sample
30 obtained from an individual, a variant CFHL gene that is correlated with the occurrence of age related macular degeneration in humans, comprising: (a) combining the sample

(referred to as a test sample) with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFHL gene that is correlated with the occurrence of AMD in humans, thereby producing a combination; (b) maintaining the combination produced in step (a) under stringent hybridization conditions; and (c) comparing hybridization that occurs in the combination with hybridization in a control. The occurrence of hybridization in the combination but not in the control indicates that a variant CFHL gene that correlates with AMD is present in the sample. In a further embodiment, the extent of hybridization is determined when comparing hybridization that occurs in the combination with hybridization in a control. The control is the same as the test sample and is treated the same as the test sample except that the polynucleotide probe is one that does not bind to a variation in the CFHL gene that is correlated with the occurrence of AMD in humans. Alternatively, the polynucleotide probe is one that binds only to a wildtype CFHL gene.

In another embodiment, the invention provides a method of detecting, in a sample obtained from an individual, a variant CFHL gene that is correlated with the occurrence of AMD in humans, comprising: (a) combining a first portion of the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFHL gene that is correlated with the occurrence of AMD in humans; (b) combining a second portion of the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a wildtype CFHL gene; and (c) determining whether hybridization occurs. The occurrence of hybridization in the first portion, but not in the second portion, indicates that a variant CFHL gene that is correlated with AMD is present in the sample.

In other embodiments, the invention provides methods of identifying or aiding in identifying an individual at risk for developing AMD. In one specific embodiment, such a method comprises assaying DNA obtained from the individual for the presence of a variant CFHL gene that is correlated with the occurrence of AMD in humans. The presence of a variant CFHL gene indicates that the individual is at risk for developing AMD.

In another embodiment, a method of identifying or aiding in identifying an individual at risk for developing AMD comprises: (a) combining a sample obtained from the individual with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFHL gene that is correlated with AMD in humans, but does not hybridize to a wildtype CFHL gene; and (b) determining whether hybridization occurs. The occurrence of hybridization indicates that the individual is at risk for developing AMD.

In another embodiment, the invention provides diagnostic kits useful for detecting a variant CFHL gene in a sample from an individual. A diagnostic kit may comprise, for example: (a) at least one container means having disposed therein a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFHL gene that is
5 correlated with the occurrence of AMD in humans; and (b) a label and/or instructions for the use of the diagnostic kit in the detection of a variant CFHL gene in a sample.

In another embodiment, a diagnostic kit useful for detecting a variant CFHL gene in a sample from an individual may comprise, for example: (a) at least one container means having disposed therein a polynucleotide primer that hybridizes, under stringent conditions,
10 adjacent to one side of a variation in the CFHL gene that is correlated with the occurrence of age related macular degeneration in humans; and (b) a label and/or instructions for the use of the diagnostic kit in the detection of CFHL in a sample. Optionally, the diagnostic kit additionally comprises a second polynucleotide primer that hybridizes, under stringent conditions, to the other side of the variation in the CFHL gene that is correlated with the
15 occurrence of age related macular degeneration in humans.

The embodiments and practices of the present invention, other embodiments, and their features and characteristics, will be apparent from the description, figures and claims that follow, with all of the claims hereby being incorporated by this reference into this Summary.

20 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A-1B are graphs showing statistical data of a genome-wide association study of genes associated with AMD. Figure 1A shows p-values of the genome-wide association scan.
25 $-\log_{10}(p)$ is plotted for each SNP in chromosomal order. The spacing between SNPs on the plot is uniform and does not reflect distances between SNPs on the chromosomes. The dotted horizontal line shows the cutoff for $p=0.05$ after Bonferroni correction. The vertical lines show chromosomal boundaries. Figure 1B shows variations in genotype frequencies between cases and controls.

Figures 2A-2D show data on SNPs that are associated with AMD. Figure 2A
30 shows linkage disequilibrium (LD) across the CFH region, plotted as pairwise D' values. Figure 2B shows a schematic of the region in strong LD with the two associated SNPs in

the data. The vertical bars represent the approximate location of the SNPs available in the data set. The shaded region is the haplotype block found in the HapMap data. Figure 2C shows haplotype blocks in the HapMap CEU data cross the region. Darker shades indicate higher values of D' . Lighter shades indicate high D' with a low LOD score. The dark lines show the boundaries of haplotype blocks. Figure 2D shows a maximum parsimony cladogram derived from haplotypes across the 6-SNP region. The number by each line indicates which of the six SNPs varies along the branch. SNP 4 is rs380390 and SNP 6 is rs1329428, which are the two SNPs initially identified as associated with AMD.

Figures 3A-3C show immunofluorescent localization of CFH protein in human retina. Figure 3A shows human retina sections stained with anti-human CFH antibody. Figure 3B shows human retina sections stained with anti-human CFH antibody pre-incubated with CFH protein as negative control. The nuclei are identified by DAPI staining. The magnified view of the boxed area in Figure 3A is shown in Figure 3C. The fluorescent and DIC channels are collected from each image and presented as the left and right pictures, respectively, in each panel. The fluorescent pictures in Figure 3A and Figure 3B are merged images from CFH labeling and DAPI stained nuclei. The DIC picture in Figure 3C is a merged image of CFH labeling and the DIC channel. The black spots in DIC images correspond to melanin granules in RPE and choroids. The anti-CFH antibody primarily stains the choroids (Figure 3A), especially strong in the wall of vessels lumen and in area close to RPE (Figure 3C), and the immunoreactivity can be competed away with purified human CFH protein (Figure 3B). The fluorescent signal from RPE arises from the autofluorescence of lipofuscin which cannot be competed away by human factor H protein. GC: ganglion cells layer, INL: inner nuclear layer, ONL: outer nuclear layer, RPE: retinal pigment epithelium. Scale bar: 40 μ m in Figures 3A and 3B, 20 μ m in Figure 3C.

Figure 4A-4E show immunohistochemistry for activated complement C5b-9. Tissues from three patients are illustrated. Figures 4A and 4B show post-mortem fundus images from patients 1 and 2, respectively. The site illustrated histologically is indicated with an asterisk. Figure 4C shows tissue from patient 1 who is immunopositive for C5b-9 throughout Bruch's membrane and in intercapillary pillars (thin black arrows). Overlying retinal pigment epithelium is hypertrophic, and associated retina demonstrated marked photoreceptor loss. Complement deposition is also present within the elastica of a

choroidal artery (double headed black arrow), as well as within the walls of a choroidal vein (white arrow). Figure 4D shows C5b-9 deposition in Bruch's membrane, intercapillary pillars (arrows) and drusen (asterisk) in patient 2. The internal aspect of a choroidal vein is also immunopositive (white arrow). Figure 4E shows tissue from patient
5 3, an 86-year old with histologic evidence of early AMD. Activated complement deposition is noted throughout Bruch's membrane, in drusen (asterisks) and in the internal wall of a choroidal vein (white arrow). Scale bar: 20 μ m in Figures 4C and 4D), 15 μ m in Figure 4E.

Figure 5 shows the polypeptide sequence for human Complement Factor H
10 (GenBank Accession CAA68704).

DETAILED DESCRIPTION OF THE INVENTION

To provide an overall understanding of the invention, certain illustrative embodiments will now be described, including compositions and methods for identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing
15 or aiding in the diagnosis of AMD. However, it will be understood by one of ordinary skill in the art that the compositions and methods described herein may be adapted and modified as is appropriate for the application being addressed and that the compositions and methods described herein may be employed in other suitable applications, and that such other additions and modifications will not depart from the scope hereof.

20 1. Overview

The discovery that variations in the CFH gene are associated with AMD is useful for the early diagnosis and treatment of individuals predisposed to AMD. The determination of the genetic constitution of the CFH gene in an individual is useful in treating AMD at earlier stages, or even before an individual displays any symptoms of
25 AMD. Furthermore, diagnostic tests to genotype CFH may allow individuals to alter their behavior to minimize environmental risks to AMD (e.g., smoking). Accordingly, the present invention relates to the identification of a variant CFH gene correlated with a predisposition to AMD, which is useful in identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD. It
30 also relates to methods for identifying or aiding in identifying individuals at risk for

developing AMD, methods for diagnosing or aiding in the diagnosis of AMD, polynucleotides (e.g., probes, primers) useful in the methods, diagnostic kits containing probes or primers, methods of treating an individual at risk for or suffering from AMD and compositions useful for treating an individual at risk for or suffering from AMD.

5 In accordance with the present invention, a common variation in the CFH gene has been shown to be strongly associated with AMD. The present invention relates to methods and compositions for detecting such variations that predispose a human to AMD. A CFH gene can either be the cDNA or the genomic form of the gene, which may include upstream and downstream regulatory sequences. The CFH polypeptide can be encoded by
10 a full length coding sequence or by any portion of the coding sequence so long as the desired activity or functional properties (e.g., enzymatic activity, ligand binding, signal transduction, etc.) of the full-length or fragment are retained. Examples of CFH nucleotide sequences include human nucleotide sequences (SEQ ID NOs: 1 or 2), a mouse nucleotide sequence (SEQ ID NO: 3), and a rat nucleotide sequence (SEQ ID NO: 4). Polynucleotide
15 probes and primers of the invention may hybridize to any contiguous portion of a CFH gene, such as those shown in SEQ ID NOs 1-4. Examples of CFH polypeptide sequences include human polypeptide sequences (SEQ ID NOs: 5 or 6 and Figure 5), a mouse polypeptide sequence (SEQ ID NO: 7), and a rat polypeptide sequence (SEQ ID NO: 8). The CFH gene may further include sequences located adjacent to the coding region on both
20 the 5' and 3' ends for a distance of about 1-2 kb on either end such that the gene corresponds to the length of the full-length mRNA. The sequences which are located 5' of the coding region and which are present on the mRNA are referred to as 5' non-translated sequences. The sequences which are located 3' or downstream of the coding region and which are present on the mRNA are referred to as 3' non-translated sequences.

25 The CFH gene is a member of the Regulator of Complement Activation (RCA) gene cluster and encodes a protein with twenty short consensus repeat (SCR) domains of 60 amino acids each. This protein is secreted into the bloodstream and has an essential role in the regulation of complement activation (Rodriguez de Cordoba et al., *Mol Immunol.* 41:355-67 (2004)). The complement system protects against infection and attacks diseased
30 and dysplastic cells and normally spares healthy cells. Cells involved in immune surveillance and response to disease are recruited to augment the lytic action of activated complement components. When C3 convertase is activated, it leads to the production of

- C3a and C3b and then to the terminal C5b-9 complex. CFH on cells and in circulation regulates complement activity by inhibiting the activation of C3 to C3a and C3b, and by inactivating existing C3b. Variations in the CFH gene have previously been associated with hemolytic-uremic syndrome (HUS) and chronic hypocomplementemic nephropathy.
- 5 Alternate transcriptional splice variants, encoding different isoforms, have been characterized.

2. CFH polynucleotide probes and primers

- In certain embodiments, the invention provides isolated and/or recombinant polynucleotides that specifically detect a variation in the CFH gene that is correlated with the occurrence of AMD. Polynucleotide probes of the invention hybridize to a variation (referred to as a variation of interest) in such a CFH gene, and the flanking sequence, in a specific manner and thus typically have a sequence which is fully or partially complementary to the sequence of the variation and the flanking region. Polynucleotide probes of the invention may hybridize to a segment of target DNA such that the variation aligns with a central position of the probe, or the variation may align with a terminal position of the probe. In one embodiment, an isolated polynucleotide probe of the invention hybridizes, under stringent conditions, to a nucleic acid molecule comprising a variant CFH gene, or a portion or allelic variant thereof, that is correlated with the occurrence of AMD in humans. In another embodiment, an isolated polynucleotide probe of the invention hybridizes, under stringent conditions, to a nucleic acid molecule comprising at least 10 contiguous nucleotides of a CFH gene, or an allelic variant thereof, wherein the nucleic acid molecule comprises a variation that is correlated with the occurrence of AMD in humans.
- 10
15
20

- In certain embodiments, a polynucleotide probe of the invention is an allele-specific probe. The design and use of allele-specific probes for analyzing polymorphisms is described by e.g., Saiki et al., Nature 324:163-166 (1986); Dattagupta, EP 235726; and Saiki WO 89/11548. Allele-specific probes can be designed to hybridize to a segment of a target DNA from one individual but do not hybridize to the corresponding segment from another individual due to the presence of different polymorphic forms or variations in the respective segments from the two individuals. Hybridization conditions should be
- 25
30

sufficiently stringent such that there is a significant difference in hybridization intensity between alleles. In some embodiments, a probe hybridizes to only one of the alleles.

A variety of variations in the CFH gene that predispose an individual to AMD may be detected by the methods and polynucleotides described herein. For example, any
5 nucleotide polymorphism of a coding region, exon, exon-intron boundary, signal peptide, 5-prime untranslated region, promoter region, enhancer sequence, 3-prime untranslated region or intron that is associated with AMD can be detected. These polymorphisms include, but are not limited to, changes that: alter the amino acid sequence of the proteins encoded by the CFH gene, produce alternative splice products, create truncated products,
10 introduce a premature stop codon, introduce a cryptic exon, alter the degree or expression to a greater or lesser extent, alter tissue specificity of CFH expression, introduce changes in the tertiary structure of the proteins encoded by CFH, introduce changes in the binding affinity or specificity of the proteins expressed by CFH or alter the function of the proteins encoded by CFH. In a specific embodiment, the variation in the CFH gene encodes an
15 amino acid other than histidine (e.g., tyrosine) at position 402 of the CFH protein. In another specific embodiment, the variation in the CFH gene encodes an amino acid other than valine (e.g., isoleucine) at position 62 of the CFH protein. Other examples of variations in the CFH gene that may predispose an individual to AMD are found in Tables 4 and 5. For example, other variant genes, such as those in which the variation is in a
20 coding region (e.g., variations that encode: an amino acid other than serine, such as alanine, at position 58 of the CFH protein; an amino acid other than arginine, such as histidine, at position 127 of the CFH protein; an amino acid other than glutamine, such as lysine, at position 400 of the CFH protein; an amino acid other than valine, such as isoleucine, at position 609 of the CFH protein; an amino acid other than serine, such as
25 isoleucine, at position 890 of the CFH protein; an amino acid other than glutamic acid, such as aspartic acid, at position 936 of the CFH protein; an amino acid other than valine, such as leucine, at position 1007 of the CFH protein; an amino acid other than asparagine, such as tyrosine, at position 1050 of the CFH protein; an amino acid other than proline, such as glutamine, at position 1166 of the CFH protein; or an amino acid other than
30 arginine, such as cysteine, at position 1210 of the CFH protein. See Tables 4 and 5) can be detected using the methods and compositions described herein for other variants. Alternatively, variant genes in which the variation is in a noncoding region, such as those listed in Tables 4 and 5, may be detected using the methods and compositions described

herein. The subject polynucleotides are further understood to include polynucleotides that are variants of the polynucleotides described herein, provided that the variant polynucleotides maintain their ability to specifically detect a variation in the CFH gene that is correlated with the occurrence of AMD. Variant polynucleotides may include, for example, sequences that differ by one or more nucleotide substitutions, additions or deletions.

In certain embodiments, the isolated polynucleotide is a probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of AMD in humans. As used herein, the term "hybridization" is used in reference to the pairing of complementary nucleic acids. The term "probe" refers to a polynucleotide that is capable of hybridizing to another nucleic acid of interest. The polynucleotide may be naturally occurring, as in a purified restriction digest, or it may be produced synthetically, recombinantly or by nucleic acid amplification (e.g., PCR amplification).

It is well known in the art how to perform hybridization experiments with nucleic acid molecules. The skilled artisan is familiar with the hybridization conditions required in the present invention and understands readily that appropriate stringency conditions which promote DNA hybridization can be varied. Such hybridization conditions are referred to in standard text books, such as *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory (2001); and *Current Protocols in Molecular Biology*, eds. Ausubel et al., John Wiley & Sons (1992). Particularly useful in methods of the present invention are polynucleotides which are capable of hybridizing to a variant CFH gene, or a region of a variant CFH gene, under stringent conditions. Under stringent conditions, a polynucleotide that hybridizes to a variant CFH gene does not hybridize to a wildtype CFH gene.

Nucleic acid hybridization is affected by such conditions as salt concentration, temperature, organic solvents, base composition, length of the complementary strands, and the number of nucleotide base mismatches between the hybridizing nucleic acids, as will readily be appreciated by those skilled in the art. Stringent temperature conditions will generally include temperatures in excess of 30°C, or may be in excess of 37°C or 45°C. Stringency increases with temperature. For example, temperatures greater than 45°C are highly stringent conditions. Stringent salt conditions will ordinarily be less than 1000 mM, or may be less than 500 mM or 200 mM. For example, one could perform the

hybridization at 6.0x sodium chloride/sodium citrate (SSC) at about 45 °C, followed by a wash of 2.0x SSC at 50 °C. For example, the salt concentration in the wash step can be selected from a low stringency of about 2.0x SSC at 50 °C to a high stringency of about 0.2x SSC at 50 °C. In addition, the temperature in the wash step can be increased from low stringency conditions at room temperature, about 22 °C, to high stringency conditions at about 65 °C. Both temperature and salt may be varied, or temperature or salt concentration may be held constant while the other variable is changed. Particularly useful in methods of the present invention are polynucleotides which are capable of hybridizing to a variant CFH gene, or a region of a variant CFH gene, under stringent conditions. It is understood, however, that the appropriate stringency conditions may be varied in the present invention to promote DNA hybridization. In certain embodiments, polynucleotides of the present invention hybridize to a variant CFH gene, or a region of a variant CFH gene, under highly stringent conditions. Under stringent conditions, a polynucleotide that hybridizes to a variation in the CFH gene does not hybridize to a wildtype CFH gene. In one embodiment, the invention provides nucleic acids which hybridize under low stringency conditions of 6.0x SSC at room temperature followed by a wash at 2.0x SSC at room temperature. The combination of parameters, however, is much more important than the measure of any single parameter. See, e.g., Wetmur and Davidson, 1968. Probe sequences may also hybridize specifically to duplex DNA under certain conditions to form triplex or higher order DNA complexes. The preparation of such probes and suitable hybridization conditions are well known in the art. One method for obtaining DNA encoding the biosynthetic constructs disclosed herein is by assembly of synthetic oligonucleotides produced in a conventional, automated, oligonucleotide synthesizer.

A polynucleotide probe or primer of the present invention may be labeled so that it is detectable in a variety of detection systems, including, but not limited, to enzyme (e.g., ELISA, as well as enzyme-based histochemical assays), fluorescent, radioactive, chemical, and luminescent systems. A polynucleotide probe or primer of the present invention may further include a quencher moiety that, when placed in proximity to a label (e.g., a fluorescent label), causes there to be little or no signal from the label. Detection of the label may be performed by direct or indirect means (e.g., via a biotin/avidin or a biotin/streptavidin linkage). It is not intended that the present invention be limited to any particular detection system or label.

In another embodiment, the isolated polynucleotide of the invention is a primer that hybridizes, under stringent conditions, adjacent, upstream, or downstream to a variation in the CFH gene that is correlated with the occurrence of AMD in humans. The isolated polynucleotide may hybridize, under stringent conditions, to a nucleic acid molecule comprising all or a portion of a variant CFH gene that is correlated with the occurrence of AMD in humans. Alternatively, the isolated polynucleotide primer may hybridize, under stringent conditions, to a nucleic acid molecule comprising at least 50 contiguous nucleotides of a variant CFH gene that is correlated with the occurrence of AMD in humans. For example, a polynucleotide primer of the invention can hybridize adjacent, upstream, or downstream to the region of the CFH gene that encodes amino acid 402 of the CFH protein. Alternatively, a polynucleotide primer of the invention can hybridize adjacent, upstream, or downstream to the region of the CFH gene that encodes amino acid 62 of the CFH protein.

As used herein, the term "primer" refers to a polynucleotide that is capable of acting as a point of initiation of nucleic acid synthesis when placed under conditions in which synthesis of a primer extension product that is complementary to a nucleic acid strand occurs (for example, in the presence of nucleotides, an inducing agent such as DNA polymerase, and suitable temperature, pH, and electrolyte concentration). Alternatively, the primer may be capable of ligating to a proximal nucleic acid when placed under conditions in which ligation of two unlinked nucleic acids occurs (for example, in the presence of a proximal nucleic acid, an inducing agent such as DNA ligase, and suitable temperature, pH, and electrolyte concentration). A polynucleotide primer of the invention may be naturally occurring, as in a purified restriction digest, or may be produced synthetically. The primer is preferably single stranded for maximum efficiency in amplification, but may alternatively be double stranded. If double stranded, the primer is first treated to separate its strands before being used. Preferably, the primer is an oligodeoxyribonucleotide. The exact lengths of the primers will depend on many factors, including temperature, source of primer and the use of the method. In certain embodiments, the polynucleotide primer of the invention is at least 10 nucleotides long and hybridizes to one side or another of a variation in the CFH gene that is correlated with the occurrence of AMD in humans. The subject polynucleotides may contain alterations, such as one or more nucleotide substitutions, additions or deletions, provided they hybridize to their target variant CFH gene with the same degree of specificity.

In one embodiment, the invention provides a pair of primers that specifically detect a variation in the CFH gene that is correlated with the occurrence of AMD. In such a case, the first primer hybridizes upstream from the variation and a second primer hybridizes downstream from the variation. It is understood that one of the primers hybridizes to one strand of a region of DNA that comprises a variation in the CFH gene that is correlated with the occurrence of AMD, and the second primer hybridizes to the complementary strand of a region of DNA that comprises a variation in the CFH gene that is correlated with the occurrence of AMD. As used herein, the term "region of DNA" refers to a sub-chromosomal length of DNA.

In another embodiment, the invention provides an allele-specific primer that hybridizes to a site on target DNA that overlaps a variation in the CFH gene that is correlated with the occurrence of AMD in humans. An allele-specific primer of the invention only primes amplification of an allelic form to which the primer exhibits perfect complementarity. This primer may be used, for example, in conjunction with a second primer which hybridizes at a distal site. Amplification can thus proceed from the two primers, resulting in a detectable product that indicates the presence of a variant CFH gene that is correlated with the occurrence of AMD in humans.

3. Detection assays

In certain embodiments, the invention relates to polynucleotides useful for detecting a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration. Preferably, these polynucleotides are capable of hybridizing under stringent hybridization conditions to a region of DNA that comprises a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration.

The polynucleotides of the invention may be used in any assay that permits detection of a variation in the CFH gene that is correlated with the occurrence of AMD. Such methods may encompass, for example, DNA sequencing, hybridization, ligation, or primer extension methods. Furthermore, any combination of these methods may be utilized in the invention.

In one embodiment, the presence of a variation in the CFH gene that is correlated with the occurrence of AMD is detected and/or determined by DNA sequencing. DNA sequence determination may be performed by standard methods such as dideoxy chain

termination technology and gel-electrophoresis, or by other methods such as by pyrosequencing (Biotage AB, Uppsala, Sweden). For example, DNA sequencing by dideoxy chain termination may be performed using unlabeled primers and labeled (e.g., fluorescent or radioactive) terminators. Alternatively, sequencing may be performed using
5 labeled primers and unlabeled terminators. The nucleic acid sequence of the DNA in the sample can be compared to the nucleic acid sequence of wildtype DNA to identify whether a variation in the CFH gene that is correlated with the occurrence of AMD is present.

In another embodiment, the presence of a variation in the CFH gene that is correlated with the occurrence of AMD is detected and/or determined by hybridization. In
10 one embodiment, a polynucleotide probe hybridizes to a variation in the CFH gene, and flanking nucleotides, that is correlated with AMD, but not to a wildtype CFH gene. The polynucleotide probe may comprise nucleotides that are fluorescently, radioactively, or chemically labeled to facilitate detection of hybridization. Hybridization may be performed and detected by standard methods known in the art, such as by Northern
15 blotting, Southern blotting, fluorescent in situ hybridization (FISH), or by hybridization to polynucleotides immobilized on a solid support, such as a DNA array or microarray. As used herein, the term "DNA array," and "microarray" refers to an ordered arrangement of hybridizable array elements. The array elements are arranged so that there are preferably at least one or more different array elements immobilized on a substrate surface. The
20 hybridization signal from each of the array elements is individually distinguishable. In a preferred embodiment, the array elements comprise polynucleotides, although the present invention could also be used with cDNA or other types of nucleic acid array elements.

In a specific embodiment, the polynucleotide probe is used to hybridize genomic DNA by FISH. FISH can be used, for example, in metaphase cells, to detect a deletion in
25 genomic DNA. Genomic DNA is denatured to separate the complimentary strands within the DNA double helix structure. The polynucleotide probe of the invention is then added to the denatured genomic DNA. If a variation in the CFH gene that is correlated with the occurrence of AMD is present, the probe will hybridize to the genomic DNA. The probe signal (e.g., fluorescence) can then be detected through a fluorescent microscope for the
30 presence of absence of signal. The absence of signal, therefore, indicates the absence of a variation in the CFH gene that is correlated with the occurrence of AMD. In another specific embodiment, a labeled polynucleotide probe is applied to immobilized

polynucleotides on a DNA array. Hybridization may be detected, for example, by measuring the intensity of the labeled probe remaining on the DNA array after washing. The polynucleotides of the invention may also be used in commercial assays, such as the Taqman assay (Applied Biosystems, Foster City, CA).

5 In another embodiment, the presence of a variation in the CFH gene that is correlated with the occurrence of AMD is detected and/or determined by primer extension with DNA polymerase. In one embodiment, a polynucleotide primer of the invention hybridizes immediately adjacent to the variation. A single base sequencing reaction using labeled dideoxynucleotide terminators may be used to detect the variation. The presence of
10 a variation will result in the incorporation of the labeled terminator, whereas the absence of a variation will not result in the incorporation of the terminator. In another embodiment, a polynucleotide primer of the invention hybridizes to a variation in the CFH gene that is correlated with the occurrence of AMD. The primer, or a portion thereof, will not hybridize to a wildtype CFH gene. The presence of a variation will result in primer
15 extension, whereas the absence of a variation will not result in primer extension. The primers and/or nucleotides may further include fluorescent, radioactive, or chemical probes. A primer labeled by primer extension may be detected by measuring the intensity of the extension product, such as by gel electrophoresis, mass spectrometry, or any other method for detecting fluorescent, radioactive, or chemical labels.

20 In another embodiment, the presence of a variation in the CFH gene that is correlated with the occurrence of AMD is detected and/or determined by ligation. In one embodiment, a polynucleotide primer of the invention hybridizes to a variation in the CFH gene that is correlated with the occurrence of AMD. The primer, or a portion thereof will not hybridize to a wildtype CFH gene. A second polynucleotide that hybridizes to a region
25 of the CFH gene immediately adjacent to the first primer is also provided. One, or both, of the polynucleotide primers may be fluorescently, radioactively, or chemically labeled. Ligation of the two polynucleotide primers will occur in the presence of DNA ligase if a variation in the CFH gene that is correlated with the occurrence of AMD is present. Ligation may be detected by gel electrophoresis, mass spectrometry, or by measuring the
30 intensity of fluorescent, radioactive, or chemical labels.

In another embodiment, the presence of a variation in the CFH gene that is correlated with the occurrence of AMD is detected and/or determined by single-base extension (SBE). For example, a fluorescently-labeled primer that is coupled with fluorescence resonance energy transfer (FRET) between the label of the added base and the label of the primer may be used. Typically, the method, such as that described by Chen et al., (PNAS 94:10756-61 (1997), incorporated herein by reference) uses a locus-specific polynucleotide primer labeled on the 5' terminus with 5-carboxyfluorescein (FAM). This labeled primer is designed so that the 3' end is immediately adjacent to the polymorphic site of interest. The labeled primer is hybridized to the locus, and single base extension of the labeled primer is performed with fluorescently labeled dideoxynucleotides (ddNTPs) in dye-terminator sequencing fashion, except that no deoxynucleotides are present. An increase in fluorescence of the added ddNTP in response to excitation at the wavelength of the labeled primer is used to infer the identity of the added nucleotide.

Methods of detecting a variation in the CFH gene that is correlated with the occurrence of AMD may include amplification of a region of DNA that comprises the variation. Any method of amplification may be used. In one specific embodiment, a region of DNA comprising the variation is amplified by using polymerase chain reaction (PCR). PCR was initially described by Mullis (See e.g., U.S. Pat. Nos. 4,683,195, 4,683,202, and 4,965,188, herein incorporated by reference), which describes a method for increasing the concentration of a region of DNA, in a mixture of genomic DNA, without cloning or purification. Other PCR methods may also be used to nucleic acid amplification, including but not limited to RT-PCR, quantitative PCR, real time PCR, Rapid Amplified Polymorphic DNA Analysis, Rapid Amplification of cDNA Ends (RACE), or rolling circle amplification. For example, the polynucleotide primers of the invention are combined with a DNA mixture (or any polynucleotide sequence that can be amplified with the polynucleotide primers of the invention), wherein the DNA comprises the CFH gene. The mixture also includes the necessary amplification reagents (e.g., deoxynucleotide triphosphates, buffer, etc.) necessary for the thermal cycling reaction. According to standard PCR methods, the mixture undergoes a series of denaturation, primer annealing, and polymerase extension steps to amplify the region of DNA that comprises the variation in the CFH gene. The length of the amplified region of DNA is determined by the relative positions of the primers with respect to each other, and

therefore, this length is a controllable parameter. For example, hybridization of the primers may occur such that the ends of the primers proximal to the variation are separated by 1 to 10,000 base pairs (e.g., 10 base pairs (bp) 50 bp, 200 bp, 500 bp, 1,000 bp, 2,500 bp, 5,000 bp, or 10,000 bp).

5 Standard instrumentation known to those skilled in the art are used for the amplification and detection of amplified DNA. For example, a wide variety of instrumentation has been developed for carrying out nucleic acid amplifications, particularly PCR, e.g. Johnson et al, U.S. Pat. No. 5,038,852 (computer-controlled thermal
10 cycler); Wittwer et al, *Nucleic Acids Research*, 17: 4353-4357 (1989)(capillary tube PCR); Hallsby, U.S. Pat. No. 5,187,084 (air-based temperature control); Garner et al, *Biotechniques*, 14: 112-115 (1993)(high-throughput PCR in 864-well plates); Wilding et al, International application No. PCT/US93/04039 (PCR in micro-machined structures); Schnipelsky et al, European patent application No. 90301061.9 (publ. No. 0381501
15 A2)(disposable, single use PCR device), and the like. In certain embodiments, the invention described herein utilizes real-time PCR or other methods known in the art such as the Taqman assay.

 In certain embodiments, a variant CFH gene that is correlated with the occurrence of AMD in humans may be detected using single-strand conformation polymorphism analysis, which identifies base differences by alteration in electrophoretic migration of
20 single stranded PCR products, as described in Orita et al., *Proc. Nat. Acad. Sci.* 86, 2766-2770 (1989). Amplified PCR products can be generated as described above, and heated or otherwise denatured, to form single stranded amplification products. Single-stranded nucleic acids may refold or form secondary structures which are partially dependent on the base sequence. The different electrophoretic mobilities of single-stranded amplification
25 products can be related to base-sequence differences between alleles of target sequences.

 In one embodiment, the amplified DNA is analyzed in conjunction with one of the detection methods described herein, such as by DNA sequencing. The amplified DNA may alternatively be analyzed by hybridization with a labeled probe, hybridization to a DNA array or microarray, by incorporation of biotinylated primers followed by avidin-
30 enzyme conjugate detection, or by incorporation of ³²P-labeled deoxynucleotide triphosphates, such as dCTP or dATP, into the amplified segment. In a specific

embodiment, the amplified DNA is analyzed by determining the length of the amplified DNA by electrophoresis or chromatography. For example, the amplified DNA is analyzed by gel electrophoresis. Methods of gel electrophoresis are well known in the art. See for example, *Current Protocols in Molecular Biology*, eds. Ausubel et al., John Wiley & Sons: 5 1992. The amplified DNA can be visualized, for example, by fluorescent or radioactive means, or with other dyes or markers that intercalate DNA. The DNA may also be transferred to a solid support such as a nitrocellulose membrane and subjected to Southern Blotting following gel electrophoresis. In one embodiment, the DNA is exposed to ethidium bromide and visualized under ultra-violet light.

10 4. Therapeutic Nucleic Acids Encoding CFH Polypeptides

In certain embodiments, the invention provides isolated and/or recombinant nucleic acids encoding a CFH polypeptide, including functional variants, disclosed herein. For example, SEQ ID NOs: 1 or 2 are nucleic acid sequences that encode CFH and SEQ ID NOs: 5 or 6 and Figure 5 encode CFH polypeptides. The subject nucleic acids may be 15 single-stranded or double stranded. Such nucleic acids may be DNA or RNA molecules. These nucleic acids may be used, for example, in methods for making CFH polypeptides or as direct therapeutic agents (e.g., in a gene therapy approach).

The subject nucleic acids encoding CFH polypeptides are further understood to include nucleic acids that are variants of SEQ ID NOs: 1 or 2. Variant nucleotide 20 sequences include sequences that differ by one or more nucleotide substitutions, additions or deletions, such as allelic variants; and will, therefore, include coding sequences that differ from the nucleotide sequence of the coding sequence designated in SEQ ID NOs: 1 or 2. Coding sequences that differ from the nucleotide sequence of the coding sequence designated in SEQ ID NOs: 1 or 2 may be tested for their ability to inhibit the activation of 25 C3 to C3a and C3b, and by inactivating existing C3.

In certain embodiments, the invention provides isolated or recombinant nucleic acid sequences that are at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 1 or 2. One of ordinary skill in the art will appreciate that nucleic acid sequences complementary to SEQ ID NO: 1 or 2, and variants of SEQ ID NO: 1 or 2 are 30 also within the scope of this invention. In further embodiments, the nucleic acid sequences

of the invention can be isolated, recombinant, and/or fused with a heterologous nucleotide sequence, or in a DNA library.

In other embodiments, nucleic acids of the invention also include nucleic acids that hybridize under stringent conditions to the nucleotide sequence designated in SEQ ID NO: 1 or 2, complement sequence of SEQ ID NO: 1 or 2, or fragments thereof. As discussed above, one of ordinary skill in the art will understand readily that appropriate stringency conditions which promote DNA hybridization can be varied. For example, one could perform the hybridization at 6.0 x sodium chloride/sodium citrate (SSC) at about 45 °C, followed by a wash of 2.0 x SSC at 50 °C. For example, the salt concentration in the wash step can be selected from a low stringency of about 2.0 x SSC at 50 °C to a high stringency of about 0.2 x SSC at 50 °C. In addition, the temperature in the wash step can be increased from low stringency conditions at room temperature, about 22 °C, to high stringency conditions at about 65 °C. Both temperature and salt may be varied, or temperature or salt concentration may be held constant while the other variable is changed. In one embodiment, the invention provides nucleic acids which hybridize under low stringency conditions of 6 x SSC at room temperature followed by a wash at 2 x SSC at room temperature.

Isolated nucleic acids which differ from the nucleic acids as set forth in SEQ ID NO: 1 or 2 due to degeneracy in the genetic code are also within the scope of the invention. For example, a number of amino acids are designated by more than one triplet. Codons that specify the same amino acid, or synonyms (for example, CAU and CAC are synonyms for histidine) may result in "silent" variations which do not affect the amino acid sequence of the protein. However, it is expected that DNA sequence polymorphisms that do lead to changes in the amino acid sequences of the subject proteins will exist among mammalian cells. One skilled in the art will appreciate that these variations in one or more nucleotides (up to about 3-5% of the nucleotides) of the nucleic acids encoding a particular protein may exist among individuals of a given species due to natural allelic variation. Any and all such nucleotide variations and resulting amino acid polymorphisms are within the scope of this invention.

The nucleic acids and polypeptides of the invention may be produced using standard recombinant methods. For example, the recombinant nucleic acids of the invention may be operably linked to one or more regulatory nucleotide sequences in an

expression construct. Regulatory nucleotide sequences will generally be appropriate to the host cell used for expression. Numerous types of appropriate expression vectors and suitable regulatory sequences are known in the art for a variety of host cells. Typically, said one or more regulatory nucleotide sequences may include, but are not limited to, promoter sequences, leader or signal sequences, ribosomal binding sites, transcriptional start and termination sequences, translational start and termination sequences, and enhancer or activator sequences. Constitutive or inducible promoters as known in the art are contemplated by the invention. The promoters may be either naturally occurring promoters, or hybrid promoters that combine elements of more than one promoter. An expression construct may be present in a cell on an episome, such as a plasmid, or the expression construct may be inserted in a chromosome. The expression vector may also contain a selectable marker gene to allow the selection of transformed host cells. Selectable marker genes are well known in the art and will vary with the host cell used.

In certain embodiments of the invention, the subject nucleic acid is provided in an expression vector comprising a nucleotide sequence encoding a CFH polypeptide and operably linked to at least one regulatory sequence. Regulatory sequences are art-recognized and are selected to direct expression of the CFH polypeptide. Accordingly, the term regulatory sequence includes promoters, enhancers, termination sequences, preferred ribosome binding site sequences, preferred mRNA leader sequences, preferred protein processing sequences, preferred signal sequences for protein secretion, and other expression control elements. Examples of regulatory sequences are described in Goeddel; *Gene Expression Technology: Methods in Enzymology*, Academic Press, San Diego, CA (1990). For instance, any of a wide variety of expression control sequences that control the expression of a DNA sequence when operatively linked to it may be used in these vectors to express DNA sequences encoding a CFH polypeptide. Such useful expression control sequences, include, for example, the early and late promoters of SV40, tet promoter, adenovirus or cytomegalovirus immediate early promoter, RSV promoters, the lac system, the trp system, the TAC or TRC system, T7 promoter whose expression is directed by T7 RNA polymerase, the major operator and promoter regions of phage lambda, the control regions for fd coat protein, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase, e.g., Pho5, the promoters of the yeast α -mating factors, the polyhedron promoter of the baculovirus system and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells or their viruses,

and various combinations thereof. It should be understood that the design of the expression vector may depend on such factors as the choice of the host cell to be transformed and/or the type of protein desired to be expressed. Moreover, the vector's copy number, the ability to control that copy number and the expression of any other
5 protein encoded by the vector, such as antibiotic markers, should also be considered.

A recombinant nucleic acid of the invention can be produced by ligating the cloned gene, or a portion thereof, into a vector suitable for expression in either prokaryotic cells, eukaryotic cells (yeast, avian, insect or mammalian), or both. Expression vehicles for production of recombinant CFH polypeptides include plasmids and other vectors. For
10 instance, suitable vectors include plasmids of the types: pBR322-derived plasmids, pEMBL-derived plasmids, pEX-derived plasmids, pBTac-derived plasmids and pUC-derived plasmids for expression in prokaryotic cells, such as *E. coli*.

Some mammalian expression vectors contain both prokaryotic sequences to facilitate the propagation of the vector in bacteria, and one or more eukaryotic transcription
15 units that are expressed in eukaryotic cells. The pcDNA1/amp, pcDNA1/neo, pRc/CMV, pSV2gpt, pSV2neo, pSV2-dhfr, pTk2, pRSVneo, pMSG, pSVT7, pko-neo and pHyg derived vectors are examples of mammalian expression vectors suitable for transfection of eukaryotic cells. Some of these vectors are modified with sequences from bacterial plasmids, such as pBR322, to facilitate replication and drug resistance selection in both
20 prokaryotic and eukaryotic cells. Alternatively, derivatives of viruses such as the bovine papilloma virus (BPV-1), or Epstein-Barr virus (pHEBo, pREP-derived and p205) can be used for transient expression of proteins in eukaryotic cells. Examples of other viral (including retroviral) expression systems can be found below in the description of gene therapy delivery systems. The various methods employed in the preparation of the
25 plasmids and in transformation of host organisms are well known in the art. For other suitable expression systems for both prokaryotic and eukaryotic cells, as well as general recombinant procedures, see Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory (2001). In some instances, it may be desirable to express the recombinant polypeptide by the use of a baculovirus expression system. Examples of such
30 baculovirus expression systems include pVL-derived vectors (such as pVL1392, pVL1393 and pVL941), pAcUW-derived vectors (such as pAcUW1), and pBlueBac-derived vectors (such as the β -gal containing pBlueBac III).

In one embodiment, a vector will be designed for production of a subject CFH polypeptide in CHO cells, such as a Pcmv-Script vector (Stratagene, La Jolla, Calif.), pcDNA4 vectors (Invitrogen, Carlsbad, Calif.) and pCI-neo vectors (Promega, Madison, Wisc.). In other embodiments, the vector is designed for production of a subject CFH polypeptide in prokaryotic host cells (e.g., *E. coli* and *B. subtilis*), eukaryotic host cells such as, for example, yeast cells, insect cells, myeloma cells, fibroblast 3T3 cells, monkey kidney or COS cells, mink-lung epithelial cells, human foreskin fibroblast cells, human glioblastoma cells, and teratocarcinoma cells. Alternatively, the genes may be expressed in a cell-free system such as the rabbit reticulocyte lysate system.

As will be apparent, the subject gene constructs can be used to express the subject CFH polypeptide in cells propagated in culture, e.g., to produce proteins, including fusion proteins or variant proteins, for purification.

This invention also pertains to a host cell transfected with a recombinant gene including a coding sequence (e.g., SEQ ID NO: 1 or 2) for one or more of the subject CFH polypeptides. The host cell may be any prokaryotic or eukaryotic cell. For example, a CFH polypeptide of the invention may be expressed in bacterial cells such as *E. coli*, insect cells (e.g., using a baculovirus expression system), yeast, or mammalian cells. Other suitable host cells are known to those skilled in the art.

Accordingly, the present invention further pertains to methods of producing the subject CFH polypeptides. For example, a host cell transfected with an expression vector encoding a CFH polypeptide can be cultured under appropriate conditions to allow expression of the CFH polypeptide to occur. CFH polypeptides may be secreted and isolated from a mixture of cells and medium containing the CFH polypeptides. Alternatively, the polypeptide may be retained cytoplasmically or in a membrane fraction and the cells harvested, lysed and the protein isolated. A cell culture includes host cells, media and other byproducts. Suitable media for cell culture are well known in the art. The polypeptide can be isolated from cell culture medium, host cells, or both using techniques known in the art for purifying proteins, including ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis, and immunoaffinity purification with antibodies specific for particular epitopes of the polypeptide. In a particular embodiment, the CFH polypeptide is a fusion protein containing a domain which facilitates the purification of the CFH polypeptide.

In another embodiment, a fusion gene coding for a purification leader sequence, such as a poly-(His)/enterokinase cleavage site sequence at the N-terminus of the desired portion of the recombinant CFH polypeptide, can allow purification of the expressed fusion protein by affinity chromatography using a Ni^{2+} metal resin. The purification leader
5 sequence can then be subsequently removed by treatment with enterokinase to provide the purified polypeptide (e.g., see Hochuli et al., (1987) *J. Chromatography* 411:177; and Janknecht et al., *PNAS USA* 88:8972).

Techniques for making fusion genes are well known. Essentially, the joining of various DNA fragments coding for different polypeptide sequences is performed in
10 accordance with conventional techniques, employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR
15 amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed to generate a chimeric gene sequence (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel et al., John Wiley & Sons: 1992).

5. Other therapeutic modalities

20 *Antisense polynucleotides*

In certain embodiments, the invention provides polynucleotides that comprise an antisense sequence that acts through an antisense mechanism for inhibiting expression of a variant CFH gene. Antisense technologies have been widely utilized to regulate gene expression (Buskirk et al., *Chem Biol* 11, 1157-63 (2004); and Weiss et al., *Cell Mol Life*
25 *Sci* 55, 334-58 (1999)). As used herein, "antisense" technology refers to administration or in situ generation of molecules or their derivatives which specifically hybridize (e.g., bind) under cellular conditions, with the target nucleic acid of interest (mRNA and/or genomic DNA) encoding one or more of the target proteins so as to inhibit expression of that protein, e.g., by inhibiting transcription and/or translation, such as by steric hinderance,
30 altering splicing, or inducing cleavage or other enzymatic inactivation of the transcript. The binding may be by conventional base pair complementarity, or, for example, in the

case of binding to DNA duplexes, through specific interactions in the major groove of the double helix. In general, "antisense" technology refers to the range of techniques generally employed in the art, and includes any therapy that relies on specific binding to nucleic acid sequences.

5 A polynucleotide that comprises an antisense sequence of the present invention can be delivered, for example, as a component of an expression plasmid which, when transcribed in the cell, produces a nucleic acid sequence that is complementary to at least a unique portion of the target nucleic acid. Alternatively, the polynucleotide that comprises an antisense sequence can be generated outside of the target cell, and which, when
10 introduced into the target cell causes inhibition of expression by hybridizing with the target nucleic acid. Polynucleotides of the invention may be modified so that they are resistant to endogenous nucleases, e.g. exonucleases and/or endonucleases, and are therefore stable in vivo. Examples of nucleic acid molecules for use in polynucleotides of the invention are phosphoramidate, phosphothioate and methylphosphonate analogs of DNA (see also U.S.
15 Pat. Nos. 5,176,996; 5,264,564; and 5,256,775). General approaches to constructing polynucleotides useful in antisense technology have been reviewed, for example, by van der krol et al. (1988) *Biotechniques* 6:958-976; and Stein et al. (1988) *Cancer Res* 48:2659-2668.

 Antisense approaches involve the design of polynucleotides (either DNA or RNA)
20 that are complementary to a target nucleic acid encoding a variant CFH gene. The antisense polynucleotide may bind to an mRNA transcript and prevent translation of a protein of interest. Absolute complementarity, although preferred, is not required. In the case of double-stranded antisense polynucleotides, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend
25 on both the degree of complementarity and the length of the antisense sequence. Generally, the longer the hybridizing nucleic acid, the more base mismatches with a target nucleic acid it may contain and still form a stable duplex (or triplex, as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

30 Antisense polynucleotides that are complementary to the 5' end of an mRNA target, e.g., the 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation of the mRNA. However, sequences

complementary to the 3' untranslated sequences of mRNAs have recently been shown to be effective at inhibiting translation of mRNAs as well (Wagner, R. 1994. *Nature* 372:333). Therefore, antisense polynucleotides complementary to either the 5' or 3' untranslated, non-coding regions of a variant CFH gene could be used in an antisense approach to inhibit translation of a variant CFH mRNA. Antisense polynucleotides complementary to the 5' untranslated region of an mRNA should include the complement of the AUG start codon. Antisense polynucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could also be used in accordance with the invention. Whether designed to hybridize to the 5', 3', or coding region of mRNA, antisense polynucleotides should be at least six nucleotides in length, and are preferably less than about 100 and more preferably less than about 50, 25, 17 or 10 nucleotides in length.

Regardless of the choice of target sequence, it is preferred that in vitro studies are first performed to quantitate the ability of the antisense polynucleotide to inhibit expression of a variant CFH gene. It is preferred that these studies utilize controls that distinguish between antisense gene inhibition and nonspecific biological effects of antisense polynucleotide. It is also preferred that these studies compare levels of the target RNA or protein with that of an internal control RNA or protein. Additionally, it is envisioned that results obtained using the antisense polynucleotide are compared with those obtained using a control antisense polynucleotide. It is preferred that the control antisense polynucleotide is of approximately the same length as the test antisense polynucleotide and that the nucleotide sequence of the control antisense polynucleotide differs from the antisense sequence of interest no more than is necessary to prevent specific hybridization to the target sequence.

Polynucleotides of the invention, including antisense polynucleotides, can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. Polynucleotides of the invention can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. Polynucleotides of the invention may include other appended groups such as peptides (e.g., for targeting host cell receptors), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., 1989, *Proc Natl Acad Sci. USA*

86:6553-6556; Lemaitre et al., 1987, *Proc Natl Acad Sci. USA* 84:648-652; PCT Publication No. W088/09810, published Dec. 15, 1988) or the blood- brain barrier (see, e.g., PCT Publication No. W089/10134, published Apr. 25, 1988), hybridization-triggered cleavage agents. (See, e.g., Krol et al., 1988, *BioTechniques* 6:958-976) or intercalating
 5 agents. (See, e.g., Zon, *Pharm. Res.* 5:539-549 (1988)). To this end, a polynucleotide of the invention may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

Polynucleotides of the invention, including antisense polynucleotides, may comprise at least one modified base moiety which is selected from the group including but
 10 not limited to 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxytriethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5- carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6- isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine,
 15 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil; beta-D-mannosylqueosine, 5-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-
 20 oxyacetic acid methyl ester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

Polynucleotides of the invention may also comprise at least one modified sugar moiety selected from the group including but not limited to arabinose, 2-fluoroarabinose, xylulose, and hexose.

25 A polynucleotide of the invention can also contain a neutral peptide-like backbone. Such molecules are termed peptide nucleic acid (PNA)-oligomers and are described, e.g., in Perry-O'Keefe et al. (1996) *Proc. Natl. Acad. Sci. USA* 93:14670 and in Eglom et al. (1993) *Nature* 365:566. One advantage of PNA oligomers is their capability to bind to complementary DNA essentially independently from the ionic strength of the medium due
 30 to the neutral backbone of the DNA. In yet another embodiment, a polynucleotide of the invention comprises at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a

phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In a further embodiment, polynucleotides of the invention, including antisense polynucleotides are -anomeric oligonucleotides. An -anomeric oligonucleotide forms
5 specific double-stranded hybrids with complementary RNA in which, contrary to the usual -units, the strands run parallel to each other (Gautier et al., 1987, *Nucl. Acids Res.* 15:6625-6641). The oligonucleotide is a 2'-O-methylribonucleotide (Inoue et al., 1987, *Nucl. Acids Res.* 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue et al., 1987, *FEBS Lett.* 215:327-330).

10 Polynucleotides of the invention, including antisense polynucleotides, may be synthesized by standard methods known in the art, e.g., by use of an automated DNA synthesizer (such as are commercially available from Bioscience, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. *Nucl. Acids Res.* 16:3209 (1988)), methylphosphonate oligonucleotides can be
15 prepared by use of controlled pore glass polymer supports (Sarin et al., *Proc. Natl. Acad. Sci. USA* 85:7448-7451 (1988)), etc.

While antisense sequences complementary to the coding region of an mRNA sequence can be used, those complementary to the transcribed untranslated region and to the region comprising the initiating methionine are most preferred.

20 Antisense polynucleotides can be delivered to cells that express target genes in vivo. A number of methods have been developed for delivering nucleic acids into cells; e.g., they can be injected directly into the tissue site, or modified nucleic acids, designed to target the desired cells (e.g., antisense polynucleotides linked to peptides or antibodies that specifically bind receptors or antigens expressed on the target cell surface) can be
25 administered systematically.

However, it may be difficult to achieve intracellular concentrations of the antisense polynucleotides sufficient to attenuate the activity of a variant CFH gene or mRNA in certain instances. Therefore, another approach utilizes a recombinant DNA construct in which the antisense polynucleotide is placed under the control of a strong pol III or pol II
30 promoter. The use of such a construct to transfect target cells in the patient will result in the transcription of sufficient amounts of antisense polynucleotides that will form

complementary base pairs with the variant CFH gene or mRNA and thereby attenuate the activity of CFH protein. For example, a vector can be introduced in vivo such that it is taken up by a cell and directs the transcription of an antisense polynucleotide that targets a variant CFH gene or mRNA. Such a vector can remain episomal or become

5 chromosomally integrated, as long as it can be transcribed to produce the desired antisense polynucleotide. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in mammalian cells. A promoter may be operably linked to the sequence encoding the antisense polynucleotide. Expression of the sequence encoding

10 the antisense polynucleotide can be by any promoter known in the art to act in mammalian, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include but are not limited to: the SV40 early promoter region (Bernoist and Chambon, *Nature* 290:304-310 (1981)), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., *Cell* 22:787-797 (1980)), the herpes thymidine kinase

15 promoter (Wagner et al., *Proc. Natl. Acad. Sci. USA* 78:1441-1445 (1981)), the regulatory sequences of the metallothioneine gene (Brinster et al, *Nature* 296:3942 (1982)), etc. Any type of plasmid, cosmid, YAC or viral vector can be used to prepare the recombinant DNA construct that can be introduced directly into the tissue site. Alternatively, viral vectors can be used which selectively infect the desired tissue, in which case administration may be

20 accomplished by another route (e.g., systematically).

RNAi constructs - siRNAs and miRNAs

RNA interference (RNAi) is a phenomenon describing double-stranded (ds)RNA-dependent gene specific posttranscriptional silencing. Initial attempts to harness this phenomenon for experimental manipulation of mammalian cells were foiled by a robust

25 and nonspecific antiviral defense mechanism activated in response to long dsRNA molecules. Gil et al. *Apoptosis* 2000, 5:107-114. The field was significantly advanced upon the demonstration that synthetic duplexes of 21 nucleotide RNAs could mediate gene specific RNAi in mammalian cells, without invoking generic antiviral defense mechanisms. Elbashir et al. *Nature* 2001, 411:494-498; Caplen et al. *Proc Natl Acad Sci*

30 2001, 98:9742-9747. As a result, small-interfering RNAs (siRNAs) and micro RNAs (miRNAs) have become powerful tools to dissect gene function. The chemical synthesis of small RNAs is one avenue that has produced promising results. Numerous groups have

also sought the development of DNA-based vectors capable of generating such siRNA within cells. Several groups have recently attained this goal and published similar strategies that, in general, involve transcription of short hairpin (sh)RNAs that are efficiently processed to form siRNAs within cells. Paddison et al. PNAS 2002, 99:1443-1448; Paddison et al. Genes & Dev 2002, 16:948-958; Sui et al. PNAS 2002, 8:5515-5520; and Brummelkamp et al. Science 2002, 296:550-553. These reports describe methods to generate siRNAs capable of specifically targeting numerous endogenously and exogenously expressed genes.

Accordingly, the present invention provides a polynucleotide comprising an RNAi sequence that acts through an RNAi or miRNA mechanism to attenuate expression of a variant CFH gene. For instance, a polynucleotide of the invention may comprise a miRNA or siRNA sequence that attenuates or inhibits expression of a variant CFH gene. In one embodiment, the miRNA or siRNA sequence is between about 19 nucleotides and about 75 nucleotides in length, or preferably, between about 25 base pairs and about 35 base pairs in length. In certain embodiments, the polynucleotide is a hairpin loop or stem-loop that may be processed by RNase enzymes (e.g., Drosha and Dicer).

An RNAi construct contains a nucleotide sequence that hybridizes under physiologic conditions of the cell to the nucleotide sequence of at least a portion of the mRNA transcript for a variant CFH gene. The double-stranded RNA need only be sufficiently similar to natural RNA that it has the ability to mediate RNAi. The number of tolerated nucleotide mismatches between the target sequence and the RNAi construct sequence is no more than 1 in 5 basepairs, or 1 in 10 basepairs, or 1 in 20 basepairs, or 1 in 50 basepairs. It is primarily important that the RNAi construct is able to specifically target a variant CFH gene. Mismatches in the center of the siRNA duplex are most critical and may essentially abolish cleavage of the target RNA. In contrast, nucleotides at the 3' end of the siRNA strand that is complementary to the target RNA do not significantly contribute to specificity of the target recognition.

Sequence identity may be optimized by sequence comparison and alignment algorithms known in the art (see Gribskov and Devereux, Sequence Analysis Primer, Stockton Press, 1991, and references cited therein) and calculating the percent difference between the nucleotide sequences by, for example, the Smith-Waterman algorithm as implemented in the BESTFIT software program using default parameters (e.g., University

of Wisconsin Genetic Computing Group). Greater than 90% sequence identity, or even 100% sequence identity, between the inhibitory RNA and the portion of the target gene is preferred. Alternatively, the duplex region of the RNA may be defined functionally as a nucleotide sequence that is capable of hybridizing with a portion of the target gene
5 transcript (e.g., 400 mM NaCl, 40mM PIPES pH 6.4, 1 mM EDTA, 50 °C or 70 °C hybridization for 12-16 hours; followed by washing).

Production of polynucleotides comprising RNAi sequences can be carried out by any of the methods for producing polynucleotides described herein. For example, polynucleotides comprising RNAi sequences can be produced by chemical synthetic
10 methods or by recombinant nucleic acid techniques. Endogenous RNA polymerase of the treated cell may mediate transcription in vivo, or cloned RNA polymerase can be used for transcription in vitro. Polynucleotides of the invention, including wildtype or antisense polynucleotides, or those that modulate target gene activity by RNAi mechanisms, may include modifications to either the phosphate-sugar backbone or the nucleoside, e.g., to
15 reduce susceptibility to cellular nucleases, improve bioavailability, improve formulation characteristics, and/or change other pharmacokinetic properties. For example, the phosphodiester linkages of natural RNA may be modified to include at least one of a nitrogen or sulfur heteroatom. Modifications in RNA structure may be tailored to allow specific genetic inhibition while avoiding a general response to dsRNA. Likewise, bases
20 may be modified to block the activity of adenosine deaminase. Polynucleotides of the invention may be produced enzymatically or by partial/total organic synthesis, any modified ribonucleotide can be introduced by in vitro enzymatic or organic synthesis.

Methods of chemically modifying RNA molecules can be adapted for modifying RNAi constructs (see, for example, Heidenreich et al. (1997) *Nucleic Acids Res*, 25:776-
25 780; Wilson et al. (1994) *J Mol Recog* 7:89-98; Chen et al. (1995) *Nucleic Acids Res* 23:2661-2668; Hirschbein et al. (1997) *Antisense Nucleic Acid Drug Dev* 7:55-61). Merely to illustrate, the backbone of an RNAi construct can be modified with phosphorothioates, phosphoramidate, phosphodithioates, chimeric methylphosphonate-phosphodiester, peptide nucleic acids, 5-propynyl-pyrimidine containing oligomers or
30 sugar modifications (e.g., 2'-substituted ribonucleosides, a-configuration).

The double-stranded structure may be formed by a single self-complementary RNA strand or two complementary RNA strands. RNA duplex formation may be initiated either

inside or outside the cell. The RNA may be introduced in an amount which allows delivery of at least one copy per cell. Higher doses (e.g., at least 5, 10, 100, 500 or 1000 copies per cell) of double-stranded material may yield more effective inhibition, while lower doses may also be useful for specific applications. Inhibition is sequence-specific in that nucleotide sequences corresponding to the duplex region of the RNA are targeted for genetic inhibition.

In certain embodiments, the subject RNAi constructs are "siRNAs." These nucleic acids are between about 19-35 nucleotides in length, and even more preferably 21-23 nucleotides in length, e.g., corresponding in length to the fragments generated by nuclease "dicing" of longer double-stranded RNAs. The siRNAs are understood to recruit nuclease complexes and guide the complexes to the target mRNA by pairing to the specific sequences. As a result, the target mRNA is degraded by the nucleases in the protein complex or translation is inhibited. In a particular embodiment, the 21-23 nucleotides siRNA molecules comprise a 3' hydroxyl group.

In other embodiments, the subject RNAi constructs are "miRNAs." microRNAs (miRNAs) are small non-coding RNAs that direct post transcriptional regulation of gene expression through interaction with homologous mRNAs. miRNAs control the expression of genes by binding to complementary sites in target mRNAs from protein coding genes. miRNAs are similar to siRNAs. miRNAs are processed by nucleolytic cleavage from larger double-stranded precursor molecules. These precursor molecules are often hairpin structures of about 70 nucleotides in length, with 25 or more nucleotides that are base-paired in the hairpin. The RNase III-like enzymes Drosha and Dicer (which may also be used in siRNA processing) cleave the miRNA precursor to produce an miRNA. The processed miRNA is single-stranded and incorporates into a protein complex, termed RISC or miRNP. This RNA-protein complex targets a complementary mRNA. miRNAs inhibit translation or direct cleavage of target mRNAs. (Brennecke et al., *Genome Biology* 4:228 (2003); Kim et al., *Mol. Cells* 19:1-15 (2005).

In certain embodiments, miRNA and siRNA constructs can be generated by processing of longer double-stranded RNAs, for example, in the presence of the enzymes Dicer or Drosha. Dicer and Drosha are RNase III-like nucleases that specifically cleave dsRNA. Dicer has a distinctive structure which includes a helicase domain and dual RNase III motifs. Dicer also contains a region of homology to the

RDE1/QDE2/ARGONAUTE family, which have been genetically linked to RNAi in lower eukaryotes. Indeed, activation of, or overexpression of Dicer may be sufficient in many cases to permit RNA interference in otherwise non-receptive cells, such as cultured eukaryotic cells, or mammalian (non-oocytic) cells in culture or in whole organisms.

- 5 Methods and compositions employing Dicer, as well as other RNAi enzymes, are described in U.S. Pat. App. Publication No. 2004/0086884.

In one embodiment, the *Drosophila* in vitro system is used. In this embodiment, a polynucleotide comprising an RNAi sequence or an RNAi precursor is combined with a soluble extract derived from *Drosophila* embryo, thereby producing a combination. The
10 combination is maintained under conditions in which the dsRNA is processed to RNA molecules of about 21 to about 23 nucleotides.

The miRNA and siRNA molecules can be purified using a number of techniques known to those of skill in the art. For example, gel electrophoresis can be used to purify such molecules. Alternatively, non-denaturing methods, such as non-denaturing column
15 chromatography, can be used to purify the siRNA and miRNA molecules. In addition, chromatography (e.g., size exclusion chromatography), glycerol gradient centrifugation, affinity purification with antibody can be used to purify siRNAs and miRNAs.

In certain embodiments, at least one strand of the siRNA sequence of an effector domain has a 3' overhang from about 1 to about 6 nucleotides in length, or from 2 to 4
20 nucleotides in length. In other embodiments, the 3' overhangs are 1-3 nucleotides in length. In certain embodiments, one strand has a 3' overhang and the other strand is either blunt-ended or also has an overhang. The length of the overhangs may be the same or different for each strand. In order to further enhance the stability of the siRNA sequence, the 3' overhangs can be stabilized against degradation. In one embodiment, the RNA is
25 stabilized by including purine nucleotides, such as adenosine or guanosine nucleotides. Alternatively, substitution of pyrimidine nucleotides by modified analogues, e.g., substitution of uridine nucleotide 3' overhangs by 2'-deoxythymidine is tolerated and does not affect the efficiency of RNAi. The absence of a 2' hydroxyl significantly enhances the nuclease resistance of the overhang in tissue culture medium and may be beneficial in vivo.

30 In certain embodiments, a polynucleotide of the invention that comprises an RNAi sequence or an RNAi precursor is in the form of a hairpin structure (named as hairpin RNA). The hairpin RNAs can be synthesized exogenously or can be formed by

transcribing from RNA polymerase III promoters in vivo. Examples of making and using such hairpin RNAs for gene silencing in mammalian cells are described in, for example, Paddison et al., *Genes Dev*, 2002, 16:948-58; McCaffrey et al., *Nature*, 2002, 418:38-9; McManus et al., *RNA* 2002, 8:842-50; Yu et al., *Proc Natl Acad Sci USA*, 2002, 99:6047-52). Preferably, such hairpin RNAs are engineered in cells or in an animal to ensure continuous and stable suppression of a desired gene. It is known in the art that miRNAs and siRNAs can be produced by processing a hairpin RNA in the cell.

In yet other embodiments, a plasmid is used to deliver the double-stranded RNA, e.g., as a transcriptional product. After the coding sequence is transcribed, the complementary RNA transcripts base-pair to form the double-stranded RNA.

Aptamers and small molecules

The present invention also provides therapeutic aptamers that specifically bind to variant CFH polypeptides that are associated with AMD, thereby modulating activity of the variant CFH polypeptide. An "aptamer" may be a nucleic acid molecule, such as RNA or DNA that is capable of binding to a specific molecule with high affinity and specificity (Ellington et al., *Nature* 346, 818-22 (1990); and Tuerk et al., *Science* 249, 505-10 (1990)). An aptamer will most typically have been obtained by in vitro selection for binding of a target molecule. For example, an aptamer that specifically binds a variant CFH polypeptide can be obtained by in vitro selection for binding to a variant CFH polypeptide from a pool of polynucleotides. However, in vivo selection of an aptamer is also possible. Aptamers have specific binding regions which are capable of forming complexes with an intended target molecule in an environment wherein other substances in the same environment are not complexed to the nucleic acid. The specificity of the binding is defined in terms of the comparative dissociation constants (K_d) of the aptamer for its ligand (e.g., a variant CFH polypeptide) as compared to the dissociation constant of the aptamer for other materials in the environment or unrelated molecules in general. A ligand (e.g., a variant CFH polypeptide) is one which binds to the aptamer with greater affinity than to unrelated material. Typically, the K_d for the aptamer with respect to its ligand will be at least about 10-fold less than the K_d for the aptamer with unrelated material or accompanying material in the environment. Even more preferably, the K_d will be at least about 50-fold less, more preferably at least about 100-fold less, and most preferably at least about 200-fold less. An aptamer will typically be between about 10 and about 300

nucleotides in length. More commonly, an aptamer will be between about 30 and about 100 nucleotides in length.

Methods for selecting aptamers specific for a target of interest are known in the art. For example, organic molecules, nucleotides, amino acids, polypeptides, target features on
5 cell surfaces, ions, metals, salts, saccharides, have all been shown to be suitable for isolating aptamers that can specifically bind to the respective ligand. For instance, organic dyes such as Hoechst 33258 have been successfully used as target ligands for in vitro aptamer selections (Werstuck and Green, *Science* 282:296-298 (1998)). Other small organic molecules like dopamine, theophylline, sulforhodamine B, and cellobiose have
10 also been used as ligands in the isolation of aptamers. Aptamers have also been isolated for antibiotics such as kanamycin A, lividomycin, tobramycin, neomycin B, viomycin, chloramphenicol and streptomycin. For a review of aptamers that recognize small molecules, see Famulok, *Science* 9:324-9 (1999).

An aptamer of the invention can be comprised entirely of RNA. In other
15 embodiments of the invention, however, the aptamer can instead be comprised entirely of DNA, or partially of DNA, or partially of other nucleotide analogs. To specifically inhibit translation in vivo, RNA aptamers are preferred. Such RNA aptamers are preferably introduced into a cell as DNA that is transcribed into the RNA aptamer. Alternatively, an RNA aptamer itself can be introduced into a cell.

20 Aptamers are typically developed to bind particular ligands by employing known in vivo or in vitro (most typically, in vitro) selection techniques known as SELEX (Ellington et al., *Nature* 346, 818-22 (1990); and Tuerk et al., *Science* 249, 505-10 (1990)). Methods of making aptamers are also described in, for example, U.S. Pat. No. 5,582,981, PCT Publication No. WO 00/20040, U.S. Pat. No. 5,270,163, Lorsch and Szostak,
25 Biochemistry, 33:973 (1994), Mannironi et al., Biochemistry 36:9726 (1997), Blind, Proc. Nat'l. Acad. Sci. USA 96:3606-3610 (1999), Huizenga and Szostak, Biochemistry, 34:656-665 (1995), PCT Publication Nos. WO 99/54506, WO 99/27133, WO 97/42317 and U.S. Pat. No. 5,756,291.

Generally, in their most basic form, in vitro selection techniques for identifying
30 aptamers involve first preparing a large pool of DNA molecules of the desired length that contain at least some region that is randomized or mutagenized. For instance, a common oligonucleotide pool for aptamer selection might contain a region of 20-100 randomized

nucleotides flanked on both ends by an about 15-25 nucleotide long region of defined sequence useful for the binding of PCR primers. The oligonucleotide pool is amplified using standard PCR techniques, although any means that will allow faithful, efficient amplification of selected nucleic acid sequences can be employed. The DNA pool is then
5 in vitro transcribed to produce RNA transcripts. The RNA transcripts may then be subjected to affinity chromatography, although any protocol which will allow selection of nucleic acids based on their ability to bind specifically to another molecule (e.g., a protein or any target molecule) may be used. In the case of affinity chromatography, the transcripts are most typically passed through a column or contacted with magnetic beads or
10 the like on which the target ligand has been immobilized. RNA molecules in the pool which bind to the ligand are retained on the column or bead, while nonbinding sequences are washed away. The RNA molecules which bind the ligand are then reverse transcribed and amplified again by PCR (usually after elution). The selected pool sequences are then put through another round of the same type of selection. Typically, the pool sequences are
15 put through a total of about three to ten iterative rounds of the selection procedure. The cDNA is then amplified, cloned, and sequenced using standard procedures to identify the sequence of the RNA molecules which are capable of acting as aptamers for the target ligand. Once an aptamer sequence has been successfully identified, the aptamer may be further optimized by performing additional rounds of selection starting from a pool of
20 oligonucleotides comprising the mutagenized aptamer sequence. For use in the present invention, the aptamer is preferably selected for ligand binding in the presence of salt concentrations and temperatures which mimic normal physiological conditions.

The unique nature of the in vitro selection process allows for the isolation of a suitable aptamer that binds a desired ligand despite a complete dearth of prior knowledge
25 as to what type of structure might bind the desired ligand.

The association constant for the aptamer and associated ligand is preferably such that the ligand functions to bind to the aptamer and have the desired effect at the concentration of ligand obtained upon administration of the ligand. For in vivo use, for example, the association constant should be such that binding occurs well below the
30 concentration of ligand that can be achieved in the serum or other tissue. Preferably, the required ligand concentration for in vivo use is also below that which could have undesired effects on the organism.

The present invention also provides small molecules and antibodies that specifically bind to a variant CFH polypeptide that is associated with AMD, thereby inhibiting the activity of a variant CFH polypeptide. Examples of small molecules include, without limitation, drugs, metabolites, intermediates, cofactors, transition state analogs, ions, metals, toxins and natural and synthetic polymers (e.g., proteins, peptides, nucleic acids, polysaccharides, glycoproteins, hormones, receptors and cell surfaces such as cell walls and cell membranes).

Antibodies

Another aspect of the invention pertains to antibodies. In one embodiment, an antibody that is specifically reactive with a variant CFH polypeptide may be used to detect the presence of a variant CFH polypeptide or to inhibit activity of a variant CFH polypeptide. For example, by using immunogens derived from a variant CFH peptide, anti-protein/anti-peptide antisera or monoclonal antibodies can be made by standard protocols (see, for example, *Antibodies: A Laboratory Manual* ed. by Harlow and Lane (Cold Spring Harbor Press: 1988)). A mammal, such as a mouse, a hamster or rabbit can be immunized with an immunogenic form of the variant CFH peptide, an antigenic fragment which is capable of eliciting an antibody response, or a fusion protein. In a particular embodiment, the inoculated mouse does not express endogenous CFH, thus facilitating the isolation of antibodies that would otherwise be eliminated as anti-self antibodies. Techniques for conferring immunogenicity on a protein or peptide include conjugation to carriers or other techniques well known in the art. An immunogenic portion of a variant CFH peptide can be administered in the presence of adjuvant. The progress of immunization can be monitored by detection of antibody titers in plasma or serum. Standard ELISA or other immunoassays can be used with the immunogen as antigen to assess the levels of antibodies.

Following immunization of an animal with an antigenic preparation of a variant CFH polypeptide, antisera can be obtained and, if desired, polyclonal antibodies can be isolated from the serum. To produce monoclonal antibodies, antibody-producing cells (lymphocytes) can be harvested from an immunized animal and fused by standard somatic cell fusion procedures with immortalizing cells such as myeloma cells to yield hybridoma cells. Such techniques are well known in the art, and include, for example, the hybridoma

technique (originally developed by Kohler and Milstein, (1975) *Nature*, 256: 495-497), the human B cell hybridoma technique (Kozbar et al., (1983) *Immunology Today*, 4: 72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., (1985) *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc. pp. 77-96).

- 5 Hybridoma cells can be screened immunochemically for production of antibodies specifically reactive with a variant CFH polypeptide and monoclonal antibodies isolated from a culture comprising such hybridoma cells.

The term "antibody" as used herein is intended to include fragments thereof which are also specifically reactive with a variant CFH polypeptide. Antibodies can be
10 fragmented using conventional techniques and the fragments screened for utility in the same manner as described above for whole antibodies. For example, F(ab)₂ fragments can be generated by treating antibody with pepsin. The resulting F(ab)₂ fragment can be treated to reduce disulfide bridges to produce Fab fragments. The antibody of the present invention is further intended to include bispecific, single-chain, and chimeric and
15 humanized molecules having affinity for a variant CFH polypeptide conferred by at least one CDR region of the antibody. In preferred embodiments, the antibody further comprises a label attached thereto and able to be detected (e.g., the label can be a radioisotope, fluorescent compound, enzyme or enzyme co-factor).

In certain embodiments, an antibody of the invention is a monoclonal antibody, and
20 in certain embodiments, the invention makes available methods for generating novel antibodies that bind specifically to variant CFH polypeptides. For example, a method for generating a monoclonal antibody that binds specifically to a variant CFH polypeptide may comprise administering to a mouse an amount of an immunogenic composition comprising the CFH polypeptide effective to stimulate a detectable immune response, obtaining
25 antibody-producing cells (e.g., cells from the spleen) from the mouse and fusing the antibody-producing cells with myeloma cells to obtain antibody-producing hybridomas, and testing the antibody-producing hybridomas to identify a hybridoma that produces a monoclonal antibody that binds specifically to the variant CFH polypeptide. Once obtained, a hybridoma can be propagated in a cell culture, optionally in culture conditions
30 where the hybridoma-derived cells produce the monoclonal antibody that binds specifically to the CFH polypeptide. The monoclonal antibody may be purified from the cell culture.

The term "specifically reactive with" as used in reference to an antibody is intended to mean, as is generally understood in the art, that the antibody is sufficiently selective between the antigen of interest (e.g., a variant CFH polypeptide) and other antigens that are not of interest that the antibody is useful for, at minimum, detecting the presence of the antigen of interest in a particular type of biological sample. In certain methods employing the antibody, such as therapeutic applications, a higher degree of specificity in binding may be desirable. Monoclonal antibodies generally have a greater tendency (as compared to polyclonal antibodies) to discriminate effectively between the desired antigens and cross-reacting polypeptides. One characteristic that influences the specificity of an antibody:antigen interaction is the affinity of the antibody for the antigen. Although the desired specificity may be reached with a range of different affinities, generally preferred antibodies will have an affinity (a dissociation constant) of about 10^{-6} , 10^{-7} , 10^{-8} , 10^{-9} or less.

In addition, the techniques used to screen antibodies in order to identify a desirable antibody may influence the properties of the antibody obtained. For example, if an antibody is to be used for binding an antigen in solution, it may be desirable to test solution binding. A variety of different techniques are available for testing interaction between antibodies and antigens to identify particularly desirable antibodies. Such techniques include ELISAs, surface plasmon resonance binding assays (e.g., the Biacore binding assay, Bia-core AB, Uppsala, Sweden), sandwich assays (e.g., the paramagnetic bead system of IGEN International, Inc., Gaithersburg, Maryland), western blots, immunoprecipitation assays, and immunohistochemistry.

6. Screening Assays

In certain aspects, the present invention relates to the use of CFH polypeptides to identify compounds (agents) which are agonist or antagonists of CFH polypeptides. Compounds identified through this screening can be tested in cells of the eye, (e.g., epithelial and endothelial cells) as well as other tissues (e.g., muscle and/or neurons) to assess their ability to modulate CFH activity in vivo or in vitro. In certain aspects, compounds identified through this screening modulate the formation of drusen deposits. Optionally, these compounds can further be tested in animal models to assess their ability to modulate CFH activity in vivo.

There are numerous approaches to screening for therapeutic agents that target CFH polypeptides. In certain embodiments, high-throughput screening of compounds can be carried out to identify agents that affect activity of CFH polypeptides. A variety of assay formats will suffice and, in light of the present disclosure, those not expressly described
5 herein will nevertheless be comprehended by one of ordinary skill in the art. As described herein, the test compounds (agents) of the invention may be created by any combinatorial chemical method. Alternatively, the subject compounds may be naturally occurring biomolecules synthesized in vivo or in vitro. Compounds (agents) to be tested for their ability to act as modulators of CFH activity can be produced, for example, by bacteria,
10 yeast, plants or other organisms (e.g., natural products), produced chemically (e.g., small molecules, including peptidomimetics), or produced recombinantly. Test compounds contemplated by the present invention include non-peptidyl organic molecules, peptides, polypeptides, peptidomimetics, sugars, hormones, and nucleic acid molecules.

The test compounds of the invention can be provided as single, discrete entities, or
15 provided in libraries of greater complexity, such as made by combinatorial chemistry. These libraries can comprise, for example, alcohols, alkyl halides, amines, amides, esters, aldehydes, ethers and other classes of organic compounds. Presentation of test compounds to the test system can be in either an isolated form or as mixtures of compounds, especially in initial screening steps. Optionally, the compounds may be optionally derivatized with
20 other compounds and have derivatizing groups that facilitate isolation of the compounds. Non-limiting examples of derivatizing groups include biotin, fluorescein, digoxigenin, green fluorescent protein, isotopes, polyhistidine, magnetic beads, glutathione S transferase (GST), photoactivatable crosslinkers or any combinations thereof.

In many drug screening programs which test libraries of compounds and natural
25 extracts, high throughput assays are desirable in order to maximize the number of compounds surveyed in a given period of time. Assays which are performed in cell-free systems, such as may be derived with purified or semi-purified proteins, are often preferred as "primary" screens in that they can be generated to permit rapid development and relatively easy detection of an alteration in a molecular target which is mediated by a test
30 compound. Moreover, the effects of cellular toxicity or bioavailability of the test compound can be generally ignored in the in vitro system, the assay instead being focused primarily on the effect of the drug on the molecular target.

In certain embodiments, the subject compounds are identified by their ability to interact with a CFH polypeptide of the invention. The interaction between the compound and the CFH polypeptide may be covalent or non-covalent. For example, such interaction can be identified at the protein level using in vitro biochemical methods, including photo-crosslinking, radiolabeled ligand binding, and affinity chromatography (Jakoby WB et al., 5 1974, *Methods in Enzymology* 46:1). In certain cases, the compounds may be screened in a mechanism based assay, such as an assay to detect compounds which bind to a CFH polypeptide. This may include a solid phase or fluid phase binding event. Alternatively, the gene encoding a CFH polypeptide can be transfected with a reporter system (e.g., β -galactosidase, luciferase, or green fluorescent protein) into a cell and screened against the library preferably by a high throughput screening or with individual members of the library. Other mechanism based binding assays may be used, for example, binding assays which detect changes in free energy. Binding assays can be performed with the target fixed to a well, bead or chip or captured by an immobilized antibody or resolved by 15 capillary electrophoresis. The bound compounds may be detected usually using colorimetric or fluorescence or surface plasmon resonance.

7. Pharmaceutical Compositions

The methods and compositions described herein for treating a subject suffering from AMD may be used for the prophylactic treatment of individuals who have been 20 diagnosed or predicted to be at risk for developing AMD. In this case, the composition is administered in an amount and dose that is sufficient to delay, slow, or prevent the onset of AMD or related symptoms. Alternatively, the methods and compositions described herein may be used for the therapeutic treatment of individuals who suffer from AMD. In this case, the composition is administered in an amount and dose that is sufficient to delay or 25 slow the progression of the condition, totally or partially, or in an amount and dose that is sufficient to reverse the condition to the point of eliminating the disorder. It is understood that an effective amount of a composition for treating a subject who has been diagnosed or predicted to be at risk for developing AMD is a dose or amount that is in sufficient quantities to treat a subject or to treat the disorder itself.

30 In certain embodiments, compounds of the present invention (e.g., an isolated or recombinantly produced nucleic acid molecule coding for a CFH polypeptide or an isolated or recombinantly produced CFH polypeptide) are formulated with a pharmaceutically

acceptable carrier. For example, a CFH polypeptide or a nucleic acid molecule coding for a CFH polypeptide can be administered alone or as a component of a pharmaceutical formulation (therapeutic composition). The subject compounds may be formulated for administration in any convenient way for use in human medicine.

5 In certain embodiments, the therapeutic methods of the invention include administering the composition topically, systemically, or locally. For example, therapeutic compositions of the invention may be formulated for administration by, for example, injection (e.g., intravenously, subcutaneously, or intramuscularly), inhalation or insufflation (either through the mouth or the nose) or oral, buccal, sublingual, transdermal,
10 nasal, or parenteral administration. The compositions described herein may be formulated as part of an implant or device. When administered, the therapeutic composition for use in this invention is in a pyrogen-free, physiologically acceptable form. Further, the composition may be encapsulated or injected in a viscous form for delivery to the site where the target cells are present, such as to the cells of the eye. Techniques and
15 formulations generally may be found in Remington's Pharmaceutical Sciences, Meade Publishing Co., Easton, PA. In addition to CFH polypeptides or nucleic acid molecules coding for CFH polypeptides, therapeutically useful agents may optionally be included in any of the compositions as described above. Furthermore, therapeutically useful agents may, alternatively or additionally, be administered simultaneously or sequentially with
20 CFH polypeptides or nucleic acid molecules coding for CFH polypeptides according to the methods of the invention.

 In certain embodiments, compositions of the invention can be administered orally, e.g., in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an
25 aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of an agent as an active ingredient. An agent may also be administered as a bolus, electuary or paste.

30 In solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules, and the like), one or more therapeutic compounds of the present invention may be mixed with one or more pharmaceutically acceptable carriers, such as

sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-
5 agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9)
10 lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.

15 Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,
20 propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming, and preservative agents.

25 Suspensions, in addition to the active compounds, may contain suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol, and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

Certain compositions disclosed herein may be administered topically, either to skin
30 or to mucosal membranes. The topical formulations may further include one or more of the wide variety of agents known to be effective as skin or stratum corneum penetration enhancers. Examples of these are 2-pyrrolidone, N-methyl-2-pyrrolidone,

dimethylacetamide, dimethylformamide, propylene glycol, methyl or isopropyl alcohol, dimethyl sulfoxide, and azone. Additional agents may further be included to make the formulation cosmetically acceptable. Examples of these are fats, waxes, oils, dyes, fragrances, preservatives, stabilizers, and surface active agents. Keratolytic agents such as those known in the art may also be included. Examples are salicylic acid and sulfur.

Dosage forms for the topical or transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required. The ointments, pastes, creams and gels may contain, in addition to a subject compound of the invention (e.g., an isolated or recombinantly produced nucleic acid molecule coding for a CFH polypeptide or an isolated or recombinantly produced CFH polypeptide), excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.

Powders and sprays can contain, in addition to a subject compound, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates, and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.

It is understood that the dosage regimen will be determined for an individual, taking into consideration, for example, various factors which modify the action of the subject compounds of the invention (e.g., an isolated or recombinantly produced nucleic acid molecule coding for a CFH polypeptide or an isolated or recombinantly produced CFH polypeptide), the severity or stage of AMD, route of administration, and characteristics unique to the individual, such as age, weight, and size. A person of ordinary skill in the art is able to determine the required dosage to treat the subject. In one embodiment, the dosage can range from about 1.0 ng/kg to about 100 mg/kg body weight of the subject. Based upon the composition, the dose can be delivered continuously, or at periodic intervals. For example, on one or more separate occasions. Desired time intervals of multiple doses of a particular composition can be determined without undue experimentation by one skilled in the art. For example, the compound may be delivered

hourly, daily, weekly, monthly, yearly (e.g. in a time release form) or as a one time delivery.

In certain embodiments, pharmaceutical compositions suitable for parenteral administration may comprise a CFH polypeptide or a nucleic acid molecule coding for a CFH polypeptide in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents. Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

The compositions of the invention may also contain adjuvants, such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption, such as aluminum monostearate and gelatin.

In certain embodiments, the present invention also provides gene therapy for the in vivo production of CFH polypeptides. Such therapy would achieve its therapeutic effect by introduction of CFH polynucleotide sequences into cells or tissues that are deficient for normal CFH function. Delivery of CFH polynucleotide sequences can be achieved using a recombinant expression vector such as a chimeric virus or a colloidal dispersion system. Targeted liposomes may also be used for the therapeutic delivery of CFH polynucleotide sequences.

Various viral vectors which can be utilized for gene therapy as taught herein include adenovirus, herpes virus, vaccinia, or an RNA virus such as a retrovirus. A retroviral vector may be a derivative of a murine or avian retrovirus. Examples of retroviral vectors in which a single foreign gene can be inserted include, but are not limited to: Moloney murine leukemia virus (MoMuLV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), and Rous Sarcoma Virus (RSV). A number of additional retroviral vectors can incorporate multiple genes. All of these vectors can transfer or incorporate a gene for a selectable marker so that transduced cells can be identified and generated. Retroviral vectors can be made target-specific by attaching, for example, a sugar, a glycolipid, or a protein. Preferred targeting is accomplished by using an antibody. Those of skill in the art will recognize that specific polynucleotide sequences can be inserted into the retroviral genome or attached to a viral envelope to allow target specific delivery of the retroviral vector containing the CFH polynucleotide. In one preferred embodiment, the vector is targeted to cells or tissues of the eye.

Alternatively, tissue culture cells can be directly transfected with plasmids encoding the retroviral structural genes gag, pol and env, by conventional calcium phosphate transfection. These cells are then transfected with the vector plasmid containing the genes of interest. The resulting cells release the retroviral vector into the culture medium.

Another targeted delivery system for CFH polynucleotides is a colloidal dispersion system. Colloidal dispersion systems include macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. The preferred colloidal system of this invention is a liposome. Liposomes are artificial membrane vesicles which are useful as delivery vehicles in vitro and in vivo. RNA, DNA and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (see e.g., Fraley, et al., Trends Biochem. Sci., 6:77, 1981). Methods for efficient gene transfer using a liposome vehicle, are known in the art, see e.g., Mammino, et al., Biotechniques, 6:682, 1988. The composition of the liposome is usually a combination of phospholipids, usually in combination with steroids, especially cholesterol. Other phospholipids or other lipids may also be used. The physical characteristics of liposomes depend on pH, ionic strength, and the presence of divalent cations.

Examples of lipids useful in liposome production include phosphatidyl compounds, such as phosphatidylglycerol, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, sphingolipids, cerebrosides, and gangliosides. Illustrative phospholipids include egg phosphatidylcholine, dipalmitoylphosphatidylcholine, and distearoylphosphatidylcholine. The targeting of liposomes is also possible based on, for example, organ-specificity, cell-specificity, and organelle-specificity and is known in the art.

Moreover, the pharmaceutical preparation can consist essentially of the gene delivery system in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery system can be produced intact from recombinant cells, e.g. retroviral packages, the pharmaceutical preparation can comprise one or more cells which produce the gene delivery system. In the case of the latter, methods of introducing the viral packaging cells may be provided by, for example, rechargeable or biodegradable devices. Various slow release polymeric devices have been developed and tested in vivo in recent years for the controlled delivery of drugs, including proteinacious biopharmaceuticals, and can be adapted for release of viral particles through the manipulation of the polymer composition and form. A variety of biocompatible polymers (including hydrogels), including both biodegradable and non-degradable polymers, can be used to form an implant for the sustained release of the viral particles by cells implanted at a particular target site. Such embodiments of the present invention can be used for the delivery of an exogenously purified virus, which has been incorporated in the polymeric device, or for the delivery of viral particles produced by a cell encapsulated in the polymeric device.

A person of ordinary skill in the art is able to determine the required amount to treat the subject. It is understood that the dosage regimen will be determined for an individual, taking into consideration, for example, various factors which modify the action of the subject compounds of the invention, the severity or stage of AMD, route of administration, and characteristics unique to the individual, such as age, weight, and size. A person of ordinary skill in the art is able to determine the required dosage to treat the subject. In one embodiment, the dosage can range from about 1.0 ng/kg to about 100 mg/kg body weight of the subject. The dose can be delivered continuously, or at periodic intervals. For example, on one or more separate occasions. Desired time intervals of multiple doses of a

particular composition can be determined without undue experimentation by one skilled in the art. For example, the compound may be delivered hourly, daily, weekly, monthly, yearly (e.g. in a time release form) or as a one time delivery. As used herein, the term "subject" means any individual animal capable of becoming afflicted with AMD. The
5 subjects include, but are not limited to, human beings, primates, horses, birds, cows, pigs, dogs, cats, mice, rats, guinea pigs, ferrets, and rabbits. In the preferred embodiment, the subject is a human being.

Samples used in the methods described herein may comprise cells from the eye, ear, nose, teeth, tongue, epidermis, epithelium, blood, tears, saliva, mucus, urinary tract,
10 urine, muscle, cartilage, skin, or any other tissue or bodily fluid from which sufficient DNA or RNA can be obtained.

The sample should be sufficiently processed to render the DNA or RNA that is present available for assaying in the methods described herein. For example, samples may be processed such that DNA from the sample is available for amplification or for
15 hybridization to another polynucleotide. The processed samples may be crude lysates where available DNA or RNA is not purified from other cellular material. Alternatively, samples may be processed to isolate the available DNA or RNA from one or more contaminants that are present in its natural source. Samples may be processed by any means known in the art that renders DNA or RNA available for assaying in the methods
20 described herein. Methods for processing samples may include, without limitation, mechanical, chemical, or molecular means of lysing and/or purifying cells and cell lysates. Processing methods may include, for example, ion-exchange chromatography, size exclusion chromatography, affinity chromatography, hydrophobic interaction chromatography, gel filtration chromatography, ultrafiltration, electrophoresis, and
25 immunoaffinity purification with antibodies specific for particular epitopes of the polypeptide

8. Kits

Also provided herein are kits, e.g., kits for therapeutic purposes or kits for detecting a variant CFH gene in a sample from an individual. In one embodiment, a kit comprises at
30 least one container means having disposed therein a premeasured dose of a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of AMD in humans. In another embodiment, a kit

comprises at least one container means having disposed therein a premeasured dose of a polynucleotide primer that hybridizes, under stringent conditions, adjacent to one side of a variation in the CFH gene that is correlated with the occurrence of AMD in humans. In a further embodiment, a second polynucleotide primer that hybridizes, under stringent
5 conditions, to the other side of a variation in the CFH gene that is correlated with the occurrence of AMD in humans is provided in a premeasured dose. Kits further comprise a label and/or instructions for the use of the therapeutic or diagnostic kit in the detection of CFH in a sample. Kits may also include packaging material such as, but not limited to, ice, dry ice, styrofoam, foam, plastic, cellophane, shrink wrap, bubble wrap, paper, cardboard,
10 starch peanuts, twist ties, metal clips, metal cans, drierite, glass, and rubber (see products available from www.papermart.com for examples of packaging material).

The practice of the present methods will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of
15 the art. Such techniques are explained fully in the literature. See, for example, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory (2001); *DNA Cloning*, Volumes I and II (D. N. Glover ed., 1985); *Oligonucleotide Synthesis* (M. J. Gait ed., 1984); Mullis et al. U.S. Patent No: 4,683,195; *Nucleic Acid Hybridization* (B. D. Hames & S. J. Higgins eds. 1984); *Transcription And Translation* (B. D. Hames & S. J. Higgins
20 eds. 1984); *Culture Of Animal Cells* (R. I. Freshney, Alan R. Liss, Inc., 1987); *Immobilized Cells And Enzymes* (IRL Press, 1986); B. Perbal, *A Practical Guide To Molecular Cloning* (1984); the treatise, *Methods In Enzymology* (Academic Press, Inc., N.Y.); *Gene Transfer Vectors For Mammalian Cells* (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); *Methods In Enzymology*, Vols. 154 and 155 (Wu
25 et al. eds.), *Immunochemical Methods In Cell And Molecular Biology* (Mayer and Walker, eds., Academic Press, London, 1987); *Handbook Of Experimental Immunology*, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986).

EXAMPLES

30 The following examples are for illustrative purposes and are not intended to be limiting in any way.

EXAMPLE 1: Whole genome SNP association for genes correlated with AMD.

Described herein is a whole-genome case-control association study for genes involved in AMD. Two crucial factors were used in designing this experiment; clearly defined phenotypes were chosen for cases and controls. The definition of a case was based on both a quantitative photographic assessment of the presence of at least some large drusen combined with photographic evidence of sight-threatening AMD (geographic atrophy or neovascular AMD). The definition of a control was based on the study participant having either no drusen or only a few small drusen. Data was analyzed using a statistically conservative approach to correct for the large number of SNPs tested, thereby guaranteeing that the actual probability of a false positive is no greater than the reported p-values.

A subset of individuals who participated in the Age-Related Eye Disease Study (AREDS) (AREDS Research Group, Arch Ophthalmol 119, 1417, (2001)) were used in the association study. From the AREDS sample, 96 case subjects were identified who, at their most recent study visit, had either unocular choroidal neovascularization (50 cases) or geographic atrophy either central or non-central to the macula (46 cases). The fellow eye of these case subjects was required to have at least one large drusen ($>125 \mu\text{m}$ in diameter), and total drusen area equivalent to a circle of at least $1061 \mu\text{m}$ in diameter. The group of study participants who had both large drusen and sight-threatening AMD was selected because there can be many precursors to the development of either choroidal neovascularization or geographic atrophy. Controls were 50 individuals from the AREDS sample who had few or no drusen ($<63 \mu\text{m}$ in diameter in each eye) for the duration of their participation in AREDS. All individuals identified themselves as "White, not of Hispanic origin." To the extent possible, the proportions of gender and smoking status were kept the same in cases and controls. Controls were purposely chosen to be older than the cases to increase the probability that they will remain without AMD (Table 1).

Table 1. Summary of sample phenotypes.

	Cases (n=96)	Controls (n=50)
Males (%)	44	54
Never smoked (%)	36	52
Formerly smoked (%)	58	48

Currently smoke (%)	5	0
Mean age (\pm s.d.) (years)	79 \pm 5.2	82 \pm 2.2
Age range (years)	65-89	78-87
One eye with neovascular AMD, other eye with at least one large drusen (%)	52	0
One eye with geographic atrophy AMD, other eye with at least one large drusen (%)	48	0
Both eyes with few or no drusen (%)	0	100

EXAMPLE 2: Genotyping and SNP identification of individuals in study population

Each individual was genotyped using the Affymetrix GeneChip Mapping 100K Set of microarrays (H. Matsuzaki et al., Nat Methods 1, 109 (2004)). This mapping assay consists of two chips (XbaI and HindIII) with approximately 50,000 SNPs each that are used for each individual. About 250 ng of genomic DNA was digested with two restriction enzymes XbaI and HindIII and processed according to the Affymetrix protocol (H. Matsuzaki et al., Nat Methods 1, 109 (2004)). The images were analyzed using GDAS software (Affymetrix). For the data obtained from each chip, two internal quality control measures were used: the call rate always exceeded 95% and heterozygosity on the X chromosome correctly identified the gender of the individual. Thirty-one identical SNPs were placed on both chips and checked that they yielded the same genotype for the same individual to ensure that no samples were confused.

Three experiments were performed to test the reproducibility of this system. First, 4 samples were processed twice with the Xba chips. Next, 2 replicates of a reference DNA positive control provided by Affymetrix were run on Xba chips alongside the samples. Finally, results for 3 individuals were compared with genotyping using the Affymetrix 10K SNP platform to test the accuracy of this assay (H. Matsuzaki et al., Genome Res 14, 414 (2004)).

An assessment of the percentage of the individuals producing a genotype call for each SNP was made in order to examine the genotyping quality for each individual SNP. A SNP with a call rate of 100% means every individual is successfully assigned a genotype for this SNP and there is no missing data. Call rates were required to be at least 85% to remove SNPs for which genotyping was consistently problematic. SNPs which are

monomorphic in the data were also removed, since these SNPs are uninformative. SNPs in which genotype frequencies deviated from the Hardy-Weinberg equilibrium expectation (HWD $\chi^2 > 25$, $P = 0.05$, 1df, after Bonferroni correction) were removed as being likely to contain genotyping errors rather than real disequilibrium. SNPs for which no homozygotes
5 were observed in the entire sample were also likely due to errors and removed. Altogether, of the 116,204 SNPs genotyped, 105,980 SNPs with a call rate of at least 85%, both alleles observed, at least one homozygote observed, and a HWD $\chi^2 \leq 25$ were found and considered. Of these, the 103,611 SNPs that lie on the 22 autosomal chromosomes were analyzed. A summary of genotyping quality can be found in Table 2.

Table 2. Genotyping quality control and informativeness.

Per-chip data quality	
Median call rate per chip	99.1%
Minimum call rate per chip	95.6%
Chips for which gender matches	292 (100%)
Per-individual data quality	
Median call rate per individual	99.1%
Minimum call rate per individual	96.7%
Average number of matches for common SNPs between two chips	30.7/31
Minimum number of matches for common SNPs between two chips*	28/31
Reproducibility	
Xba Repeat concordance (4 replicates)	99.886%
Xba Positive control concordance (2 replicates)	99.870%
10K concordance (3 replicates)	99.767%
Call rate (per-SNP)	
Total number of SNPs	116204
SNPs with 100% call rate	81456
SNPs with call rate between 85% and 100%	33262
SNPs with call rate less than 85%	1486
Locus Polymorphism	
Number of SNPs with no polymorphism observed	8538
Number of SNPs with minor allele frequency < 0.01	3604
Number of SNPs with only heterozygotes observed	19
Number of polymorphic SNPs with no heterozygotes observed	71
Hardy-Weinberg Equilibrium	
Number of SNPs significantly out of equilibrium	231

*For the most part, when SNPs do not match it is due to one of the SNPs not being called. In only 3 out of 4485 comparisons is a mismatch observed, which is equivalent to 99.93% concordance.

EXAMPLE 3: Statistical analysis of SNP association with disease status

Allelic association with disease status was tested for each SNP. A 2x2 contingency table of allele frequencies was constructed. The Pearson χ^2 value and a P-value were calculated, based on the central χ^2 distribution under the null hypothesis of no association with 1 degree of freedom. This nominal P-value was corrected for multiple testing by applying the Bonferroni correction, in which only SNPs with a p-value less than $0.05/103,611 = 4.8 \times 10^{-7}$ were considered. This produced a Bonferroni-corrected P-value. This correction is known to be conservative and thus may "overcorrect" the raw p-values (L. M. McIntyre, E. R. Martin, K. L. Simonsen, N. L. Kaplan, *Genet Epidemiol* 19, 18 (2000)). While this technique may overlook real associations, it adjusts for the large number of multiple comparisons and yields p-values that do not underestimate the false positive rate.

Two methods of genomic control were used to look for population stratification, GC and GCF (B. Devlin, S. A. Bacanu, K. Roeder, *Nat Genet* 36, 1129 (2004)). In the first method, the median χ^2 value was taken for allelic association with a number of SNPs assumed to be unassociated with the disease (null SNPs). The test statistic $\chi^2_{(1)}$ values were divided by this median, and tested for significance using the χ^2 distribution. Alternatively, for the GCF method, the mean rather than the median of the null χ^2 statistics was used; significance of the quotient was tested using the F(1,L) distribution, where L is the number of null SNPs used (B. Devlin, S. A. Bacanu, K. Roeder, *Nat Genet* 36, 1129 (2004)). Two different sets of unassociated SNPs were used: all the SNPs successfully genotyped except the two significant (see below) ones, and the set of 31 SNPs that are in common between the two chips used in the assay (see Example 2 above).

The candidate region was defined by looking for adjacent SNPs in which all four gametes were observed (R. R. Hudson, N. L. Kaplan, *Genetics* 111, 147 (1985)) and bounding the region there. To look at linkage disequilibrium between SNPs in the candidate region, haplotype frequencies in the region were inferred using PHASE version 2.1 (M. Stephens, P. Donnelly, *Am J Hum Genet* 73, 1162 (2003); M. Stephens, N. J. Smith, P. Donnelly, *Am J Hum Genet* 68, 978 (2001)). Based on the inferred haplotype frequencies across the entire region, pairwise linkage disequilibrium was calculated by first computing the two-locus haplotype frequencies implied by the overall haplotype

frequencies. The measure of linkage disequilibrium, D' , was then calculated using standard equations (D. L. Hartl, A. G. Clark, Principles of Population Genetics (Sinauer Associates, Sunderland, MA, ed. Third, 1997)) and plotted using the program GOLD (G. R. Abecasis, W. O. Cookson, Bioinformatics 16, 182 (2000)).

5 To define the smaller haplotype blocks within the 4-gamete region, the HapMap data website was used (<http://www.hapmap.org>). Genotypes for SNPs in the region between SNPs rs10494744 and rs10484502 were downloaded. Genotypes for the CEU population (CEPH Utah population of northern and western European ancestry) were downloaded and visualized using Haploview version 3.0. Haplotype blocks were then
10 defined using the method and parameters of Gabriel et al (S. B. Gabriel et al., Science 296, 2225 (2002)).

Haplotypes across the narrower region defined by the HapMap block were also inferred using PHASE version 2.1. Haplotypes with an estimated frequency of at least 1% were considered for further analysis. Phylogenetic trees were built using the maximum
15 parsimony of PHYLIP 3.62 ("dnaphars" program). The odds ratio in a nested clastic framework was calculated for the haplotypes (P. Armitage, G. Berry, Statistical Methods in Medical Research (Blackwell Scientific Publications, Oxford, ed. Second, 1987); A. R. Templeton, E. Boerwinkle, C. F. Sing, Genetics 117, 343 (1987)).

Odds ratios, confidence intervals, and population attributable risk were calculated
20 as described in P. Armitage, G. Berry, Statistical Methods in Medical Research (Blackwell Scientific Publications, Oxford, ed. Second, 1987). The population frequency of the alleles of interest (see Example 4 below) is relatively high, 23% for and 41% for homozygous rs380390 and rs1329428, respectively. Therefore, the odds ratios necessarily calculated from the case control design study used here will over-estimate (without changing the
25 significance levels) the equivalent relative risk estimate needed to calculate lifetime risk. A prospective cohort study design will provide valid estimates of lifetime risk in persons who have and have not inherited the alleles.

EXAMPLE 4: Polymorphisms in the Complement Factor H gene are associated with AMD

Of the autosomal SNPs, only two, rs380390 and rs10272438, are significantly associated with disease status (Bonferroni corrected $p=0.0043$ and $p=0.0080$, respectively; Figure 1A). One criticism of case-control association studies such as this one is that population stratification can result in false positive results. If the cases and controls are drawn from populations of different ancestry, with different allele frequencies, it is possible to detect these population differences instead of loci associated with the disease. All individuals in this study self-identify their ethnicity as non-Hispanic white and all of the case and control individuals are drawn from the same AREDs population. There was some differential recruiting of cases from office practices and recruiting of controls from radio and newspaper advertising (AREDS Research Group, Ophthalmology 107, 2224 (2000)). Finding two SNPs out of >100,000 implied no genetic stratification, but genomic control methods were used to control for this possibility (B. Devlin, S. A. Bacanu, K. Roeder, Nat Genet 36, 1129 (2004)). It was consistently found that the significance of the tests was not inflated and that, therefore, these two SNPs are significantly associated with disease.

SNP rs380390 was successfully genotyped in all individuals. In 21 individuals, no genotype was determined for SNP rs10272438, and it appears to be excessively out of Hardy-Weinberg equilibrium ($HWE\chi^2=36$), indicating possible genotyping errors. Missing genotypes were determined by resequencing. After including these additional genotypes, the association was no longer significant after Bonferroni correction. Furthermore, the SNP with the third lowest p -value, rs1329428 (Bonferroni corrected $p=0.14$), is located 1.8 kb away from rs380390 on the same chromosome. The genotype frequencies at these two neighboring loci clearly vary between the case and control populations (Figure 1B). Homozygotes for the C allele of rs380390 and the C allele at rs1329248 clearly have an increased risk of developing AMD (Table 1). The risk conferred by these genotypes accounts for approximately 45% (rs380390) to 61% (rs1329248) of the cases observed in the population (Table 3). Therefore, we decided to focus on these two SNPs as marking our most promising locus.

Table 3. Risk ratios and population attributable risks for various genotypes and haplotypes.

	rs380390 (C/G)	rs1329428 (C/T)
Risk allele	C	C
Allelic Association χ^2 nominal p-value	4.1e-08	1.4e-06
Odds ratio (dominant) (95% CI)	4.6 (2.0-11)	4.7 (1.0-22)
PAR (95% CI)	70% (42%-84%)	80% (0%-96%)
Frequency in HapMap CEU	0.70	0.82
Odds ratio (recessive) (95% CI)	7.4 (2.9-19)	6.2 (2.9-13)
PAR (95% CI)	46% (31%-57%)	61% (43%-73%)
Frequency in HapMap CEU	0.23	0.41

Dominant and recessive refer to the risk factor consisting of having at least one copy (dominant) or two copies (recessive) of the risk allele. PAR is the population attributable risk. The dominant odds ratio and PAR compare likelihood of AMD in individuals with one copy of the risk allele versus individuals with no copy of the risk allele. The recessive odds ratio and PAR compare likelihood of AMD in individuals with two copies of the risk allele versus individuals with no more than one copy of the risk allele. The population frequencies for the risk genotypes are taken from the CEU HapMap population (CEPH collection of Utah residents of northern and western European ancestry).

rs380390 and rs1329428 lie in an intron of the gene for complement factor H (CFH). As both of these SNPs are noncoding and neither appears to alter a conserved sequence, these two SNPs may be in linkage disequilibrium with a corresponding functional mutation. To circumscribe the region in which the functional mutation may lie, the linkage disequilibrium throughout this region was analyzed (Figure 2A). The two associated SNPs lie in a region of high linkage disequilibrium that is around 500 kb long. As this region is longer than other typically observed blocks of high linkage disequilibrium (S. B Gabriel et al., Science 296, 2225 (2002)) and there are long stretches in this region where there are no SNPs in our dataset (Figure 2B), other data sources with denser SNP coverage were used to narrow down the region.

Data from the International HapMap project was used to analyze patterns of linkage disequilibrium in a population of residents of Utah with ancestry from northern and western Europe (the CEPH sample) (The International HapMap Consortium, Nature 426, 789 (2003)). In the 500 kb region of interest, there are 152 SNPs in the HapMap data set. Using a standard definition of linkage disequilibrium blocks (S. B Gabriel et al., Science

296, 2225 (2002)), it was found that the two associated SNPs lie in a block that is 41 kb long and entirely contained within the CFH gene (Figure 2C).

There are six SNPs from the present study's data set in this 41 kb region. These SNPs form four predominant haplotypes with a frequency greater than 1% (Table 4).

- 5 Combined, these four haplotypes represent 99% of the chromosomes in this study. Reconstructing inferred haplotypes and building a phylogenetic tree allowed assessment of the evolutionary relationship between haplotypes (Figure 2D). Using inferred haplotypes for each individual, the odds ratio of disease in a nested clastic framework under both dominant and recessive models were computed (A. R. Templeton, E. Boerwinkle, C. F. Sing, Genetics 117, 343 (1987)). The highest risk is conferred by haplotype N1, which is the only haplotype containing the risk allele at SNP rs380390.

Table 4. Haplotypes in the haplotype block that harbors the putative disease variant.

Name	rs2019727	rs10489456	rs3753396	rs380390	rs2284664	rs1329428	Frequency
N1	A	C	T	C	C	G	0.59
N1	A	C	T	G	C	G	0.0068
N3	A	C	T	G	T	A	0.12
N4	A	T	C	G	C	G	0.15
N5	T	C	T	G	C	A	0.12
N6	T	C	T	G	C	G	0.0071

- 15 Haplotype frequencies are estimated using the program PHASE (M. Stephens, P. Donnelly, Am J Hum Genet 73, 1162 (2003); M. Stephens, N. J. Smith, P. Donnelly, Am J Hum Genet 68, 978 (2001)). The SNPs used to construct the haplotypes are the SNPs from the mapping microarrays found in the 41 kb haplotype block defined by the HapMap data. Frequencies are the estimated frequency of each haplotype in the combined case and control population. The two SNPs that show association in the initial analysis are indicated in boldface.

- 20 Having at least one copy of this haplotype increases the risk for AMD 4.6-fold (95% CI 2.0-11). Having two copies of this haplotype increases the risk for AMD 7.4-fold (95% CI 3.0-19). Therefore, functionally relevant mutation should be found in the context of haplotype N1. This mutation will occur somewhere in the CFH gene, as the 41 kb haplotype block is entirely within CFH.

EXAMPLE 5: Resequencing confirms that variations in CFH are correlated with AMD

To identify the functional mutation underlying susceptibility to AMD, 96 individuals (66 cases and 30 controls) were chosen for exonic resequencing, including the exon/intron junctions. Most of these individuals were selected either because SNP rs380390 was homozygous (representing opposite risk groups) or SNP rs10272438 was not successfully genotyped (the same plates were used to re-sequence this SNP for genotyping). Three additional individuals were randomly selected to get a total of 96 for a full plate. Primer design, PCR amplification, bi-directional sequencing of PCR products, and mutation analyses were performed by Genaissance (New Haven, CT).

All CFH exons were sequenced, including those outside of the 41kb block, as well as the region of SNP rs380390 as a control. Priority was given to sequencing homozygotes at SNP rs380390 to make it easier to determine haplotypes. SNP rs380390 was successfully resequenced in 93 individuals; the genotype derived from resequencing matched the original genotype in all cases. A total of 50 polymorphisms were identified; 17 of these have a minor allele frequency of at least 5% (Table 5). Of these 17, three represent non-synonymous mutations. If these SNPs are ranked based on the allelic association χ^2 measure, SNP rs1061170 is the most associated among the non-synonymous SNPs. This SNP represents a mutation between tyrosine and histidine. This SNP is located in exon 9 of CFH, only 2 kb upstream of the 41 kb haplotype block. Adding this SNP to the haplotype analysis reveals that 97% of the chromosomes with the highest-risk haplotype (N1) also have the risk allele (His).

Table 5. New polymorphisms identified through resequencing.

Region	Position	Change	Type	MAF	AA Change	rs Number
promoter	120992	A/G	noncoding	0.005263		
promoter	120865	A/G	noncoding	0.010526		
promoter	120546	C/T	noncoding	0.242105		rs3753394
promoter	120410	T/C	noncoding	0.005263		
promoter	120294	A/G	noncoding	0.005263		
intron 1	99391	C/T	noncoding	0.117021		rs511397
exon 2	99242	T/G	nonsynonymous	0.005319	Ser 58 Ala	
exon 2	99230	G/A	nonsynonymous	0.117021	Val 62 Ile	rs800292
intron 2	99114	G/A	noncoding	0.005319		
intron 3	98283	T/C	noncoding	0.005263		

intron 3	98188	T/G	noncoding	0.005263		
exon 4	96315	G/A	nonsynonymous	0.005263	Arg 127 His	
exon 7	87139	A/C	synonymous	0.415789		rs1061147
intron 7	83059	T/C	noncoding	0.005263		
intron 7	82966	G/T	noncoding	0.410526		rs482934
intron 7	82957	A/G	noncoding	0.005263		
exon 9	82232	C/A	nonsynonymous	0.005208	Gln 400 Lys	
exon 9	82226	C/T	nonsynonymous	0.414894	His 402 Tyr	rs1061170
intron 9	58652	T/C	noncoding	0.005319		
exon 10	58516	G/A	synonymous	0.22043		rs2274700
intron 10	58319	A/G	noncoding	0.005319		rs203678
intron 10	58260	C/G	noncoding	0.005319		
intron 10	56838	G/T	noncoding	0.367021		rs203674
exon 12	47084	G/A	nonsynonymous	0.005263	Val 609 Ile	
intron 12	46992	T/G	noncoding	0.005208		
exon 13	45721	A/G	synonymous	0.143617		rs3753396
exon 15	43875	A/G	synonymous	0.005376		
intron 15	40549	A/G	noncoding	0.215054		rs7514261
intron 15	40445	C/T	noncoding	0.021277		
intron 15	40412	G/C	noncoding	0.365591		rs380390
intron 15	40335	G/C	noncoding	0.005319		rs380060
intron 15	40179	C/T	noncoding	0.215054		rs7540032
intron 15	35577	T/G	noncoding	0.005208		rs435628
intron 15	35537	C/A	noncoding	0.357895		rs375046
intron 16	35263	C/T	noncoding	0.005263		rs428060
exon 17	34821	C/T	synonymous	0.026316		
exon 17	34786	G/T	nonsynonymous	0.005263	Ser 890 Ile	rs515299
intron 17	31825	A/C	noncoding	0.005319		
exon 18	31689	G/T	nonsynonymous	0.154255	Glu 936 Asp	rs1065489
intron 18	30673	T/G	noncoding	0.005556		rs385892
intron 18	30547	T/C	noncoding	0.111702		rs16840522
intron 18	30546	A/G	noncoding	0.005319		rs385543
exon 19	30396	G/T	nonsynonymous	0.005319	Val 1007 Leu	rs534399
intron 19	28886	T/C	noncoding	0.154255		rs513699
exon 20	28877	C/T	synonymous	0.154255		rs513729
exon 20	28867	A/T	nonsynonymous	0.015957	Asn 1050 Tyr	
intron 20	28592	A/G	noncoding	0.012987		

intron 20	26589	G/C	noncoding	0.005618		
exon 22	25219	C/A	nonsynonymous	0.005556	Pro 1166 Gln	
exon 22	25088	C/T	nonsynonymous	0.005618	Arg 1210 Cys	

Location of each polymorphism refers to the position on GenBank accession AL049744.8 (SEQ ID NO: 9), or the complementary DNA strand of GenBank accession AL049744.8. MAF is minor allele frequency.

Other data support the finding that mutations in CFH are correlated with AMD.

The gene for CFH is located on chromosome 1q31, a region that had been previously identified by six independent linkage scans to be involved in AMD (J. Majewski et al., Am J Hum Genet 73, 540 (2003); J. M. Seddon, S. L. Santangelo, K. Book, S. Chong, J. Cote, Am J Hum Genet 73, 780 (2003); D. E. Weeks et al., Am J Hum Genet 75, 174 (2004); G. R. Abecasis et al., Am J Hum Genet 74, 482 (2004); S. K. Iyengar et al., Am J Hum Genet 74, 20 (2004); and D. W. Schultz et al., Hum Mol Genet 12, 3315 (2003)). In one of these linkage studies, using a single large pedigree the authors concluded that mutations in a different gene in this region (HEMICENTIN-1), was responsible for AMD (D. W. Schultz et al., Hum Mol Genet 12, 3315 (2003)). This conclusion was based on the observation that of all the polymorphisms tested, only the HEMICENTIN-1 mutation perfectly cosegregated with disease status. Mutations in HEMICENTIN-1, however, have not been found to be generally associated with AMD in three separate, independent population-based association studies (G. R. Abecasis et al., Am J Hum Genet 74, 482 (2004); M. Hayashi et al., Ophthalmic Genet 25, 111 (2004); and G. J. McKay et al., Mol Vis 10, 682 (2004)). Mutations in CFH, as disclosed herein, are therefore more likely to be the cause of linkage signals observed at chromosome 1q31.

Example 6: Immunolocalization of C5b-9 complex in the eyes of patients suffering from AMD

Various components of the complement cascade, including the terminal C5b-9 complex, have been identified as components of drusen in the eyes of patients with AMD (L. V. Johnson, W. P. Leitner, M. K. Staples, D. H. Anderson, Exp Eye Res 73, 887 (2001); R. F. Mullins, S. R. Russell, D. H. Anderson, G. S. Hageman, FASEB J 14, 835 (2000)). The eyes of four patients with AMD were examined to look for the presence of C5b-9 (Figure 4). Post-mortem retinas from four donors were examined. Three were obtained through the Foundation Fighting Blindness (FFB) eye donor program. All of these had a clinical diagnosis of dry AMD. One pair of eyes embedded in paraffin was

obtained from an 86 year old Caucasian female through the autopsy service of the Yale School of Medicine. No clinical history was available. Histologically, these retinas have multiple large or coalescing drusen with minimal RPE and photoreceptor loss consistent with a diagnosis of early AMD. Approval for research on human post mortem donor eyes
5 was obtained from the Yale School of Medicine.

Upon enucleation, eyes were fixed in 4% paraformaldehyde, 0.5% glutaraldehyde in 0.1 M phosphate buffer for several days. The fixed eyes were transferred to 2% paraformaldehyde for storage. Six 0.5 cm circular punches were taken from each of the AMD donor eyes. Three of these were selected from the central retina at the junction of
10 atrophic and more normal retina, and the remaining three from peripheral retina. Retinal plugs were embedded in paraffin and sections cut at 5 μ m.

Following deparaffinization and rehydration, antigen retrieval was performed by boiling sections in a microwave oven for 10 minutes in 10 mM sodium citrate (pH 6.0). Sections were allowed to cool for 20 minutes, prior to a 5-minute endogenous peroxidase
15 block in 5% H₂O₂. Immunohistochemistry was performed using a mouse monoclonal antibody against human activated complement C5b-9 (Quidel Corporation, San Diego, CA, catalogue #A239). Primary antibody was applied at a concentration of 1:250 in 1X PBS. Biotinylated goat anti-mouse (cat # BA9200) secondary antibody (Vector, Burlingame, CA) was used at a concentration of 1:200. Nickel enhanced diaminobenzidine (DAB; cat
20 # SK4100; Vector) was used to visualize bound antibody. Negative controls were obtained by omission of the primary antibody. Images were obtained with a Zeiss Axioplan microscope equipped with differential interference contrast lenses and a Zeiss Axiocam digital camera.

Immunofluorescence Microscopy for CFH

25 Donor eyes were embedded in optimal cutting temperature compound (OCT; Miles Laboratory, Elkhart, IN), snap frozen, and stored at -70°C. Frozen retina sections were cut at 8 to 10 μ m and placed on slides (Superfrost/Plus; Fisher Scientific, Fair Lawn, NJ). All human eyes were obtained with the informed consent of the donors, and the research with
30 human eyes was performed in accordance with the tenets of the Declaration of Helsinki and the Institutional Review Board (IRB).

For immunofluorescence labeling, frozen sections of human retina were fixed in 4% paraformaldehyde in phosphate buffer saline (PBS) for 10 minutes. The tissue sections were blocked for 30 minutes with 5% normal donkey serum (Jackson ImmunoResearch, West Grove, PA), diluted in IC buffer (PBS, containing 0.2% Tween-20, 0.1% sodium azide), and incubated for 1 hour at room temperature with a goat anti-human Factor H antibody (Quidel, Santa Clara, CA) diluted 1:200 in staining buffer (IC buffer plus 1% normal donkey serum). Sections were washed repeatedly in IC buffer and incubated for 1 hour with the nuclear dye 4',6'-diamino-2 phenylindole (DAPI; 1 µg/mL) and Alexa-488 Donkey anti-goat antibodies (Molecular Probes, Eugene, OR) diluted 1:250 in staining buffer. After repeated washing with IC buffer, sections were covered in mounting medium (Gel Mount; Biomedex, Foster City, CA) and coverslipped. For the control, the same concentration of anti-human factor H antibody was preincubated for 1 hour with purified human factor H protein (Calbiochem, La Jolla, CA) at the ratio of 3 µg for 1 µl of antibodies. The pretreated antibodies were then used to stain tissue sections as just described. Specimens were analyzed on a laser scanning confocal microscope (model SP2; Leica Microsystems, Exton, PA) equipped with Nomarski optics. Immunolabeled and negative control sections were imaged under identical scanning conditions. Images were processed with Photoshop (Adobe Systems, San Jose, CA).

In all patients, deposition of activated complement C5b-9 was noted in Bruch's membrane. Immunostaining frequently extended to include the intercapillary pillars, and was strongly present within drusen. Staining was rarely noted in the stroma vascularis. However, when it was present, it was invariably located in the inner (toward the retina) walls of choroidal veins, and in severe cases, arteries. No immunostaining for C5b-9 was noted in the retina or elsewhere in sections. The negative control failed to exhibit any staining. These and other biochemical analyses of the composition of drusen may indicate that AMD results from an aberrant inflammatory process in which inappropriate complement activation plays a role (G. S. Hageman et al., *Prog Retin Eye Res* 20, 705 (2001)). This is supported by a mouse model of AMD in which complement components are found in the drusen (J. Ambati et al., *Nat Med* 9, 1390 (2003)).

Moreover, both age and smoking, two significant risk factors for AMD, influence plasma levels of complement factor H (J. Esparza-Gordillo et al., *Immunogenetics* 56, 77 (2004)). CFH sequences have also been observed in an EST library derived from human

RPE and choroid (G. Wistow et al., *Mol Vis* 8, 205 (2002)). Immunofluorescence experiments confirm that CFH is present in this region of the eye (Figure 3). The fluorescent images and their corresponding DIC images obtained from two different areas of human retina sections show strong staining in choroid vessels and area close to RPE (likely to be underneath the Bruch's membrane) (Figure 3). This finding is consistent with the observation that the RPE and choroid produce mRNA for several complement components found in drusen (R. F. Mullins, S. R. Russell, D. H. Anderson, G. S. Hageman, *FASEB J* 14, 835 (2000)). Drusen of similar composition to that found in AMD are found in the eyes of patients with membranoproliferative glomerulonephritis type II (MPGNII), a kidney disease (R. F. Mullins, N. Aptsiauri, G. S. Hageman, *Eye* 15, 390 (2001)); factor H deficiency can cause MPGNII (S. R. D Cordoba, J. Esparza-Gordillo, E. G. d. Jorge, M. Lopez-Trascasa, P. Sanchez-Corral, *Mol Immunol* 41, 355 (2004)). Our immunostaining experiments (Figures 3 and 4) suggest a pathogenesis of AMD in which loss, impairment, or deficiency of factor H results in complement deposition in choroidal capillaries (more severe) and choroidal vessels (less severe) with subsequent leakage of plasma proteins in to Bruch's membrane. Finally, nutritional supplementation with zinc at 80 mg/day decreases the risk of AMD; biochemical studies have shown that factor H function is sensitive to zinc concentration (AREDS Research Group, *Arch Ophthalmol* 119, 1417, (2001); A. M. Blom, L. Kask, B. Ramesh, A. Hillarp, *Arch Biochem Biophys* 418, 108 (2003)).

The present invention provides among other things polynucleotides useful for identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD. While specific embodiments of the subject invention have been discussed, the above specification is illustrative and not restrictive. Many variations of the invention will become apparent to those skilled in the art upon review of this specification. The full scope of the invention should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.

All publications and patents mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.

Also incorporated by reference in their entirety are any polynucleotide and polypeptide sequences which reference an accession number correlating to an entry in a public database, such as those maintained by The Institute for Genomic Research (TIGR) (www.tigr.org) and/or the National Center for Biotechnology Information (NCBI) (www.ncbi.nlm.nih.gov).

5

Table 6. Primer sequences used in resequencing.

Region	Forward primer sequence	Reverse primer sequence
promoter	AGAATCGTGGTCTCTGTGTGTGG	AGCAGCTGGTGATATCCTCTGG
promoter	TCAAATGAGAGTGAGCCAGTTGC	CTGTCACAACGTCAGTTCTCC
exon 1	GTGGGAGTGCAGTGAGAATTGG	AACTCAACAATGTCAAAAGCC
exon 2	GATAGACCTGTGACTGTCTAGGC	GGCAATAGTGATATAATTCAAGGC
exon 3	ACCTCAGCCTCCCAAAGTGC	TGCATACTGTTTTCCCACTCTCC
exon 4	AAGCAGGAGGAGAAGGAGGAAGG	CAGGCTGCATTCGTTTTTGG
exon 5	CCACTCCCATAGAAAAGAATCAGG	ACTTCTTTGCCACCAGTCTCTTCC
exon 6	GATAAATCATTTATTAAGCGG	GAACCTTGAACACAGAAAATGC
exon 7	GGATGACTTTGGAGAAGAAGG	TATGAGTTTCGGCAACTTCG
exon 8	TCATCTTCATTAACAAAGACC	AGATCTATTTTGGTCACTTTGC
exon 9	CTTTGTTAGTAACTTTAGTTCC	TTATACACAGTTGAAAAACC
exon 10	GGCAACTCTGAGCTTATTTTCC	AGAGTAGGAAAAGCCTGAATGG
exon 11	CATAGATTATTTTGTACGG	CAAAACTCCCTTCTTTCCC
exon 12	ATCTGATGCCCTCTGTATGACC	ATTCACTACTCAATACATGTCC
exon 13	CACCATTCTTGATTGTTTAGG	GAATCTCCATAGTAATAAGG
exon 14	CAATGTGTTGATGGAGAGTGG	ATTGAATTATAAGCAATATGC
exon 15	CATTCAGCGACAGAATACAGG	GTGTGTGTGTGTGTGTGTGC
intron 15	AAGGCAGGAAAGTGTCTTATGC	GTCAAATTACTGAAAATCACC
exon 16	AACTGTTACACAGCTGAAAAG	GTGGTGATTGATTAATGTGC
exon 17	GGTGGAGGAATATATCTTTGC	ATAGAATAGATTCAATCATGC
exon 18	CGATAGACAGACAGACACCAGAAGG	CAGCTATAATTTCCACAGCAGTCC
exon 19	GTGTAATCTCAATTGCTACGGCTACC	CAAGTAGCTGGGACTTCAGATGC
exon 20	TAGTTTCATGTCTTTTCCTC	GAATTTTAAGCACCATCAGTC
exon 21	CCAGGACTCATTCTTTTACC	CTTTCTGACAGAAATATTTGG
exon 22	TGATGTTTCTACATAGTTGG	GGAGTAAAACAATACATAAAAAATG

Table 7. Variations in CFH identified through resequencing that may be correlated with the occurrence of AMD. Each variation is shown in the context of its surrounding DNA sequence. Location of each variation refers to the position on GenBank accession AL049744.8, or the complementary DNA strand of GenBank Accession AL049744.8.

Region	Position	Common/Variant	Common/Rare	Rare/Rare	\log_{10} HW P-value	Change	Sequence Context
promoter	128992	94	1	0	0	A/G	GTACTGGGTTTCTGGGATGAAT [A/G] AIGTTCAGTGTGACCTTGGTG3
promoter	128665	94	0	1	-2.2764618	A/G	ACAAAGTCTTAAATAATCAGCATTTG [A/G] AITTTGTTGATTTTGGATATATAAA
promoter	128546	57	30	8	-0.7719879	C/T	AGGGTTTATGAATAATCCAGAGGATAT [C/T] ACCAGCTGCTGATTTGCACATATCA
promoter	128410	94	1	0	0	T/C	AGATKACATGAGAAATGGGTTTAAC [T/C] TCTGGCATTTCTGGCTTGGCTT
promoter	128294	94	1	0	0	A/G	TTTTCAGCAAGTCTTTCTCTGCACT [A/G] ATCCAAATCTTGGAGAGAGAAC
intron 1	99391	72	22	0	0.4512837	C/T	TAAATATACGTGACATTTAAATAGA [C/T] ACTTATKACATATTTGTTTAA
exon 2	99242	93	1	0	0	T/G Ser 38 Ala	CTATAAATGCCGCCCTCGATATAGA [T/G Ser 38 Ala] CTCCTGGAAATGTAATATGGTATG
exon 2	99230	72	22	0	0.4512837	G/A Val 62 Ile	CCCTGGATATAGATCTCTGGAAAT [G/A Val 62 Ile] TAATAATGGTATGCAAGAGGAGAA
intron 2	99114	93	1	0	0	C/A	GAAACTAGGCTGTAATAAATACTTAA [G/A] ATTAAATATGTAGCAATTATGCTT
intron 2	98485	75	20	0	0.2285278	-T/T/Q	CATACAAATGCATACTTTT [T/T/Q] CGTTTGAAGAAAGGCCCTGTGGACAT
intron 3	98283	94	1	0	0	T/C	ATATATTTTAAAGGTTATATATTT [T/C] TCTATGAGCATTTAAATAAGTAATA
intron 3	98188	94	1	0	0	T/G	GGATACCATATATCTCTTAACAT [T/G] GAAAATTTAAATGAGATATAACTT
exon 4	96315	94	1	0	0	G/A Arg 127 His	CAATCTCTAGGTGAGATTAATATACC [G/A Arg 127 His] TGAATGTGCACAGATGATGCACT
intron 4	96211	94	1	0	0	-T/T/Q	AAATAATATCTAAGATTTAAATAAA [T/T/Q] GTCTTACATTTAAATAATCTTAAAGT
exon 7	87139	46	19	30	-7.9849797	A/C (C) Ala 307 Ala	ATCTTCAACCCGGGGAATAATACAC [A/C (C) Ala 307 Ala] AAATCCACAAGTACTGCTGTGATAC
intron 7	83071	94	1	0	0	-A/TGAGATATAGAA/Q	AGACCTCTCTGTACATATCTCAGT [A/TGAGATATAGAA/Q] CATCTGAGTCTCTATCATTTGTTTGG
intron 7	83059	94	1	0	0	T/C	TTACATATCTCAGTCACTGAGTTC [T/C] ATCAATTTGTTTGAACCTAGAAACCC
intron 7	82966	48	16	31	-10.039855	C/T	TGATAAATAATTTATCTCTAATATAGA [C/T] TGTATTATACAGTAAATTTCTTTA
intron 7	82957	94	1	0	0	A/G	TTTATCTCTAATATGAGTGTATT [A/G] CAGTAAATTTCTTTATACTTTT
exon 9	82332	95	1	0	0	C/A Gln 409 Lys	TCTTTATTTGGAATAATGATATAAT [C/A Gln 409 Lys] AAAATCATGGGAAGAAAGTTTGTACA
exon 9	82226	46	18	30	-8.6058781	C/T His 402 Tyr	TTTGGAAAATGGATATAAATCAAAAAT [C/T His 402 Tyr] ATGGAGAAGAAAGTTTGTACAGGTAA
intron 9	58652	93	1	0	0	T/C	TATATTACATATTTACTTAAATTTCT [T/C] ATAAATTTGTTATTTGATCATATGCTT
exon 10	58516	59	27	7	-0.8677698	G/A Ala 473 Ala	ATACATATGCTTAAAGAAAAGAG [G/A Ala 473 Ala] AAATAATCAATTCAAACTAGATATG
intron 10	58319	93	1	0	0	A/G	TGGGGCTGATATTAATTTCAATTGGA [A/G] AAGATAAGAAAATAAAACCTTCCAGG
intron 10	58260	93	1	0	0	C/G	AGACATCAATTTTCTTCTTTTCA [C/G] ATTAATTTACTCAGATATATAGTCTGT
intron 10	56838	54	11	29	-13.687209	G/T	TTTGTACGGTACCTATTTATTATAGA [G/T] ATCTAAATCAATAAAGCTTTTCTTTC
exon 12	47084	94	1	0	0	G/A Val 609 Ile	ATTACAAATAGTTGGACCTAATTC [G/A Val 609 Ile] TTCAGTCTTACCCTTGGATTGTC
intron 12	46992	95	1	0	0	T/G	ATTGCTGAATTAAGAAATTAGAATCT [T/G] GAATACCACTTTTCTTCTATTAAT
exon 13	45721	71	19	4	-1.0457792	A/G Gln 672 Gln	TAAATGAAGGACCTTAATAAATTTCA [A/G Gln 672 Gln] TGTGTTGATGGAGATGGCAACTT

exon 15	43875	92	1	0	0	A/G Gly 783 Gly	CTAACATAAGGTACAGATGTAGAGG [A/G Gly 783 Gly] AAAGAAGGATGATACACACATCTT
intron 15	40549	60	26	7	-0.9218916	C/A	AATCTAGAAATTATCTCTCCAGATT [G/A] TTCTCTTCAGAAATTTTGAGTATAT
intron 15	40445	90	4	0	0	C/T	CTCTGGAAATTCATTATATGATA [C/T] GATTCACTTTTCATGCGCTTTTTC
intron 15	40412	54	10	29	-13.609694	G/C	TTTCATTCGCTTTTTCATCACTT [C/C] GTCATATAACTTTTGATAATTGGATT
intron 15	40335	93	1	0	0	G/C	TCATTAAACTTATTTGATTTCCCTT [G/C] AGATTCTGGGTGTGGCTTTCTAT
intron 15	40179	60	26	7	-0.9218916	C/T	CCACATGGTAGTANTTCATCTGGAT [C/T] TTAAGCTATCTTCACCTTTTATTTAT
intron 15	35577	95	1	0	0	T/G	CAATZAAATTTATTTTCATCAAAA [T/G] ICTAATTTTAAATTTTATTTT
intron 15	35537	55	12	28	-12.224741	C/A	TTTATTTTATTTTATTTATATAA [C/A] ATTAATTTATTTTAAATAATTTT
intron 16	35263	94	1	0	0	C/T	AKGAGTTATATCTCTCTTGCTT [C/T] GTGTAACAAGAGAGAGCTCTTC
exon 17	34821	90	5	0	0	C/T His 878 His	GTTCACAACCCTCAGATAGAACAA [C/T His 878 His] GGAACCAATTAATTCATCCAGGTCTT
exon 17	34786	94	1	0	0	G/T Ser 890 Ile	AATTCATCCAGGCTTCACAAAGAAA [G/T Ser 890 Ile] TTAATGCACATGGGACTAAATTCAGGT
intron 17	31825	93	1	0	0	A/C	ATTGTTGTTACTCTCTGTGATGTC [A/C] TAGTAGCTCTGTATGTTTATTTT
exon 18	31689	70	19	5	-1.4115003	C/T Gln 936 Asp	GGCTTCCTTGTAATCTCCACCTGA [G/T Gln 936 Asp] ATTCTCATGGTGTGTAGCTCAACA
intron 18	30573	89	1	0	0	T/G	GGTACGGCTACCAATATTTCTTCAG [T/G] CTCTTAATATCATTTCTTAICTHIA
intron 18	30547	78	11	5	-2.9065654	T/C	TGTTGTACAGTATTCATGATTTCTA [T/C] ATATGCTATTTTAGAATCCATTAC
intron 18	30546	93	1	0	0	A/G	TTTGTACAGTATTCATGATTTCTAT [A/G] TATCGCTATTTTAGAATCCATTACA
exon 19	30396	93	1	0	0	G/T Val 1007 Leu	CAIACCCATGGGAGAGAGAGAAAGGAT [G/T Val 1007 Leu] TGTATAAGGCGGGTGGAGCAAGTGAC
intron 19	28886	65	29	0	0.9350138	T/C	GGTGGAAACCCTCTTTTCTTCTA [T/C] TCAGACACCTCTGTGTGGAATCGGC
exon 20	28877	65	29	0	0.9350138	C/T Thr 1046 Thr	ACTCTCTTTTCTTATTCAGACAC [C/T Thr 1046 Thr] TCCGTGTGGAATCGGCCCCACAGTAC
exon 20	28867	91	3	0	0	A/T Asn 1050 Tyr	TTTCTATTCAGACACCTCTCTGTGTG [A/T Asn 1050 Tyr] ATCCGCCACAGTACAAAAATGCTTA
intron 20	28592	75	2	0	0	A/G	AAATAGATTTTTCAAATGCCAAATAAA [A/G] TGACTGATGGTCTTAAAAATTCANT
intron 20	26589	88	1	0	0	G/C	TGATATTATATACAGTCTGTGTTT [G/C] CGTTTGGCTTATTTGAACTTGTTATT
exon 22	25219	89	1	0	0	C/A Pro 1166 Gln	GGTTACTGTTTTTATTTTTCAGATC [C/A Pro 1166 Gln] GGGTGAATATCCCGAGAAATTATG
exon 22	25088	88	1	0	0	C/T Arg 1210 Cys	TAAACGGGATATCGTCTTTCATCA [C/T Arg 1210 Cys] GTTCTCACACATTGCGAACCAACATG

Table 8. Variations in CFHL1 that may be correlated with the occurrence of AMD. Each variation is shown in the context of its surrounding DNA sequence. Location of each variation refers to the position on GenBank Accession AL049741.7, or the complementary DNA strand of GenBank Accession AL049741.7.

Region	Position	Common/Uncommon	Common/Uncommon	Star/Star	Log HW P-value	Change	Sequence Context
promoter	24624	49	9	22	-10.77769145	A/G	AAATAACCAATCTCAAGTCCCATC [A/G] GAACAAATATTTTGAAGTAAAT
promoter	24638	57	24	2	0	C/G	ACCCATCTCAAGTCCCATCAGAA [C/G] AAAATATTTTGAAGTAAATTTGT
promoter	24650	50	9	24	-11.71118554	T/C	AAAGTCCCAICAGAAACAAATATTT [C/T] TGAAGTAAATTTTGTCAACAAATT
promoter	24687	49	8	22	-11.37724888	T/G	AACAAATATTTTGAAGTAAATTT [T/G] GTTCACAAATTTTGGGAACCATTAC
promoter	24558	74	2	0	0	G/T	ACATACCAAAAATATTTCTTGATTT [G/T] ACTTTTATAGTCTAAAATAAGAA
promoter	24543	49	6	20	-11.82719892	-C/T	TCCTGATTTGACCTTTTATAGTCTA [-C/T] AAAATATGAAACATTTAAAGAAGTT
promoter	24482	68	19	5	-1.372873106	C/T	TTTTTTTTTTTTTTTTTTTGAGA [C/T] GGAGTCTGGCTGTCACCTTGGCT
promoter	24445	74	19	0	0.229044145	G/A	CTGTCACTCTGGCTGGAGGGAGTG [G/A] TGGGATCTCAGCTCAGTGGGAACTC
promoter	24426	68	20	5	-1.259964884	C/T	GGAGTGTGGGATCTCAGCTCAGTG [C/T] GAACCTCTCCCTCCGAGTTCAGGCC
promoter	24412	74	19	0	0.229044145	C/T	TCAGCTCAGCTGGGAACTCAGCTCC [C/T] GAGTTCACGCCATCTCTCTGCCCTCA
promoter	24404	74	12	1	-0.363372133	C/T	CTGGGAACCTCCCTCCGAGTCTCA [C/T] GCCATCTCTCTGCTCAGCTCCCA
promoter	24303	80	14	0	0	T/G	TTTCAGTAGAGATGGGGTTTCACCA [T/G] GTTAGCCAGGATGGTCTGAAGTTAC
promoter	24182	74	19	1	0	C/T	CTGAATCAGCTCAGCTCTGCTCTA [C/T] TGATGTAGCTGAACTCTGGCTAGA
promoter	24141	92	1	0	0	C/T	CTTGGCTAGAAAGAGAGGGGCTT [C/T] CTCTTCTCTCTCAAGTGGCCATTT
exon 1	23873	93	1	0	0	C/G	TCATGCTATAAGCTGTTAATGAAG [C/G] AGATTCAAAGCAACACCAACAC
exon 1	23857	93	1	0	0	C/A	TAATGAAGCAGATTCAAAGCAACA [C/A] CACCACCCTGAAAGTATTTTAACT
intron 1	23622	77	12	5	-2.667405836	C/G	ATTTTAAATGAGTTAATAATTAAT [C/G] TATTTTATGGAATATCTTTCTAACA
intron 1	23583	78	13	0	0	A/G	TACTTTTACATGCAATTAAAGAG [A/G] AAATAGAAATAAATTTAGTCTCTCC
intron 1	18334	71	0	20	-20.66326969	-T/T	AGTCATGCTACTCTAGTACTGATG [-T/T] GTTTTCACTCTCTAAATTGACACTG
intron 1	18264	73	6	19	-20.20038135	C/T	GGATTAAAGCTTAAATGAAGAAAAA [C/T] ACTATAAGTGAATGATTAAATAT
intron 2	17916	74	10	7	-4.384231059	G/A	GAATAGAGAAAGGATATGCCAGCAA [G/A] ATCAATAGGCTTGATATCAACAG
intron 2	16939	65	17	8	-2.859665125	C/T	ATCCACTGCTCTAGCTTCCAAAG [C/T] GCAGAGATTACAGAGTGAGCCACT
intron 2	16934	60	11	20	-10.15791403	A/G	CTGGCTCAGCTCTCAAGGGAG [A/G] GATTACAGAGAGAGGCCACTTCACC
intron 2	16837	89	1	0	0	T/G	ACTTCCATCTCTGACATTAATCCGT [T/G] TTGGTCTTAGGACTGTGTTCTT
intron 3	16599	60	11	19	-9.704247488	G/A	TAIGCTGTATCTATTATTAAGTTT [G/A] AGAGAAATAAATCTTTTACAGGT
intron 3	16543	59	11	20	-10.05211275	T/A	AFAGGTTTGGCCACATCTTTATC [T/A] TATTCATTTGATTTTCAGTTCCAA
intron 4	13227	85	5	0	0	T/C	TTGATATTAATAAGTCTGTTT [T/C] GTATTTGCTTATTTGAACTGTAT
exon 5	13128	89	1	0	0	T/C Pro 211 Pro	ATTCACGGGAAATGTGGGCCCTC [T/C Pro 211 Pro] CCACCTATAGACAATGGGACATTA
exon 5	13092	66	17	7	-2.450783559	G/A Pro 223 Pro	ACAAATGGGACATTTCTCATTTCC [G/A Pro 223 Pro] TTGTACGATATGCTCCAGCTTCAT
exon 6	11741	59	11	29	-10.05211275	G/T Arg 302 Arg	AATCACTGGAATTTGTGTGTAAGAG [G/T Arg 302 Arg] GBAATACGCTTTTCATCAAGTTCTC
exon 6	11705	19	11	60	-9.704247488	T/A (9) Arg 314 Arg	TTTCATCAGCTTTCACACATTTGCGTTA [T/A (9) Arg 314 Arg] ACAACAAGTTGGGATGGGAACTGG
exon 6	11593	19	11	60	-9.704247488	A/C	TTAGATTAATAATAGTCTTAAATTT [A/C] ATTTTAAAGTATTTTACTCTCT

Table 9. Variations in CFHL3 that may be correlated with the occurrence of AMD. Each variation is shown in the context of its surrounding DNA sequence. Location of each variation refers to the position on GenBank Accession AL049741.8, or the complementary DNA strand of GenBank Accession AL049741.8.

Region	Position	Common/Commut/Rare	Rare/Rare	Log HW P-value	Change	Sequence Context
promoter	3779	86	2	0	A/G	ATTGTACCAATTGTGGGGGGGG [A/G] AAAAAACCTTGGCCATGCAACAGC
promoter	4364	63	17	-3.220465172	T/G	AAATCCACAGATGATGTGGAACCCAC [T/G] AACTGGAATTATTTGAGCACTTTTGT
promoter	4465	64	17	-3.26153442	A/C	TCAATGGTAGTGCCTTAAATTCAGA [A/C] CCACACTTGGTAACTAAATAAGAAA
promoter	4502	64	17	-3.699998612	C/A	AACTAATAATGAAGATTTCAAACC [C/A] CAAACAGGGGAACCTGAAACTTTGT
exon 1	4607	88	1	0	G/C Gly 18 Ala	ACCTTGGGGTTTCCTGTCTAAATG [G/C Gly 18 Ala] ACAAGTAAAGTTAAAAGAGATCTAA
intron 2	9382	79	2	-1.495387193	T/C	ATGTTATCGGATCTTATTAAATA [T/C] GGTAACTAATAATTTAATATACTTT
intron 4	19710	56	15	-2.955634972	-T/T 0	TCCACATATAAAGTATTTTTT [-T/T 0] CAGATCTTCAGAAAAGTGTGGGC
exon 5	19820	56	14	-4.079180573	C/T Pro 241 Ser	GTCAAGATCGAGTACCAATGCCAG [C/T Pro 241 Ser] CCTACTATGAACTTCAGGGTCTTAA
exon 5	19885	58	14	-3.249405761	A/T Pro 262 Pro	GTAAATGGAGAGTGGTGGGAACCCAG [A/T Pro 262 Pro] AGATGCATACGTAAAGTCTTAAAT
intron 5	19917	58	14	-3.249405761	T/A	ATACGTAAAGTCTTAAATTTCTAGA [T/A] CTGAGAAAATCAGAGTAATAAGTT
intron 5	19928	79	1	0	T/C	CTTAAATTTCTAGATCTCTGAGAAA [T/C] CAGAGTAATAAGTTTGTATATTGCT
intron 5	20057	78	0	-2.195899652	G/A	CAGATCTTAAATATAAAGTGTATAA [G/A] CTGGAATAATTCATGTAAACAAATG
intron 5	22921	69	1	0	G/T	TATTTAATCCTAACACACACATAG [G/T] ATGCATTTTATTTCTCATGAAAGA
exon 6	23027	69	1	0	TA/-? 280 ?	GAAAGAAAACATGAATATAAATAACA [TA/-? 280 ?] AAGTTAAAAGGAAGAGTACAGAA
exon 6	23203	66	3	-1.147796072	G/A	ATAAGGCAGCATTTGTACCCATAAT [G/A] TATGTCAACTTCCACTTTCCACT
exon 6	23322	68	0	-5.252863221	A/G	AAAGAAAATTAATATAATAGTTTCA [A/G] TTTGCAACTTAATATATTCATAAA

Table 10. Variations in CFHL4 that may be correlated with the occurrence of AMD. Each variation is shown in the context of its surrounding DNA sequence in Chromosome 7:32512024-33512123.

Region	Position	Common/Commut/Rare	Rare/Rare	Log HW P-value	Change	Sequence Context
promoter	7013	93	1	0	C/T	GTTTATTTCAACGTGATGCAACA [C/T] GGCTCTATCTTCATTTCTCTCC
promoter	7369	91	4	0	C/G	AATAGTTGCAAGACCTTTCATCC [C/G] TGTATTAAACCTCTCTTACTTAA
promoter	7577	91	5	0	C/A	CTGAACCTTTGATATTACTAAGTGA [C/A] CTTAAAGCCCTAGCTTTGTGGTAGT
promoter	7585	95	1	0	C/G	TGATATTTACTAAGTACCTTAAAG [C/G] CCTAGCTTTGGGTAGTGCCTTAA
exon 2	22144	94	2	0	T/C Asp 76 Asp	GGGATACATTCACCTGCACACAAGA [T/C Asp 76 Asp] GGGTGGTTGCCAACAGTCCATGCC
exon 3	32436	94	1	0	T/C Ile 132 Ile	CAGATGGAAATCTTCAGGTTCAAT [T/C Ile 132 Ile] ACATGTTTGGAAAATGGATGTCAG
intron 5	37640	88	4	-2.226371993	T/G	GGTAAAGTCATATGTAGCACAAT [T/G] AATAACTATTAACATTTGGATAT
intron 5	37701	69	18	-1.933721388	G/A	TATTTATCCTAAACTACATATTAG [G/A] ATGCATTTTATTTGCTCATGAAAG
exon 6	37894	74	19	-0.208237586	G/A Gly 306 Gln	ACCATTGAAATTATCTGTGAATTCG [G/A Gly 306 Gln] ATATAATGGGAATACATCACTCTCA

ClaimsWe claim:

1. An isolated polynucleotide for the detection of a variant CFH gene, in a sample from an individual, comprising a nucleic acid molecule that specifically detects a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans.
2. The polynucleotide of claim 1, wherein the polynucleotide is a probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans.
3. The probe of claim 2, wherein the variation encodes an amino acid other than histidine at position 402 of the CFH protein.
4. The probe of claim 3, wherein the variation encodes tyrosine at position 402 of the CFH protein.
5. The probe of claim 2, wherein the probe is a DNA probe.
6. The probe of claim 5, wherein the probe is from about 8 nucleotides to about 500 nucleotides.
7. The probe of claim 5, wherein the probe is from about 10 nucleotides to about 250 nucleotides.
8. The probe of claim 5, wherein the probe comprises one or more non-natural or modified nucleotides.
9. The probe of claim 8, wherein the one or more non-natural or modified nucleotides are radioactive, fluorescently, or chemically labeled nucleotides.
10. A polynucleotide primer that hybridizes, under stringent conditions, adjacent to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans.
11. The polynucleotide primer of claim 10, which hybridizes immediately adjacent to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans.
12. A pair of polynucleotide primers that specifically detect a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans,

wherein the first polynucleotide primer hybridizes to one side of the variation and the second polynucleotide primer hybridizes to the other side of the variation.

13. A pair of polynucleotide primers that hybridize to a region of DNA that comprises a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans, wherein the polynucleotide primers hybridize to the region in such a manner that the ends of the hybridized primers proximal to the variation are from about 20 to about 10,000 nucleotides apart.

14. The pair of polynucleotide primers of claim 12, wherein the variation encodes an amino acid other than histidine at position 402 of the CFH protein.

10 15. The pair of polynucleotide primers of claim 14, wherein the variation encodes tyrosine at position 402 of the CFH protein.

16. The pair of polynucleotide primers of claim 12, wherein the primers are DNA primers.

15 17. The pair of polynucleotide primers of claim 16, wherein the primers are each from about 8 nucleotides to about 500 nucleotides.

18. The pair of polynucleotide primers of claim 16, wherein the primers are each from about 10 nucleotides to about 250 nucleotides.

19. The pair of polynucleotide primers of claim 16, wherein the primers comprise one or more non-natural or modified nucleotides.

20 20. The pair of polynucleotide primers of claim 19, wherein the one or more non-natural or modified nucleotides are radioactive or fluorescently labeled nucleotides.

21. A method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of age related macular degeneration in humans, comprising:

25 (a) combining the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans, but not to a wildtype CFH gene; and

(b) determining whether hybridization occurs,

30 wherein the occurrence of hybridization indicates that a variant CFH gene

that is correlated with the occurrence of age related macular degeneration is present in the sample.

22. A method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of age related macular degeneration in humans,
5 comprising:

- (a) combining the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans, thereby producing a combination;
- 10 (b) maintaining the combination produced in step (a) under stringent hybridization conditions; and
- (c) comparing hybridization that occurs in the combination with hybridization in a control, wherein the control is a polynucleotide probe that does not bind to a variation in the CFH gene that is correlated with the
15 occurrence of age related macular degeneration in humans or binds only to a wildtype CFH gene, and the sample is the same type of sample as in (a) and is treated the same as the sample in (a), and
wherein the occurrence of hybridization in the combination but not in the control indicates that a variant CFH gene that correlates with age related
20 macular degeneration is present in the sample.

23. The method of claim 22, wherein the extent of hybridization is determined in step (c).

24. A method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of age related macular degeneration in humans,
25 comprising:

- (a) combining a first portion of the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans;
- 30 (b) combining a second portion of the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a wildtype CFH gene; and

(c) determining whether hybridization occurs,
wherein the occurrence of hybridization in the first portion but not in the
second portion indicates that a variant CFH gene that is correlated with the
occurrence of age related macular degeneration is present in the sample.

5 25. The method of claim 21, wherein the variation encodes an amino acid other
than histidine at position 402 of the CFH protein.

 26. The method of claim 25, wherein the variation encodes tyrosine at position 402
of the CFH protein.

10 27. The method of claim 21, wherein the sample comprises cells obtained from the
eye, ear, nose, teeth, tongue, epidermis, epithelium, blood, tears, saliva, mucus, urinary
tract, urine, muscle, cartilage, skin, or any other tissue or bodily fluid.

 28. The method of claim 21, wherein the polynucleotide probe is a DNA probe.

 29. The method of claim 21, wherein the polynucleotide probe is from about 8
nucleotides to about 500 nucleotides.

15 30. A method of detecting, in a sample obtained from an individual, a variant CFH
gene that is correlated with the occurrence of age related macular degeneration in humans,
comprising:

20 (a) combining the sample with a pair of polynucleotide primers, wherein the
first polynucleotide primer hybridizes to one side of DNA encoding amino
acid 402 of the CFH protein and the second polynucleotide primer
hybridizes to the other side of DNA encoding amino acid 402 of the CFH
protein;

 (b) amplifying DNA in the sample, thereby producing amplified DNA;

 (c) sequencing amplified DNA; and

25 (d) detecting in the DNA the presence of a variation that encodes an amino
acid other than histidine at position 402 of the CFH protein,
wherein the presence of the variation indicates that a variant CFH gene that
is correlated with the occurrence of age related macular degeneration in
humans is detected in the sample.

31. A method of identifying or aiding in identifying an individual at risk for developing age related macular degeneration, comprising assaying a sample obtained from the individual for the presence of a variant CFH gene that is correlated with the occurrence of age related macular degeneration in humans, wherein the presence of a variant CFH
5 gene indicates that the individual is at risk for developing age related macular degeneration.

32. A method of identifying or aiding in identifying an individual at risk for developing age related macular degeneration, comprising:

- 10 (a) combining a sample obtained from the individual with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans, but does not hybridize to a wildtype CFH gene; and
- 15 (b) determining whether hybridization occurs, wherein the occurrence of hybridization indicates that the individual is at risk for developing age related macular degeneration.

33. A method of identifying or aiding in identifying an individual at risk for developing age related macular degeneration, comprising:

- 20 (a) obtaining DNA from an individual;
- (b) sequencing a region of the DNA that comprises the nucleotides that encode amino acid 402 of the CFH protein; and
- 25 (c) determining whether a variation that encodes an amino acid other than histidine at position 402 of the CFH protein is present in the DNA, wherein the presence of the variation indicates that the individual is at risk for developing age related macular degeneration.

34. A diagnostic kit for detecting a variant CFH gene in a sample from an individual, comprising:

- 30 (a) at least one container means having disposed therein a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans; and

(b) a label and/or instructions for the use of the diagnostic kit in the detection of a variant CFH gene in a sample.

35. A diagnostic kit for detecting a variant CFH gene in a sample from an individual, comprising:

- 5 (a) at least one container means having disposed therein a polynucleotide primer that hybridizes, under stringent conditions, adjacent to one side of a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans; and
- (b) a label and/or instructions for the use of the diagnostic kit in the
10 detection of CFH in a sample.

36. The diagnostic kit of claim 35, additionally comprising a second polynucleotide primer that hybridizes, under stringent conditions, to the other side of the variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans.

15 37. A composition for treating a subject suffering from age related macular degeneration, comprising:

- (a) an effective amount of an isolated or recombinantly produced wildtype CFH polypeptide, or a fragment thereof; and
- (b) a pharmaceutically acceptable carrier.

20 38. The composition of claim 37, wherein the CFH polypeptide or the fragment thereof inhibits the activation of C3.

39. A method of treating a subject suffering from age related macular degeneration, comprising administering to the subject an effective amount of the composition of claim 37.

25 40. A composition for treating a subject suffering from age related macular degeneration, comprising:

- (a) an effective amount of an isolated or recombinantly produced nucleic acid molecule coding for a CFH polypeptide, or a fragment thereof; and
- (b) a pharmaceutically acceptable carrier.

41. A method of treating a subject suffering from age related macular degeneration, comprising administering to the subject an effective amount of the composition of claim 40.

42. A method of detecting, in a sample obtained from an individual, a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans, comprising:

(a) combining the sample with an antibody that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and

10 (b) determining whether binding occurs, wherein the occurrence of binding indicates that a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration is present in the sample.

43. A composition for treating a subject suffering from or at risk for age related macular degeneration, comprising:

15 (a) a nucleic acid molecule comprising an antisense sequence that hybridizes to a variant CFH gene or mRNA that is correlated with the occurrence of age related macular degeneration in humans; and

(b) a pharmaceutically acceptable carrier.

44. The composition of claim 43, wherein hybridization of the antisense sequence to the variant CFH gene reduces the amount of RNA transcribed from the variant CFH gene.

45. The composition of claim 43, wherein hybridization of the antisense sequence to the variant CFH mRNA reduces the amount of protein translated from the variant CFH mRNA, and/or alters the splicing of the variant CFH mRNA.

25 46. The composition of claim 43, wherein said nucleic acid molecule includes one or more modified nucleotides or nucleosides that enhance in vivo stability, transport across the cell membrane, or hybridization to a variant CFH gene or mRNA.

47. A method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of the composition of claim 43.

30

48. A composition for treating a subject suffering from or at risk for age related macular degeneration, comprising:

- 5 (a) a nucleic acid molecule comprising a siRNA or miRNA sequence, or a precursor thereof, that hybridizes to a variant CFH gene or mRNA that is correlated with the occurrence of age related macular degeneration in humans; and
- (b) a pharmaceutically acceptable carrier.

49. The composition of claim 48, wherein hybridization of the siRNA or miRNA sequence to the variant CFH gene reduces the amount of RNA transcribed from the variant
10 CFH gene.

50. The composition of claim 48, wherein hybridization of the siRNA or miRNA sequence to the variant CFH mRNA reduces the amount of protein translated from the variant CFH mRNA, and/or alters the splicing of the variant CFH mRNA.

51. The composition of claim 48, wherein said nucleic acid molecule includes one
15 or more modified nucleotides or nucleosides that enhance in vivo stability, transport across the cell membrane, or hybridization to a variant CFH gene or mRNA.

52. A method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of the composition of claim 48.

20 53. A composition for treating a subject suffering from or at risk for age related macular degeneration, comprising:

- (a) an aptamer that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and
- (b) a pharmaceutically acceptable carrier,
- 25 wherein binding of the aptamer to the variant CFH polypeptide reduces the activity of the variant CFH polypeptide.

54. A method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of the composition of claim 53.

55. A composition for treating a subject suffering from or at risk for age related macular degeneration, comprising:

- 5 (a) a small molecule that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and
- (b) a pharmaceutically acceptable carrier,

wherein binding of the small molecule to the variant CFH polypeptide reduces the activity of the variant CFH polypeptide.

56. A method for treating a subject suffering from or at risk for age related macular
10 degeneration, comprising administering to the subject an effective amount of the composition of claim 55.

57. A composition for treating a subject suffering from or at risk for age related macular degeneration, comprising:

- 15 (a) an antibody that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and
- (b) a pharmaceutically acceptable carrier,

wherein binding of the antibody to the variant CFH polypeptide reduces the activity of the variant CFH polypeptide.

58. A method for treating a subject suffering from or at risk for age related macular
20 degeneration, comprising administering to the subject an effective amount of the composition of claim 57.




FIG. 1A




FIG. 1B



FIG. 2A




FIG. 2B



FIG. 2C




FIG. 2D




FIG. 3A



FIG. 3B





FIG. 3C

FIG. 4



Polypeptide Sequence for Homo sapiens Complement Factor H
(GenBank Accession CAA68704)

1	mrllekicl	mlwaicvaed	cnelpprint	eiltgswsdq	typegtqaiy	kcrpgyrslg
61	nvimvcrkge	wvalnplrkc	qkrpcghpgd	tpfgtftltg	gnvfeygvka	vytcnegyql
121	lgeinyrecd	tdgwtnidipi	cevvkclpvt	apengkivss	amepdreyht	gqavrfvcns
181	gykiegdeem	hcsddgfwsk	ekpkcveisc	kspdvingsp	isqliyken	erfqykenng
241	yeysergdav	ctesgwrplp	sceekscdnp	yipngdyspl	rikhrtgdel	tyqcrngfyp
301	atrgntakct	stgwipaprc	tlkpcdypdi	khgglyhenm	rrpyfpvavg	kyysyycdeh
361	fetpsgsywd	hihctqdgws	pavpcrlkcy	fpylengyng	nhgrkfvqgk	sidvachpgy
421	alpkaqtvtc	cmengwsptp	rcirvktcsk	ssidiengfi	sesqytyalk	ekakyqcklg
481	yvtadgetsq	sircgkdgws	aqptcikscd	ipvfmaratk	ndftwfklnl	tlðyechdgy
541	esntgsttgs	ivogynngwsd	lpicyerece	lpkiðvhlvp	ðrkkdqykvg	evlkfsckpg
601	ftivgpnsvq	cyhfglspdl	pickeqvqsc	gpoppellingn	vkektkeeyg	hsevveyycn
661	prflmkgpnk	iqcvdgetwt	lpvciveest	cgdipalehg	waqlssppyy	ygdsvvefncs
721	esftmighrs	itcihgwtq	lpqcvaidkl	kkckssnlii	leehlknkke	fdhnsniryr
781	crgkegwih	vcingrwdpe	vncsmaqiql	cppppqipns	hnmðttlnyr	dgekvsvlcq
841	enyligegee	itckdgrwqs	iplcvekipc	spppqieltgt	insrrssqes	yahgtklst
901	ceggfrisee	nettcyngkw	ssppqceglp	cksppeiishg	vvaðmadsyq	ygeevtykcf
961	egfgldgpai	akclgekwh	ppaciktðcl	slpsfenaip	ngekkðvyka	geqvtytcat
1021	vykðdgaðnv	tcinsrwtgr	ptcrðtscvn	pptvqnaiv	srqmskypsg	ervryqcrsp
1081	yemfgdeevm	clngnwtetp	qckdðtgkcg	ppppidngdi	tafpisvyap	asvevycqn
1141	lyqlcgnkri	tcnngqwsqp	pkclhpcvis	reimenynia	lrwtakqkly	srtgesvefv
1201	ckrgyrlssr	shlrlttcwd	gkleypctcak	r		

FIG. 5

1/64

SEQUENCE LISTING

<110> Yale University
Hoh, Josephine

<120> METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS

<130> YU-PWO-038

<150> US 60/629,363

<151> 2004-11-18

<150> US 60/649,479

<151> 2005-02-02

<150> US 60/672,346

<151> 2005-04-18

<160> 59

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 4004

<212> DNA

<213> Homo sapiens

<400> 1

```

cctttttgcag caagttcttt cctgcactaa tcacaattct tggagagagga gaactggaag 60
ttgtgaacag agtttagctgg taastgtcct cttaaaagat ccaaaaaatg agacttctag 120
caaagattat ttgccttatg ttatgggcta tttgtgtagc agaagattgc aatgaacttc 180
ctccaagaag aaatacagaa attctgacag gttcctggtc tgaccaaaca tatccagaag 240
gcacccaggc tatctataaa tgcgcgcctg gatabagatc tcttggaat gtaataatgg 300
tatgcaggaa gggagaatgg gttgctctta atccattaag gaaatgtcag aaaaggccct 360
gtggacatcc tggagatact ccttttggtt cttttacct tacaggagga aatgtgtttg 420
aatatggtgt aaaaagctgtg tatacatgta atgaggggtt tcaattgcta ggtgagatta 480
attacogtga atgtgacaca gatggatgga ccaatgatat tccatatatg gaagttgtga 540
agtgtttacc agtgacagca ccagagaatg gaaaaattgt cagttagtgc atggaaccag 600
atcgggaata ccattttgga caagcagtag ggtttgtatg taactcaggg tacaagattg 660
aaggagatga cgaatgcat tgttcagacg atgggttttg gagtaaaagag aaaccaaagt 720
gtgtggaaat ttcattgaaa tcccagatg ttataaatgg atctctata tctcagaaga 780
ttattttataa ggagaatgaa cgatttcaat ataaatgtaa catgggttat gaatacagt 840
aaagaggaga tgcctgtatg actgaatctg gatggcgtcc gttgccttca tgtgaagaaa 900
aatcatgtga taatccttat attccaaatg gtgactactc acctttaagg attaaacaca 960
gaactggaga tgaatcagc taccagtgtt gaaatggttt ttatcctgca acccggggaa 1020
atacagcaaa atgcacaagt actggctgga taccctgctc gagatgtacc ttgaaacctt 1080
gtgattatcc agacattaaa catggagggtc tatatcatga gaatatgcgt agaccatact 1140
ttccagtagc tgtaggaaaa tattactcct attactgtga tgaacatttt gagactccgt 1200
cagggaagtta ctgggatcac attcattgca cacaagatgg atggtcgcca gcagtaacct 1260
gcctcagaaa atgttatttt ccttatattg aaaaatggata taatcaaaat catggaagaa 1320
agttttgtaca gggtaaatct atagacgttg cctgccatcc tggctacgct cttccaaaag 1380
cgcagaccac agttacatgt atggagaatg cctggtctcc tactcccaga tgcactccgt 1440
tcaaaacatg tccaaatca agtatagata ttgagaatgg gttttattct gaatctcagt 1500
atacatatgc cttaaaagaa aaagcgaaat atcaatgcaa actaggatat gtaacagcag 1560
atgggtgaaac atcaggatca attacatgtg ggaagatgg atggtcagct caacccacgt 1620
gcattaaatc ttgtgatatc ccagtattta tgaatgccag aactaaaaat gacttcacat 1680
ggtttaagct gaatgacaca ttggactatg aatgccatga tggttatgaa agcaatactg 1740
gaagcaccac tggttccata gtgtgtggtt acaatgggtg gtctgattta cccatatgtt 1800
atgaaagaga atgcgaactt cctaaaatag atgtacactt agttcctgat cgcaagaaag 1860
accagtataa agttggagag gtgttgaaat tctcctgcaa accaggattt acaatagttg 1920

```


2/64

```

gacctaatc  cgttcagtgc  taccactttg  gatttgtctc  tgacctccca  atatgtaaag  1980
agcaagtaca  atcatgtggg  ccacctctgt  aactcctcaa  tgggaatggt  aaggaaaaaa  2040
cgaaagaaga  atabggacac  agtgaagtgg  tgggaatatta  ttgcaatcct  agatttctaa  2100
tgaagggacc  taataaaatt  caatgtgttg  atggagagtg  gacaaacttta  ccagtgtgta  2160
ttgtggagga  gagtacctgt  ggagatatat  ctgaacttga  acatggctgg  gccagctttt  2220
cttccccctc  ttattactat  ggagattcag  tgggaattcaa  ttgctcagaa  tcattttaca  2280
tgattggaca  cagatcaatt  acgtgtattc  atggagtatg  gacccaactt  cccagtggtg  2340
tggcaataga  taaacttaag  aagtgcnaat  catcaaatat  aattatactt  gaggaacatt  2400
taaaaaacaa  gaaggaattc  gatcataatt  ctaacataag  gtacagatgt  agaggaaaag  2460
aaggatggat  acacacagtc  tgcataaatg  gaagatggga  tccagaagtg  aactgctcaa  2520
tggcacaaat  acaattatgc  ccacctccac  ctcagattcc  caattctcac  aatatgacaa  2580
ccacactgaa  ttatcgggat  ggagaaaaag  tatctgttct  ttgccaagaa  aattatctaa  2640
ttcaggaagg  agaagaaatt  acatgcaaa  alggagatg  gcagtcaata  ccactctgtg  2700
ttgaaaaaat  tccatgttca  caaccacctc  agatagaaca  cggaaccatt  aattcatcca  2760
ggctcttcaca  agaaagttat  gcacatggga  ctaaatggag  ttatacttgt  gaggggtggt  2820
tcaggatata  tgaagaaaat  gaaacaacat  gctacatggg  aaaatggagt  tctccacctc  2880
agtgtgaagg  ccttccctgt  aaatctccac  ctgagatttc  tcatggtgtt  gtactctaca  2940
tgtcagacag  ttatcagtat  ggagaagaag  ttaoctacaa  atgttttgaa  ggttttgaa  3000
ttgatgggccc  tgcaattgca  aaatgcttag  gagaaaaatg  gtctcaccct  ccatcatgca  3060
taaaaaacaga  ttgtctcagt  ttacctagct  ttgaaaatgc  catacccatg  ggagagaaga  3120
aggatgtgta  taaggcgggt  gagcaagtga  cttacacttg  tgcaacatat  taaaaaatgg  3180
atggagccag  taatgtaaca  tgcatttaata  gcagatggac  aggaaggcca  acatgcagag  3240
acacctcctg  tgtgaatccg  cccacagtac  aaaatgctta  tatagtgtcg  agacagatga  3300
gtcaatatcc  atctggtgag  agagtacgtt  atcaatgtag  gagcccttat  gaaatgtttg  3360
gggatgaaga  agtgatgtgt  ttaaatggaa  actggaaggga  accacctcaa  tgcaagatt  3420
ctacaggaaa  atgtgggccc  cctccacctc  ttgacaatgg  ggacattact  tcattccctg  3480
tgtcagtata  tgcctcagct  tcatcagttg  agtaaccaatg  ccagaacttg  tatcaacttg  3540
agggtaacaa  gcgaataaca  tgtagaatg  gacaatgggc  agaaccacca  aaatgcttac  3600
atccgtgtgt  aatatccoga  gaaattatgg  aaaattataa  catagcatta  aggtggacag  3660
ccaaacagaa  gctttattcg  agaacagggt  aatcagttga  atttgtgtgt  aaaoggggat  3720
atcgtctttc  atcagttct  cacacattgc  gatgaaacatg  ttgggatggg  aaactggagt  3780
atccaaacttg  tgcaaaaaga  tagaatcaat  cataaagtgc  acacctttat  tcagaacttt  3840
agtattaaat  cagttctcaa  ttctattttt  tatgtattgt  tttactcctt  tttattcata  3900
cgtaaaattt  tggattaatt  tgtgaaaatg  taattataag  ctgagaccgg  tggctctctt  3960
cttaaaaagca  ccatattaaa  tcttggaaaa  ctaaaaaaa  aaaa  4004

```

<210> 2

<211> 1702

<212> DNA

<213> Homo sapiens

<400> 2

```

ctttttgcag  caagttcttt  cctgcactaa  tcacaattct  tgggaagagga  gaactggacg  60
ttgtgaacag  agttagctgg  taaatgtcct  cttaaaagat  ccaaaaaatg  agacttctag  120
caaagattat  ttgccttatg  ttatgggcta  tttgtgtagc  agaagattgc  aatgaacttc  180
ctccaagaag  aaatacagaa  attctgacag  gttcctgggt  tgaccaaaaca  tatccagaag  240
gcacccaggg  tatctataaa  tgccgcccgt  gatatagatc  tcttggaat  gtaataatgg  300
tatgcaggaa  gggagaatgg  gttgctctta  atccattaag  gaaatgtcag  aaaaggccct  360
gtggacatcc  tggagatact  ctttttggtt  cttttaccct  tacaggagga  aatgtgtttg  420
aatatgggtg  aaaagctgtg  tatacatgta  atgaggggta  tcaattgcta  ggtgagatta  480
attacogtga  atgtgacaca  gatggatgga  ccaatgatat  toctatatgt  gaagttgtga  540
agtgtttacc  agtgacagca  ccagagaatg  gaaaaattgt  cagtagtgca  atggaaccag  600
atcgggaata  ccatttttga  caagcagtac  ggtttgtatg  taactcaggg  tacaagattg  660
aaggagatga  agaaatgcac  tgttcagacg  atggtttttg  gagttaaagag  aaaccaaagt  720
gtgtggaaat  ttcattgcaaa  tcccagatg  ttataaatgg  atctctata  tctcagaaga  780
ttatttataa  ggagaatgaa  cgattttcaat  ataaatgtaa  catgggttat  gaatacagtg  840
aaagaggaga  tgcgttatgc  actgaatctg  gatggcgtcc  gttgccttca  tctgaagaaa  900
aatcatgtga  taatccttat  attocaaatg  gtgactactc  acctttaagg  attaaacaca  960
gaactggaga  tgaaatcacg  taccagtgtg  gaaatgggtt  ttatccttga  accoggggaa  1020
atacagcaaa  atgcacaagt  actggctgga  taccgtctcc  gagatgtacc  ttgaaacctt  1080
gtgattatcc  agacattaaa  catggaggtc  tatatcatga  gaatatgcgt  agaccatact  1140
ttccagtagc  tgtaggaaaa  tattactctt  attactgtga  tgaacatttt  gagactccgt  1200

```

3/64

caggaagtta	ctgggacac	attcattgca	cacaagatgg	atgggtcgcca	gcagtacccat	1260
gcctcagaaa	atgttatttt	ccttatttgg	aaaatggata	taatcaaat	catggaagaa	1320
agtttgtaca	gggtaaatct	atagacgttg	cctgccatcc	tggtacgct	cttccaaaag	1380
cgacagaccac	agttacatgt	atggagaatg	gctgggtctcc	tactcccaga	tgcatccgtg	1440
tcagcttttac	cctctgaact	tctgategaa	ggtcacccct	ctccagcttg	agtggatcaa	1500
agatgacaag	ggccaatgga	accaagtttg	agtcttgcca	ggccaactact	tgggtcctga	1560
gtatgggtgac	tagtatctgt	tttgttatgt	gtgtattatt	ccagccagaa	tgggaaatgc	1620
taattcagct	cctccaggca	gcccaatggg	gctgggtggct	ttgagattat	taaactcttt	1680
ctctgctgca	aaaaaaaaaa	aa				1702

<210> 3

<211> 4252

<212> DNA

<213> Mus musculus

<400> 3

aagtctttcc	ctgctgtgac	cacagttcat	agcagagagg	aactggatgg	tacagcacag	60
atttctcttg	gagtcagttg	gtcccagaaa	gatccaaatt	atgagactgt	cagcaagaat	120
tatttggctt	atattatgga	ctgtttgtgc	agcagaagat	tgtaagggtc	ctcctccaag	180
agaaaattca	gaaattctct	caggctcgtg	gtcagaacaa	ctatatccag	aaggcaccca	240
ggctacctac	aaatgccgcc	ctggataccg	aacacttggc	actattgtaa	aagtatgcaa	300
gaatggaaaa	tgggtggcgt	ctaaccctac	caggatatgt	cgaaaaagc	cttgtgggca	360
tcccggagac	acaccctttg	ggctcctttg	gctggcagtt	ggatctcaat	ttgagtttgg	420
tgcaaaaggtt	gtttatacct	gtgatgatgg	gtatcaacta	ttagggtgaaa	ttgattaccg	480
tgaatgtggg	gcagatggct	ggatcaatga	tattccacta	tgtgaagttg	tgaagtgctc	540
acctgtgaca	gaactcgaga	atggaagaat	tgtgagtggg	gcagcagaaa	cagaccagga	600
atactatttt	ggacaggtgg	tgcggtttga	atgcaattca	ggcttcaaga	ttgaaggaca	660
taaggaaatt	cattgtctcag	aaaatggcct	ttggagcaat	gaaaaagccac	gatgtgtgga	720
aattctctgc	acaccaccgc	gagtggaana	tggagatggg	ataaatgtga	aaccagttta	780
caaggagaat	gaaagatacc	actataagtg	taagcatggg	tatgtgccc	aagaaagagg	840
ggatgcctgc	tgcacaggct	ctggatggag	ttctcagcct	ttctgtgaag	aaaagagatg	900
ctcacctcct	tatatcttaa	atgggtatct	cacacctcac	aggattatcc	acagaagtga	960
tgatgaaatc	agatatgaat	gtaattatgg	cttctatcct	gtaactggat	caactgtttc	1020
aaagtgtaca	cccactggct	ggatccctgt	tccaagatgc	accttgaaac	catgtgaatt	1080
tccacaatto	aaatatggac	gtctgtatta	tgaagagagc	ctgagaccca	acttcccagt	1140
atctatagga	aataagtaca	gtctabaagt	tgacaacggg	ttttcaccac	cttctgggta	1200
ttcttgggac	taccttcgtt	gcacagcaca	aggggtgggag	cctgaagttc	catgcgtcag	1260
gaaatgtgtt	ttccattatg	tggagaatgg	agactctgca	tactgggaaa	aagtatatgt	1320
gcagggtcag	tcttttaaaag	tccagtgtta	caatggctat	agtcttcaaa	atggtcaaga	1380
cacaaatgaca	tgtacagaga	atggctgggtc	ccctcctccc	aatgtcatcc	gtatcaagac	1440
atgttcagca	tcagatatcc	acattgacaa	tggatttctt	tctgaattct	cttctatata	1500
tgctctaaat	agagaaacat	cctatagatg	taagcaggga	tatgtgacaa	atactggaga	1560
aatatcagga	tcaataactt	gccttcaaaa	tggatggcca	cctcaacctc	catgcattaa	1620
gtcttgtgat	atgcctgtat	ttgagaattc	tataactaag	aataactagga	catgggttaa	1680
gctcaatgac	aaattagact	atgaatgtct	cgttggattt	gaaaatgaat	ataaacatac	1740
caaaaggctct	ataacatgta	cttattatgg	atggtctgat	acaccctcat	gttatgaaag	1800
agaatgcagt	gttcccactc	tagaaccgaa	actagtcgtt	tccccagaa	aagaaaaata	1860
cagagtttga	gattttgttg	aattctcctg	ccattcagga	cacagagttg	ggccagattc	1920
agtgcacatgc	taccactttg	gatgggtctcc	tggtttccct	acatgtaaaag	gtcaagtagc	1980
atcatgtgca	ccacctcttg	aaattcttaa	tggggaaatt	aatggagcaa	aaaaagttga	2040
atacagccat	ggtgaagtgg	tgaaatatga	ttgcaaacct	agattcctac	tgaagggacc	2100
caataaaatc	cagtgtgttg	atgggaattg	gacaaccttg	cctgtatgta	ttgaggagga	2160
gagaacatgt	ggagacattc	ctgaacttga	acatggctct	gccaagtgtt	ctgttctccc	2220
ctaccaccat	ggagattcag	tggagttcat	ttgtgaagaa	aacttcacaa	tgattggaca	2280
ttgggtcagtt	tottgcatta	gtggaaaaatg	gacccagctt	cctaaatgtg	ttgcaacaga	2340
ccaaactggag	aagtgtagag	tgtgaaagtc	aactggcata	gaagcaataa	aaccnaaatt	2400
gactgaattt	acgcataact	ccaccatgga	ttacaaatgt	agagacaagc	aggagtacga	2460
acgctcaatc	tgtatcaatg	gaaaaatggga	tcctgaacca	aactgtacaa	gcaaaacatc	2520
ctgcccctct	ccaccgcaga	ttccaaatac	ccaagtgatt	gaaaccaccg	tgaataactt	2580
ggatggagaa	aaattatctg	ttcttttgcca	agacaattac	ctaactcagg	actcagaaga	2640
aatggtgtgc	aaagatggaa	gggtggcagtc	attacctcgc	tgcattgaaa	aaattccatg	2700
ttcccagccc	cctacaatag	aacatggatc	tattaattta	cccagatctt	cagaagaaag	2760

4/64

```

gagagattcc attgagteca gcagtcacga acatggaaact acatttcagct atgtctgtga 2820
tgatgggttc aggatacctg aagaaaaatag gataaacctgc tacatgggaa aatggagcac 2880
tccacctcgc tgtgttggaac ttccctgtgg acctccacct tcaattccctc ttggtagctgt 2940
ttctcttgag ctgagagagtt accaacatgg ggaagaggtt acataccatt gttctacagg 3000
cttttgaatt gatggaccag cattttattat atgcgaagga ggaaagtggc ctgacccacc 3060
aaaatgcata aaaacgggatt gtgacgtttt acccacagtt aaaaatgcc taataagagg 3120
aaagagcaaa aaatcatata ggacaggaga acaagtgaac ttcagatgtc aatctcctta 3180
tcaaatgaat ggctcagaca ctgtgacatg tgtaaatagt cgggtggattg gacagccagt 3240
atgcaaagat aattccctgtg tggatccacc acatgtgcca aatgctacna tagtaacaag 3300
gaccaagaat aaatatctac atgggtgacag agtacgttat gaatgtaata aacctttgga 3360
actatattggg caagtgggaag tgatgtgtga aaatgggata tggacagaaa aaccaaagtg 3420
ccgagaactca acagggaaat gtgggcctcc tccacctatt gacaatggag acatcacctc 3480
cttgcctatta ccagtatatg aaccattatc atcagttgaa tatcaatgcc agaagtatta 3540
tctccttaag ggaagaaga caataacatg tacaatgga aagtggctctg agccaccaac 3600
atgcttacat gcatgtgtaa taccagaaaa cattatggaa tcacacaata taattctcaa 3660
atggagacac actgaaaaga tttattccca ttccagggag gatattgaat ttggatgtaa 3720
atatggatat tataaagcaa gagattcacc gccatttcgt acaaagtga ttaatggcac 3780
catcaattat ccacttgtg tataaaatca taatacattt attagttgat tttattgttt 3840
agaaaggcac atgcatgtga ctaatatact ttcaatttgc attgaagtat tgtttaactc 3900
atgtcttctc ataaatataa acatttttgt tataatggtg ttaacttgta actttaaaaa 3960
ctattgccaa aatgcaaaag cagtaattca aaactcctaa tctaaaatat gatatgtcca 4020
aggacaaact atttcaatca agaaagtaga tgtaagttct tcaacatctg tttctattca 4080
gaacttttct agattttcct ggataccttt tgatgtaagg tcttgattta cagcggataa 4140
aggatatatt gactgattct tcaaatat atgatttccc aaagcatgta acaacaaaac 4200
tatcatatat tatatgacta atgcatacaa ttaattacta tataatactt tc 4252

```

<210> 4

<211> 4250

<212> DNA

<213> Rattus norvegicus

<400> 4

```

acagcacata cttctctctg agtcaactgc tcccagatag atccaagaca tgagactgtc 60
agcaagaatt atttggctta tattatggac tgtttgtgta gcagaagatt gtaaaaggtc 120
tccccaaga gaaaattcag aaattctctc aggttcgtgg totgaacaac tatattcaga 180
aggcactcag gcaacctaca aatgcgcgcc tggataccga acacttggtg ctattgtaaa 240
agtatgcaag aatggagaal gggtagcttc taacctca aggatatgtc ggaaaaggcc 300
atgtggggcat cccggagaca caccctttgg gtcccttagg ctggcagttg gatctgaatt 360
tgaatttggt gcaaaagggtg tttatacatg tgatgaaggg taccactct taggtgaaat 420
tgattaccgt gaatgtgatg cagatgggtg gaccaatgat attccaatat gtgaagttgt 480
gaagtgcctg ccagtgcacg aactggagaa tggagaatgt gtgagtggtg cagccgaacc 540
agaccaggaa tattattttg gacaggtggt acgtcttgaa tggcaactccg gcttcaagat 600
tgaaggacag aaagaaatgc actgctcaga aaatggcctc tggagcaatg aaagccaca 660
gtgtgtggaa atttcttgcc tggcaccacg agttgaaaat ggagatggta tatatctgaa 720
accagtttac aaggagaatg aaagattcca atataaatgt aagcaagggt ttgtgtacaa 780
agaaagaggg gatgctgtct gcacgggttc tggatggaa cctcagcctt cctgtgaaga 840
aatgacatgt ttgactccat atattccaaa tggatatctac acacctcaca ggattaaaca 900
cagaattgat gatgaaatca gatatgaatg taanaatggc ttctatctctg caaccogac 960
acctgtttca agtgtacaa ttactggctg gatccctgct ccaagatgta gcttgaaaac 1020
ttgtgatttt ccacaattca aacatggacg tctgtattat gaagaaagcc ggagacccta 1080
cttcccagta cctataggaa aggagtacag ctattactgt gacaacgggt ttacaacgcc 1140
ttcacagtca tactgggact accttcgttg cacagtaaat ggggtgggagc ctgsagttcc 1200
atgcctcagg caatgtatct tccattatgt ggaatatgga gaatctttat actggcaaaag 1260
aagatatata gagggtcagt ctgcaaaagt ccagtgtcac agtggctata gtctccaaa 1320
tggtcagatg acaatattat gtacagaaaa tggctgttcc cctccctcca aatgcgtccg 1380
tatcaagact tgttcagtat cagatataga aattgaaat ggggtttttt ctgaatctga 1440
ttatacatat gctctaaata gaaaaacacg gtatagatgt aaacagggat atgtaacaaa 1500
taccggagaa atatcaggaa taattacttg tcttcaagat ggatgggtcac ctogacccctc 1560
atgcattaaag tcttgtgata tgcoctgatt tgagaatgct atgactaaga ataataacac 1620
atggttttaa ctcaatgaca aattagacta tgaatgtcac attggatatg aaaatgaata 1680
taaacatacc aaaggtctca taacatgtac ttaatgtgga tggctotagta caccctcctg 1740
ttatgaaaga gaatgcagca tccccctgtt acaccaagac ttagttgttt ttcccagaga 1800

```

5/64

```

agtaaaatcac aaagttggag attcgttgag ttctctcttgc cgttcaggac acagagttgg 1860
agcagattta gtcaatgct accacttttg atgggtccct aatttcccaa cgtgtgaagg 1920
ccaagtaaaa tcatgtgacc aacctcttga aatcccgaaat ggggaaataa agggaaacaaa 1980
aaaagttgaa tacagccatg gtgacgtggt ggaatatgat tgcaaaccta gatttctact 2040
gaagggaccc aataaaatcc agtgtgttga cgggaagtgg acaaccttgc cgtatgtgct 2100
tgagtatgag agaacatgtg gagaccttcc tgcacttgag catggctctg tccagttatc 2160
tgteccctccc taccaccaag gagatttcagt ggagttcact tgtgcagaaa ccttcacaat 2220
gattgggcat gcagtagttt totgcattag tgggaagtgg accgagcttc ctcaatgtgt 2280
tgcaacagat caactggaga agtgtaaagc ccgaagtca actggcatag atgcaattca 2340
tccaaataag aatgaattta atcataactt tagtgtgagt tacagatgta gacaaaagca 2400
ggagtatgaa cattcaatct gcatcaatgg aagatgggat cctgaaccaa actgtacaag 2460
aaatgagaaa agattctgoc ctccctcccc acagattcca aatgcccag tgattgaaac 2520
cacagtgaat tacttggatg gagagaaagt atctgttctt tgccaagatg gttacctaac 2580
tcaggggcca gaagaaatgg tgtgtaaaca tgggaagtgg cagtctgtac cacgctgcac 2640
ggaaaaaatt ccatgttccc agccccctaa aattgaacat ggatctatta agtcgcccag 2700
gtcctcagaa gagagagatt taattgagtc cagcagttat gaacacggaa ctacattcag 2760
ctatgtctgt gatgatggat tcaggatata tgaagaaaat agggtaacct gcaacatggg 2820
aaaaatggagc tctctgcctc gttgtgttgg aatcccttgt ggacccccac ctccaattcc 2880
tcttgggtatt tcttctcatg aactagaaaag ttccaatat ggagaggagg ttacatacaa 2940
ttgttctgaa ggttttgaa ttgatggacc agcatttatt aaatgtgtag gaggacagtg 3000
gtctgaacca cccaaatgca taaaaactga ttgtgacaac ttgcccacat ttgaaattgc 3060
caaacogaca gaaaagaaaa aaaaatcata caggtcagga gaacaagtga cattcagatg 3120
tccacctccg tatcgaatgg atggctctga cattgtcaca tgtgttaata cgaagtggat 3180
tggacagccg gtatgcaaag ataattcctg tgtgaatcca ccacatgtgc caaatgctac 3240
tatactaaca aggcacaaga ctaaaatatc atctgggtgac aaagtacgtt atgactgtaa 3300
taaacctttt gaattatttg gggaagtggg agtcatgtgc caaaacggga tttggacaga 3360
accacogaaa tgcaagatt caacagggaa atgtgggccc cctccacctt ttgacaatgg 3420
agacatcacc tcttgtcat taaccagtata tgcaccatta tcatcagttg aatatcaatg 3480
ccagaactat tatctactta agggaaataa gatagtaaca tgtagaaatg gaaagtggct 3540
tcagccacca acctgcttac atgcatgtgt gataccagaa gatatttatg aaaaacataa 3600
tatagttctc agatggaggg aaaaatgcaaa gatttatcc caatcagggg agaattatga 3660
attcatgtgt aaacctggat atagaaaatt cagaggatca cctccgtttc gtacaaagtg 3720
cattgagggg cactcaatt atcccacttg tgtabaaaat cgtatatacaa ttattagtaa 3780
accttatgga tgaacctttg tttagaaatg cacatgtata ttactaatac agtttgaatt 3840
tacatttgaa atattgttta gctcatttct tctaataagt atataaactt tttttatatg 3900
gtggttaate agtaacttta cagactgttg ccacaaagca agaacattgc attcaaaact 3960
cctaataccaa aatatgatat gtccaaggac aaactatgtc taagcaagaa aataaattgt 4020
agttcttcaa tgtctgtttt cattcaggac ttttcagatt ttcttgata ccttttgttg 4080
ttaggttctg attcacagt agtggagac acactgactc tgacttcasa ttagtattac 4140
ttgccaatac ataacaacca aactatcata atatacaaaa tgtatacagc taattactgt 4200
gtcctacctt tgtatcaata aagaaatcta agaaagttct tgcttatgaa 4260

```

<210> 5

<211> 1231

<212> PRT

<213> Homo sapiens

<400> 5

```

Met Arg Leu Leu Ala Lys Ile Ile Cys Leu Met Leu Trp Ala Ile Cys
 1          5          10          15
Val Ala Glu Asp Cys Asn Glu Leu Pro Pro Arg Arg Asn Thr Glu Ile
          20          25          30
Leu Thr Gly Ser Trp Ser Asp Gln Thr Tyr Pro Glu Gly Thr Gln Ala
          35          40          45
Ile Tyr Lys Cys Arg Pro Gly Tyr Arg Ser Leu Gly Asn Val Ile Met
          50          55          60
Val Cys Arg Lys Gly Glu Trp Val Ala Leu Asn Pro Leu Arg Lys Cys
          65          70          75          80
Gln Lys Arg Pro Cys Gly His Pro Gly Asp Thr Pro Phe Gly Thr Phe
          85          90          95
Thr Leu Thr Gly Gly Asn Val Phe Glu Tyr Gly Val Lys Ala Val Tyr
          100          105          110

```

6/64

Thr Cys Asn Glu Gly Tyr Gln Leu Leu Gly Glu Ile Asn Tyr Arg Glu
 115 120 125
 Cys Asp Thr Asp Gly Trp Thr Asn Asp Ile Pro Ile Cys Glu Val Val
 130 135 140
 Lys Cys Leu Pro Val Thr Ala Pro Glu Asn Gly Lys Ile Val Ser Ser
 145 150 155 160
 Ala Met Glu Pro Asp Arg Glu Tyr His Phe Gly Gln Ala Val Arg Phe
 165 170 175
 Val Cys Asn Ser Gly Tyr Lys Ile Glu Gly Asp Glu Glu Met His Cys
 180 185 190
 Ser Asp Asp Gly Phe Trp Ser Lys Glu Lys Pro Lys Cys Val Glu Ile
 195 200 205
 Ser Cys Lys Ser Pro Asp Val Ile Asn Gly Ser Pro Ile Ser Gln Lys
 210 215 220
 Ile Ile Tyr Lys Glu Asn Glu Arg Phe Gln Tyr Lys Cys Asn Met Gly
 225 230 235 240
 Tyr Glu Tyr Ser Glu Arg Gly Asp Ala Val Cys Thr Glu Ser Gly Trp
 245 250 255
 Arg Pro Leu Pro Ser Cys Glu Glu Lys Ser Cys Asp Asn Pro Tyr Ile
 260 265 270
 Pro Asn Gly Asp Tyr Ser Pro Leu Arg Ile Lys His Arg Thr Gly Asp
 275 280 285
 Glu Ile Thr Tyr Gln Cys Arg Asn Gly Phe Tyr Pro Ala Thr Arg Gly
 290 295 300
 Asn Thr Ala Lys Cys Thr Ser Thr Gly Trp Ile Pro Ala Pro Arg Cys
 305 310 315 320
 Thr Leu Lys Pro Cys Asp Tyr Pro Asp Ile Lys His Gly Gly Leu Tyr
 325 330 335
 His Glu Asn Met Arg Arg Pro Tyr Phe Glu Thr Pro Ser Gly Ser Tyr
 340 345 350
 Tyr Ser Tyr Tyr Cys Asp Glu His Phe Glu Thr Pro Ser Gly Ser Tyr
 355 360 365
 Trp Asp His Ile His Cys Thr Gln Asp Gly Trp Ser Pro Ala Val Pro
 370 375 380
 Cys Leu Arg Lys Cys Tyr Phe Pro Tyr Leu Glu Asn Gly Tyr Asn Gln
 385 390 395 400
 Asn His Gly Arg Lys Phe Val Gln Gly Lys Ser Ile Asp Val Ala Cys
 405 410 415
 His Pro Gly Tyr Ala Leu Pro Lys Ala Gln Thr Thr Val Thr Cys Met
 420 425 430
 Glu Asn Gly Trp Ser Pro Thr Pro Arg Cys Ile Arg Val Lys Thr Cys
 435 440 445
 Ser Lys Ser Ser Ile Asp Ile Glu Asn Gly Phe Ile Ser Glu Ser Gln
 450 455 460
 Tyr Thr Tyr Ala Leu Lys Glu Lys Ala Lys Tyr Gln Cys Lys Leu Gly
 465 470 475 480
 Tyr Val Thr Ala Asp Gly Glu Thr Ser Gly Ser Ile Thr Cys Gly Lys
 485 490 495
 Asp Gly Trp Ser Ala Gln Pro Thr Cys Ile Lys Ser Cys Asp Ile Pro
 500 505 510
 Val Phe Met Asn Ala Arg Thr Lys Asn Asp Phe Thr Trp Phe Lys Leu
 515 520 525
 Asn Asp Thr Leu Asp Tyr Glu Cys His Asp Gly Tyr Glu Ser Asn Thr
 530 535 540
 Gly Ser Thr Thr Gly Ser Ile Val Cys Gly Tyr Asn Gly Trp Ser Asp
 545 550 555 560
 Leu Pro Ile Cys Tyr Glu Arg Glu Cys Glu Leu Pro Lys Ile Asp Val
 565 570 575
 His Leu Val Pro Asp Arg Lys Lys Asp Gln Tyr Lys Val Gly Glu Val
 580 585 590
 Leu Lys Phe Ser Cys Lys Pro Gly Phe Thr Ile Val Gly Pro Asn Ser
 595 600 605

7/64

Val	Gln	Cys	Tyr	His	Phe	Gly	Leu	Ser	Pro	Asp	Leu	Pro	Ile	Cys	Lys	610	615	620
Glu	Gln	Val	Gln	Ser	Cys	Gly	Pro	Pro	Pro	Glu	Leu	Leu	Asn	Gly	Asn	625	630	635
Val	Lys	Glu	Lys	Thr	Lys	Glu	Glu	Tyr	Gly	His	Ser	Glu	Val	Val	Glu	645	650	655
Tyr	Tyr	Cys	Asn	Pro	Arg	Phe	Leu	Met	Lys	Gly	Pro	Asn	Lys	Ile	Gln	660	665	670
Cys	Val	Asp	Gly	Glu	Trp	Thr	Thr	Leu	Pro	Val	Cys	Ile	Val	Glu	Glu	675	680	685
Ser	Thr	Cys	Gly	Asp	Ile	Pro	Glu	Leu	Glu	His	Gly	Trp	Ala	Gln	Leu	690	695	700
Ser	Ser	Pro	Pro	Tyr	Tyr	Tyr	Gly	Asp	Ser	Val	Glu	Phe	Asn	Cys	Ser	705	710	715
Glu	Ser	Phe	Thr	Met	Ile	Gly	His	Arg	Ser	Ile	Thr	Cys	Ile	His	Gly	725	730	735
Val	Trp	Thr	Gln	Leu	Pro	Gln	Cys	Val	Ala	Ile	Asp	Lys	Leu	Lys	Lys	740	745	750
Cys	Lys	Ser	Ser	Asn	Leu	Ile	Ile	Leu	Glu	Glu	His	Leu	Lys	Asn	Lys	755	760	765
Lys	Glu	Phe	Asp	His	Asn	Ser	Asn	Ile	Arg	Tyr	Arg	Cys	Arg	Gly	Lys	770	775	780
Glu	Gly	Trp	Ile	His	Thr	Val	Cys	Ile	Asn	Gly	Arg	Trp	Asp	Pro	Glu	785	790	795
Val	Asn	Cys	Ser	Met	Ala	Gln	Ile	Gln	Leu	Cys	Pro	Pro	Pro	Pro	Gln	805	810	815
Ile	Pro	Asn	Ser	His	Asn	Met	Thr	Thr	Thr	Leu	Asn	Tyr	Arg	Asp	Gly	820	825	830
Glu	Lys	Val	Ser	Val	Leu	Cys	Gln	Glu	Asn	Tyr	Leu	Ile	Gln	Glu	Gly	835	840	845
Glu	Glu	Ile	Thr	Cys	Lys	Asp	Gly	Arg	Trp	Gln	Ser	Ile	Pro	Leu	Cys	850	855	860
Val	Glu	Lys	Ile	Pro	Cys	Ser	Gln	Pro	Pro	Gln	Ile	Glu	His	Gly	Thr	865	870	875
Ile	Asn	Ser	Ser	Arg	Ser	Ser	Gln	Glu	Ser	Tyr	Ala	His	Gly	Thr	Lys	885	890	895
Leu	Ser	Tyr	Thr	Cys	Glu	Gly	Gly	Phe	Arg	Ile	Ser	Glu	Glu	Asn	Glu	900	905	910
Thr	Thr	Cys	Tyr	Met	Gly	Lys	Trp	Ser	Ser	Pro	Pro	Gln	Cys	Glu	Gly	915	920	925
Leu	Pro	Cys	Lys	Ser	Pro	Pro	Glu	Ile	Ser	His	Gly	Val	Val	Ala	His	930	935	940
Met	Ser	Asp	Ser	Tyr	Gln	Tyr	Gly	Glu	Glu	Val	Thr	Tyr	Lys	Cys	Phe	945	950	955
Glu	Gly	Phe	Gly	Ile	Asp	Gly	Pro	Ala	Ile	Ala	Lys	Cys	Leu	Gly	Glu	965	970	975
Lys	Trp	Ser	His	Pro	Pro	Ser	Cys	Ile	Lys	Thr	Asp	Cys	Leu	Ser	Leu	980	985	990
Pro	Ser	Phe	Glu	Asn	Ala	Ile	Pro	Met	Gly	Glu	Lys	Lys	Asp	Val	Tyr	995	1000	1005
Lys	Ala	Gly	Glu	Gln	Val	Thr	Tyr	Thr	Cys	Ala	Thr	Tyr	Tyr	Lys	Met	1010	1015	1020
Asp	Gly	Ala	Ser	Asn	Val	Thr	Cys	Ile	Asn	Ser	Arg	Trp	Thr	Gly	Arg	1025	1030	1035
Pro	Thr	Cys	Arg	Asp	Thr	Ser	Cys	Val	Asn	Pro	Pro	Thr	Val	Gln	Asn	1045	1050	1055
Ala	Tyr	Ile	Val	Ser	Arg	Gln	Met	Ser	Lys	Tyr	Pro	Ser	Gly	Glu	Arg	1060	1065	1070
Val	Arg	Tyr	Gln	Cys	Arg	Ser	Pro	Tyr	Glu	Met	Phe	Gly	Asp	Glu	Glu	1075	1080	1085
Val	Met	Cys	Leu	Asn	Gly	Asn	Trp	Thr	Glu	Pro	Pro	Gln	Cys	Lys	Asp	1090	1095	1100

8/64

Ser Thr Gly Lys Cys Gly Pro Pro Pro Pro Ile Asp Asn Gly Asp Ile
 1105 1110 1115 1120
 Thr Ser Phe Pro Leu Ser Val Tyr Ala Pro Ala Ser Ser Val Glu Tyr
 1125 1130 1135
 Gln Cys Gln Asn Leu Tyr Gln Leu Glu Gly Asn Lys Arg Ile Thr Cys
 1140 1145 1150
 Arg Asn Gly Gln Trp Ser Glu Pro Pro Lys Cys Leu His Pro Cys Val
 1155 1160 1165
 Ile Ser Arg Glu Ile Met Glu Asn Tyr Asn Ile Ala Leu Arg Trp Thr
 1170 1175 1180
 Ala Lys Gln Lys Leu Tyr Ser Arg Thr Gly Glu Ser Val Glu Phe Val
 1185 1190 1195 1200
 Cys Lys Arg Gly Tyr Arg Leu Ser Ser Arg Ser His Thr Leu Arg Thr
 1205 1210 1215
 Thr Cys Trp Asp Gly Lys Leu Glu Tyr Pro Thr Cys Ala Lys Arg
 1220 1225 1230

<210> 6
 <211> 449
 <212> PRT
 <213> Homo sapiens

<400> 6
 Met Arg Leu Leu Ala Lys Ile Ile Cys Leu Met Leu Trp Ala Ile Cys
 1 5 10 15
 Val Ala Glu Asp Cys Asn Glu Leu Pro Pro Arg Arg Asn Thr Glu Ile
 20 25 30
 Leu Thr Gly Ser Trp Ser Asp Gln Thr Tyr Pro Glu Gly Thr Gln Ala
 35 40 45
 Ile Tyr Lys Cys Arg Pro Gly Tyr Arg Ser Leu Gly Asn Val Ile Met
 50 55 60
 Val Cys Arg Lys Gly Glu Trp Val Ala Leu Asn Pro Leu Arg Lys Cys
 65 70 75 80
 Gln Lys Arg Pro Cys Gly His Pro Gly Asp Thr Pro Phe Gly Thr Phe
 85 90 95
 Thr Leu Thr Gly Gly Asn Val Phe Glu Tyr Gly Val Lys Ala Val Tyr
 100 105 110
 Thr Cys Asn Glu Gly Tyr Gln Leu Leu Gly Glu Ile Asn Tyr Arg Glu
 115 120 125
 Cys Asp Thr Asp Gly Trp Thr Asn Asp Ile Pro Ile Cys Glu Val Val
 130 135 140
 Lys Cys Leu Pro Val Thr Ala Pro Glu Asn Gly Lys Ile Val Ser Ser
 145 150 155 160
 Ala Met Glu Pro Asp Arg Glu Tyr His Phe Gly Gln Ala Val Arg Phe
 165 170 175
 Val Cys Asn Ser Gly Tyr Lys Ile Glu Gly Asp Glu Glu Met His Cys
 180 185 190
 Ser Asp Asp Gly Phe Trp Ser Lys Glu Lys Pro Lys Cys Val Glu Ile
 195 200 205
 Ser Cys Lys Ser Pro Asp Val Ile Asn Gly Ser Pro Ile Ser Gln Lys
 210 215 220
 Ile Ile Tyr Lys Glu Asn Glu Arg Phe Gln Tyr Lys Cys Asn Met Gly
 225 230 235 240
 Tyr Glu Tyr Ser Glu Arg Gly Asp Ala Val Cys Thr Glu Ser Gly Trp
 245 250 255
 Arg Pro Leu Pro Ser Cys Glu Glu Lys Ser Cys Asp Asn Pro Tyr Ile
 260 265 270
 Pro Asn Gly Asp Tyr Ser Pro Leu Arg Ile Lys His Arg Thr Gly Asp
 275 280 285
 Glu Ile Thr Tyr Gln Cys Arg Asn Gly Phe Tyr Pro Ala Thr Arg Gly
 290 295 300

9/64

Asn Thr Ala Lys Cys Thr Ser Thr Gly Trp Ile Pro Ala Pro Arg Cys
 305 310 315 320
 Thr Leu Lys Pro Cys Asp Tyr Pro Asp Ile Lys His Gly Gly Leu Tyr
 325 330 335
 His Glu Asn Met Arg Arg Pro Tyr Phe Pro Val Ala Val Gly Lys Tyr
 340 345 350
 Tyr Ser Tyr Tyr Cys Asp Glu His Phe Glu Thr Pro Ser Gly Ser Tyr
 355 360 365
 Trp Asp His Ile His Cys Thr Gln Asp Gly Trp Ser Pro Ala Val Pro
 370 375 380
 Cys Leu Arg Lys Cys Tyr Phe Pro Tyr Leu Glu Asn Gly Tyr Asn Gln
 385 390 395 400
 Asn His Gly Arg Lys Phe Val Gln Gly Lys Ser Ile Asp Val Ala Cys
 405 410 415
 His Pro Gly Tyr Ala Leu Pro Lys Ala Gln Thr Thr Val Thr Cys Met
 420 425 430
 Glu Asn Gly Trp Ser Pro Thr Pro Arg Cys Ile Arg Val Ser Phe Thr
 435 440 445
 Leu

<210> 7
 <211> 1234
 <212> FRT
 <213> Mus musculus

<400> 7
 Met Arg Leu Ser Ala Arg Ile Ile Trp Leu Ile Leu Trp Thr Val Cys
 1 5 10 15
 Ala Ala Glu Asp Cys Lys Gly Pro Pro Pro Arg Glu Asn Ser Glu Ile
 20 25 30
 Leu Ser Gly Ser Trp Ser Glu Gln Leu Tyr Pro Glu Gly Thr Gln Ala
 35 40 45
 Thr Tyr Lys Cys Arg Pro Gly Tyr Arg Thr Leu Gly Thr Ile Val Lys
 50 55 60
 Val Cys Lys Asn Gly Lys Trp Val Ala Ser Asn Pro Ser Arg Ile Cys
 65 70 75 80
 Arg Lys Lys Pro Cys Gly His Pro Gly Asp Thr Pro Phe Gly Ser Phe
 85 90 95
 Arg Leu Ala Val Gly Ser Gln Phe Glu Phe Gly Ala Lys Val Val Tyr
 100 105 110
 Thr Cys Asp Asp Gly Tyr Gln Leu Leu Gly Glu Ile Asp Tyr Arg Glu
 115 120 125
 Cys Gly Ala Asp Gly Trp Ile Asn Asp Ile Pro Leu Cys Glu Val Val
 130 135 140
 Lys Cys Leu Pro Val Thr Glu Leu Glu Asn Gly Arg Ile Val Ser Gly
 145 150 155 160
 Ala Ala Glu Thr Asp Gln Glu Tyr Tyr Phe Gly Gln Val Val Arg Phe
 165 170 175
 Glu Cys Asn Ser Gly Phe Lys Ile Glu Gly His Lys Glu Ile His Cys
 180 185 190
 Ser Glu Asn Gly Leu Trp Ser Asn Glu Lys Pro Arg Cys Val Glu Ile
 195 200 205
 Leu Cys Thr Pro Pro Arg Val Glu Asn Gly Asp Gly Ile Asn Val Lys
 210 215 220
 Pro Val Tyr Lys Glu Asn Glu Arg Tyr His Tyr Lys Cys Lys His Gly
 225 230 235 240
 Tyr Val Pro Lys Glu Arg Gly Asp Ala Val Cys Thr Gly Ser Gly Trp
 245 250 255
 Ser Ser Gln Pro Phe Cys Glu Glu Lys Arg Cys Ser Pro Pro Tyr Ile
 260 265 270

10/64

Leu	Asn	Gly	Ile	Tyr	Thr	Pro	His	Arg	Ile	Ile	His	Arg	Ser	Asp	Asp
		275					280				285				
Glu	Ile	Arg	Tyr	Glu	Cys	Asn	Tyr	Gly	Phe	Tyr	Pro	Val	Thr	Gly	Ser
		290					295				300				
Thr	Val	Ser	Lys	Cys	Thr	Pro	Thr	Gly	Trp	Ile	Pro	Val	Pro	Arg	Cys
305					310					315					320
Thr	Leu	Lys	Pro	Cys	Glu	Phe	Pro	Gln	Phe	Lys	Tyr	Gly	Arg	Leu	Tyr
				325					330					335	
Tyr	Glu	Glu	Ser	Leu	Arg	Pro	Asn	Phe	Pro	Val	Ser	Ile	Gly	Asn	Lys
				340				345					350		
Tyr	Ser	Tyr	Lys	Cys	Asp	Asn	Gly	Phe	Ser	Pro	Pro	Ser	Gly	Tyr	Ser
		355					360					365			
Trp	Asp	Tyr	Leu	Arg	Cys	Thr	Ala	Gln	Gly	Trp	Glu	Pro	Glu	Val	Pro
		370					375					380			
Cys	Val	Arg	Lys	Cys	Val	Phe	His	Tyr	Val	Glu	Asn	Gly	Asp	Ser	Ala
385					390						395				400
Tyr	Trp	Glu	Lys	Val	Tyr	Val	Gln	Gly	Gln	Ser	Leu	Lys	Val	Gln	Cys
				405					410					415	
Tyr	Asn	Gly	Tyr	Ser	Leu	Gln	Asn	Gly	Gln	Asp	Thr	Met	Thr	Cys	Thr
			420					425					430		
Glu	Asn	Gly	Trp	Ser	Pro	Pro	Pro	Lys	Cys	Ile	Arg	Ile	Lys	Thr	Cys
		435					440					445			
Ser	Ala	Ser	Asp	Ile	His	Ile	Asp	Asn	Gly	Phe	Leu	Ser	Glu	Ser	Ser
		450					455					460			
Ser	Ile	Tyr	Ala	Leu	Asn	Arg	Glu	Thr	Ser	Tyr	Arg	Cys	Lys	Gln	Gly
465					470					475					480
Tyr	Val	Thr	Asn	Thr	Gly	Glu	Ile	Ser	Gly	Ser	Ile	Thr	Cys	Leu	Gln
				485					490					495	
Asn	Gly	Trp	Ser	Pro	Gln	Pro	Ser	Cys	Ile	Lys	Ser	Cys	Asp	Met	Pro
			500					505					510		
Val	Phe	Glu	Asn	Ser	Ile	Thr	Lys	Asn	Thr	Arg	Thr	Trp	Phe	Lys	Leu
		515					520					525			
Asn	Asp	Lys	Leu	Asp	Tyr	Glu	Cys	Leu	Val	Gly	Phe	Glu	Asn	Glu	Tyr
		530					535				540				
Lys	His	Thr	Lys	Gly	Ser	Ile	Thr	Cys	Thr	Tyr	Tyr	Gly	Trp	Ser	Asp
545					550					555					560
Thr	Pro	Ser	Cys	Tyr	Glu	Arg	Glu	Cys	Ser	Val	Pro	Thr	Leu	Asp	Arg
				565					570					575	
Lys	Leu	Val	Val	Ser	Pro	Arg	Lys	Glu	Lys	Tyr	Arg	Val	Gly	Asp	Leu
				580				585					590		
Leu	Glu	Phe	Ser	Cys	His	Ser	Gly	His	Arg	Val	Gly	Pro	Asp	Ser	Val
		595					600					605			
Gln	Cys	Tyr	His	Phe	Gly	Trp	Ser	Pro	Gly	Phe	Pro	Thr	Cys	Lys	Gly
		610				615					620				
Gln	Val	Ala	Ser	Cys	Ala	Pro	Pro	Leu	Glu	Ile	Leu	Asn	Gly	Glu	Ile
625					630					635					640
Asn	Gly	Ala	Lys	Lys	Val	Glu	Tyr	Ser	His	Gly	Glu	Val	Val	Lys	Tyr
				645					650					655	
Asp	Cys	Lys	Pro	Arg	Phe	Leu	Leu	Lys	Gly	Pro	Asn	Lys	Ile	Gln	Cys
			660					665					670		
Val	Asp	Gly	Asn	Trp	Thr	Thr	Leu	Pro	Val	Cys	Ile	Glu	Glu	Glu	Arg
		675					680					685			
Thr	Cys	Gly	Asp	Ile	Pro	Glu	Leu	Glu	His	Gly	Ser	Ala	Lys	Cys	Ser
		690					695				700				
Val	Pro	Pro	Tyr	His	His	Gly	Asp	Ser	Val	Glu	Phe	Ile	Cys	Glu	Glu
705					710					715					720
Asn	Phe	Thr	Met	Ile	Gly	His	Gly	Ser	Val	Ser	Cys	Ile	Ser	Gly	Lys
				725					730					735	
Trp	Thr	Gln	Leu	Pro	Lys	Cys	Val	Ala	Thr	Asp	Gln	Leu	Glu	Lys	Cys
			740					745					750		
Arg	Val	Leu	Lys	Ser	Thr	Gly	Ile	Glu	Ala	Ile	Lys	Pro	Lys	Leu	Thr
		755					760					765			

11/64

Glu Phe Thr His Asn Ser Thr Met Asp Tyr Lys Cys Arg Asp Lys Gln
 770 775 780
 Glu Tyr Glu Arg Ser Ile Cys Ile Asn Gly Lys Trp Asp Pro Glu Pro
 785 790 795 800
 Asn Cys Thr Ser Lys Thr Ser Cys Pro Pro Pro Gln Ile Pro Asn
 805 810 815
 Thr Gln Val Ile Glu Thr Thr Val Lys Tyr Leu Asp Gly Glu Lys Leu
 820 825 830
 Ser Val Leu Cys Gln Asp Asn Tyr Leu Thr Gln Asp Ser Glu Glu Met
 835 840 845
 Val Cys Lys Asp Gly Arg Trp Gln Ser Leu Pro Arg Cys Ile Glu Lys
 850 855 860
 Ile Pro Cys Ser Gln Pro Pro Thr Ile Glu His Gly Ser Ile Asn Leu
 865 870 875 880
 Pro Arg Ser Ser Glu Glu Arg Arg Asp Ser Ile Glu Ser Ser Ser His
 885 890 895
 Glu His Gly Thr Thr Phe Ser Tyr Val Cys Asp Asp Gly Phe Arg Ile
 900 905 910
 Pro Glu Glu Asn Arg Ile Thr Cys Tyr Met Gly Lys Trp Ser Thr Pro
 915 920 925
 Pro Arg Cys Val Gly Leu Pro Cys Gly Pro Pro Pro Ser Ile Pro Leu
 930 935 940
 Gly Thr Val Ser Leu Glu Leu Glu Ser Tyr Gln His Gly Glu Glu Val
 945 950 955 960
 Thr Tyr His Cys Ser Thr Gly Phe Gly Ile Asp Gly Pro Ala Phe Ile
 965 970 975
 Ile Cys Glu Gly Gly Lys Trp Ser Asp Pro Pro Lys Cys Ile Lys Thr
 980 985 990
 Asp Cys Asp Val Leu Pro Thr Val Lys Asn Ala Ile Ile Arg Gly Lys
 995 1000 1005
 Ser Lys Lys Ser Tyr Arg Thr Gly Glu Gln Val Thr Phe Arg Cys Gln
 1010 1015 1020
 Ser Pro Tyr Gln Met Asn Gly Ser Asp Thr Val Thr Cys Val Asn Ser
 1025 1030 1035 1040
 Arg Trp Ile Gly Gln Pro Val Cys Lys Asp Asn Ser Cys Val Asp Pro
 1045 1050 1055
 Pro His Val Pro Asn Ala Thr Ile Val Thr Arg Thr Lys Asn Lys Tyr
 1060 1065 1070
 Leu His Gly Asp Arg Val Arg Tyr Glu Cys Asn Lys Pro Leu Glu Leu
 1075 1080 1085
 Phe Gly Gln Val Glu Val Met Cys Glu Asn Gly Ile Trp Thr Glu Lys
 1090 1095 1100
 Pro Lys Cys Arg Asp Ser Thr Gly Lys Cys Gly Pro Pro Pro Pro Ile
 1105 1110 1115 1120
 Asp Asn Gly Asp Ile Thr Ser Leu Ser Leu Pro Val Tyr Glu Pro Leu
 1125 1130 1135
 Ser Ser Val Glu Tyr Gln Cys Gln Lys Tyr Tyr Leu Leu Lys Gly Lys
 1140 1145 1150
 Lys Thr Ile Thr Cys Thr Asn Gly Lys Trp Ser Glu Pro Pro Thr Cys
 1155 1160 1165
 Leu His Ala Cys Val Ile Pro Glu Asn Ile Met Glu Ser His Asn Ile
 1170 1175 1180
 Ile Leu Lys Trp Arg His Thr Glu Lys Ile Tyr Ser His Ser Gly Glu
 1185 1190 1195 1200
 Asp Ile Glu Phe Gly Cys Lys Tyr Gly Tyr Tyr Lys Ala Arg Asp Ser
 1205 1210 1215
 Pro Pro Phe Arg Thr Lys Cys Ile Asn Gly Thr Ile Asn Tyr Pro Thr
 1220 1225 1230
 Cys Val

12/64

<210> 8
 <211> 1235
 <212> PRT
 <213> Rattus norvegicus

<400> 8
 Met Arg Leu Ser Ala Arg Ile Ile Trp Leu Ile Leu Trp Thr Val Cys
 1 5 10 15
 Val Ala Glu Asp Cys Lys Gly Pro Pro Pro Arg Glu Asn Ser Glu Ile
 20 25 30
 Leu Ser Gly Ser Trp Ser Glu Gln Leu Tyr Ser Glu Gly Thr Gln Ala
 35 40 45
 Thr Tyr Lys Cys Arg Pro Gly Tyr Arg Thr Leu Gly Thr Ile Val Lys
 50 55 60
 Val Cys Lys Asn Gly Glu Trp Val Pro Ser Asn Pro Ser Arg Ile Cys
 65 70 75 80
 Arg Lys Arg Pro Cys Gly His Pro Gly Asp Thr Pro Phe Gly Ser Phe
 85 90 95
 Arg Leu Ala Val Gly Ser Glu Phe Glu Phe Gly Ala Lys Val Val Tyr
 100 105 110
 Thr Cys Asp Glu Gly Tyr Gln Leu Leu Gly Glu Ile Asp Tyr Arg Glu
 115 120 125
 Cys Asp Ala Asp Gly Trp Thr Asn Asp Ile Pro Ile Cys Glu Val Val
 130 135 140
 Lys Cys Leu Pro Val Thr Glu Leu Glu Asn Gly Arg Ile Val Ser Gly
 145 150 155 160
 Ala Ala Glu Pro Asp Gln Glu Tyr Tyr Phe Gly Gln Val Val Arg Phe
 165 170 175
 Glu Cys Asn Ser Gly Phe Lys Ile Glu Gly Gln Lys Glu Met His Cys
 180 185 190
 Ser Glu Asn Gly Leu Trp Ser Asn Glu Lys Pro Gln Cys Val Glu Ile
 195 200 205
 Ser Cys Leu Pro Pro Arg Val Glu Asn Gly Asp Gly Ile Tyr Leu Lys
 210 215 220
 Pro Val Tyr Lys Glu Asn Glu Arg Phe Gln Tyr Lys Cys Lys Gln Gly
 225 230 235 240
 Phe Val Tyr Lys Glu Arg Gly Asp Ala Val Cys Thr Gly Ser Gly Trp
 245 250 255
 Asn Pro Gln Pro Ser Cys Glu Glu Met Thr Cys Leu Thr Pro Tyr Ile
 260 265 270
 Pro Asn Gly Ile Tyr Thr Pro His Arg Ile Lys His Arg Ile Asp Asp
 275 280 285
 Glu Ile Arg Tyr Glu Cys Lys Asn Gly Phe Tyr Pro Ala Thr Arg Ser
 290 295 300
 Pro Val Ser Lys Cys Thr Ile Thr Gly Trp Ile Pro Ala Pro Arg Cys
 305 310 315 320
 Ser Leu Lys Pro Cys Asp Phe Pro Gln Phe Lys His Gly Arg Leu Tyr
 325 330 335
 Tyr Glu Glu Ser Arg Arg Pro Tyr Phe Pro Val Pro Ile Gly Lys Glu
 340 345 350
 Tyr Ser Tyr Tyr Cys Asp Asn Gly Phe Thr Thr Pro Ser Gln Ser Tyr
 355 360 365
 Trp Asp Tyr Leu Arg Cys Thr Val Asn Gly Trp Glu Pro Glu Val Pro
 370 375 380
 Cys Leu Arg Gln Cys Ile Phe His Tyr Val Glu Tyr Gly Gln Ser Leu
 385 390 395 400
 Tyr Trp Gln Arg Arg Tyr Ile Glu Gly Gln Ser Ala Lys Val Gln Cys
 405 410 415
 His Ser Gly Tyr Ser Leu Pro Asn Gly Gln Asp Thr Ile Leu Cys Thr
 420 425 430
 Glu Asn Gly Trp Ser Pro Pro Pro Lys Cys Val Arg Ile Lys Thr Cys
 435 440 445

13/64

Ser	Val	Ser	Asp	Ile	Glu	Ile	Glu	Asn	Gly	Phe	Phe	Ser	Glu	Ser	Asp
450						455					460				
Tyr	Thr	Tyr	Ala	Leu	Asn	Arg	Lys	Thr	Arg	Tyr	Arg	Cys	Lys	Gln	Gly
465					470					475					480
Tyr	Val	Thr	Asn	Thr	Gly	Glu	Ile	Ser	Gly	Ile	Ile	Thr	Cys	Leu	Gln
			485						490					495	
Asp	Gly	Trp	Ser	Pro	Arg	Pro	Ser	Cys	Ile	Lys	Ser	Cys	Asp	Met	Pro
			500					505					510		
Val	Phe	Glu	Asn	Ala	Met	Thr	Lys	Asn	Asn	Asn	Thr	Trp	Phe	Lys	Leu
		515					520					525			
Asn	Asp	Lys	Leu	Asp	Tyr	Glu	Cys	His	Ile	Gly	Tyr	Glu	Asn	Glu	Tyr
530						535					540				
Lys	His	Thr	Lys	Gly	Ser	Ile	Thr	Cys	Thr	Tyr	Asp	Gly	Trp	Ser	Ser
545				550						555					560
Thr	Pro	Ser	Cys	Tyr	Glu	Arg	Glu	Cys	Ser	Ile	Pro	Leu	Leu	His	Gln
			565						570					575	
Asp	Leu	Val	Val	Phe	Pro	Arg	Glu	Val	Lys	Tyr	Lys	Val	Gly	Asp	Ser
			580					585					590		
Leu	Ser	Phe	Ser	Cys	Arg	Ser	Gly	His	Arg	Val	Gly	Ala	Asp	Leu	Val
		595					600					605			
Gln	Cys	Tyr	His	Phe	Gly	Trp	Ser	Pro	Asn	Phe	Pro	Thr	Cys	Glu	Gly
610					615						620				
Gln	Val	Lys	Ser	Cys	Asp	Gln	Pro	Leu	Glu	Ile	Pro	Asn	Gly	Glu	Ile
625				630						635					640
Lys	Gly	Thr	Lys	Lys	Val	Glu	Tyr	Ser	His	Gly	Asp	Val	Val	Glu	Tyr
			645						650					655	
Asp	Cys	Lys	Pro	Arg	Phe	Leu	Leu	Lys	Gly	Pro	Asn	Lys	Ile	Gln	Cys
			660					665					670		
Val	Asp	Gly	Lys	Trp	Thr	Thr	Leu	Pro	Ile	Cys	Val	Glu	Tyr	Glu	Arg
		675					680					685			
Thr	Cys	Gly	Asp	Leu	Pro	Ala	Leu	Glu	His	Gly	Ser	Val	Gln	Leu	Ser
690					695						700				
Val	Pro	Pro	Tyr	His	His	Gly	Asp	Ser	Val	Glu	Phe	Thr	Cys	Ala	Glu
705				710						715					720
Thr	Phe	Thr	Met	Ile	Gly	His	Ala	Val	Val	Phe	Cys	Ile	Ser	Gly	Arg
			725						730					735	
Trp	Thr	Glu	Leu	Pro	Gln	Cys	Val	Ala	Thr	Asp	Gln	Leu	Glu	Lys	Cys
			740					745					750		
Lys	Ala	Pro	Lys	Ser	Thr	Gly	Ile	Asp	Ala	Ile	His	Pro	Asn	Lys	Asn
		755				760						765			
Glu	Phe	Asn	His	Asn	Phe	Ser	Val	Ser	Tyr	Arg	Cys	Arg	Gln	Lys	Gln
770					775							780			
Glu	Tyr	Glu	His	Ser	Ile	Cys	Ile	Asn	Gly	Arg	Trp	Asp	Pro	Glu	Pro
785				790					795						800
Asn	Cys	Thr	Arg	Asn	Glu	Lys	Arg	Phe	Cys	Pro	Pro	Pro	Pro	Gln	Ile
			805						810					815	
Pro	Asn	Ala	Gln	Val	Ile	Glu	Thr	Thr	Val	Lys	Tyr	Leu	Asp	Gly	Glu
			820					825					830		
Lys	Val	Ser	Val	Leu	Cys	Gln	Asp	Gly	Tyr	Leu	Thr	Gln	Gly	Pro	Glu
		835					840					845			
Glu	Met	Val	Cys	Lys	His	Gly	Arg	Trp	Gln	Ser	Leu	Pro	Arg	Cys	Thr
		850				855					860				
Glu	Lys	Ile	Pro	Cys	Ser	Gln	Pro	Pro	Lys	Ile	Glu	His	Gly	Ser	Ile
865				870						875					880
Lys	Ser	Pro	Arg	Ser	Ser	Glu	Glu	Arg	Asp	Leu	Ile	Glu	Ser	Ser	Ser
			885						890					895	
Tyr	Glu	His	Gly	Thr	Thr	Phe	Ser	Tyr	Val	Cys	Asp	Asp	Gly	Phe	Arg
			900					905					910		
Ile	Ser	Glu	Glu	Asn	Arg	Val	Thr	Cys	Asn	Met	Gly	Lys	Trp	Ser	Ser
		915					920					925			
Leu	Pro	Arg	Cys	Val	Gly	Ile	Pro	Cys	Gly	Pro	Pro	Pro	Ser	Ile	Pro
930						935						940			

14/54

Leu Gly Ile Val Ser His Glu Leu Glu Ser Tyr Gln Tyr Gly Glu Glu
 945 950 955 960
 Val Thr Tyr Asn Cys Ser Glu Gly Phe Gly Ile Asp Gly Pro Ala Phe
 965 970 975
 Ile Lys Cys Val Gly Gly Gln Trp Ser Glu Pro Pro Lys Cys Ile Lys
 980 985 990
 Thr Asp Cys Asp Asn Leu Pro Thr Phe Glu Ile Ala Lys Pro Thr Glu
 995 1000 1005
 Lys Lys Lys Lys Ser Tyr Arg Ser Gly Glu Gln Val Thr Phe Arg Cys
 1010 1015 1020
 Pro Pro Pro Tyr Arg Met Asp Gly Ser Asp Ile Val Thr Cys Val Asn
 1025 1030 1035 1040
 Thr Lys Trp Ile Gly Gln Pro Val Cys Lys Asp Asn Ser Cys Val Asn
 1045 1050 1055
 Pro Pro His Val Pro Asn Ala Thr Ile Leu Thr Arg His Lys Thr Lys
 1060 1065 1070
 Tyr Pro Ser Gly Asp Lys Val Arg Tyr Asp Cys Asn Lys Pro Phe Glu
 1075 1080 1085
 Leu Phe Gly Glu Val Glu Val Met Cys Gln Asn Gly Ile Trp Thr Glu
 1090 1095 1100
 Pro Pro Lys Cys Lys Asp Ser Thr Gly Lys Cys Gly Pro Pro Pro Pro
 1105 1110 1115 1120
 Ile Asp Asn Gly Asp Ile Thr Ser Leu Ser Leu Pro Val Tyr Ala Pro
 1125 1130 1135
 Leu Ser Ser Val Glu Tyr Gln Cys Gln Asn Tyr Tyr Leu Leu Lys Gly
 1140 1145 1150
 Asn Lys Ile Val Thr Cys Arg Asn Gly Lys Trp Ser Gln Pro Pro Thr
 1155 1160 1165
 Cys Leu His Ala Cys Val Ile Pro Glu Asp Ile Met Glu Lys His Asn
 1170 1175 1180
 Ile Val Leu Arg Trp Arg Glu Asn Ala Lys Ile Tyr Ser Gln Ser Gly
 1185 1190 1195 1200
 Glu Asn Ile Glu Phe Met Cys Lys Pro Gly Tyr Arg Lys Phe Arg Gly
 1205 1210 1215
 Ser Pro Pro Phe Arg Thr Lys Cys Ile Glu Gly His Ile Asn Tyr Pro
 1220 1225 1230
 Thr Cys Val
 1235

<210> 9

<211> 150626

<212> DNA

<213> Homo sapiens

<400> 9

gatcataatg gtatacaaca attaacatca gaataaaaact tggaaaacttt acaaacacttt 60
 ggaaattaaa caacatgtac atttaaaacc aatggctcaa tgaaggaact aaaaaaaatt 120
 tggaaagtgt ttgagacaaa tgacaatgga agcacagcat actataatag atgagataga 180
 gcaaaaccag ttctaagagg aaattttata acaataaatg ccttatcaaa agaataaat 240
 ctctcaaata aacaaccana cattgcaoct taaggagcta aaaattttaag aacaacatta 300
 ctaaaaacaa gtogaaaaag aaataataaa gatcagagca gaaacaaaca acgcagagac 360
 taagtgttag tatgacaaaa tcagtaaagc aaagatttta aaaaaaattg acaaacattt 420
 tcttagacta agaaaaataa gggagacgat ccaataaat aaatcagag aggaaaaagg 480
 agacattaca tctggttcta cagaaacaca aaggatcata aaactataa ggaacaattg 540
 tttgccata aattgggtata cctggaagaa atggacaaat ttttggacac atacaacata 600
 ccaagattga attaggaata aatagaaatc taaacagaca aataatgagt aagttgatta 660
 aatcagtaat aaatttcacc catcaaaaaa gcccacaaacc tgttatcgtc actgctgaat 720
 tctaccaaat attaaaaaaa aaaaaactca gagtaatttt tctcaaaacta tgccaaaagc 780
 aaagaaaatg gaatttttcc aacttattgt agcatgccag cattgccctg ataccacaaac 840
 caaacaagga aacaacacaa aaagaaaact acaggctgat gtccctgttg aacagaggtg 900
 ttaaaattct taataaaaata cacaaaaaag tgaattttctg ttcctttggt tgtttgtttt 960

15/64

tgagaagagg	tctctctctg	tcagcccggt	tggaacgcag	gggtgccatc	ctggtcggt	1020
ctatcctcga	cctcttgggc	tcagcaatc	ctttcacctc	atcctccaga	gtagctggga	1080
ctataggcct	gggtcaacac	accagctaa	ctcaaaagct	aactgcagtt	tttaaaaata	1140
gagtataatt	aaaacaagg	ttgtatgtac	aatgttgaat	catacaactt	aaaacgtgga	1200
gggtcagaa	gagatcaact	cttctacccc	caccccgac	atagggcaat	atcgtatag	1260
gtcacacttt	tagaaaatca	cttgacctct	gattcgatgt	tggataatac	tgttacctgc	1320
ttcactgact	gtgacagtc	tcatacaaa	ctaaactact	ccccctcata	aatgttttga	1380
aatatctcaa	gacagtcatt	ataatgotat	aactctatct	ttttgcatgc	ttcttatgct	1440
ataattttct	taactcttca	actatctata	tattctcttc	tatgccatga	tagttggaaa	1500
ccaatcattt	taaaacgtgg	taggctaagt	acggatatatt	attacagaca	tgatatttgg	1560
tgggcaaaac	acacagttga	gagtaacttt	ttgacactga	aaaacatcat	ttcctcatga	1620
agcctgaaa	agatagatgt	tctctcagtt	accacatttg	tctattaata	ttagggttat	1680
taafgaaaa	cttcattttc	ctccacttaa	tttactttta	aagctaaata	caaatgttgt	1740
ttccactaag	taaatctgct	aaacaaaaaa	taaaaaattc	tttttgactt	gaatgcctca	1800
tgaatgattt	atctgttctt	aacagataaa	taaaaaagac	tttttttttt	ttttgagaca	1860
gaatcttctg	cagttgcccc	ggctggagtg	cagtgactog	atctccgctc	actgcaagct	1920
ctgctctctg	gattcacgca	ataatccccc	ctcagctccc	cgagtagctg	ggactacaga	1980
cgcccgccac	cacgcccaga	taattttttt	tgtatatatt	ttagtagaga	cggggtttcg	2040
ccctgttagc	caggatggct	ttgatctcct	gaactcgiga	tcgcccctcc	tcggcctccc	2100
aaagtgtctg	gattacaggt	gtgagccact	gtgcccggcc	aaaaagacat	ttttgaagga	2160
agttaaaatt	tttaattaaa	acatgttctg	gatttttttt	gctttgaaga	ttagtctctt	2220
tgagataaat	ggtatagagt	aatattcttt	gaatgtatat	gtgaatttca	gtatagacat	2280
aggtttgtct	taatagctat	ttcgtctgag	tcagctataa	aaatattcca	tgctctatbt	2340
gttcataata	tagtaattat	tgacagaaca	ttttttgggg	gaaattcatg	tcaatcattc	2400
tcattacctc	tctcaataat	aactgaactt	ctgcaattgt	gggtgtccct	ttcactcaat	2460
ttttttctgt	caaaaacga	aaacaaacag	gcgcaaaaaa	accctggcaa	taacctttga	2520
taaacatcgt	ctctcaacca	ttttcttctg	agattgcagc	aatcataact	agtttctctg	2580
tcttgacctc	tcattctttg	aatctatttt	cctgtgtata	aattaatgac	ctttcatctg	2640
gtcattttat	ttctccactt	aaaatcttta	atggatctca	agtcagctaa	caggacaaga	2700
acctcatttt	actttctctc	cttctactaa	ctagatgtgg	tctcttcagc	aattctggag	2760
gtttttatcag	catttaattta	aactgagctt	atctacaact	ataccaagtt	aagctcaagc	2820
tgccagttca	gggtgcacgc	attagcaatg	athtgttttt	ggaaaagaga	gacaagaaat	2880
atgactgtaa	cataaaaaat	ctgatattgt	gcaaatatct	tcagatata	aaacattttg	2940
tttagttttg	tggcattttg	ttgttatgct	atggcatgca	ttcttaccat	agttagaatt	3000
catgtgtcag	ataagatata	ttattgacat	aaaaataaag	tgcataagac	aatgtacaaa	3060
tatgtatata	ttcttaccat	ctataggtat	gtatacctat	agaatgttga	acaacacac	3120
aattttaata	gcatacatt	tatgtttact	ctataattat	ggaacaagtg	atagaaaata	3180
gtattttacat	tctattttgt	atgaaaactt	aagaatataa	ttaaataaaa	gttaagtttg	3240
aatcatcata	aaccagagag	aactagaaag	acgctagtgg	cacaacagct	ttagtgtgca	3300
gatgagaaga	ctaagttcag	agaagtgaac	tctttacttt	gaggggaagc	tttgcagttt	3360
acagaactgg	atccagaggg	ttgttggggc	acgcatgaca	ccttctctga	cccagctccc	3420
caagcatgga	tgcacagttt	tctgctgagt	tctctctcgg	tattggaaaa	tcgaaacttc	3480
cggccctgtg	gtaacctcct	gagatactct	tacattttct	tatgatttga	ggatattttg	3540
tcgaggttag	aaagggacat	aaactaaagg	aatcatttta	aatctttctt	tttttcttca	3600
tttttatttt	tatttttaat	agtcttgctc	tgtctccaaa	gctagagtgc	agtggcacta	3660
tattgggtca	cgtaaacctc	tgtctccggg	gttcaagtga	ttctctctgc	tcagtctcct	3720
gtgaagctgg	aattacaggt	gtgtgcccgc	acatccagct	atttttttaa	acttttagta	3780
gagacagcat	ttcatcatgt	tggccaactc	ctggcctcaa	gtgatctgct	cgccttggcc	3840
ctcgaaaagt	ctgggattta	tgtgtgagcc	atcctgctcg	gccccaaatt	atttttctta	3900
gtcaacgata	atttcgaacc	tgaagtgaat	ttttcatggg	ttaggtttgt	ttctaaaaat	3960
cgttctttcc	actaaaaggc	actggaattt	catagagaaa	ttattgaaac	ttagtctgta	4020
gtaggaaaag	tcaaggaaa	tatgggtctc	tatgttatgc	caaagcttaa	tgggggcaca	4080
tgaatatata	acagaagcca	tcttcttagt	gagatgtgaa	acaaatttca	gcattccaaa	4140
gaagtacaat	ggcaattaac	tgtaatgcat	ttgttactgt	aatgatcagt	ttaaaaggga	4200
tttaaaaagc	accctgctct	acaatgttaa	ttgtcactct	tgacactttg	ttatggcaac	4260
tctagttagt	gaatataaaa	tttatacaat	tctgaaagga	tattcataat	taaaataaat	4320
gttattgaca	acctattttt	aaataagtat	aaataactta	tgacttgatg	gaagaataat	4380
tggccaatac	aaattcaatg	sacattataa	taggttacaa	ttacaaaatt	tctgtcaagt	4440
ttgtctttca	aatagcgtgg	tttccaaaag	aattgggtgt	cogattttat	tgttcagaa	4500
tgaatatatc	actaccatta	aaaaaatttt	attagcataa	gcaattcaca	aagtatgtcc	4560
ttcattaatg	atatgaaaaa	tctttcttag	atttgattta	ctagattctg	aatatagatg	4620
aatacagata	tatatacaca	taaagtattc	aacaagacaa	aatcagcag	gaaaatacac	4680

ccaagatgta	attaccaaat	tctgatgaat	agcctctaaa	atctgtgtgg	tggctacata	4740
tatatatata	tattcttgag	taaaaagtaa	aaaattat	ttagttatta	atgttctttt	4800
aaataaattgt	gtaaatatca	tggatattcat	ctgctagagc	taccataaca	aagtaccact	4860
gatttccatag	aaatttat	tctcacagtt	ctggaggcta	atagtttgag	atagagctgt	4920
caacaggatt	ggattcttct	gagacctctt	cctttgcctt	gtaaatgggt	gtattctttc	4980
tatgccttgc	gtgatctttc	tctatatggt	gtgttcttat	ttctcttctc	tatatagaca	5040
ccagttatata	tggagtagga	cccacctgaa	tcattggcct	tttaacttaat	tacatcttta	5100
agcactcctt	ctccaaatgc	agtcacattc	tcagggtattg	ggaatttggg	ctttaacaaa	5160
tgaatttttgg	cgggatgcaa	ttgagccaat	gotactgaat	acacaaagat	gtttctctct	5220
aaaccaagact	ttgaaagtaa	cccaatgagt	tactttctcc	tttgagaaat	ataggtgcga	5280
cccaaatttta	caagacattt	tgcctcaagt	tactcttaca	aagagttcat	tggaggagac	5340
aagttttcaa	ctggaatata	agataaggaa	gaatttgtca	tcattctttt	ctatagtgtc	5400
tttaagaaaag	taagtaagaa	agtatagtgc	atattgctttt	ctaattccag	tcatttcaga	5460
atggtactac	ttttcttctt	ttcattctac	tttaattctat	tttaattctta	tttgaaaaaa	5520
atgtacctgt	atcagttcag	tttaacaaagg	aaataacagg	agaatttctc	tttttttcca	5580
tttttagcaca	gatcaagttt	gattttgcac	aacaaataaa	actagcaaat	catgtgatag	5640
ataatactgt	aaaacctaaa	gctctttacc	tagaatcaaa	taaagtggca	tagcttttag	5700
aagagagggt	gagggaaaag	atactctcat	aaattgataa	ttggatttcc	agtattctcc	5760
tccactacat	ttggtgaaat	attatgaagt	tttggataat	tacaaaattt	gtattcttca	5820
ttaatggcca	caaaccttgg	attgtccatg	acatttgacc	catgtggttc	cactgctaatt	5880
gttacgatat	agttctttta	tatgcaaggc	ctgcattcaa	aaaggtagtt	aatatagaaa	5940
atatatgact	gttgaggaga	aaacaaatca	gtgaacaata	acataaagct	ataaaaaata	6000
attatgtatt	tattttattga	acattttgcta	gtgagctcag	aaatgcaaaa	tttactgtca	6060
tttaaaaagta	agttaagcat	atagtctact	ttttgattat	attcatgthg	tgattttacat	6120
gttgtgattt	acatgttggc	aatcttggtt	aaatattaag	ttcatattaa	tggttaattca	6180
tttttagcagc	tttctttagg	tatttatagaa	ataaaagaaa	ctgcagaatt	taaaatgtat	6240
tattttgatgt	tttgatatat	gaatctataa	aaaatcacca	tctgttaagat	tatgaaaata	6300
tcagtcactc	cccttgcatt	acaaataaga	aactctctga	cattttaagg	ttagaatctg	6360
tctagtgcaca	tgtttctctac	ttaaagtttc	atgagtatat	tcacatatct	ccataatcaa	6420
tattaaatgt	cttttacact	gtagaactta	taaaacaaag	aaaatattat	tcattgttta	6480
agttaaaaatg	agataaatat	taataaaaatt	aaattctgtt	atagtcttac	aaaatatgct	6540
atttctacta	gcatagtgaa	taaatctctc	ttggttcata	aaaaattgta	gacatggaga	6600
cataggaagc	tagatattac	atgaagttac	atttaagatg	ggagctgagt	gttttagatct	6660
ctttcaattt	accttgtcca	ttagcatagg	aaacccacaa	ggttagaatg	acatttaatta	6720
gtaacaacat	gttagatatt	ctcagtagta	tagtaatgca	aaagtttcag	ttgtactggt	6780
tggagtttga	aatctttcat	tattagttac	caagggtgat	tccgaatttg	aggaaactac	6840
cacgaagcta	ggccttttaag	gtcacttagt	aaatatcaaa	gttcagagag	ttttgcaaaa	6900
tgcctcaata	attccagtta	gtggtttccac	aacctctgt	ggaattgatt	ccctgaaatg	6960
tacttgtaaa	atattattta	gggacagtaa	tggactgaat	ccaaaagtaa	tataaacat	7020
taatttat	tatctctcat	tttttgagta	aagagagtat	caataaagg	aacgaaaggo	7080
ttctgcaact	actggaagaa	ctgagggaac	aaaggtcata	aatgctatth	ccagaaaatt	7140
ccgaagttca	ggaatcttag	tgatgcccc	ctaattatcc	attgtactgc	agtygatgtt	7200
tcttaggaaa	acttccagaa	gcaaggaaa	ctactgttgg	tgatctcagc	tgctaccagc	7260
agctgctacc	agataatgoc	ttgcctttca	ccttggtcca	gttttcttta	ggtacatctc	7320
atgggggaat	ctaagggaga	agcaagctaa	aatacaaaata	cagctacaaa	tacaaataca	7380
agctaaaaat	aaaatagctt	gtaaaatata	aatacaaaat	aaaataaaaa	ttctaataac	7440
agatcgtatt	aggaataaat	agaaaaatcaa	aacaaacaaa	taatgagtaa	gttgattaaa	7500
tcagtaataa	aattcaccta	tcaaaaaagc	ccaacgcctg	ttatcttccac	tgctgaattc	7560
aaccaaacag	tataaaaaac	tggtagtatt	ttttttcaaa	ctatgcataa	aataaagatg	7620
agcagacata	cacaaaccaa	tagatgtaac	atatcacaat	aacagaaatca	acaaaaactat	7680
atgatcattt	tcatagaagt	actaaaaaca	tttgagaaac	tttgacattt	cttcattgata	7740
aagagtctcc	acaaattagg	cagagcagag	ccagatgggtg	gaataggaga	caccaaccat	7800
tcccttccaa	agataccaag	tttaacaaeta	tgtacacaga	aaaaaaaaaa	aacaccttca	7860
taaaaatgaaa	acattatcag	attagcactc	atagtacatg	gttttaactt	catatccctg	7920
aaagaggcac	gtaagagata	ggtcagacaa	ctttgagtca	ctgacactac	cctttccctt	7980
ctccccacac	ttgcagctgt	gccatgatgt	acagagcctt	gctctaggca	ctgagggagg	8040
gagaacatag	caatttgtgag	gcattgaaca	aatgctgtg	ctggttagagc	agaaaggaaa	8100
gccaaaccaa	actcagctaa	cccttcccca	tggagggagt	atttaaacca	atgctagcca	8160
tgaacgtatt	gctgacggca	ggggctctgaa	atcaagttcc	cacaaatctt	gccacctagg	8220
gctacctacc	atgcatttgt	tctctaaaata	aactagaaa	acagtctagg	acataaggac	8280
tgcacacata	tgtgagtctt	agtgctgaac	taggtcaga	gactatggac	tgggggaaga	8340
cacagaatat	tcagagacac	caactgcacc	agctgaggca	gccaagagca	tgctggcctc	8400

```

accccaacccc taaccccagg cttcacattt cacagctcca aaagaaaccc cttccttctg 8460
cttgaggaga ggagagggaa gaacggggaa gactttgtct tacatcttgg atatcagctc 8520
agacaaagca ggatagggca actgtcaaa gaaatgagggc cctgctttaa gccctagctc 8580
ccagatgaca tttcttgaca taccctgaac caaaagggaa cccaatgcc tgaaggaaat 8640
gatgcagtc tggcagcalt caccagcct aactgaagag cccctggccc tcaataacct 8700
gcagtgatac ccagatacta tgttgagggc cttaggtgag cctctgagac ttgctggctt 8760
caggtaccag catggccaca ggggatagag aaccacctgg gctcccaggg tcccagttc 8820
ctggacttga ctgggtgggtg gcatttttgg acataccatg gaccagatgg gagcccagtt 8880
cccagaaggg tgaatcctag gctagccagc attcaccaca aactgactta ggagcaccta 8940
aaccttaagg gaacatcagc agttgtotgg cagtaactct catggcctgg agtgggtgta 9000
gaocataggg tgaggctcct ctgactttgg aaaggggagg gaacagtggag gaggattttt 9060
ttttattatt atactttaag gtttagggta catgtgcaca acgtgaagg tagttaocta 9120
tgtatacatg tgccatgttg gtgtgctgaa cccagtaact cgtcatttaa cttaggttat 9180
atctccaaat gctatccctc cccctccccc ccacccccc ccacaacatt ttaacttgca 9240
atatgactgc cagcccagat acagtacatc ataactcaa gcagacatct aagggtttttg 9300
aaactgggtc cctggaaacc accctgggtc agggggccctc atcactctga attctctcag 9360
atcatgtgca agaccatcaa tagagtaccc ccgaaggtct gaaagaacca ctgcattggg 9420
gggattttga caccctgtaa agaagttaca gtttaggtca caacacccaa gtcctttcaa 9480
acatgtggaa catcttgcca agaaggatgg ttacaattaa gccagacag tgaagaaaaa 9540
aataaataac taactcttca gtgcccagac acagaagaat atctgctagc attaacgcca 9600
tccaggaaaa cccgacctca ccaaatgaac taacaaaagc accagggaaac aatcctagag 9660
aaactgagtt atgtcacctt tcaaacacag aattcaaaaat agttttgttg aagaaactca 9720
aagaaaaatc agataacaca gagaaggaat tctgaactct atcagataaa ttgacaaaag 9780
agattgaaat aattttaaaa aatcaagcag agattcttga gccgaaacat gaattgaca 9840
tactgaagaa gatattacac gtgctattct ttaatagcag aatagatcaa gcagaagaaa 9900
gaattgttga gcttgaagac aagctatgtg aaaatacaca gtcagaggag acaaaaaaat 9960
aaagaattaa aaacaatgaa gtatgcctac aggatctaaa aaataacctc caaaaagcaa 10020
atctaagagt attcaacctt aggaagaagt agagaacgag ataggagtag aaagtttatt 10080
caaatggata atcacaaga acttcccasa cctagagaat gatattctata ccaggtacta 10140
gaaggttata ggatgccaa gcatatttaac ccaagaaga ctacctcaac tcatttaata 10200
taaatcaaat acaatggagc accaatacat ctggtagcag gctttttaga ggaatcctta 10260
caggagtgat atgacacatg ctgacagaaa aataacgttt atcctagagt agaatactg 10320
gtgaaaatat cctttaaaca taagaagaa ataaagacat tctcagataa gcasaagggt 10380
aggaatttta ttatgccaga cctgtcctac aagaatgtct aaagggaaata tttcaatcaa 10440
aaaatttaaa tcatgaacaa taatcacctg aagacacaaa tctcaactgg aatagtaagt 10500
acatagaaaa atacagaata ttaaaacact gcaactgggt tgtgtgaagt aatatcctaa 10560
gtagaagac taataatga actaatgaaa cataataact acagattttc aagacatagt 10620
ctgtacaata agataaaaa agaaacaaca aaaagtttga aagcagaagg gaaaattaa 10680
gtggagagta tttatgagtt ttctttggct tgtttgttta tgcaaacagt gtttaagttg 10740
tttctgggtt taagatagta tttgcaatcc ttatggcaag ttgaaacaaa aaattaaaga 10800
atctggaaat taagaatat gccctgaat gcacagtggg tcaatgaaga aattaaaata 10860
tttgtgaaa caaatgataa tggaaacaca aaacctatgg gatatagcag ttttagtacc 10920
aagagaaaaa tttatagcta taagtgacta cataaaaaag aaaggaaaaa cttcaaataa 11040
acaatttggg gatttatgtt aaagsactag aaaaggaagg gcaatccaaa tccaaaatta 11100
ttagaagaaa ataaataata aatatcacag cagataaact tgaaattgaa atgaataaaa 11160
tacaagatc aatgaaacat aagttgttat tttaaaata taaacatgct gatcaacctt 11220
tatccagact aagagaaaaa gagtggagaa tcaaataaat aaaatcagaa atgaaaagga 11280
aacattacat ctgactctgg agaaattcaa gcaatcatta ttggccacta tgtggaatga 11340
tattccaata aattggaaaa tctagaagaa atggacaaat tcttagacac ataaaaacta 11400
ctaagattga agcagaagaa aatccaaaac ctgaacagat caattattaa tacaagttaa 11460
gagatcaaag ccagaataaa aagctctcata gtaagaaaaa gctcaggaca tattggcttc 11520
actgttgaat tctccctaac atttaaaaga gaactagtag caattctact ctaactattt 11580
tgaaaaatag agggaggaga ggagcaaata ctccaatgt gaggtcaata ttacctgaa 11640
aagaaaaatc acaaaagaca cattaaaaaa agaatactac aggtcaatat ctctgacaaa 11700
tgtaattgta aaaattctca acaaaagsat agcaaacaaa tttacagca tactagaag 11760
atcattcaac atgacaaaat gggattttat cttgagatgc aaagatggct caacatatc 11820
aactcaatca atgtaataca tcataccaac acaatgaagg atataaaaca catgattatt 11880
tcaattgatt ccaaaaaggc atttgataaa attcaaaatc cttcatgata aaacactaaa 11940
gaaaactgaa gatagaagga acacacccaa acataatcaa agctgcattt gacagacaca 12000
cagctactct caaactgaat ggagaaagtc tgaataaatt tctcaaaagt actggaacat 12060
gacaaggata cccacttcac cactgttatt caacataata ctggaagtc tggctacagc 12120

```


agtttagacaa	gagaggggata	taaaggtatc	caaactgaaa	agaaagaagc	caaattatct	12180
ttgtttgcag	atggtataag	tttttttcga	taaacgtaag	gtaatcacca	gaaaactatt	12240
agaactgata	aacaaatcca	gtaaagggtgc	aagatataat	atcaacataa	aaaaccagta	12300
gcattttgtat	atgttgacag	caaacaatct	gaaaaaaatc	ctaaaggtaa	tcccattttac	12360
agtaaccaca	gataaaaata	aataattaga	tattaaccaa	agaagtcaaa	gatctctata	12420
agaaaaacag	taaaaacacta	aaaatagaag	ttgaagagga	caccaaaaat	aaaaaagata	12480
tttcatgata	atggactgga	aggatcaata	ttgttataat	gtccatacta	cccaaggcaa	12540
totacagatt	caagaaatca	ctatgaaaat	accagggaca	ttcttcacag	taatagagaa	12600
aaacaatcct	aaaatttttta	tggtaccaca	aaagctaaag	gtacccaaaa	tagctaaagc	12660
tatcctaagc	aataaaaaaca	aaactgaagg	aataacatta	cotgacttca	aattatacta	12720
cagagtttga	gtaactaaaa	cagcatagta	ctggcataaa	aacagacata	cagtctaatg	12780
gaacagaata	gagaacacag	aaacaaatct	acacatctac	agtgaatgca	tttttgacaa	12840
agggagcgttg	tggaaaaagac	agtctcttca	attaacgggtt	ctaggaaaac	tggatttttca	12900
tatgcagaag	aatgaaacta	gacctctatg	tttcaccata	tccaaaaatc	aaatcaaagt	12960
gataaagact	taagtctaag	acctcaaat	atgaaaacttc	taccagaaaa	cattgggggaa	13020
aatctcaagg	acttttgttct	ggggcaaaaat	ttcttcagca	ataactcaca	agcacaggca	13080
agcaaaagcag	aatgggacaa	atgagatcac	atcaagttta	aaatgttctg	cacagcaaac	13140
gcacacaatga	acaaagtga	gaaataacac	tgagtgaggac	aaaatatttg	aaactaccca	13200
tctgacaagg	gattaataac	cagaataatt	aaagagctca	aacaactcta	tcagaaatca	13260
tctaataatc	agatcaaaaa	agggcaaaaag	atctgaatat	agatttctta	aaaggatata	13320
ttcaaatgga	aaacagacat	gtgaaaagaf	gatcaacata	actgatcabc	agagaaatgc	13380
aaatcagaac	tacagtgaga	tatcatctca	ctccagtga	aatggcttat	atggaaaaga	13440
gagaaaaata	cagatgctaa	tgaggatgtg	gagaataggg	aaatcttgya	cactgttggg	13500
gggaatgtaa	attaatacaa	ccactatgga	gaacagtttg	gaggtttctt	agaaaaactaa	13560
aaattgagct	accttatgat	ccagccatcc	taatgctgtg	tatacaacag	cagtgtacgg	13620
aaatcagtgt	atggaagcgg	tatctgcaca	cctatgtttg	ttgcctcact	gtatacaata	13680
gctacgattt	ggaagccacc	aaagtgtcca	tcaacagatg	aatgaataaa	taaaatgtgg	13740
cacacataca	caatggagta	ctactttggc	ataataaaga	atgagatcca	atcattttgca	13800
acaacatgga	tggaactgga	gatcattatt	ttaagtgaag	ttagccaggc	acagaaatac	13860
aaacctcaca	tgttctcact	tatctgtggc	acttaaaaat	caaaacaatt	gaactcttgg	13920
acatagaaaag	ttgaaggatg	gttactagag	actgtgaagg	gtggtatagg	gctagagggg	13980
agatggggat	gggtcaatgtg	tacgaaaaaa	aatagaaaaa	ataaataagt	ccatctatct	14040
gacagcacaa	tgggttggct	atagtcaatg	ataacttact	tgtacatttt	aaaaataact	14100
atacagattt	attggatggg	tggaactcaa	aggaaagata	cttgagggca	tgtatacccc	14160
attccccatg	atgtgctcat	ttcacattgt	atgctgtat	caaaacattc	taagtactcc	14220
atcaatacat	acacchactg	tacacctatg	atgtgcacag	gaaaaattta	aaacatatgt	14280
atagaagaaa	agtaacccaa	taccataaat	agcatatatg	acaaaoccat	aggtaacttt	14340
tatatcccat	gggtgtcatc	acaatgtgtt	attggcattg	accagagtag	aataaaaacac	14400
tactagatat	gtaaagaagc	agaaaaatag	gcccatattt	agaagaaaaa	gatctatcaa	14460
taatyctaaa	gacaaaccat	atagtaaaata	tagtaaaata	agcaaaaact	cctccataac	14520
tttaaaataa	ctgcaaaaaca	taagacaaaa	atcttcagga	aaatatatac	gtaaatgttg	14580
aagagagggtg	gaatttccagt	tgaataatga	cacttagcca	agtataacag	gttactgaaa	14640
acatttttcag	ttataatgaa	attttactct	atctgtaagt	agtgttcgta	aaaactttat	14700
aaaagtattg	taattttttaa	aactatttgt	agtattttta	agatgggtgt	ttttgaaatt	14760
ctataaaaaa	ataatctttt	tgaaaataat	tttatttttt	caagtgtccc	aacctttttg	14820
aacatctgtg	attgggtcaga	aatatggatg	ataataaact	ttaaaataca	gcacaagggtg	14880
ttttcaaaag	tctttgcata	aatataatc	agaaattact	gaccaaggac	cttagtgaag	14940
aacaccagga	atccactaat	attgttaagt	gtgctattaa	caaaaaaaga	gtcagccctt	15000
tcatttaatta	ctttttaaag	tatagcatag	caaaaaacct	tgaactatca	aaatgacaca	15060
caaaagtaag	taggttctct	agcggttatt	taggagttta	tatgacttta	tgtattagtt	15120
gatagtattt	taattttttc	aatattcagt	gaatacaaaag	tgaaataccc	aaactgaaac	15180
atgcttcata	cttttatctt	tttttacata	aaattttctc	tatggaaata	tttttagatt	15240
acataaaaag	tgtaaagagt	attcagataa	ggtcttttgt	aatctgaaaa	tcaataaaaac	15300
aaagattaga	tttattacat	gaatgtcaaa	tgaacttatt	ttttgttaaga	taagcatact	15360
tacaaaagac	atttagcttc	tctttctgta	gtagttagaa	aggctaggct	taaatatatt	15420
aaatagaata	tatgtactca	gcaatattga	aatatataat	attatcacta	ttattattat	15480
tattatttaag	tgtgaacacc	atgctgtgaa	atagatagta	aaatgtatc	ctctagtcta	15540
actgaaaatt	tatacccttt	gaccaacacc	tcctagaaaac	accgcatcc	cttcagcttc	15600
tggttaaccac	cactctactc	tcacctctct	taaatttgaa	ttctcttagat	ttccacatatc	15660
aatagatca	tgcaggattt	ttcttttgtg	tgactttatt	tttagatagca	taatgtccac	15720
tagattcctc	cacgttttcc	ctattgacaa	aatgtctctc	tttttagttt	gtatagtatt	15780
ctactgtgta	tctataccac	atattctctt	tttgtaaaaa	ttttcattta	ttttttattg	15840

19/64

gcaataaaaa	ttgcarataat	ttattatgta	aaacatatgt	tgttgaanta	tgtatacatt	15900
agatagtggc	taaatcaagc	taataaataat	atgcttttcc	tcacataact	ctcattttttg	15960
tgtgtgggtga	gactgcttaa	aatctacact	aagtagtttt	caagaataca	acatattatt	16020
gttaactaaa	gtcaccatatt	tttacaacgg	attgcatgta	taagtgcatt	catgtgggtt	16080
tgtctgtctt	attccaccta	acttaattgt	ctccctgttt	attctatgtt	cttgaaaatg	16140
caggatttcc	ttttttcaaa	gctgaatagt	attacattgt	gtatatagac	cacattttct	16200
ttatctatct	atctgtaattg	gatacttaag	ttgattccat	attttggcta	ttataaataa	16260
tgtgttaattg	aagatgggaa	tgcagataac	tctttgacat	actgattcct	ttttctttgt	16320
acatatattc	agtagtagga	ttactggatt	gattatattgt	tctgcttttc	attttttgaca	16380
aactctatag	tattttccat	aatggctata	ctaataatca	tttccatcaa	caatgtgcaa	16440
gtgtgtcctt	ttctccacat	gtttgataac	acttgatgtt	tttttgtatt	gttgataata	16500
atacttgttg	gccattggta	cgtctttctt	tgagaaatgt	ccattcaggt	acattggcta	16560
tttttaaaatt	ggttaattcc	tttttattag	ccattgagtt	gagttcctta	tatatatttg	16620
atattaacgc	tttatcagat	atatggcttg	caaataattt	tccaactcct	gagttgtctc	16680
ttcactctgg	gcattgttta	ctttgctgtg	cagaagcttt	ttagtttgat	gtaatacaat	16740
gtgtgtattt	ttccttttgt	tgcctatgct	tggggaaacca	atccaagaaa	tcatagccca	16800
gaccaatgtc	atgtattttt	ttctctttta	tttccctcta	gcagttttat	agtttcaagc	16860
tttcatatgc	agctcttacc	aatattctgag	tagttttatg	tagtgtgaaa	cagtggatca	16920
attacattct	tctatgtgtg	aatatccgat	tttccagca	agatgtattg	aagagactat	16980
tattttccct	atgtgagttc	ttgtcatctt	tattgaaaat	atattgaatt	ctattctgtt	17040
ttattgggtg	cttggttttt	gccaatgtca	tgtatctgtg	cctataatag	cattatatca	17100
taattcaaaaa	tttagaagtg	taattgctcc	agctttgttc	tttttaatac	aaattacttt	17160
gaccttcggg	atctcttgtc	atttcataca	tatttttgaa	ctgtttttca	ttttctgtgt	17220
aaaaatgaca	ttagaatttt	gatggggact	gcattgaaac	cttacctctt	tttgtgtaat	17280
atgaacattt	tatccatatt	aaattcttga	gtccctgaac	atgggtattt	tttctgttta	17340
tgtgtgtctt	cttcaatttg	tttcatcaat	attgtattgt	ttaaaatata	tagattttttg	17400
agatccttgg	ttaaattttc	tccaaatttt	attttttggg	gttatccaga	aaggaaataga	17460
tcttttaaaat	tcttttttcag	acagttttat	gttagtatat	aagaaagaaa	aaagcaaaat	17520
ctaagcatga	agaacacaag	tgaaaattaa	tatacaactc	tatggattcg	gtaatagggt	17580
gaaccagaga	taagaagtat	ttaaatcatt	tttgaaaaga	agattcacac	tcagagtcaa	17640
ctatctaggg	gcaaaaataaa	cacaaagaaa	ttttaatttt	cacttagtag	tttaactact	17700
aatagcaacg	tttcattaca	cttttgacat	tttcatgaat	gagtcagtaa	agacaaatga	17760
gagaagaata	tattttaatga	gcataaacat	atagtttagat	agaataaata	agatctagta	17820
tttgatagca	caacagggtg	actatagtea	aaagtaattt	attgcacatt	ttaaaataag	17880
agggataaatt	ggattgtttg	taacacaaag	aaagtataaa	tgtatagatg	gatgaatacc	17940
tcattttacc	tgatgtgatt	attacacott	gtatgcctgt	atcaaaaat	tttatgtacc	18000
tcatacatac	tcagacgtac	catatactca	caaaaatgaa	aacatgtata	tactaaagtt	18060
gttttcacag	atgtattatt	aaatttgaat	tgtaaaatcc	agtgagaaca	acaaactttt	18120
atattttatt	tatatttcaa	agattttacc	acaaaaaatc	cctgaaaata	atttatattc	18180
caaagtattg	gacattccca	tctattacca	atacttcatg	gttcttgagt	tctaaaatttt	18240
attctgcttt	aaaaataatc	agactttcta	ggaaagggtg	atgattttga	atgttgggca	18300
gaggaaatat	aaagtgaact	tagaacctgt	tatgtgaaa	aaaaaaagaga	gaataactca	18360
gataaaaatta	gggcacatga	gaagcaatga	ggagccagtt	tccagagata	tccagattga	18420
ataaatcaaa	atacacgact	ccaaggtgat	acaaacaact	acaaacaaca	aaaaaccttt	18480
ctgttttttac	aaaaagacat	attttatatt	caaaacctag	aagtaatat	ttgggtccatt	18540
aacttccatt	tttactgatt	aatgtaatca	attttttcc	ccctabaaaa	gtatcattgg	18600
caaatacaaa	tttttatatt	cacgttatac	aacataatt	tttgatatac	ataacatttt	18660
ataatgatta	tcataatgaa	gctaatoaaa	tatccaatat	ctcaccttgt	taccttttgt	18720
atgaatgaca	tcagaacact	taagaactat	tgtctttgta	atttcaaaata	tataatata	18780
tattaataac	tatagtcac	atgctttaca	ctaggtctcc	agaaattatt	tgtcttaaaa	18840
cttgtatcct	ctgactgaca	tctctctatt	tctccactg	tgcaacccct	ggtaacctata	18900
cttctactct	ccatatctat	gagctcaggt	gtttttttag	ttccaaatat	aatgacatc	18960
atgcagcatt	tgtctttctg	tgtctgggtt	acttcaacta	cttaatatct	gccatgttta	19020
tcaatgttgt	taaaaaagac	agatttgcct	tctttttaaa	ggcagaattt	aatgtattcc	19080
actgtatata	tgccacacat	tttctttatt	caatcatctt	tgacagaaac	ataagttgtt	19140
tccatatcat	agctattgtg	aacaatcctg	caaaaaacat	gagagtgcag	atattttctta	19200
gacatactga	ttttgttttc	tttggttata	cacccagaag	tgggaattgct	gagtcatgag	19260
atagttctat	gttttaattt	ttgaggaacc	tccatatagt	tttctacaa	ggctgtaaca	19320
atctacattc	ccacccataa	tgtacaagtg	tttctttttt	tccacatcct	aaccaacact	19380
tgtcattggg	cttcagtgaa	attattgaaa	aattttatgg	gacaaacccc	caaaaagaat	19440
cagccattta	gaacacagata	actcatttta	ggcagaggca	agacaatggt	aaggatgaag	19500
cccacagogg	cagactagcc	acactaattt	gtgagaaaaa	aataattttg	cccacatctg	19560

20/64

gattaaagat	gactgatgac	taagagcaga	atcaatagtc	aacaccataa	ttagttcatt	19620
ttacaaaattc	tgatgggaaa	atcaatgtta	tagcaaaatt	tccattcagt	gagacccaag	19680
accattgcac	ccagatgagg	tgtagtagac	aagagaagag	tgttttgttt	ttgagactga	19740
gtctggctcc	gttgcccagg	ctggagtgc	gtggggcaat	ctcagttcac	tggaagctcc	19800
gootgcccgg	ttcaggccat	tctcctgct	cagcctcccc	agtagctggg	actacaggcg	19860
cccaccacct	cgcccgacga	ttttttttta	tttttagtag	agacgggggt	tcacogtgtt	19920
agccaggata	gtctogabct	cttgacctcg	tgatcctcac	gcttcggcct	cccaaaagtg	19980
tgggattaca	ggcgtgagcc	acggcgcccg	gccagcaagg	gaatagtttt	taacggaaag	20040
tgtattaaac	aagtgggaat	aagaacctga	aacatttctt	caaagatttg	taacaagagc	20100
tgaacatga	gtttatcagt	atgatcctga	atacaaaaca	taatcaaagc	aatggcatat	20160
caaaggtgga	agtggcccaa	tgaagcaaaa	agcaggccag	tcaggagaaa	acatcatggc	20220
aacagtttat	gagatggcca	aggcatttta	ctagttgagt	tctggaaggc	caaagagaaa	20280
catttgcttc	tttaagagaat	gttttagaaa	agttttcaaa	gctttagcag	aaaaatgccc	20340
aggaaaactt	catcagagag	tctcctccca	ccagaacaat	gctcctgctc	attcctctca	20400
acagacaaaa	acaattttgt	gagaattttt	atgggaaatc	tttgagcatt	ctacatttaa	20460
agtcctgggt	tgccctctcc	tgaattcttt	cttttgccca	attttaaaaa	atcttacaaa	20520
gggtacccat	tgtttcagtt	aatttatgtg	aaaagactgc	ctaactgga	tatagttcca	20580
gaaccatcga	gtcttttaggg	atggactaaa	tggcttgat	cactgttttc	aaaagtgtgt	20640
tgaacttgat	ggagcttatg	tttaagaaata	aagtgtagtt	ttaaaatttt	cttattttta	20700
ttcaattttc	catgaatatt	tggaagtgc	tttatatatg	catgatttta	tttcggagct	20760
tttaattctg	tctatgtatc	ttttttgtat	caggactaaa	ctgtctgat	tattatagat	20820
ttgtagtgt	atttgaaacc	agagagcatg	atagtgtgct	gtctcttctc	tttttgtctt	20880
gttaagactgc	tttagctatt	tggtgtctct	tgttctatat	taattttaga	attttttttc	20940
catttctgct	aaagatgtgt	ttagaatatt	gacaatattg	catggaatct	ggagttttag	21000
gtattgaaga	caattttata	atattgattc	ttttgatcct	tgaagacagg	acatcttttc	21060
atttatttgt	gttttctcca	atttctttca	tcaatatttc	atagttttca	gagtacagaa	21120
ctctcatctc	cttgctttga	tttagtctca	agtattttat	tatttttgat	gctattgtaa	21180
attagatgtt	tgttttcaat	ttcttatctc	aatagcttgc	tgtagtgta	tgaatgtga	21240
actgctctct	tctgtagatc	ttgtacctgc	caactttact	gaattgggta	ttacttttag	21300
caaagtttgg	tgaagtctct	gggttttcca	tgtatataat	gagatcatgg	catctgcaaa	21360
cagagacaaa	tgttttcttt	tcaaatctcc	atgcctaaac	gctctagcca	ggatttccag	21420
cactatgttg	aacataagtg	gtgagagcga	gcctccttgt	tttttttttt	ttttctgac	21480
atagacaaaa	atgtttcaac	ttttcactct	tgagtataat	gttaaatgtg	agcctgtgat	21540
atgtagcctt	tattgtcttg	gggtaatttc	ttttatggct	aattttgtga	gactttttat	21600
catgaaagga	tgtagatttt	gttaaatgct	ttttctgtat	ctattgagat	gaatatataa	21660
tttttgcttt	tcattctttt	aattcgggtg	ggaacagtaa	ttgattgggt	tatatatact	21720
atctttacat	cccagatata	cattactttt	cattatggcg	aatgattcct	ttaatgtgtt	21780
gtcttcaact	tggaagtatt	ttgttgagca	tttttgcttc	tatatctcat	aagaatattg	21840
acctataaatt	gttttttgra	gtgtccatgt	gtggctttgg	tgtagtatg	attttttgac	21900
tcataataata	aaactgagag	ttcactctta	aatttttgac	agaatttgag	aaggattagt	21960
gttgattctt	taaatgtttg	gtaggattcc	atccatcatg	aagccatgag	tttttttgt	22020
tttgttttgt	ttttttgatg	agagactttt	tattacttgt	tcatttttct	tactcattac	22080
tggtctgtat	taatttttga	tttcattatg	tttcagtaat	cgtggtaggt	tgtagatgtc	22140
tatgaatata	tttgtttcca	ttaggttatc	caacagttat	atgttggcat	ataactgttc	22200
atagcgggtc	cttctgggtt	ttgtattttc	tgtgctatca	gttacaatgt	ttcctgtttc	22260
atttctaaatt	ttattttgtc	cttctctctt	ttttagttca	gctaaagggt	tgtcaatctt	22320
gttttatatt	tcaaaaagca	actctagttt	ttgtggatcc	tctattattt	ttcagctctg	22380
ttttattttc	ttctgttctg	taccttacta	ttttttctct	tccagtagct	ttgggttaat	22440
tgtagtcaatt	catatctcta	ttcctgagat	acaaagttac	ttgctttatt	aggatcttca	22500
tttagaattgt	tgcttttcca	aacatccctt	tatactgctt	ttgttgcata	ccatattgtt	22560
tttcttcaatt	gcccatttgg	tttttgcttt	tctcaagata	tttttaaat	tccctttgaa	22620
atttccctaac	atttctctctg	ttgttcoggga	tcattgttgt	taatttccat	gtattttgtga	22680
tatgtaattt	caatcttttt	ctattgtttt	ctagtttcat	atgacaatgt	taaaaaaatt	22740
tatatlggag	attatacctt	aaaatttttt	aagacttgtt	ttgtggcccc	acatatgac	22800
gaatgttcta	ttaggtctct	gtgtgcttga	gaagaatgtt	tattctactg	ttgtcaaatg	22860
ttttattgat	ttctgtatag	ataggtccat	ttgttctaatt	atagagttca	agtccaatgt	22920
tactattact	gcatttttgt	actgtctatc	cattgttgaa	tgtgggttat	tgaagtcccc	22980
tttcattgct	cccattgtga	ctatttcttc	cttttagatgt	attaatgctt	gctttataag	23040
tgactccttt	gtataatgac	gtgcatacat	atttgcaata	gttataatct	atttgtgaat	23100
tttagttaat	gttagtatag	cttctctgtt	tctttttaca	gatttgactt	aaaattcaat	23160
tttgttttatc	cctatgctgt	ccccctgctt	ttcttttggt	ttccattttac	atggaacata	23220
		gctatgggtgt	gcatagtagt	accctttcaa	aatatgtgtg	23280

21/64

ttacgtcctc	atcactatgg	tgatagtagc	aggaagtaag	gacttttttag	gtgattaggt	23340
catgaggatt	ccaccctaatt	acattggatt	agtctttttta	caaagaagag	tcatgggaact	23400
cccttgcccc	ttccacattg	taaggacata	gtaggaaggc	accatagtgg	gaaggcacca	23460
aaacagggag	caagccctta	caagacatca	aatcagttgg	tatcttaagc	tggaaaatct	23520
cagcctctaa	aaactglatga	aataaatttc	tatttttttat	aaactagcca	gttttatggta	23580
atctcttata	gtggctcaaa	tgtactaaaa	caatttagga	ataaacgtat	attcccaaat	23640
gttaacatta	ctatcaacat	aagttgctaa	ttataacaaa	tgtocttttag	atctttgaaa	23700
tctggctttc	ctcaactcaa	gcaattttatc	taaatacagga	tcactaacia	ggagacagcc	23760
tgagtatata	agccacctga	ttttatacag	taagaagtaa	taagggtatca	ttaaataata	23820
tttgtgtgtg	attattgata	tctttattttt	tcacataatg	gcttcacctc	cttttatgagt	23880
ttaaaaatgtt	ccraatcaaa	aatgatitita	cctaactagt	gctgattaaa	aagaatgaat	23940
ataaaaaatta	catttcagaa	ccttactatc	gaaattttcca	aaactcttct	actccaaaaa	24000
tacttaagag	gctattttgat	gttaagatca	ttactgatga	aatcttttato	attctcaaca	24060
tgcaccgct	tgccttgtag	acatcattat	tttaaaataa	atttgtgtttt	tgtttccaaa	24120
gtgatatabg	ttaaaggtag	aaaaatcaga	ggataccgat	atatacaaaa	gaattaaacc	24180
ctaactttta	ccccatgtat	ctctaaatac	acacacacac	acacgcacac	actcacatcc	24240
atatacatgt	atacacacac	acacacacac	acacacacac	ttatctatag	ttttgaattt	24300
cctggcgaatg	ttttttctat	aaacattaaa	tcaggggcaaa	agtatcatgt	ttctatgttt	24360
gcaagttagt	gcattgcaagt	gagcatgtta	taactgatac	tgtgtttttta	ttttttgtat	24420
gtttatgttg	taatatattat	ataccctatt	acgttttaac	tcctctttat	gatttagttg	24480
cattatcacg	tgtgttagat	tgacatcttg	tagaagtatc	tacatttcat	cagttttggt	24540
gcatttatgt	attgatatac	cttttgggtgc	atttatgtat	tgataaatag	taattactta	24600
tatctcattta	ccaacatgag	ttaaagacttg	acttgggtttt	tacatctttg	taaagtgata	24660
taattttgaa	atcagagaca	atgatatgct	ttccattttc	tgtaaaaacag	tgagcctcag	24720
aagctgtgga	gaaagctttg	ggagatttaa	tgatgatgaa	cagaaataaa	gtctgaaaaa	24780
ttgcgtctaa	ttctttgcca	caaacattttt	atgaactgga	cacaacogtt	agttttccag	24840
gatttaatat	gggtgctttta	agaagagagc	caccgggtctc	agcttataat	tacattttca	24900
caaattaatc	caaaaattttta	cgtatgaata	aaaaggagta	aaacaataca	taaaaaatga	24960
aatttgagaac	tgattttaata	ctaaagttct	gaataaaagg	gtgcacttta	tgattgattc	25020
tatctttttg	cacaagtttg	atactccagt	ttcccatccc	aacatgttgt	tcgcaatgtg	25080
tgagaagacg	atgaaagacg	atatcccggt	ttacacacaa	attcaactga	ttccactgtt	25140
ctcgaataaa	gcttctgtttt	ggctgtccac	cttaattgcta	tgttataatt	ttccataatt	25200
tctcgggata	ttacacacgg	atctgaaaat	aaaaaacagt	aaacataaaa	cattaagtag	25260
tatgcaaatc	ttcatagact	ttcaggttttt	caagtagaat	gttatatgat	ggttcaggaa	25320
ttattttctca	aaacactatc	caaaccaact	atgtagaaac	atcatattga	tttgaataaa	25380
cttagaatgg	taatcgatgt	gaaaatgagg	ttcgatgttt	aatgtatgag	aattagggtg	25440
gtattatcaa	tgatttcatta	catcagttgt	catttttagga	tccttgcgtt	ttagaactta	25500
tcattgtctgc	tttttgabtaa	gatattgggtc	aaagagtaca	aactttcagc	tataatattga	25560
ataagaactt	ggaatcaaac	atagagatct	agtgatattt	agagctaata	atattgtatt	25620
gttttatttga	aaattggtaa	gaaagcagat	tttaagtgtc	ctcaccacaa	acacacacac	25680
acatactcac	acacccacct	acacccaatg	ctaagcatag	gtgatgaaga	atgtgtcaat	25740
taattttgtgg	taacttttgt	agcataaata	tatcaaaaaca	acataattgtc	aaacatcaca	25800
atataattttt	atttgtcaac	taaatgcttt	aaaaataaat	ataaatataa	agagaaaaat	25860
tactttttttt	gttgtttttta	ttgagacgga	gtctcgtctt	gtcaccacag	ctggagtgca	25920
gtggcgcgaa	ctcggctcac	tgcaacctcc	gcctcccggt	ttcccgccat	tttccgtgct	25980
cagactcccg	actagctggg	actacagggtg	cccgtcacca	tgccggttat	tattattatt	26040
ttgtattttt	agtagagacg	gggtttccac	gtgttagcca	ggatgggtct	caatctctctg	26100
acctcgtgat	ctgcgcgcct	cagcctccca	aagtgtctggg	attacagggtg	tgagccaccg	26160
cacccagccc	ttaaagagaaa	aattttctaaa	ctttactttc	tgacagaaat	atttggtagg	26220
caagcattca	gcagaatggg	tgttcaataa	tctgtgagta	ttttgttaca	aacagtgaat	26280
tatcagactc	atcacagaga	tttttccagc	cacgtgaata	ttaaagtact	tacgttaagca	26340
ttttgggtgg	tctgaccatt	gtccattttct	acatgttatt	cgcttggtac	cctcaagttg	26400
atacaagttc	tggcattggg	actcaactga	tgaagctgga	gcataatactg	acaacgggaa	26460
tgaagtaatg	tcccrattgt	caataggtgg	agggggccca	cattttctctg	tagaatctaa	26520
aaaacatcat	ttcatcactt	gatttggttg	gagagcaaat	caaaaataca	gttcaaataa	26580
ggcaaacgca	aacacagcac	tgtatataat	atcaaacagt	ttgtgatttc	tgggtgaaga	26640
aatgagtcct	ggaagaaatt	ttaacccttt	aaactgaaag	taatatattt	aagttctctt	26700
ctccgtactg	aaagaacaca	taaaacatta	acaaatattg	ctgcttatgg	tagaccaggga	26760
ttaagaaatg	tctttccgaa	tgaatacatg	ctaaacatag	aaaactatga	caaagggaagt	26820
ttctttatttc	atatttcgaa	aatcccatag	gaattataaaa	atggaaaagt	atgacaaaaa	26880
ttttttaaaa	acactgaata	tacttaataa	tacatgggga	gctgacagac	aaataaatcc	26940
atgaacttga	acatacagca	atataaatta	cccactctga	aaataaactg	aaaaacaaaa	27000

22/64

actgaactga	gacattcaga	aaaatacaac	aacaaataat	gocgatgcag	aaaaagaaga	27060
gaaaggatat	tgggctggaa	aaatgaataa	ataaaatgat	gootgaaaac	ttcccatttt	27120
gaccataagg	tataaaactta	tattttaagaa	gctgagtgaa	ctccaaagag	gataaaaaaca	27180
ttggaatttta	taccaatata	cattaaaaata	aaactacttt	aaaaaaaagea	aaaaatacct	27240
tgaagcaaac	tagacaaaaa	ctatgctttt	cctogagggg	atcaacaatt	caaatgatgc	27300
tgagtttttc	atctataacc	atgtggcagc	gttttcaagt	gttcaaaagaa	ctgtcaactc	27360
caaatttgat	atccagtgac	acgatotttt	acaagtaagg	ggatcaatac	agacattctc	27420
agagaaaggg	ataccaaggy	aattttgtct	cagtagacct	atgcctaaag	attaactaaa	27480
ggaattcttc	aaattaaaat	aaaacagata	aaagaaagag	cttgagactt	taggactctg	27540
aaaaaataga	aaaatagaat	ggataaacag	aggagtcatt	ataacaggat	atctttttcc	27600
tcataagttt	tttcaattat	gttcgatatt	tgaagcaagt	gagtttaata	tggagctcaa	27660
tgtatgcaga	gaaaatacta	gtggcattta	tacttacaac	gtggagagtg	taaatggatc	27720
tacatgaaag	taaggtttcc	atattccagt	tgtagattta	aatgtcagtg	ccagttagaca	27780
gtaatatatt	attacatata	tagtattagc	tagagcaaca	acttttttaa	aggaggagaa	27840
aagctatata	aagagataga	atggaaaaaca	atacatatga	atcgaattta	atctccttaa	27900
taattttccct	acagggaatg	gaggaatagg	gaastaggac	tgaaccccag	aggsaacagg	27960
cagaaacaaa	taaacgcacg	agattttaagt	cctatatatc	aataattatt	ttaagtgtaa	28020
atggtccaag	tgcaccagtt	aacaggccat	gaaaggatga	atggatatgt	aaacatgacc	28080
caactatatt	ctgtctacaa	aaactcactt	caataataaa	cataggtaga	gtctaagtaa	28140
aatagtgaaa	aaaaaaatac	agaaaaacat	taatttttaa	acataaaggt	gagtaagata	28200
caattttcctt	tttttggttc	ccttatttca	tctctttata	ttagaatgac	ccaggactat	28260
gtgctcggac	ttctttttat	aaatcacagtc	agtcacacac	ctttaaatat	aatccatata	28320
ctgaagatgc	ccacatttat	atcacagttc	atgatctctc	ttcaactgcc	tattccatat	28380
cttagaatgc	acatcactta	tggtgtgcaa	atgcacataa	tgtatctttt	attcacogta	28440
ttcctgagaa	ggaactaagt	gttgtaatgc	ttaaaaagta	ttgtttttca	ggttccaaact	28500
ctcaattttgg	tcgaatcttt	ctggaaaaata	atatacccta	ttacttgrgt	tctgttcaca	28560
ggaagaattg	aatttttaagc	accatcagtc	atttttattg	catttgaaaa	atctattaat	28620
aaaaatgact	tcatttttgt	taaatcaaca	tatttttaacc	ctgctatact	ccccaaaaat	28680
gttaaaagaa	atataatact	ctacottttgc	attgaggtgg	ttcogtccag	tttccattta	28740
aacacatcac	ttcttcaccc	ccaaacattt	cataagggct	cctacattga	taacgtactc	28800
tctcaccaga	tggataattta	ctcatctgtc	tcgacactat	ataagcattt	tgtactgtgg	28860
gcggattcac	acaggaggtg	tctgaantaga	aaaaaaaagaa	gtggttccac	ctagtgttca	28920
ttttgagtag	caaatcaact	gataacagtt	acaaatatat	ttcaagacga	attttaaata	28980
agtagacaat	ctcatcaaat	attttgttga	ttttaataaa	tttaaatgta	atattgagga	29040
aaagacatga	aactattttt	tgttaaggta	aagcgttgat	gtttttaaatt	tcttcttcat	29100
ccttcogctag	aacactgata	gacctttatt	tttcccttct	ggaagccagt	gtaaacgaaa	29160
gttttccctgg	atatctctct	ttgagtttga	gtaaacaaat	attaccagtt	ctattttatt	29220
aacattaatt	tataaaatgc	aaaaagtcag	cataaataga	ttatgtgata	ccagattttt	29280
gtttgcaatc	atcctgctta	tacatttttag	cctcttataaa	ataaaactca	ataggcattt	29340
tcttagcgaa	taagcaaaaga	attaaaaaca	catttttgaaa	attacccaag	ttaaaaggag	29400
gaagaatggg	taatcaaagg	atccaaattg	gagatgtgga	aaaatttttt	taaaaagcct	29460
ataataataa	aaataacctc	agataattta	attgccaatg	abtaaggata	ttatgctgaa	29520
caatgcacaa	tccatcagag	agtttcatat	cctgtgtgag	tgaatagact	atagcaatgc	29580
ttctcactoy	gaagtgtaaa	tagaattccc	tggaggtgtt	ggtaaaacag	tttcaggggt	29640
ttactttgag	acttttgatt	ctggatgtct	agaatgagct	tacggaattt	tatttttcatt	29700
tcaaacatct	tccaagaaga	tgatgatgct	aocggtttag	cgaccacact	ttgagaacta	29760
ttgagctaag	attaatcact	aaatactcag	ttccatcttt	ttattttttag	gcatacagct	29820
actttgtcct	gcgtaaaaaa	cttaattttat	gtccattttta	atgatgttag	agacaattct	29880
atatttttatt	cccaaaaacac	tctatataaa	taaaattgtac	ttatatattt	atttattttca	29940
ggtttatttta	ttttttttgag	acggaatctc	actctgtcac	cctgggttga	gtgcagtggt	30000
acgatcttgg	cccacttcaa	tcttcatctc	cctgggttcaa	gcgattctcc	tgccctcagtc	30060
tcccaagtag	ctgggacttc	agatgcattg	caocatgcct	cactattttt	ttgtattttt	30120
agtagagacg	ggtttttcacc	atgttggcca	ggttgggtct	gaactcctga	cctcaagtga	30180
tccgccacc	tccggctctcc	aaagtgtgtg	gattcacagg	gccagccact	gggttgggtc	30240
cacacattat	atbaataaat	tttgaaaatt	caccaaaagta	cctctgcact	ttggccttcc	30300
tgtccatctg	ctattaatgc	atgttacatt	actggctcca	tccattttgt	aatatgttgc	30360
acaagtgtaa	gtcacttgct	caccogcctt	atcacacatc	ttctctctct	ccatgggtat	30420
ggcatttttca	aagctaggta	aactgagaca	atctgtttct	gaaataggaa	aaatatgtat	30480
ttgttcogca	aatcttttaa	aataggttac	atacaatata	tgtaatggat	tctaaaatag	30540
cgatatatag	aalcaatgaa	tactgtacaa	catttttctt	ataacttgag	aaaatatatt	30600
agccattttg	tcttaattac	attaaattct	ttaaaatcta	ttaaaaatc	aagatagaaa	30660
tgatattaga	agactgaaga	aatattggta	gcogtagcaa	ttgagattac	acattttttt	30720

23/64

gttcacatta	tttttgtcca	tacttgccac	ctgataiggt	taggctttgt	gtccctaccc	30780
aaatctcacc	ttgaataata	atctccagggt	gttgagagag	agacctgggtg	ggaagtgtatt	30840
ggatcatgggt	ggcagtttcc	cacatgctgt	tctcacgatg	gtgagtgagt	tctcacaaga	30900
tatgatgatt	taataactgt	ttagaagttc	ctccctcact	cactcctctc	tctcctgcc	30960
ccttgtgaag	aagggtgctg	cttccccctc	agcggttaatg	gtaagtttca	tgacacctcc	31020
tcagtcatga	ggaactgtga	tcaattaaaa	ttttttcttt	tataaattac	ccagtcctcag	31080
gaaggtcttt	acagcagtg	gaaaaacggaa	taatacacca	cctatatattg	gtgtgcattt	31140
ccaaattttt	tgcttctatc	aaatgtgaaa	tacttataat	gattttttta	aatatttccag	31200
aaaaatgtact	tataggcaga	ttgttgataa	actgacagaa	gattgaaata	tgtggagatt	31260
gatgagtaga	ggcagctgtg	ccctaagaac	agagatgaga	agtctgagaa	tatacatcag	31320
aggatgctta	aagttcacac	aagatgatgt	gaaaaatgaac	taatttggct	tataatgtca	31380
aatgttttaa	ttactacagc	tataatttcc	cacagcagtc	cagaatatcc	aagaaaacct	31440
tatgaatttc	tagagtcct	gtttactttc	ttattgggtac	cacttacact	ttgaatgaag	31500
aatattttat	atacatataa	taaaattcaa	tgaccatac	ttatgcatga	tggagggtga	31560
gaccattttt	ctcctaagca	ttttgcaatt	gcaggcccat	caattccaaa	accttcaaaa	31620
catttgtacg	taacttcttc	tccatactga	taactgtctg	acatgtgagc	tacaacacca	31680
tgagaaatct	caggtggaga	tttacaagga	aggcctaaaa	aaaaaagaat	gaattcaggt	31740
ttcactaaat	cataaattta	attttatatg	cctgttttaa	tattaaagtag	ttttatttga	31800
aaataaacaa	tacaggagct	actatgacat	cacagagaag	taacacaaat	gtttcctaaa	31860
actagccttc	tgggtgtctg	ctgtctatcg	gactgtcacc	aactgaagaa	ggacttgaaa	31920
ctaaaaatag	caatacattt	cagaaagaga	tcatctatgc	ctggtaaaca	atgctctctg	31980
aaacttacta	gtgataataa	galacacatt	gagagttaac	gattccaggt	aaaacataat	32040
atattgtagg	aaataagaag	gggcattgtg	ggaagaatgt	aaaagaagtt	ttaaaacata	32100
gtggcaaaag	aaacatgaca	acttgcagaa	caggttttagc	tgtgtcccca	cccaaatctc	32160
atcgtgaatt	gcaattgcc	taactctcac	gtgttgggga	tgggacctgg	tgggagaaaa	32220
ttgaatcatg	agggcgattt	ttcctctgct	gctgttctca	tgatactgcg	tgagttctcc	32280
tgagatctga	tgggtttata	aggagctttt	ctgtctttgc	tttgcacttc	tccttctctg	32340
catcatgtga	agaaggacat	gtttgcttac	ccttccacca	gggtttgtaag	tttcttgagg	32400
cctccacagc	atgtggaatt	gtgagtcaat	tacacctctt	tcctttataa	aktatgcagt	32460
cctgggtagt	cttttatagc	agcatgataa	cagactaata	cagtaaatgt	gtactgcaga	32520
gagtagggtg	ctgctgtaaa	gataaccaaa	aatgtggaag	cagcttttga	actggataac	32580
aggcaggggt	tagaacattt	tggaggggtc	agaagaagac	aggagaatgt	taaaatgttt	32640
ggaacttctc	agggagttgg	acggtctaga	agacaagatg	tgggaaagtt	tggcacttcc	32700
tagaggcttg	ttgaatggct	ttgaccaaaa	tactcacagt	gatatggaca	atgaagtcca	32760
ggatgggggtg	gtcacagatg	aagatgagggt	gaggaacttg	tttgaaactg	gagtaaaaggt	32820
cactcctgct	atgcaaagag	actgggtggca	tattgcctg	ccttagagat	ctgtggaaat	32880
ttgaacttga	gagagatgat	ttagggtatc	tggcagaata	aacttctaag	tggcagaagag	32940
ctcaagagga	agcagagcat	aaaagtgttg	aaaatgtgca	gcttgtlaaat	gcaatagaaa	33000
ataaaaacttc	atttttctgg	ggagaaattc	aagcctgctg	cagaaatttg	caaaaataat	33060
aaggagccaa	agttaatcac	caagacaatg	gggaatatat	ctccggggca	tgtcagaggc	33120
cctcatgaca	ccccacccca	tcacaggccc	agaagcccag	gagggaaaaa	tggthtgatg	33180
gacctggatc	aggtccctgc	tgcctcatgc	agcctcagga	ctgtatocca	gctgcttccg	33240
ctccagctgt	ggctaaaaag	ggccaacaaa	cagcttgggtc	cattgcctca	aagggtgaaa	33300
ccccagcct	tgggtgatta	catgtagtct	tgggctgtg	ggtgcacaca	agtcaagaat	33360
tgaggttttg	gaacctacaa	ctaggttgca	gaggatatat	gaaaatacct	ggatgtccag	33420
gcagaagttt	gctgcagggg	ggagcccaca	tggagaacct	ctgctaggcc	attgaggaaa	33480
ggaaatgtgg	ggtcagagcc	ctcacataga	gtcccccactg	aggcactgcc	ttgtggagct	33540
gtgagaacag	gaccacaatc	attgaagccc	cagaaatgga	gatccatcaa	tagcttgcac	33600
tatgttctctg	gaaaagccac	agacactcaa	tgccagccca	tgaaagcaac	caggaggggg	33660
acaaagccac	atctgcacaa	ggctgtggga	gcccactctc	tgcacagca	tgacctgaat	33720
gtgagacatg	gagtcaaagg	agataatctt	ggaaatttaa	ggtttaatga	ctgccctatt	33780
aaatttcaga	cttccatcaa	gcabatagcc	actttgtttc	agccatttcc	tccttttttg	33840
aatggaagca	tttaccceat	cctgtatccc	ccatttgttc	taggaaataa	ccaacttgct	33900
tttgatttta	caggetcata	agcagagagg	acttgccttg	tctcagatga	gactttggat	33960
atgaactttt	gagttaatgc	tggaaataagt	taagatttgg	aggactgttg	ggaaggcatg	34020
attgtgtttt	gaattgtgag	gacatagact	tgggataggg	catgggtggaa	tgataggatt	34080
tgactgtatc	tccaacccaa	taacaatttg	aattgtactt	cccataatct	ccatgttttg	34140
tgggagggac	tcagtaggaa	gtagttgaat	aatgggggca	gttatcccca	tgtttctgtt	34200
ctcaggatag	tgagtgtgtt	ttcatgagat	ctaattggltt	tataagggcc	ttttcccttt	34260
ggtcagaact	tctccttctc	gtcttcatgc	gtttgcttct	cctccacca	tgattgttaag	34320
tttccataaga	cctcctcagc	catgcagaac	agtgagccaa	ttaaaccttt	ttttgtatgt	34380
ataaattatc	cagtattggg	cagttcttta	tggcagcatg	agaataatac	agataggtht	34440

24/64

aatttcacta	gatattat	tttaattg	gaatacaa	tgactctat	atgaacaa	34500
aaaattaa	taaataga	agattcaat	atgcacaa	tattttaat	gtataatat	34550
ttaattat	tatatatg	gtaattct	ttattcccc	cactttgata	acaagagatt	34620
atttttat	attctact	aaacagaa	tgagtatt	tattggccta	accttcacac	34680
tgaggtgg	aactccatt	tcccatgt	catgttgt	catttttct	agatatccct	34740
aaaccaccc	cacaagtata	actcaatt	gtcccatgt	cataacttt	ttgtgaagac	34800
ctggatga	taatgggtcc	gtgttctat	tgagggtgt	gtgaacatgg	aattttttct	34860
aaatgaag	tgaaaatcaa	agggttaaaa	acaaataaaa	tacttaaat	gaaatataaa	34920
actaaata	atttcoggat	ttaaagtga	tataatttga	acaaataaaa	ttattttaaa	34980
acaaaaac	attagaaact	cgcaaagata	tattcctcca	ccatatctat	gttaccatcc	35040
tcttgttcaa	taatcatctt	catctcatgt	ttgttcacda	caaggattaa	aatatgcacg	35100
aatggaaa	ttatctgaca	tttacataat	attccaaaga	ttttggctgt	attttgtcca	35160
aaaaactg	agagtgggtga	ttgattaat	tgcctagggt	ctaahhhtatt	ttgtcaggat	35220
aaagtaaat	acacagagaa	agaactctct	tcttgtttac	acgaagcaca	agagaatatt	35280
aacctcatt	gaaagaatta	tgtaaaaaaa	attatacact	actgaccaac	acagagtgggt	35340
attgactg	atcttccatc	tttgcacgta	atthcttctc	cttccctgaat	tagataatth	35400
tcttggcaaa	gaacagatac	tttttctcca	tcccgcataat	tcagtgtgggt	tgtcatattg	35460
tgagaattgg	gaatctgagg	tggaggtggg	cataattgta	tttgtgccac	taaaaaatat	35520
taaaaatata	attaatgtta	taataaaaaa	taaaaaataa	aaatattaaa	attgaatttt	35580
ttgatgaaaa	ataatttata	tgattaaaaa	agaataaata	gaaagatcaa	taactgtttc	35640
ataaattatc	acatattaat	tatgatgttt	ttgtatgcaa	atattatact	tttcagctgt	35700
gtaacagtta	cattaaacaa	tagaactttt	ggcttgtatt	ctcatagact	ttcttgtagt	35760
tttttcatat	attctttgtt	taataaattt	gcataattta	tgtaaatattg	atthtaatta	35820
ttttgagcct	ttagaatgtt	ttaatggaat	tacacactct	taattacatg	cattaaatga	35880
aaattgatat	ctataatcaa	atgtatcagg	attggattaa	aacactcaca	aattttctgc	35940
caatggaaatc	tgattagcca	gaagtgaat	tatatgtagt	taataatcaa	tttggtagctg	36000
acacttgacc	aatataagca	ttaaatataa	tcactagtga	tttatagtgt	gctattttaaa	36060
acttgaaact	cccttagagc	ttttatttac	tagcttacct	gtactgttta	gggatattta	36120
aatggatgtt	atgcacccag	tttaattgc	tgcacagcct	ggcttttagt	gtataatcac	36180
atataaagac	acctttgtaa	actcacagct	agctcctgt	taaaactgca	tacatcagaa	36240
atatctcatt	ttttcataat	atgaaaatga	agctatgct	gtttgactga	cgggggagtt	36300
tagaaagcatc	tgggagcatt	ctataatccc	ttgattttcc	tttctcctat	catagtgtat	36360
gctctacttc	acctaaagct	ttatgtaatc	gtactatagg	aaatcatggc	aatgattttta	36420
agtgtctgac	atthtgttat	caattcaggg	agacgttttg	atgaacaaaa	cttcattataa	36480
ggttattgat	aatgtcaggt	ttcttttttt	cgttatgat	aaagtatttc	atatttatca	36540
aaagtattht	gcttattttct	gtttttccat	atthtgaah	gtthtttaaca	ttctcatcaa	36600
tttatttttt	tttaagattaa	tggtcaacta	tttatgcttg	aatgattott	tccttctatt	36660
tttgttgggt	gtacattcct	gtctaccttc	tagattgtag	tacctgttgc	ttttattttt	36720
ttatttgttt	tttctgatgc	atgttataat	gctaaatata	tctctgtttc	agctgtatcc	36780
cattgattht	aatgtgtacc	acaatcatta	ttattttaatt	taaagtattt	gctgatagta	36840
aacaattaa	aaagagatta	tttaacattt	tgtgacatgg	caaaataaatt	tgaagaacat	36900
tgtgacccag	tatagcctaa	ttctacattt	agtgtgtatg	catattttta	tttgaataa	36960
gaaccgttag	caaggttagac	tatgtgctga	gcaatttaaaa	aactgagttg	ttcaaaatat	37020
tgaaattttc	ccagtattct	ttcacaaag	aattaaatta	gaaaccagca	aaaatcactt	37080
atctagaaaa	aaacaaatat	tttgaaatta	aacaataaac	ttccatataa	ttaatcatca	37140
acagacaaac	cacaagacaa	atgagaaaaa	atthcaaatc	aaataaaaaa	gaactctctc	37200
tctctgtctc	cagacacata	gaacatacac	acacacacgt	gtgtaaacatt	ctgggacaca	37260
gctaaagcag	tgtttaaaag	aatagagctt	taaagtthta	tattttcaca	gtatgatagt	37320
ttatgaccat	gttttcatth	ttcacccctaa	gattgagaaa	agtgaattta	aaactgaagt	37380
catcagaagg	aagaaaaacag	taaaatcagt	gaagaagaga	aaacggacaa	agaaacacag	37440
agaagggaga	aaattagcaa	agctaaaaatc	agtaaaacat	aatataaacta	aaaaatacag	37500
agcaaatgga	gaaaattttaa	aggcattaca	attggthttt	gaaaatatta	ataaaattga	37560
ggacaaagta	aaaacaatga	tcaagattta	aaaaatgac	aatattgagg	atgaaagagg	37620
gcagtgaac	cagcagcatg	ccagtatagg	aagccaccac	tctcccttcc	ccccacaggc	37680
acactgattc	aabgcagata	ctggaaacaa	ttccctttat	gagaaatcaa	gaaaccagtt	37740
caaagccctc	tgcaaccccc	ttaaagtaaac	agagaccaat	atattttgac	tgcctctctcc	37800
tcagagagga	aagataagag	tgaactaagc	atctatctac	ctagcttttg	ggggagcatc	37860
ctaaagtaaa	ggtttctctc	ttgcttgtgt	aggagcactt	aacgatacct	gcaataactct	37920
agtttctctg	gggtaaaaata	aagagctagg	cagggagtg	tgtcagcaaa	atggcagag	37980
tggaagctcc	tgactctctc	tccacccaag	aatgtcctaa	aaaaacatct	attcataaat	38040
gaactcctcc	tgaagaaaaa	tgaagaggac	gttaaaggag	tcctacttaa	caggcaacaa	38100
agacaacatt	cacattgaac	aagtaagaaa	agttgcaaca	caatggagca	tggaacccag	38160

25/64

ccctgttcac	tgcaccacac	aattagaaaa	ggaatctcaa	aaaccagtt	tctccttgtg	38220
gagaagtttt	tggatctcac	ataaagcacc	ctgtgttttg	gcccctaatt	cactaatttt	38280
ggaagcagag	gagattaaac	acatgagagt	ctctctagat	cacaggaaaa	atggtggtat	38340
gatacaagtg	ctgaagagct	tccagaaaact	tcattcctta	atagcagttc	agagaagggg	38400
ctgaaaaaac	agtcocctgt	ttctcccgag	aagttttatg	atatattcct	cctgtggcta	38460
cttagaggtc	tgaattctaa	aaaacttgca	gtctggattc	taaltgaactt	gcatacaggca	38520
cttctctage	eggttcccg	ggctcacccc	agtgatacat	ccagggtacat	taatcactct	38580
tagaacaagt	ttgtccacac	aaacttgagt	gcccctaactt	ttadaacttt	cattcagggg	38640
ctgtattota	aagctcttag	ttctgaggag	agaggggcaca	aaatataatcc	agagtctatc	38700
tagaccactg	aaaaaagaaa	tggcgtttta	tatgggtgtg	taagcacttc	caggagcttc	38760
attgcccacg	agcagtgcag	agaaaagggt	tttaaaatgc	agctccctcg	tttactctca	38820
aaaagggttg	tgtcatccat	caagtgtctc	aacctttaca	gttaactcca	aaaggactcc	38880
tcttaaaaact	cttaactgtc	acagcagata	ttagaaaaat	accagttctcc	atagatcgta	38940
aagcaaatag	atgggtcttaa	aatgctatgt	aaaaactcca	ggcgctatgc	caaattggag	39000
cagtgcagaa	aaggaaagag	aaagtccaat	ttccattttct	ctgtcgaaag	ggcttagggc	39060
acatactttc	actggctact	taatgaactg	gocctctatcg	agcttgacaca	gggtatctaa	39120
tgacgcaaac	aaaaaataat	cttcccgacg	ccaaagccaa	agtttggcac	ttcatgagtc	39180
tgcgcccaat	gataaattca	gatttatcca	ttcttctctgg	accaagttta	gccatgcatt	39240
caaagatgtg	caactctata	gtcccaactc	aagagatcgt	ctccttaaca	aaactacact	39300
gggagatgat	agagatctgc	attcctgaaa	ggcctacat	cacagaatac	aaaaagcttg	39360
taatacaatg	gactcatttc	aagcagatac	ctcttcaggga	tcagagcatg	cagcctgaat	39420
attagtacag	gtattagcca	cagattcttt	acttggtgta	atacagagag	agagtggggg	39480
ataaacacgc	acattcactt	tcactatgaa	aatagaagta	agtaaataca	cagccaagtc	39540
ttcaatatht	tcagctacat	ctagacctcc	tggctcctaa	ctgtttgggtc	ccaggtcctg	39600
aaaagatgtg	gcacattcta	acctccaggg	ggccacaaaa	aataagagac	agcagtcctc	39660
acaaagactt	gagaggcaca	tgaaaatctc	tggctggaaa	aattagttag	gtctttctcc	39720
tatatgaagc	cagtctgata	agactgagaa	aggccattgt	cttatctatt	gcatagaaac	39780
actgtgaggt	aaagaaaaata	aagaaacaaq	atatcataac	tccaaaacaaa	agaacaagat	39840
gagtctccag	aaattgacct	gaggggaagt	gatatagggt	ttttactcaa	gaaagaatto	39900
aaaataattgg	tcataaagat	actcactgag	accaagagag	caatgcaaaa	acaaattaac	39960
tactttcaaca	aagaggtaga	aagtattttt	aaaataccaa	acaaaaatca	caaatttgag	40020
aatactataa	ctgaacggaa	aagttttaaa	gaggtattca	tcagcagact	agatgaaggga	40080
gaagaaggaa	ttagtgaact	tgaagtcaaa	ttactgaaaa	tcaccaaatc	tgagaaccac	40140
aataaacaca	taaaataaata	aaagtgaaga	tagcttaaga	tccagatgga	atactacctt	40200
gtggaataac	gtatgcatta	tcaccatggt	aaaaacagaa	agaaacacaa	cgatacagaa	40260
aatataattca	aaaaaataat	gacagaaaac	tttcaacaac	tgggaaagaa	atagaacccc	40320
acaccacata	actcacaagg	aatcaaaata	agtttaatga	aagatagtca	ctttaagaca	40380
taacacaaac	aaattatcaa	aagttataga	ccaagtattg	aaaaaagcca	atgaaaagtg	40440
aatgggtaca	taaaatggaa	tttccacaag	actatcagtg	gattactcaa	cagaaacctt	40500
gcaggccata	aggaagtggg	atgatatact	caaaattctg	aaagaaaaca	actgccaaag	40560
aataattcta	gattccacta	ttctgtctta	aaaacaaaag	agtgataaag	gctttctgag	40620
attgaaaaaa	agctgagaga	gcataaggac	actttcctgc	cttacaagaa	atgtttaagg	40680
gagttcttga	aggtgaaaga	agaggatgct	aattagtaac	atgaagatgt	taaagtataa	40740
aacttactag	taaaagtaag	cacaatatga	aattcaaaac	ctctaatact	gtaatagtga	40800
tgggtaataa	cagctagcat	aaaggttaaa	aggcaaaagt	ggtagaagaa	gctgaagcta	40860
caaactttgt	taagagatac	gaattattga	aagatgcaaa	gcattgtgac	aaatagaaaa	40920
catggggagg	gcagagtaaa	atttagatat	tttatatgta	atcaaaatto	agttcctatc	40980
agcttaaaat	acctgtttata	agatatgtta	tgcaggccta	aggataacta	caacttcaaa	41040
tagccttttta	taagggtatgc	tatgcaagcc	taaggatagc	caaaagcaaa	acatctaata	41100
gatacacaaa	agattaaaag	aaaaaatcct	aagcatatgg	ctacagaaag	tcatcaaac	41160
atgaataaag	caagcaagaa	agaaacaaag	aattttaaaa	acaaccagaa	cacaattaac	41220
aaattaccac	tataaatcct	tacctatcta	aaattacttt	aatgggaat	ggaatatatt	41280
ctataatcaa	aaggcataga	atgactaaat	aaatcaaaaa	ttaatatcca	attataaact	41340
gcttacaatt	gacttacttc	actgtaacgt	aaattcacag	attgcagtga	aggcatggaa	41400
aaaaacctat	aaaaataaaa	actaaaagag	aacaggggta	gttatactca	tttcagacaa	41460
aatagaceag	ggaaaaattg	tataaaggta	caaagaaagt	tattatataa	tgatagtggg	41520
gtcaattttg	caagataata	caactattat	aaacctatat	atgcacccaa	catcaaagca	41580
actaaatata	taaaggaaaac	atttaggaat	ctgaatggag	atgtggactg	caacacagta	41640
atagttaggg	atatcaatat	tttactttca	acgttgagac	agatcatcca	gacagaatat	41700
caataaggaa	acattaaact	taaacataaa	tttataccac	atagattgga	cagacatata	41760
aagaacattc	cacataacaa	aaaaacacat	attcttctca	aatgcgcaca	gaatattccc	41820
cagaatatgt	tatatgttag	gccacaaaa	aagtcttate	aaathcaaga	agaactgaat	41880

25/64

catatcaagt	cacttttctg	acaacaaagg	tatgaaatga	gaaatcaata	ataggaggaa	41940
ctatggaaaa	ttttaaatta	ggtgaaaatt	agacaatatg	ctctgaaaca	atcatagggt	42000
caaaaccattt	taaataaatt	taaaaatatt	ttcagtaaaag	gagaatggaa	acaaaacgta	42060
gcaaaaactta	tgggatgcag	caaaagtagt	tctaaagatgg	atgttttttag	gaataattgc	42120
ctatlatcaag	aaagtggaaa	gaactcaaat	aaacagtcta	gtagtacacc	tcaaagaagc	42180
agaaaaacat	gaacaaacta	gtcaattcca	aaattagtag	aaggatggaa	atcataaaga	42240
tcagagtata	agtaagtata	atagagcccc	caaagcagta	caaaatatca	atgaaaatag	42300
ttttttttta	gataatcaaa	aattgacaaa	gctttaacca	gaataactaa	aaaagagaga	42360
tacgggttaa	agaaacacaa	gatoggagat	gaaaaggggtg	atattacaac	tgatatcaaa	42420
aaaatacaaaa	gtataatgag	agaccgttat	tagcaattat	atgccaacaa	attgggataac	42480
ctagaaagaaa	tggataaatt	tctagacaca	cagcctacga	cgattaattc	agaggaaata	42540
gaaaatctga	acagagtaat	catgaggcga	cagattaaagt	cagtaataaa	atgtttccca	42600
tcaaaagaaaa	tccaaagacct	galggcttca	ttgctgaatt	ataacaacat	tttagaaagg	42660
actaatacca	attcttctaa	aacgaactcca	aaaatttgat	gaggagatca	tttttctaac	42720
tcattctagt	ggcccaacat	tactctggaa	ccaaaacvag	acaaggacac	aacgcaaaaa	42780
gaaaactaca	ggcaaaatcc	cctgatgaac	ataggtacaa	aacccctcaa	cactatacta	42840
ggaaaacaaa	tcctacagca	cattaaaaag	atcattcact	atgatcaaat	gggtttaatc	42900
caagaatagt	aaaggtcggt	taacataggg	aaattagtaa	aggtgatgca	tcccattaac	42960
agaaagggag	ataactatac	gatcatttta	ataatcttat	atagaatggc	taaaactata	43020
aaacttcaag	aaaaaactgt	agaacatgta	cacttcactg	catatatata	ttatttgcct	43080
ctttaaggac	tctaaacata	ttgaaatggt	gatagcagat	tagtttttgt	attggttgtc	43140
aatgctttct	gtatatccct	gactggcaga	cattggtaaa	aatattgaag	ttagtgggc	43200
aaggaaaccc	acaattggat	agcaaaatac	agatatataa	tatgagaaga	ctggataaaa	43260
acctacacta	ttcaagtga	actgtatgtg	tcaatatgac	taacttttca	agatagatga	43320
acaataaatt	aatagataaa	tagatgatta	ggtagatgaa	caggtagatg	aatagacaga	43380
gagatagatt	aaataaatga	atcaacagaa	atagatatag	atacatatcat	acatgcatac	43440
agacatatat	aaacagatac	atagtagtta	ttggcataga	cagaggtata	ggcacaggaa	43500
catttggttga	caagaaaagg	aatgagaagc	actggctctc	caacagtaat	gatgacatgt	43560
agtgcctggg	ttatgtgtgt	gtgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	43620
atactaaaag	taactaattc	acagggcaca	gttaataatta	ggaacagtgt	tttcattagt	43680
ttcttagttta	tcctgccttat	tcagtagcat	ttgtaataat	aaatagctaa	agttttttaa	43740
agacacacat	acctattact	tttccaaatg	agaaatagaa	taatlttctg	aaaacaaaat	43800
aagagcttac	ttgagcagtt	cacttctgga	tcccatcttc	catttatgca	gactgtgtgt	43860
atccatcctt	cttttctctt	acatctgtac	cttatgttag	aattatgac	gaattccttc	43920
ttgtttttta	aatgttctct	aagtataatt	aaatttgatg	atttgcactt	cttaagttta	43980
tctattgtcta	taaaataaat	atatttttat	gaaaattcaa	atgataggaa	tcaaaaccaac	44040
tattacatba	aaatagttat	aaagtaata	gtattagcat	ggtaaaatta	tgacttaatc	44100
attataaatt	tcaccaacca	agttattcct	gatcacattg	catcaaaatg	ctattatgtc	44160
aaaatataag	cctgttatcc	tgtcgtgaa	atgttagaga	tacctatcag	aagacatttt	44220
attctttggg	aaatacaaaa	tatcattgga	tatttcattg	gataaataag	tatgattgga	44280
cattaggaact	cttagaattc	aggaccaggg	aaaactttag	gaaaaatctc	agtttagaga	44340
aaagtgaatg	aggggtcccca	agatcctccc	ggtttagtcat	caaagaggca	aaatgatttt	44400
aaagattgta	catctcaagt	gtgaatcacc	tgagattttac	ttgcctctct	gctgatcaag	44460
acatgagatt	tacagtgtga	agtccgtcaa	gtagaggggc	gtcctgactc	agtcctgtac	44520
tacctcatgc	cactcagcta	taccactgat	gtagaggggc	tgtagggccc	caaccctgca	44580
gcacattcac	ttattttggc	tgatatggaa	caaactgaaa	aattatcact	tttgggaagct	44640
ttaagagaga	aaagaatcct	atgggagagt	agtaagtagg	tattttgtca	actttgtttc	44700
tttgcttctc	agtgcctaaa	atacaataac	atacaataac	aataatattt	atattttata	44760
taaaactgtt	ataatttctc	agtaattagt	actcatattt	aatcatatga	taatttttta	44820
atatttttgt	tttttaaaga	aagagtctta	ctctgttgcc	caggctggaa	tgacacaatag	44880
agctcactgc	aatctogaat	tcctggcctt	aagcaatcat	tctctctcag	cctcccaagt	44940
agctggatta	caggcatgca	ccaccacacc	ttactaattt	acaaaatttt	ttttatagag	45000
atgggctttt	gcttatattgc	ccacactagt	gtctacctcc	tggcctcaag	caatcttctt	45060
gccttggcct	cctgaagtgt	tgaggttata	ggcgtgagca	accacctggg	cctcacatga	45120
caatttttgt	aaagtaaaatg	ttgcttcaca	cttttaataa	taaaacaatac	tgthattcaga	45180
cgacagaaaga	ttcataaaat	tataattact	gctttatttt	ttctttctag	acacatattg	45240
aatataaagc	aatatgcasa	agattggbct	catattgaag	actggaaatg	ttgaggcata	45300
totgtaaaat	tcaaaaaatat	agttgcaatt	attgttgtta	caataaaaaat	attaaacttt	45360
gttaaatgtt	gatttaagaa	gggtattctc	acccacacac	tggggaagtt	gggtccatcac	45420
ttcatgaata	cagtaatttg	atctgtgtcc	aactatttga	aatgattorg	agcaattgaa	45480
ttccactgaa	tctccatagt	aataaggagg	ggaagaaagc	tgggcccagc	catgtttcaag	45540
ttcaggtata	tctccacagg	tactctcttc	cactatgtaa	attttacaaa	aaaagtttat	45600

27/64

tgtgaaaaca	tgatgtatgt	gttttagata	caaaatacaa	aagttttgac	aagttttaat	45560
attaatat	tatacattac	caatacacac	tggttaaagt	gtccactctc	catcaacaca	45720
ttgaatttta	ttaggtccct	tcattagaaa	tctaggattg	caataaatatt	ccaccacttc	45780
actgtgtcca	tattctctct	togtttttttc	cttaacattc	ccattgagga	gttcaggagg	45840
tggaccacat	gattgtactt	gctctatagt	agaaatacta	tgtaaatat	ggttaaatfg	45900
tctgtttttac	aatataaaaa	ttcagtaaaa	tggaaagatt	ttcttctctt	attcatgtat	45960
tcttcattat	gtaacttatt	atagcatcct	aaacaatcaa	gaatgggtgt	catattgtat	46020
tacttatact	aaattgtcat	attgaaggta	tattaaaatg	ttaaaatatg	ctcagacttc	46080
tagatatctt	aaagatgcaa	gaaaaccaat	tagcaaatgt	ggttatgaaa	atcatgttaa	46140
ttttttacatt	tcatggaaaac	atttttatcat	aacatttttg	aaaaatatca	taactgaggc	46200
aagcattttga	tcaacataaa	gttttgactaa	tcaatacaag	caactgaatt	gaatataagc	46260
tgcttaataa	ttgttttagac	acacccgggt	aaacttaagt	tgcagcccac	actatataaa	46320
atgtccagaa	tggatgttga	cattttcaagc	aaaatgaaaa	ttacacaaaga	aatccctcca	46380
ttgtcagcca	ctagtatggt	ttaaatgttt	gtcacctcca	accccatggt	gaaacttcac	46440
ccccagtgtt	tcaggtgggg	tctaatggga	gatgtttgga	tcatgggtat	ggatctctca	46500
tgaacagatg	aatgccccct	ctcaggggtga	gttctcactc	tattagctcc	tgggaagagct	46560
ggttctttaa	aaagagcctgt	cactgcccctg	ctctctctct	tgcttctctc	ctcatcatgt	46620
ggttctctgga	cacagtggct	ctctctctct	attctgtggc	tctcactgaa	46680	
tgcagatgcc	cgatcttgaa	ttttatagtc	atgtatagtc	tgagccaaat	aaaacatttt	46740
tacaaatcat	ccagactcag	ttatctcttt	atagaacat	aaacctaaag	tagactaaga	46800
ccgacacac	ctgtgtgtct	gggaataactt	ccagcacatc	gttcaagaaa	cagtggagat	46860
taacttaagt	gactgaatct	caggtattca	gtactcaata	catgtccttc	acaggcaaat	46920
atgtgactta	attcattaga	ttacaggcaa	tgggagccca	aacaaaatta	ataagaaaaa	46980
agttgggtatt	caaagttcta	attcttattt	cagcaattgt	aagataagca	ttcacottta	47040
cataltggga	ggtcaggaga	caatocaaa	tggtagcact	gaacgggaatt	aggtccaaat	47100
attgtaaaac	ctgggttgca	ggagaatttc	aacacctctc	caactttata	ctggctcttc	47160
ttgcgatcag	gaactaagt	tacatctatt	ttaggaaagt	cgattctctc	ttcttgaaaa	47220
aggtaaaaaa	atttcatgag	aatatataat	taatcatgtc	caaagttaat	tttcatatag	47280
ccacaataaa	gtgaggttga	tattgggtca	tacagagggg	catcagataa	atccttttcc	47340
ctgtaaagaa	tgctacatat	tatgttttat	atcgtgtcta	aattgaaatg	gaacttttat	47400
ataaatgtta	tggatttgaa	atatactctg	tctaaaaatt	aatttgtaaa	ttcaacttat	47460
ttacaatgaa	tctagtttta	atcactgaca	ttaatgaaat	ttaatattac	tttttttact	47520
caaaaacatga	aattactctc	tcatattaaa	aaagaaaagt	gcattatagac	cagaattggg	47580
gcttttttgaa	aacaagatga	ctgactaagg	agtttggaca	caagttctcc	tcagaagaaa	47640
gaaccaaagt	tacaggtaaa	tgatcataac	ttgaaaaata	tttaagagag	ggtgcaggag	47700
cgtcatagag	aaacctgga	gagaagccaa	agcatggaaa	aagacagaag	caagagcctg	47760
acaaagcttg	actaggacc	tgtgggacct	catagaaagt	gtaggtagga	gtctctctgg	47820
ctccctgcag	ctcacctgt	ggatccaagc	catcagagag	ctctctctgt	ttcgtgaaca	47880
cacacactgg	tgtgagtga	gatttgggaa	cttcttgagg	gcattacacc	aaactactag	47940
ttgaataggg	tcatctgcct	tccccttggg	cctgagctgc	agtggttaggt	ttcatgcttg	48000
cagtgcactc	atgtggggac	tgtttctact	ccaggaaact	cagccctctg	tcccataac	48060
accagagccg	cacaaatatt	cctgtgcacc	ttgttggatg	tggcagtcac	ccatagctgg	48120
ctggacccaa	aggagttaca	gcattcccaa	tagtttaaac	accagggagg	ctattcctaa	48180
tggaaaagtgc	aaacaaaggaa	cacccttctg	ggcaaaagag	actgtagcat	tcactttcct	48240
gtgtgcaaga	gcaacctgct	tgtgggctga	aaatgactac	gccacttoca	gcagacacgc	48300
agacgcggtg	tttggctctg	caagggagga	gtatagatcc	atcccaggag	cccaatgggt	48360
ccagcgcctg	ggcacggatg	tagagagggg	aacatgtccc	gtggatocaa	ttctgtgttc	48420
atagctgtgg	tactctgcaa	aggagactgg	tgtagacaca	ccagaggagc	gacattgttag	48480
gggtatttag	gggtggctac	aactccactg	gtcatgtgcc	caatgaagcc	aggccttgca	48540
gaaagacaa	ctacgggtat	ctccccaggg	tcttcccctg	acacccctgt	cagggtgggt	48600
gcttgtgtct	atccttggag	catccaaggg	tgagcttagt	ggtacagatc	tatcccgtct	48660
tgtccccagc	tctcagacc	actgtacctt	tcacagatca	gtccatttct	tggggcaaca	48720
gagagtctcc	cataaacagt	gacaagcata	ggctcatctg	cctctgctgc	agctggctct	48780
tacctgtccg	tgcacacctac	tgtcctgaat	gttgaactgc	acagcccagt	gcaaaatgct	48840
gacactaggg	catgatgcag	aacaagggtta	gttttctgog	tagtccctcca	taccagccct	48900
tcaggagggca	gtaagcctcg	tcatacacccc	agtacataac	tactacaacc	agcaatttaag	48960
aaagccatca	tacaaaagtt	atctctaac	aaggtactca	aacagagctc	ttaccactga	49020
aagaacccag	aacctaaacc	aaatagccct	atcacacata	catcgtagtc	atattctcaa	49080
agggaaaaaa	aaaatcctgt	ctgttggaaa	ctggacttaa	aaataagaag	ggatagttca	49140
tctggatgag	aagaacccac	tgaacacatt	ctggaagtat	gatttaaaac	agcgtattac	49200
aacactcgca	aaggatcaca	ctaactcttc	agcaataagt	cctaaccocaa	ataaaatctt	49260
tgaatatccca	aagaatttaa	aatattttatt	ttaaagtagc	taaatggagt	ccaagagaaa	49320

gttgaaaagc	aacacaaaaga	aattagaaaa	aaaactcagg	atatgaatga	aaaatgtact	49380
aaaaatattt	tttaaaaaaa	aaatagaact	tatggaaatt	aaaaattcat	tgaagaatta	49440
caaaatatag	ttgaaagath	taattacaga	ttacatcaag	cagaaaaact	tgctctcaga	49500
gcttgaagac	aggtctttcc	aattaaccct	gtcagacaaa	aataaagagc	aaataacatt	49560
ttttaatgag	caaaggthtt	gagaaaaatg	acgttctaaa	aaatgagaaa	acttaagagt	49620
tatagatatt	cttgagggag	aagaaaaagc	taaaaaaacc	tttttgagga	aaatttatct	49680
cctottgccc	tottgctaga	gacatagaaa	tccttatata	agaggctcag	ataacaccag	49740
gaagatgcat	tgcgagatga	actttacaaa	acatatagtc	atcaggctat	ctaaagtcaa	49800
tgtgaacggg	aaaaattata	aaatcagcaa	gagaaaagca	tctaataaac	tataacggaa	49860
atctogtaag	actaacagtg	gacttctcag	cagaaactgt	acaagccaga	agatatttgt	49920
gtcctattht	cagggttctt	aaagaaagat	tagttcatat	ttattgaaaa	aacatatatt	49980
agagatatat	tttgtatttt	gctaaactaa	acttcataaa	tgaagaatat	ataaagtott	50040
tcccaacaaa	gctaatacta	aggaagtcca	tcaccactag	aaatccactt	taggaattca	50100
ccccacaaga	aatgatccag	ggagtccctga	acatggaaaat	agatgggtcaa	tactcaatat	50160
cataaagaca	tgcaaaagta	caaaactcac	aggtcttatt	aaaaaattac	acagttggga	50220
ctacaaaacca	gctaggttaac	aactaacata	atgacaagaa	caaaacctca	catgacaata	50280
tttaactthta	acataaatag	attaaatggt	ccacttaaaa	gatataagatt	tgtggaccaaa	50340
atatggaaaa	cagaaaccaa	ccacatgctg	ctcaaaagaa	acccacctaa	cttagagaaa	50400
cctatacaaaa	ctcatggtaa	aggtatggag	acagatattht	tgaacaacag	aaacaaaaag	50460
catthtggtat	agttatatth	atatataaaa	aaagatttca	aatcaacaag	aaaaaaaaga	50520
caagaagttc	attacacaat	gataaaggaa	gcaagaagat	ataacaattc	taaatatata	50580
tgactcraaa	acctcagcac	tcagatthcat	aaatgaaatg	ctactagagc	taagttagaaa	50640
gataaacagc	aatataatga	gggcaagcaa	cctccacacc	cccaatgact	atactagaca	50700
gattgcaggg	acaaaaaaat	aaacaaagaa	acctcatact	taaatlbggac	tytagaacia	50760
atggacctaa	cagacattth	aacgacattc	caccaacaaa	octcagaata	tatgtttttc	50820
tcacctgtgc	atggaaacatt	ctocaaaaata	gacctatgct	taggctacag	ctacaaagca	50880
agttcccaaaa	atthtaaaag	ttagaataaa	tatcaagtat	cttatcagaa	cttgggtgaaa	50940
tataactata	aatcaatatc	ataaagaatt	ttcaaaaacta	tcocatataca	tgaaaaattaa	51000
atgacctgct	tctgggtgat	tgtgaattaa	actaaaaatt	ttcttcacag	caaaggaaat	51060
aataaacaga	gtaaacagac	aacctcagaa	tggaagaaaa	tatttgcaaa	ctatgaatct	51120
gaaaaagggc	taatatccag	aatctgcaaa	gaactgaaac	aaacacaaca	gaaaaaaaaa	51180
taataatccc	atgaaaaagt	ggacaaaagga	tatgaagaga	tattttgcaa	aagaagacat	51240
gaaaatgacc	aagaaatatg	aaataaaaaa	tcaatatcag	taatcatcag	agaaatgcga	51300
attaaaaaaa	tgagttatca	tcttacatta	gacacagtg	ccactgtcaa	atagtcaaaa	51360
aataataaat	gttgggtgaca	gtgaggagaa	agaagaatgc	ttatacgtct	ttgggtgggaa	51420
tgtaaatatg	tacaacctct	atggaaaaca	gaatggacat	ttoccaaaga	actaaaaaca	51480
gaactaccat	ttcaccagc	aatcccacta	ctgtgtatct	acccaaagga	aatcaattat	51540
catatcaaaa	tgataccag	actcatatgt	ttatagcctc	actactcaca	gtagcaataa	51600
tatggaatca	aactaattgt	ccaccaacag	atgattggat	aaagaatatg	tggtatagat	51660
atatgcnaha	gaatactact	cagccaaaac	aaaaaatata	aagaaaaaaa	aagaataaaa	51720
tcattgcttc	agaagcaaca	tgtataaaac	taaaggccat	tatttttaggt	aaaataattc	51780
agattcagaa	agtaaaatcc	cacatatbgt	cactttatag	tgagagctaa	ataatgcgta	51840
catatggaca	gagagtgtct	agtaacagac	attggagact	cagaaatgtg	gcaggatagc	51900
aggagggtga	gggaataagaa	attacctaata	gggtgcaatg	ttcagtattt	gggtgatgaa	51960
tacactaaaa	gtacagactt	caccactatg	caatatatcc	atgcaacaaa	actgcatttg	52020
gaccatctaa	acatatataa	catagaaatt	aaaattttta	aaataaaaga	acacatcata	52080
aaacaccatg	gaaatatctt	aagaagttaa	atthataata	gaactgggga	ggatcccgag	52140
aataatgatg	gtataatata	tgtcattgca	gagtcaatga	taactttatt	taactgaaac	52200
taaaccaacct	caaatgattt	ctgggtctcat	catgtttata	attcttgatg	actgacatat	52260
acatcacaaa	aagggtaaatt	ctcatcaaa	atthattagt	gaagatatat	gcactaagaa	52320
attaattaaa	attgggtattt	ttgttttaag	taatcaagga	aaaagaacct	aaaatagcat	52380
ttctaataata	ttttaagtta	aaaaaaatat	aaaaaacaca	taattaatat	attacaataa	52440
aagaaaacaa	accaagataa	atthttcaagt	tcacatggaa	aggcaaatcc	taggtatcct	52500
gaatattttat	gttaacatat	aacaahttht	gttatatgta	ctattttat	caatgtttta	52560
taaatttgat	aattattctg	attcagataa	gaaatgtgta	aaattatctc	ttacatgttt	52620
ataattttta	aaaatcagca	acattactaa	atattatcca	aaatattatt	tttctbattc	52680
agaatccctc	tttcttgcta	acttagaaaa	gtacaagcta	gaattcataa	attagaatca	52740
tactaaaaag	aaaattaatt	acatcataac	ctcaattatt	aaaatacaat	tacaaaatta	52800
gatttaaaaac	tattottaaa	agtaatgtca	caaaataata	actacaaaaa	tttgcttttg	52860
tgthttgttt	aatgagthtt	gcagattatt	tgagaaaatc	acacttgaat	gagaatcact	52920
gggattttct	tcttaaaagt	ctataccaat	ctctacata	gcaattcttt	tttttgtatg	52980
tgtgttttgt	caogtatttt	gtgctaattt	tatataaatt	ctgtctgttg	taatatgtgt	53040

29/64

aaaagcatta	tcttaaaaag	gaaggttaag	atcttgatta	ttgggtatta	ttcaaatgct	53100
gtatttatat	agaggtaata	acttacaaaa	cgtgatttag	agaagaatgt	gaatggacac	53160
tccatgaatt	agaaatattt	ttcttcatct	aaaactcaaa	accctaagtc	ctagtactag	53220
atatgtgaaa	tgtaaatatg	aahhhttaac	tctgagatac	atactcctta	tttagcttaa	53280
gtgctccata	ataacaattc	tgtggaaaacc	tttccacaaa	gaagagacct	cctaggacac	53340
ttgaaatata	ctcagatgtc	tgtcaatcca	catgcagttt	tctgttacct	ggctgagaga	53400
agaatatattg	aaaagaatac	taagctggta	tttcttcgtt	taatggttgg	aggcctgtac	53460
tatactagca	aattcctagt	tatgtgttca	aatgatctta	agtctttgta	caatttgcaa	53520
tagaaagaca	ttttctacat	cagcttctac	tgctatgtcc	gccactccaa	ctttctctcc	53580
tttaggtttt	catttcatgt	ctggtgattg	gaaagactac	tgaagcaata	tattcacaat	53640
tttgtgttct	tttttgaaga	agacccctca	aaattgtaaa	agcttctggc	ttcataaaaa	53700
ctaaatttac	ctatcatcac	agaaaaagaa	tttatgagtc	tcttaaatla	agcctccccc	53760
tctcaattag	agcaaaaactc	aacctcttta	tgatccatgc	ctactcttcc	aatgttatca	53820
aatgtctctc	tcctccacta	aatccaggat	tcagatttta	tgatctttga	atthttattaa	53880
aaaggtcaag	ttcttgcgtg	cctcagctgt	tgacataacc	cttctcacta	taacaaatgg	53940
ctttcaacca	ttctttgcat	cgatgacttc	ctatgtaaaa	cagatctcca	gttctctccc	54000
tccatatttc	tatctcaatt	attggatttt	ctatttctct	gtacacagtg	atacataaaa	54060
tatatattta	atatatttat	tacttgata	tttggcttat	ctcttttttag	ttttccactg	54120
tcttatatta	gaataaaaatc	tctggataag	tagacctgtg	ottgtgtttt	caccattttc	54180
tcctgtccta	tgataggtgt	ttacaacago	aggaatgagt	caaatttaac	tggaaccttg	54240
acactgcctt	tcactacaaa	tgtactcatt	ctctttctca	gctgtgacta	tttcaaaaact	54300
tttctattct	acctagtact	cttctctctc	cttgcgccac	acactattca	atctcagatg	54360
acctgtcttc	atacttcaaa	acagaatcca	tcagcttcta	ccattttcca	acgttactgc	54420
tcattttctc	tcccatctcc	tgtcacaaaag	ttgtaagcag	tctgtttgcc	acctgtccca	54480
aggttgttaag	cagctctgtt	gccaccaaaag	cacaatacct	ccacagtagc	tgtgagtcct	54540
ttccctctgc	atthttctcag	ggcaactatg	taagtcatgt	gttcagcctt	tgagctccc	54600
cttttgctgt	atctgctctg	gtgtcttcca	tcttttttct	tttaattatc	ccttcagtcg	54660
acaactttcc	tcaagcaata	ttctgatctt	cctattagat	tcaaagccag	aatcttgaaa	54720
gagttatgtc	tacagtctgt	attgaatgtc	tacgtcatta	tttttatbgy	cagattctat	54780
gtagggctct	tctctctctac	tctattaaaa	tcactttttg	ttacacttgt	cattggcctg	54840
tacotttact	atactctcac	aattttctga	cagaatataa	taactaaatt	agaaatattt	54900
atcactttga	taatgatatt	aaggtaatta	aattacaact	tctttgactt	tatttatata	54960
ggcactatgg	caataaatat	ttataaatat	tttagctctg	taactaacac	aatcctttga	55020
aatattagaa	ctgtttgtaa	atatgtgaca	ttttaccaac	aagaaagagt	caacaaagct	55080
tcaaatagac	ttgctgtggt	ggccaaagat	acatgcccag	caagcagtg	aattagaatt	55140
cagacaggat	gaattattaa	gcaatctgtt	acactacctt	ttcatttaata	atttccctat	55200
ttttatgtct	atggcaacat	tctagatttt	ttctctctgt	ctctctgggtc	ctcctttttt	55260
ccccattttc	tttactatct	attgctcttc	tgtcttatat	ataaatgtgg	taatgtttca	55320
gggcttctc	ttgagctctt	tgtctttttc	attctgtatt	cttatccaat	ttagcgtcat	55380
catthtatatg	atgatattcc	gaastgcata	tctctctctc	agatgcata	ccaactccac	55440
acttcacata	tccagttttg	atthttccatt	ggcgactcaa	tcataatgtg	tccaagtcaa	55500
aagttgcaaa	gccccctcaa	aatgcattct	atccagtcag	taccatttta	caaaatgggt	55560
attgccattt	acctacatac	ttgtgagaaa	acaattgaaa	acaaacatgt	gagtccctta	55620
atctcactct	ttttcacacc	caacatttag	taacatcacc	tgtacttttc	atcacctaaa	55680
tgtttttcaa	atcagccttc	tgtctctgac	ctccccctac	atcactctct	ctcagtcctc	55740
acactttctc	acctacactg	gactcatggt	gtcgcctctt	gctacaaaa	agtacagcat	55800
ccaggaaaaac	aatccaacaa	aactagaaat	caaatattac	cattctcttt	cttaaaaactc	55860
ttttatgggt	tttcatttag	cataaaatga	atccaaatga	tatgatgctt	tgagctgac	55920
tggataattg	tttctctggc	tccatcttag	cctcagcagg	atagactctg	ctttaccacc	55980
ttgaaatata	ttgttttgtt	tttacagctt	tgacatattt	tttctttggc	ttggaacact	56040
ctgcatatac	ttgtttttcc	acagagccaa	tcttctctct	aaccttgaaa	aatagatggc	56100
tgattgagaa	acgtaaatga	gattcatgta	atggctttca	gaacttttca	aatttagaaa	56160
ataaagaact	acactcagaa	agtacagaaa	ttaacacaca	agatagaaga	tgtaaatgtag	56220
aaattaaaaa	acaaaattag	ctgaggaagt	tgtaaccaa	tataattttg	gtaataagt	56280
ctaggttcta	aataatttga	agctttttat	ttagggtaac	aaaagcaatt	atattataat	56340
cacaaatctg	gaaggtagg	ggccatag	aagtattaat	ttaatgcact	acttttagaga	56400
tatttttcaa	actcccttct	tttcccagtt	tatgtcaaat	caggagatat	cttgattttta	56460
atcaacattc	cttaacaatt	cctctatata	attcaaat	ttaaaattgg	aaaacagatt	56520
tattttcatt	ttgaaaatga	atttctgaaa	aaccagta	taccataaca	tatgggttaa	56580
tcagaccaac	cattgtaacc	acacactatg	gaaccagtg	tgcttccagt	attgctttca	56640
taaccatcat	ggcatctata	gtccaatgtg	tcattcagct	taaaaccatgt	gaagtcattt	56700
ttagttctg	cattcataaa	tactgggata	tcacaagatt	ctagtgcata	aaaaatttag	56760

30/64

aatgtcattt	ctaattgtcat	ctaataaaca	atctgagtat	ttcccattct	aagaagaaaa	56820
agctttattg	attagatcta	ctaataaata	ggtaccgtac	aaaaataatc	tatgactggg	56880
gagaatttgt	tgctcgtaaaa	tagttgtcaa	aagtgaaggt	atatctttct	acacaacatt	56940
ttttttcatt	gcttaagccc	caaaatatat	tttaaaaaca	ttttttctta	ttcattttata	57000
ctaaagcatt	tatgacaatg	ctagtaataa	aacaggccat	tacagggtata	cattatttttt	57060
taaagaaaa	cataacagaa	ttttgtlaaat	taagagtcca	aactaattcg	tagttgagac	57120
atattgtaaaa	aggagaaaaa	gactgaaaaa	ataaattoct	atgttatata	agacatttttc	57180
tctttaataa	taagaaaaatc	ttaaaagaat	aattaataaa	aatttagtat	aaaatttagct	57240
tttttatgag	gactaacatt	ttttgtlaaac	tagacctcat	attaagcaca	gacattaaaa	57300
aatgaaaaaca	gtatacatga	ataccttatt	caacttoactt	aacatgagta	tattaaatat	57360
tacttcaaat	atattactga	gagggcaggag	gatcatttga	gattaagagt	tggagaccag	57420
cctggctaac	atggcaaaac	cctgtctcta	ttaaaaatac	gaaaatttagg	caggcatgat	57480
ggagggtggc	tgtaatccca	gctattcagg	aggctgaggt	aggagaattg	cttgaaaacg	57540
gaaaatggag	gttgacgtga	gccaagatca	tggcactgca	ctccagcctg	gcccagcaca	57600
gagcaagact	ccatctctct	ctctctctct	ctctctctct	ctctctctct	ctctctctct	57660
ctctatatat	atatatatat	atatatatat	atatatatat	atatacgtat	acacacacac	57720
acacacacac	acacatatata	ctgagtgggt	ttgcaaaaaa	taagacaaat	tgaaccaatt	57780
gttcccagaa	aatttttcata	aatatctaga	tagtgtggta	gggaaatctt	cataaataac	57840
tagatagtgt	ggtagggaas	tcatacaaca	gagcagaaat	tggtaccatc	taggaatatt	57900
ttgtctctct	actacctaaa	tatttatgaa	aaattttctaa	gagggagagt	attcagttatt	57960
agacatatcc	tacagtgtca	aactctacaaa	ttatagaggt	taaaattattt	tgatgttatg	58020
cactaggcat	ccatatcttc	aataaaaaaca	ttgctttctgt	atctaggagt	aaagaatttg	58080
atgtaaaagt	ctaattcttat	aaaacagata	tatatlaaca	gtcataaagg	tctcagctaa	58140
agcaaaatca	gttttaaacca	gaatacacac	aaagctccct	aacttgtttc	tgttaacgat	58200
aatgctttag	agtaggaaaa	gootgaatgg	aaagacagac	taatatctga	gtaattaatg	58260
tgaaaaggaa	aaaaaattga	tgtctgcttt	gttccctgcag	gttttttttt	cttatctttt	58320
caaatgaat	tatatcagcc	cccacaaaaa	gactaaagtt	agttaaacttt	tgtgtatcat	58380
ctggataatc	aatacaaaaca	taataaatta	cttactaatg	cacgtgggtt	gagctgacca	58440
tccatcttte	ccacatgtaa	ttgatcctga	tgtttccacca	tctgctgtta	catatcctag	58500
tttgacttga	tattttcgctt	tttcttttaa	ggcatatgta	taotgagatt	cagaaataaa	58560
cccattctca	atatctatac	ttgatttggg	acatgtttct	aaaagggaag	agaataagaa	58620
aaagacaagc	atatgatcaa	taacatttta	taagaattta	agtaatatgt	aaatataaaa	58680
aataatgagt	cattttgtaac	tgaaaacctg	gataaccata	agcattccaaa	tacttaagtc	58740
aaggaaaaata	agctcagagt	tgccaaagac	attacatcaa	gactcttcat	cactttttta	58800
aacaaggctc	tatttaagac	acttacaatt	atttctaaga	aattattgga	aactctgttg	58860
tctaattggat	tttgaattct	acagcatgtc	agaaactcaat	agacaatgag	tattattttct	58920
taggaatttt	taactctgac	tattgtagat	cttctggcaa	ttccaaatct	catttagcca	58980
attggagtat	ctgagatcct	gtgatgatct	ttagaaaatct	gccaaaataa	ttttcatagc	59040
ctttggctcc	aagaatttga	aatgtcattc	ttattgtgtg	cttcaaaagta	aatggacatg	59100
tggaattcaa	agaagacgag	gaacagtaac	agattttattt	atcttgaaag	gccaaaatga	59160
tgattcctca	aatttatgtag	aacttaactt	gaagagtggt	aagtttaact	ttctgttaac	59220
tgatgataga	aattactgtc	ggttacatgc	acatgtatgt	ttattgctggc	attatttcaca	59280
atagcaaaaga	cttgggaacca	acccaatgt	tcaacaaatga	tagactggat	taagaaaaatg	59340
tggtacatat	acaccatgga	atactatgca	gccataaaaa	atgaggaggt	catgtccttt	59400
gtagggacat	ggatgaaatt	ggaatcactc	attctcagta	aactatcgca	aggacaaaaa	59460
accaaaccac	acatgttctc	actcatagat	gggaactgaa	caatgagaac	acgtggacac	59520
aggaagggga	acatcacact	gtggggactg	ctgtgggggtg	gggggagggg	ggagggatag	59580
cattaggaga	tataogtaat	gctaaatgac	aggttaattgg	gtgcagcaca	ccagcatggc	59640
acatgtatac	atatgttaact	aacctgcaca	ttgtgcacat	gtaccctaaa	acttaagta	59700
taataataat	aataataata	ataacccaaa	aaaagaaatt	actgtcgttt	actaggttgc	59760
ttcccagaac	tcagcttcat	tttttaataa	ctcatggata	aggagaaaaa	cagaagagga	59820
aacatttaaat	atttttgaatt	gaatgataat	aaaaacatat	taaaattaaac	ttggttgagt	59880
gacactcgaa	caatcctcag	agggaatttt	atcattatat	agctataaaa	gaaaagaata	59940
aaaaactgaaa	ataaattatt	atttataata	aattataaca	aagaaaccag	acaaaatcca	60000
gcatgagtat	aaattttgaa	acaaatccaa	atatgagaag	aaaccaataa	gaaaacaatc	60060
aglacagaca	atttaaaaag	gtaaaagacc	aggcaagaat	aatcaagtaa	aacagagttc	60120
ttgcccacaa	taagggaatg	gaacaaaata	gatgaaaata	acattttcag	acattggaaa	60180
gcaggaagca	cctaattcca	gagaaaaagt	gacaatgaga	tgagttccat	catcaaagtg	60240
actttatgct	gggagaaatt	ttccaaacag	cagcatggag	aaggagaatt	cagcagaaag	60300
tcccacactt	gctgagttag	agaaacaaaa	ctcagtggtc	ccaaagaaga	tgagttcact	60360
agaatctgca	ggaaaacagag	tyagaaasga	agaaactatg	gagtgaagg	gctctacaaa	60420
tttccacagc	aactccctag	attatttggc	tgaatattga	cactctggag	agtagagcaa	60480

31/64

aactccccaa	gaatggacaa	aggataccta	tcagatgaag	aacactacca	gagaacaaaa	60540
aggtaaagga	ttcccagagc	acacacacaa	cacagggaga	catttaaatg	gaatcaatca	60600
gagtagaaag	actcgtttga	acatctaggt	cacgtagtag	agacatcaga	agcagcttaa	60660
tattctgaac	aaactatctc	tgggggtttt	taagcttttt	aaaagcttma	aaataagcct	60720
tgaagaact	aagttgaccc	aaaacaaaac	taaacttaaa	aaaaaattaa	aacaagttaa	60780
ccttgggggt	tcacagatgt	acagacttga	gaagttccaa	agctgcttct	cttagccaaa	60840
atacagaatg	gagttaaaaa	aaaatccaca	ttttggtaat	aataccctct	tcacacctcc	60900
ctccaaaaat	cacagtaaat	cttttatgga	atactcacc	tactccagcc	aaacactgat	60960
tgatatacta	tatatcaaaa	gttggggaat	ggcactagag	cagtatgaaa	taaatgtgtg	61020
tcactaaata	cctgggatag	aaaatgacgg	tgttccactt	caataacctt	agcctctacc	61080
attagatatt	agtaaaagta	gaaaaaatta	atctcaaagt	aagcagaaga	aatactacaa	61140
taaaagatcg	agatgaaata	ataaagaagt	aatatgtat	ataaacaagg	aaaccnaaag	61200
cttgttattt	tagatctcta	taattgagaa	acctttagac	agactaaatc	agaaaaaata	61260
acacaaattg	cttataacag	caatgacaga	aatgacatca	ttatggtttt	tacatatatt	61320
aaaagaaaaa	taaaaaatat	tctgaataat	gccatgtcaa	taaatccaag	aacttgaatg	61380
aattaaaaaa	ttactgaagc	cacaaaactat	catggctctc	tcaagaagga	ttaggtagca	61440
ttaataaatt	ctgtctatta	aacaaattga	atttttcgtt	gatggatgaa	atacaaaaaa	61500
tttagttata	aatctaghaa	aatacaggat	ctgtatgctt	aaaataaaaa	aaactagggt	61560
aagactgtat	gatcttacta	aatcaaaagga	tatataatat	tcattggattg	aaaaatttaa	61620
tactattaca	tatcagttct	ccccagattc	atctgtgaat	gtgtcccgat	tctagtgaat	61680
aaccaagcac	aatgtttttg	acatacgaac	atgctgattc	taaagtcata	tggaaaggta	61740
aaggggctaa	aacagctaaa	caattcttca	aaagataaga	gaagttgaaa	aactcacatt	61800
accnaatttt	aagacttaaa	aaaagctaca	gtgagtaaa	gatctcatga	tactggttaa	61860
aggacaaaaa	cgtgggaagaa	tagaagagaa	aacgggtgtc	agaaatagac	tcacatgcat	61920
ggatcgatcc	tataaatagc	ttctattcta	ttttgttata	agactatcag	gttcacatgc	61980
ccactgttta	gcaatagacc	aatacgtctg	gacagtaggg	tttgacgcaa	agaaaggctt	62040
taatcaacac	aagggcacca	aacaagggaat	tgggaggatt	ctcaagcccc	agatctgttc	62100
tgagaagggg	ctatgtgcaa	gagaccttaa	ggggatcatg	gaggggtgac	ggctagaaaa	62160
tttgggttgt	caattgggtca	gggttaagggg	gatgaagtca	ccaggatgtg	gaacctgcat	62220
tatttctctg	gtcagctttt	tgtctgggtc	tttagaccag	ctgatgtgtg	tgtctgtgtg	62280
tctgtgtgtg	tatgtttgtg	tgtgtgtgtg	tgttttgttt	ttgagcaaga	tgatcttgtc	62340
ctgttgccca	tctggatttc	agtagcgtga	tcacagctca	ctgcaacttc	tgcctcccag	62400
gctcaagtgg	tctctccacc	tcagatctcc	tgagcagctg	gtactacaga	cctgtgccat	62460
aatgcccgcc	taatttttta	attttttgtg	aaaatgaggt	tttgcttgtt	tgaccagtat	62520
gttgctaggt	ttttttttca	tatgcagaac	ctaaaggaga	aactcatgca	gaaagattat	62580
catctcacaa	tgtcttagat	tttatctata	gaaaggaaaa	ggaccaaaaat	gtcttgtgac	62640
aagggtctct	ttatcctagg	gtagtaatac	atgaccagct	acagagaagt	tggacaaatg	62700
gaaagctgat	ttagtgatta	ctgttgattt	tcttgaaatc	atagttgaat	ttttcccccct	62760
taatcaattt	tatataactt	tcctagggac	agtttccagtt	ccttccgggc	ttgatccctt	62820
ctcaattctg	aggtgtaaaa	gctaatatgg	tatgaatcgg	gcaatggcca	ttctagcttc	62880
tttttgctga	cacggggcac	agagagagag	tcaggattag	aggaatgaaa	ccgtcttgta	62940
acaacctgca	agctgttata	cccagcttag	gtgctggat	gaacatgtta	gtacttcagt	63000
ctatgggttt	attgtaatat	ttaattgaat	catgtaaatt	ataatcccta	taaacagaat	63060
tgtgagcttg	aaactcaaga	gtccttgaaa	aatggactgg	aaaacatgga	gtatgcaggc	63120
ggaaagctca	aaaaactatt	cagacatagg	gtctgttgta	gagacatatg	gtctccaggc	63180
agactgctga	aatattttct	ttagtttggt	ttttatttta	ccagaagcat	tgatataagt	63240
acaacaggtg	gtattgatca	ctgtacagac	tctctctctg	aaagccaaga	gaaaatcaag	63300
tgtagttcog	ttgtcaagaa	ctatctgggc	aagtaaatgt	gaagagtttt	ctcagcctca	63360
atgttcttag	cagcctcttt	tgcatttatt	tctgtggttg	ccaataagtt	tctgatcatg	63420
tcccagtgag	tgtatactcc	atagctagga	ctogtgatgc	ctagaaggct	ctgccaccag	63480
atatattgat	atatgctctg	cagtcccttt	tggagtcggt	gggaaaaatg	gcagaatatc	63540
ttgtcattag	gatggactga	gaagtatctc	agtaagttag	agcctttaat	atacaggtta	63600
ttgagacacc	agtgggcttg	ccctaacaga	ggagggtctg	atcctatgoc	acaaataaac	63660
atgtaccaag	ggggcacaca	ggtaaaagcc	tcaagggtgc	atttattgat	ggattttttc	63720
atggggaata	tagacaaaat	gaattgaact	agggatcttt	ttttacaggc	tccccagaat	63780
ttgtgtgata	ttccccactg	taaatatttt	tggcatagta	aggagaaact	tttagtttta	63840
tttcccttct	cctagctgog	tttgtctgoc	cagtatgcca	tgggcatggy	agggcctatg	63900
taatggaatg	actttccatt	tatgataggc	agagagagat	tgacacatgg	ggtgggtgat	63960
totttggtgta	ctattacttg	gacctggaaa	gtagccatgg	aaagaagctg	gtgcagatag	64020
gtagtcatat	ttgggaacat	cagaaaagta	gtgacaagta	tgactaacag	aaaatgctta	64080
ttttggaatg	tttgggggag	ttactgacag	atccatcatt	ctggttaagtt	tottccagtg	64140
gcaatacctt	gaaacagttg	aactacagtg	ttgctatgoc	tgtctaggca	ctgtagtaac	64200

32/64

aggagagggta	taattagaag	ttttaaaaca	agagtgacca	tttctsaatt	ttagaatgtc	64260
cacataatga	gtggcatgag	actatgttag	catggcatag	aatgtctaga	aaatctataa	64320
gtctaacaaat	tgtattgacc	aaggcaatta	tgaagtaatg	tctataaggg	tagcaattgt	64380
aattatctag	gcaattataa	tgaccaagta	aatatatggc	ttaagcatte	agtaaggcag	64440
ggaatagaca	ggaaggatc	tcaccttttt	atataaaata	attataataa	caaacattcc	64500
tggtatgctc	aaagtaacta	ttgtagttgt	caagaagaca	tatgtttttg	ctaatttcat	64560
taaagttact	tatctgatat	ttttcctcaa	aagataattg	aggcccatca	aagattttact	64620
tatccatttca	gatagggttg	agacagtctc	tgaagttgaa	gtggcctctc	tacattttctt	64680
gataggacaa	gaatctggcg	gggcggtttt	tatatggctg	tggtgaatcc	agggctotaag	64740
tccttcaagc	tgaacagagg	aatgggtcac	cagtcctgct	ttgcatggcc	tcttttcactg	64800
tgttttaagt	ggtcccccagg	atgtcgactt	ttcctgggtct	tgagcagaac	ccagtctctg	64860
ggttggtatgg	gatgaaagag	aatgtcagtt	ggataccaca	atctgctgga	accacaaact	64920
cgtgaatagt	agtttaaagta	caaccclaaag	attgtgtatg	tttgataata	totaattttat	64980
ttatgtgtat	gttattggca	ttccttagtc	tgagaaggta	acggaagaat	gatctcccat	65040
gtaaaattttt	taaagggctt	aattttaagcc	cacttttagg	gaccaccctt	actctgagca	65100
gggcaatgga	cagaatgtta	ttccaggttg	ttagttcttt	ggcaaatctt	agctaaaaat	65160
tgttttggtt	tatatagtat	gatttatctt	ttgagttttt	tcagtagact	tcagttctgca	65220
ggctgtatga	agattccaga	ttatgctgag	ggcctggaa	atatgggtgtc	ctaggctaca	65280
gaaattgcac	tatggtcaca	ctggatggag	acaggccacc	taaaacctgag	ggtaattctt	65340
tcaccaagg	ctctcattag	ctcagacatt	ctcttgggtct	tcagcgggaa	tgattttgtt	65400
tatcttga	atgtatctaa	aaatacaagc	aaghatttaa	aatttccctgc	taccttggc	65460
atcaoggtaa	aatcaatttg	ccagtcctct	aatagccctg	cacctcttgc	ttgaatcctt	65520
ggtactgggg	gtggaggacc	agtcttaaga	ttgttctggg	caccaagtag	gtatttttaa	65580
attatttttt	ggatagtcct	ctttaagttg	gtcccaaga	catagtcctg	gatcaattga	65640
agggtygc	gootgccata	ctgtgtggta	tcattgtatg	gtttgatgat	atctgtcaca	65700
agatacttgg	gcaccagaac	ctttctctcc	gtgtcacata	tcactcatt	ttgagttctt	65760
tgattggagt	caaagtctca	atogaattct	ctctttacat	cttcttccat	taggtaggga	65820
ttttaggctg	aagttttattt	cagggattaa	tggcattagg	aaggcttttg	gcattttttt	65880
ctctgttcac	ctcttttagtg	gootgctctg	cctagtgatt	ttttttttct	tgctaccaa	65940
ttgtccatcc	actgatgtcc	atggtagtgt	attatagcta	ctttcttggg	taccaagact	66000
gcctttagtc	aggctaagat	ttcttttagca	tgtttaattg	ttttcttttt	taaatcatca	66060
aaggttaaga	gcccgttttc	tttccaaacg	gccccatgag	catggacaac	aataaaaaca	66120
tacctggaat	cagagtaatc	ggtgactcag	gagtcctttac	ctagttggga	tgccctgatt	66180
aggactctaa	gttctgcctt	ctgtgcogat	gaaccacagag	ggagtgtctc	tgcatctagg	66240
atctgtcaca	gggttacaat	agcatactca	gccttctgtt	gtccgtgggtg	cataaagctg	66300
ctttctcag	tgaatatattt	taagtcacag	tttttaaagg	gaatttttgg	catgtctggg	66360
tgaatagaac	acacttgctc	agtaatttat	atgcaatcat	gtatagggtt	atbttagcagg	66420
atttaaagca	gaaacagctc	tcaaagtaac	actaggatta	tccaggagga	tgacctgata	66480
cctattcagt	cttctagagg	taagtcagta	gctccacttc	tgttccaa	aatagcatac	66540
acagtatggg	gtgtgtacag	tgctaggtta	acccaaagtg	aactcttctg	cctcctggag	66600
aagatcacaa	gtggtgcccag	tggtctcagag	ataagaagtc	caacccatca	taacaatgtc	66660
cagctgtttt	gaaaagtagg	ctacagggct	catgatatcc	cccaagtctt	gggttaactac	66720
tcctaaaccc	atcccttctc	tctcatgtat	gaacaaatca	aatggcttct	ttagttcagg	66780
gggtctcagt	agccagatcc	attagtaatt	tttacttaat	ggttagaaag	gccttttgac	66840
attccttgct	cattctagaa	gtcaagtgtc	tggctcttagg	gcttcataga	gacattttgc	66900
tataagccca	aaataagaaa	atgaaatatg	gcaacattca	gccataccta	aaaacccttc	66960
acagctgctg	ccatgtcctg	agtctggcca	ccctgacaag	agcttctctc	cagtcogaaa	67020
gcagattact	ctgctcctga	gaaaattcaa	acctaaaata	tataattgag	tttttcaata	67080
tttgtgattt	ttttcttggg	tactttggat	ccccatccag	acaaaaaaaa	aatgtaaaagc	67140
cagtataata	ttctgggtcaa	tttgccatag	ttgtgtctggc	ttctaatatg	ccgtcaacat	67200
atataagcaa	agttctcattt	ttcaattgga	gggtcccaaaa	ctccttagca	tgtatttccc	67260
ccggacgggt	agtgagtttt	tgaagccttg	atggagcctc	atccagcaat	actatcattt	67320
agcttttagtg	tcagagtcctt	cctattcaaa	ggcaaacact	tcattgggact	ctggactcag	67380
gggaatcacg	atgaaggcat	ccttcagatt	caagactgaa	caccagtaca	actcactggg	67440
taaagtcagt	aataatgtat	aagcatcagt	tatcaccaga	taaatggctt	tgaaaatttg	67500
cctagtagcc	ctcaaatcct	gtacaaaacca	ataatcctca	gttccatgtt	tttgtcctgg	67560
caagacaggt	atgtttacatg	agaaacaagg	aattcttctc	gtattgcagg	aaggccatca	67620
gcagaggcta	aatgcattgc	tgtgcctttt	ctctcaagg	gcgtgctttt	agattttggca	67680
gcgccactcc	tgcacaaaaac	ttgacttgta	ctggagatgc	agttttttgt	ttccctggcc	67740
tcccatctgc	ccatgttttc	ggactaacct	ttggagatgc	ctcttcaggg	gtgcaggcac	67800
tttcaaggat	ctccagttgt	aataatattg	cctgcagagc	acatgcttgg	tctgaaggca	67860
cctggatgtc	caatcatctc	agagaaaaag	taatcttagc	atttagtttg	gttaagagta	67920

ctgcccctaac	aggacgggag	cagtggtctca	cacctgtaat	cccagctccc	agcacttttg	67980
gaggccaaag	agggcagatt	acctcatgtc	aggagttaa	gacgagccag	gcaaacatgg	68040
tgaaaccttg	tctctactaa	aaatataaaa	attagctggc	tgtgggtggc	cacgctgtga	68100
atcccagcta	ctogggaggc	tgagacagga	aaattgcttt	agctcgtgag	gtggagggtt	68160
cagtggagcca	gagggttgag	tgagccacaa	tctgtccaco	acagtcocagc	ctggggcgata	68220
gggcaagact	ctgtctcaaa	acaaaaacaa	acaaaacaa	aacaaaaaag	gaagactttc	68280
cccaacaaag	ggataggaca	ttcaaggatg	tatagaaaaa	ctctgtcttt	tttttttttt	68340
tttttttttt	gacagagtct	tgtctgttcc	cccaggctgg	agtgcagtgg	catgatcttg	68400
gctcacttgc	aagctctgoc	tcccogattc	acgcogttct	tctgcctcag	cctcccgagt	68460
agccgggact	acaggtgccc	accaccatgc	ccgactaatt	ttttgtattt	ttagcagaga	68520
cggggtttca	ctgtgttagc	caggatggto	togatctcct	gaccttgtga	tctgcccac	68580
tcagcctccc	aagggtgctgg	cattacagga	gtgagccacc	gcgcccagca	aaaaactgtg	68640
ctttaaatga	ctttactcta	gctgacaatc	caaaatttgg	aggaatgatc	tcacagcat	68700
ttttcttgag	atttcagtca	ccttcattat	ttctgaggaa	agtttagacc	accagatatt	68760
taacacccaa	tagatggcac	catgtctact	agaaagtcca	gaagctgatt	tctcaccato	68820
atcaggatct	caagccccat	gtgggaaata	tggaggtgt	tgtctgggtc	aggagaagcc	68880
cctgggtgct	accattttctg	gtctttttct	ttagtatctc	tctcaagctc	cccagctatc	68940
ccaggctatt	gggtgggcaga	aggtgtactg	tttaacatca	ggctttgtag	ggcatgagaa	69000
attttccact	cagtgtcccc	cctgttgcag	taagcacact	gggtgggaac	tgcactggga	69060
tgtccgtttt	tattggcctt	tgggggcccc	gggtggttota	ccatagatgg	agtgtctgat	69120
gacggccctt	gttgtgggtc	agggactact	agggctcagag	ccacagataa	caagtcagct	69180
tgcacttttc	attatttctt	gtgtttttatt	ttccactctt	ttaaacttgtg	atcagtaaat	69240
acattaaaaa	caatcttcac	taattgagac	aaaaacatgt	ccaatgcctc	agctacgttt	69300
tgttaacttt	tctgaatata	tgggggcactt	tgttggabaa	acatcatggt	agctatcatc	69360
aaattttctg	gggtcttctg	gtcaatatcc	atttattctc	tgaaagcttc	aaagacttgt	69420
tctaagaatt	ccaaagcaac	cctcattagg	cttctgcttg	accatcctgg	accttactga	69480
gactccttbg	cctgggcact	ccttgcagca	ggctgatcaa	aatgcagttt	tgatagtgtt	69540
caaggttaga	tctatctoca	gtgttttatat	tccatcccag	gtcagaggtg	ggaactgcaa	69600
tctgagcagc	tgccttactt	ggattactgg	gagagtcaat	gtgaataaga	tcagcctttt	69660
ccttagcttt	ttctaaaaac	attcttttgtt	tctctcaagt	caacaaaata	ttgagcaaat	69720
tgggggtgoc	tgtcaggla	gggttctgtg	tggcaaatac	agaggagaat	agattcttca	69780
tatgcttttg	atgttttttt	tttttttttc	aatcctgttc	cttccataaa	cttttagatct	69840
tctcaataaa	taggcataatt	atttttcttaa	ttaagtaggt	tggaaagtga	gaacagagaa	69900
taaaccaaga	taaatcctat	aggctggcct	gtggcagcaa	cacctcctgt	aagcagttgt	69960
tatggggaaa	ctgcctctca	gaaccagagt	gactccccgg	ctaaatggag	ttccctgttg	70020
ggtataagaa	gtgacacctt	gcctaaatgg	agtcacctgt	tgggttataa	gaagttagaga	70080
tcatacctgt	tgcctccgat	ttgtgacttt	ttgggtgggtg	ggactctgga	gaggcgccag	70140
tagtgcctgt	gcagctcccc	cataaagtgg	aggggggtga	gtcataggtt	cctttaactg	70200
aaccatcata	gcactcatctt	tttcttgtaa	atcagtccaa	acagctctta	atttcttact	70260
ttatcatgat	tttacctttt	tctacattgt	tgtacttttc	caaagcaaca	taaaacatta	70320
tacatagggt	atttcatctc	attcctcttc	cttcttacaa	aacaaatcta	gctacaggat	70380
ogtactgtaa	gcactgagac	catgcagtgg	ccactgttct	cogaaatcca	gtgggtatta	70440
aggtttaagc	atgttaaaaa	gtaagataat	ctttttttgt	ttcatggaat	gatagacaaa	70500
ggcctttcaa	ttttggaaga	tgcagcccat	cagggttgca	ttgtgggtta	ctttgggaga	70560
actaagggac	agcccttagt	tcatgagagc	taagtaagct	gctagggttt	gtctctgggt	70620
ctgtcccagt	ggaaaggggg	cactaggcag	tgagtaaatg	ccctcaaaag	gagtgaacct	70680
gacctggctt	gccacaaaata	gttacgagat	tgtcagattt	gtatgcctgc	tgcacagcaa	70740
cagaacaata	cactgagaca	gtgggggttg	ctgacagaga	agagttaaat	aatctcaag	70800
ccaccagccc	cattgggctg	cctggaggag	ctgaattagc	atttcccat	ctggctggaa	70860
taatacacac	ataacaaaac	agatactagt	caccatactc	aggacccaag	tattgacctg	70920
gcaagactca	aaacttggtt	cattggccct	tgtcatcttt	gatccactca	agctggagag	70980
ggatgacott	ogatcagaag	ttcagagggt	aaagcctggg	aaagattgaa	gagcagatga	71040
ttaccctgag	ttaggcttgc	tgagattcca	ctagcaactc	cttcaggact	aactgaatgt	71100
gactgaccaa	acaagaagag	ttccctgagt	tagtaatttc	ttccactagt	aatttcttca	71160
gggttaagct	ccacaaacat	aaatacatat	aacaagacaa	agacaaaaca	aagacctttc	71220
catataaagt	ttcagattcc	aaaatccaag	accattttct	ccaagcaatg	ccctctagtc	71280
tttttccatc	tgaagggaga	tctcctcaaa	taagttctta	ccttagactta	gggagtgtca	71340
acaagacctc	aaagaggcca	caagacctct	aagacgaaaa	caggcacaca	cacacagaa	71400
gaaatggggt	gccagctgct	ctgagaaaac	tcaacttgaga	cttcttctga	gaccagaaat	71460
ggtttctctg	ctgcagacaa	ggttgtgtgc	tgaagtcag	cactgcccctg	ccaacacaga	71520
agggcccttc	taagggccct	agttcatcat	aactaagcag	cttcttgagc	ttctctctgg	71580
gtcagcccca	gtggcatggg	ggcactggac	tgtaggtaaa	tgactgcaag	gagagtggct	71640

tggcaatgaat	ttttttttct	tttttttttt	tttttttttt	agacgggaatc	tcaatctgtc	71700
tcccaggatg	gagtgacgtg	gcacgatctt	ggctcactgc	aacctctgcc	tcccagggttc	71760
aagtgtattc	ccagccctag	cctcccaagt	aactgggatt	acaggccatgt	gccaccatgc	71820
ctgggcaact	tttgtatttc	tagtagagac	agggtttcac	catgttggcc	agcctgggtc	71880
cgagctcctg	acctcaagta	atctgocctc	ctttgocctc	taaagtgtctg	ggattacagg	71940
tgtgagccat	catgtctggg	tgcttgccat	gaatttttat	aagattgtaa	ggtttgtatg	72000
cctgctgtgc	agcaacagaa	tataccaaga	cagtggagtt	tgcaacagag	agttttacaa	72060
ttgcaaggtc	acaaaacaag	gacatgagaa	gaattctcaa	gactcaaacc	catttcactg	72120
aagctttctg	ggcaagaatc	tttgaagggg	gagtggctgg	aaaaattgagg	tcatcaattg	72180
attcgggttaa	gggggctgaa	atcatcagga	tatggaaagt	acattcttcc	ctaagttgag	72240
tttcttgtca	agcctttcag	aatggctggc	atcagtagtt	ttgttagtat	gcagaacctc	72300
aaggagaaaac	tcaaatggaa	agtttgtcat	ctcataattgt	cttaaaatttt	aactaaagaa	72360
cagaaaaaga	acaaagattc	tagtgacaaa	gattatgtta	tcctggacta	gtaatcagtg	72420
accagctata	aggaagtggg	tcaatggaaa	gctagcccaa	tgattaccat	tgattgtcct	72480
acaagcctag	ttgaatttta	ctttttctct	cttaactgtt	tttaaaaaatt	ttttgaggat	72540
gtttttcaatt	taaaaaagga	gcaaaggcaa	ttcaataaag	aaaacatagt	cttttaaaaa	72600
agtgtactctg	gaacagtaac	gcataccaaat	gcaaaataat	aacctctctac	atattctctca	72660
tacctcatatc	aaaaattaac	tcatataact	aagtgtaaaa	tgtaaacttc	tagaactgta	72720
tatggccttg	gtttaggcaa	ggaaatttta	gatgacacaa	agagcgtaat	ctataaatga	72780
aaaatgtgat	aacatcaaaa	ttacataact	ttgtctcatga	aaagagacta	ttagagagaa	72840
aagtaaaagt	acagatgcaa	gaaaaatatt	tgcaaaatat	ttactcagtg	aagggccttg	72900
agccacaata	tatcatgtag	tctcaaaaatt	cctaatggga	agaaacaact	caatggaaaag	72960
tgggcaaaaat	ttagacagtg	ttcaccaaaag	gaggtacata	gatggtaaat	aagtacaaaag	73020
aagatgctaa	gcagcattag	tcactagggga	atcacacaca	tattagaatg	cgaaacaact	73080
gataattttaa	tggaaaaaaa	aacacattat	ctcaaaaggct	ggcaagggttg	aaaacagttt	73140
ggatctcaca	tacactgagt	atgtgaagggt	acaatgtatg	atcgctcagg	gttttttaaaa	73200
gtctattttct	tataaaaaatg	aacacatatt	tagtatgata	tttgctatgg	gtgtttttac	73260
aatagctctct	ataatttttga	gatattgttcc	atcaatacct	agttttattga	gtgtttttac	73320
catgaagggg	tgttgaattt	tattgaagggc	cttttctgca	tctatttgagt	taattatgtg	73380
ttttttgtca	ttcatattat	tgatttgtat	atgttgaaac	agccttgcat	cacagagata	73440
atgggagact	gtctcattgt	aataagcttt	tagatatgct	gctggatttg	ctttgocagt	73500
attttattga	ggattttcgc	attgatgttc	atcagggata	ttagactgaa	attttctttt	73560
tctgttgtgt	ctctgocagg	ttttgggtatc	aggatgatgc	tggctccata	aaatgagttt	73620
aggaggagac	cttctttttc	tattgttttga	aatagtttcc	aaagggaatgg	taccaactcc	73680
tcttagtacc	tctggtagaa	tttggctgta	aatccatctg	gtcctgggct	attttctggt	73740
ggcaggctat	taattactac	cacaatttca	gaacttgtgt	ttggcctatt	cagggttttg	73800
acctctttct	tctgctttag	tgttggggagc	gtgtatgtgt	ccaggaattt	atccatttct	73860
tccagatttt	ctactttatt	tgtgtagagg	tgtttatagt	attctctgat	ggtagtttgt	73920
atttctctgg	gatcagtggt	gataccctct	ttatcatttt	tattgtgtct	atttgattct	73980
tctgtctttt	cttctttatt	agtatggcta	gtagtgtact	ttgttaattc	tttctaaaaa	74040
ccagctcctg	ggtgcattga	ttttttgaag	ggttttcatg	tctctatctc	caggctctgt	74100
ctgatcttag	ttatttcttg	tcttctgcta	gcttttgaat	ttgtttgtct	ttgctctctc	74160
aattcttttt	ttattattat	tatactttaa	gttttaggggt	acatgtgcac	tacgtgcagg	74220
ttagttacat	atgtatacat	gtgccatggt	ggtgtgtctc	acccattaac	tcttcattta	74280
acattaggtt	tatctcctaa	tgctatccct	ccccctccc	cccaccccac	aacaggcccc	74340
ggtgtgtgat	gttccccctc	ctgtgtccat	gtgttctcat	tgttcaattc	ccacctatga	74400
gtgagagcat	gcgatgcttg	ggtttttgtc	attggcatag	tttgctgaga	atgatgggtt	74460
ccagcttcat	ccatgtccct	acaaaaggaca	tgaactcttc	ttttttatgg	ctgcatagta	74520
ttctatgggtg	tatatgtgct	acattttctt	aatccagtct	atcattgttg	gacatttggg	74580
ttgggttccaa	gtctttgcta	ttgtgaatag	tgcgcgaata	aacatacgtg	tacatgtgtc	74640
tttatagcag	catgatttat	aatcctttgt	gtatataccc	agtaatggga	tggttaggtc	74700
aaatgggtatt	totagttata	gatccctgag	gatctagaca	atgacttcca	caatggttga	74760
actagtttac	agttccacca	acagtgtaaa	agtgttccta	tttctccaca	tctctccgg	74820
cacctgttgt	ttcctgactt	tttaattgatc	gocattctaa	ctgggtgtgag	atgggtatctc	74880
attgtgggtt	tgatttgcat	ttctctaatg	accagtgtatg	ctgagcattt	tttcatgtgt	74940
cttttggctg	cataaatgtc	ttcttttgag	aagtgtctgt	tcatatcctt	cacctacttt	75000
ttgatggggg	tgtttgtttt	tttcttgtaa	atttgtttga	gttcattgta	gattctggat	75060
attagccctt	tgctcagatga	gtagattgca	aaaattttct	cccatctctg	aggttgccctg	75120
ttcactctga	tggtagtttc	tttthgtgtg	cagaagctct	ttagtttaat	tagatcccat	75180
ttgtcagttt	tggctgtgtg	tgccattgtc	tttgggtatt	tagacatgaa	gtccttgccc	75240
atgcctatgt	cotgaatggt	attgcctagg	ttttcttcta	gggtttttat	ggtttttagat	75300
ctaacattta	agtcttttaat	ccatcttgaa	tttaattttg	tataagggtg	aacgaaggga	75360

tccagttttaa	gctttctaca	tatggctagc	ctgttttccc	agcaccattt	attaaataag	75420
gaatccctttt	cccatttctt	gtttttctca	ggtttgtcaa	agatcagatg	gttgtggata	75480
tgtagcatta	tttctgaagg	ctctgttctg	ttccattggg	ctgcactctt	gttttggtac	75540
cagtaccatg	ctattttggg	tactgtgggc	ttgtagtata	gtttgaagtc	aggttagcatg	75600
atgcctccag	ctttgttctt	ttgtcttagg	attgaacttg	caatgcgggc	tctttcttgg	75660
ttccatataa	actttaaagt	agttttttcc	aattctgtaa	agaaagtcac	tggtagcttg	75720
atgggggatgg	catgctgcca	aaggtaattt	atagattcaa	tgccatcccc	atcaagctct	75780
atttcttttta	attgaggtgt	taggggtgtc	agtttagatc	tttcccactt	tctgatgtgg	75840
gcatttagtg	cgataaattt	tctctaaaag	actgctttaa	ctgtgtccca	gatattcttg	75900
tacattgtgt	ctgtcttctc	attgggtttc	aggaaacttat	ttacttctgc	cttactttca	75960
atatttactc	agtagtcatt	cagtagcagg	ttgttcagtt	tccatgtagt	tgtgtagtgt	76020
tgaatgagtt	tcttaactct	gattttcta	ttgatttcac	tgtggtctga	gagactgttt	76080
gttgtgggtt	ttgttctttt	gogtttggct	gggagtgttt	tacttccaat	tatatggctg	76140
atcttagaat	aagtgtctatg	tagtgccaag	aagaacactt	gacttctggg	ggagagttct	76200
gtagatgtct	attaggtcca	gttgggtccg	agtttaggtc	aaattgggaa	tatctttgtt	76260
aattttctgt	ctcgttggatc	tgtctaggat	ggcactagta	ttgggagttt	tggaccagac	76320
aatcaggcaa	gagaaagaaa	taaggagtat	tcaaatagga	agagaggaa	tcaaatgttc	76380
tcttttttgc	gatgacatga	tgggtatatt	agaaaacccc	actgtctcaa	cccagaaact	76440
ccttaagctg	ataagtaact	tcaggaaagt	ctcaggatgc	aaaatcaata	tgcaaaaaatc	76500
acaagcattc	ctatacatca	gtaatagaca	gaaagccaaa	tcattgagtga	actcccattc	76560
acaattgcca	caaagaaaat	aaaatacgtc	gaaatacaac	ttacaaggga	tgccgaaggaa	76620
ctcttcaagg	agaactacaa	accactgtct	agggaaataa	gagagggcca	aaataaatag	76680
aaaaatattc	catcctcatg	gataggaaga	atcaatatca	tgaaaatggc	catattgccc	76740
aaagttagtt	atacatacaa	tgtatattcc	atctagctat	cattatcttt	cttcacagaa	76800
ctaagaaaaa	tgttttaaat	ttcatatgaa	accaaaaaaa	gggtcccatct	agccaagaca	76860
atcctaatac	aaaagcacaa	agctgatgca	tcaggctacc	tgattttcaaa	ctatactaca	76920
agactacagt	aaccaaaaac	acatggtact	tgtaccagaa	cagatatata	ggccaatgga	76980
gcagaaacaga	ggcctcagaa	ataaacaccac	acatctacaa	ccatttgatc	ttcaacaaac	77040
ctgacaaaaa	caagcaatag	ggaaaagatt	ccctattgaa	taaatgggtg	agggaaaatt	77100
ggctagccat	atgcagaaaa	ctgaaaactg	acccttccct	tacaactaat	ataaaaaatta	77160
actcatgatg	tgttaaaagt	ttaaatgtaa	gacctaaaaa	cataaaaaac	atagaaaaaa	77220
acctaggcag	taggtttatt	aggacatagg	catgggcaaa	gacttcatga	ctaaaaacac	77280
aaaagcaatg	gcaacaaagg	ccaaaattga	caaattgggt	ctaattaaac	taaagagctt	77340
ctgcacagca	aaagaaacta	tcacacagat	gaataggcaa	tctacagaat	gggagaaaaa	77400
ttttgcaatc	tatccatctg	acagaggtct	aatatcaaga	atctacaagg	aacttaacaa	77460
aatttataag	aaagaaacaa	adaaccacac	caaaaaagt	gtgaaggata	tgaacagaca	77520
cttttcaaaa	gaagacattt	atgcagtcag	caaatacatg	aaaaacaagc	tattgtcact	77580
ggtcattaga	gaaatgcaaa	tcaaaaaccac	aattgagaaac	caattcacgc	cagttagaat	77640
gccgatcatt	aaaacatctg	gaaaccacag	gtgctggcga	ggatggggag	aaataggaaa	77700
gttttactct	gttgggtggga	gtgtaaat	gttcaaccat	agtgggaagc	agtgtggcaa	77760
ctcctcaag	atcaagaacc	agagatacca	tttgaccag	caatcccatt	actgggtata	77820
tacccaaagg	aatataaact	atttctactat	aaaggcacat	gcacacatat	gtttatcaca	77880
gcaccatttg	cagtagcaaa	gatttggaa	caaccacaa	gcccataaat	gatagactgg	77940
ataaagaaaa	tgtggcacat	atacaccatg	gaatactatg	cagccataaa	ttgaatgagt	78000
tctgttcttc	tgcagggaca	tggacgaagc	tggaaaccat	catcttcagc	aaactaacac	78060
aggaacagaa	aacaaaaacac	cacatattct	cactcataag	tgagagttga	tcaatgagaa	78120
cacatggaca	tagggagggg	aacatcacac	accggggctt	gttgggggtg	gcggggaaa	78180
gggagagaga	gcactcaggac	aaagagctaa	ttcatgcaag	gcttacaacc	tagatgacgg	78240
gttgatgggt	gcagcaaaac	accatggcac	acgtatactt	atgtaacaaa	cctgcacgtt	78300
ctgcacatat	atcccagaac	ttaaagtata	ataataataa	aacacacaca	cacacacaca	78360
cacacacaca	cacacaccat	ttatctaaca	aaccagctct	tagatatgta	tccatgagga	78420
ataaattttg	gtttatataa	aaactgcaga	tgaatatatt	tcttaacagc	atgattcaca	78480
aatgccaaaa	acaatgcaaa	tgccttcaaa	caacatgaatg	gattaacaga	ccgtgatata	78540
tgatataatg	gaataatact	tagcaataaa	aaaagggtgt	ctgggtagtg	tgtgaatc	78600
ctatgcccatt	cagcccccatt	ctcccagag	cctgaatact	ttcttgtcta	gtgcatccac	78660
agtttatact	acctgctgt	tagtcaacta	gtagtctttg	atgaaatcct	atgccattca	78720
gctccatccc	gcccagagca	tgaatcctcc	cttctgtctg	tgtatgcacc	agcctgttag	78780
tcacttagta	gtattcccaag	ttatcagggt	gaaaaacata	gtctacttgg	gttttatact	78840
attaatcatt	tccgggcattt	actggggagc	ctgggaacata	tcccacatga	ataagaggga	78900
ctagtgcagc	ttttttctct	cacaggtaag	tagagactac	tctgtctatc	ttcagaagaa	78960
tcatttcagat	ggcactagta	attcaagttt	tacaagtcaa	gagaaattga	tattctgtga	79020
tttatctggc	aaatttttta	tttaaatgac	tatttttaaag	gaaactacag	ccagtttgca	79080

ttcataaagg	atacactcca	atatatatct	actgtactca	ctcaagtatg	tttaattttt	79140
tctgcataatt	ctcaccaacat	ggttatgagg	aatttagatt	ttattaaatt	gaaaaacaat	79200
gtgattcact	gacaattgac	tgtacatgaa	aatataacgt	tgatatctca	atctgaaga:	79260
gaagctaaga	cttgittaatt	atatgacaac	cgtaaagtag	ctaaataacc	tgactaaagt	79320
acagggtcta	gcctgaagag	taaaatagta	acattcttaa	gaataacttg	agccagacaa	79380
acttgggaca	aaaggaaaaga	aggaaggag	gaaggaaagga	aggaaggag	ggagggaggg	79440
agggagggag	ggaggtgaca	gagggaggga	gggaaggggag	ggagggaggg	aagaaaagaaa	79500
gaaggaaaaga	gaaagaaaaga	aagaaaagaaa	gaaagaaaaga	aagaaaagaaa	gaaagaaaaga	79560
aagaaaagaaa	gaaagaaaaga	aagaaaagaaa	aagggaaggga	aagagaaaaga	aagaaaagaaa	79620
gaaaaagaaa	ggaggggaaa	gagaaaagaaa	gaaagagagaaa	aaagaaaag	aaggagagaaa	79680
gtagacaaaag	aaagggaagaa	agaaaaaaga	atgaaaagaaa	gaaaaagaaa	gaagggaagag	79740
aaggaaaagaa	agaaaagaaa	agaaaagaaag	agaaaagaaa	gaaaaagaaa	aagaaaagaaa	79800
gaaaaagaaa	ggaggaagg	aaagaaaagag	aaaaaataag	tagttgattc	tacaatcagc	79860
tccaaaaatca	aaccaagagg	cataaacgtt	gattgagttg	tttgatatca	ggagaaaattg	79920
catatctaatt	caaggcatat	cattagcctc	aattaatctg	tgaagaaaaa	aataaaaagta	79980
atgggatcat	ctgacactga	atgatgagac	aaaaaagaga	ctgatgaagc	aaaaagattt	80040
gggtgaaaag	ccatgattag	gggtgaaaagt	catatocata	cttattaaaa	acctatatta	80100
attaaaaattc	agggagtgga	gggtgcagcg	agggagagac	gcgacattgc	actccagcct	80160
gggtgacaga	gtgagattct	atctcaaaat	aaaataaata	aataaaattc	aatagagggg	80220
tactgcaatg	ctgggttaaaa	aattgtttac	taatagtga	gaatactcag	agtaatagtl	80280
atttgtgtgtg	tgtatacaca	cacaatgtac	aaaatataca	ataaaaaata	tactgtttga	80340
gaaaggtact	ataaaaattg	ttaggggaaat	gttgaagttta	ccatatttca	tttaaacatg	80400
aaatacagcc	attatcatga	ataaaatcaa	cacaaaatat	ttttaaaaata	tgaagagaaa	80460
aggtaaactta	taacttttta	gaataaagaa	tagtatagtg	gctctatgtt	tttgaggtat	80520
tccttttaaat	agaaaacaaga	aacattcctc	atgaaaaaag	attgactatt	atgtagttaga	80580
atgagcaact	tatgttcata	atgcagaaaa	aaggaaagaa	aaatactagc	cacaaagaga	80640
atacatttgc	attacgtata	abtaaaagag	atttttatatt	cagaatttgtt	aagatgattc	80700
caactaataa	taccaaaact	ctcaaaaagg	taaaataaaga	aaatcaact	gcatttccaa	80760
agattagaag	cattaaatac	caattaaact	gtgaatatat	attctaaacc	cagtttagtgg	80820
taaaagaaaat	gcaaatttac	actataatgt	tataacattt	tatagccatt	caatttgttaa	80880
atattaaaaat	gtgacatcac	caatcattaa	catgtaaaaa	aagaagtaac	tgttgatata	80940
aatgtatgtt	ggataaata	ctgtaggaaa	ccttctagag	tagaatatgc	acaagatctc	81000
agaataccca	tttgtactta	catatactag	agaaagtcaa	atagctttac	tgtaaaaatg	81060
tcataatcact	gcttgaatat	atgaattatt	gggtatcctc	gtattttactt	tctatttttaa	81120
actataattg	tataattatt	ttgagtcaaa	tgattgatcc	caatgtacat	attaatattg	81180
atataggagt	tgagaaaaaa	ttgttttaggc	agataatgag	gggtacagcag	tccttgataa	81240
ggtttttctc	tttaaatgaa	ggcagccccc	aaatcatttt	cttttctaac	aagaggagcc	81300
tgtaaaatcg	aactgcaaac	atagacaagc	aagctggag	cttgcaaggt	gaatgccagc	81360
agttgtgcca	ataggaaaag	gctacctggg	actaggcatg	ttcatatggc	aggtgcactc	81420
tcctttctct	ttgccagcca	cgtgtacagt	aaggagaaaag	caactgtggc	ctggccaggc	81480
aaagatccca	tttgattaat	aagattaggg	tggggggggc	agcttctctg	catattatgt	81540
aaatgtcaca	cctagtttaa	ccaatctttg	ggccttatgt	aaatcagaca	ctgcttctc	81600
aagaccgttt	ataaaatcca	gtgcactcca	ccaggggcag	ggattcactt	tcaggtgccg	81660
ctctctctca	caagagagga	agctgtcttc	ctttctcttt	cttttgcta	ttaaacctgt	81720
gctcctaacc	tcactccttg	tgtgtgtcca	cgtccttaat	cttcttggtg	tgagataaac	81780
aacctcagat	atttacccag	acaatgatgc	cgttccaata	cgaactcatt	taaccaacaa	81840
gtatttgtgt	caaatctctt	tactgtattc	ttgactaatg	cccattaata	ggagaattta	81900
ttttactatg	tacttatcaa	gaaatttgtta	tattccattta	tacacagttg	aaaaaccasa	81960
taactaaatag	gtccattggg	aaaacaagg	gacataaaca	ttttgccaca	attaatatag	82020
atgagtctta	gaatgtcctc	tatgttactt	agaaagacat	gaacatgcta	ggatttcaga	82080
gtagtgtact	tactgacacg	gatgcactcg	ggagtaggag	accagccatt	ctccatcacat	82140
gtaactgtgg	tctgcgcttt	tggagagagc	tagccaggat	ggcaggcaac	gtctatagat	82200
ttaccctgta	caaacctttc	tccatgatcc	tgatttatatc	catttttccaa	ataaggaaaa	82260
taacattttc	ctaaggacca	taacaatgat	aaataaataa	agtaaatgag	aaacataaat	82320
ttgtctcaaaa	tagtatatta	caattatbtt	tacaatattt	aaataagatt	gcataaacat	82380
ccaaaaataaa	tgtataactg	aagacgaact	aaagttacta	acaaagggtt	gcacaaaaag	82440
aaatatcaat	attcaatatt	acttatcttt	agtttttata	attaatagat	gtataaatta	82500
tatagatatt	ctcataaagt	ccctatatatt	atttctcctg	tgattttcaa	gaagaaaccc	82560
tcataataga	aaagatctat	tttggctact	ttgcttgaac	aactcttttc	ttggccctat	82620
ttctgttaca	taagacaggt	gtaatcactt	atgtgctctc	ctttcttcga	tctttgaaag	82680
tttttatcat	atatatagca	gttcagaggt	ttacttactg	aggcatggta	ctgctggcga	82740
ccatccatct	tgtgtgcaat	gaatgtgatc	ccagtaactt	cctgacggag	tctcaaatg	82800

37/64

ttcatcacag	taataggagt	aatattttcc	tacagctact	ggaaagtatg	gtctacgcat	82860
attctcatga	tatagaccto	catgtttaat	gtctggataa	tcacaagggt	tcacttgcaa	82920
taaaaatttt	aaaaaaagta	taaagaaatt	ttactgtaat	aaacactcat	attagagata	82980
aatttttate	actgaattat	attctotttt	tagtataatt	acacattcca	ttaggggttc	83040
taggtcaaaa	caaatgatag	aactcagatg	actgagatat	gtaacaagaa	ggctcttggt	83100
aatgaagatg	aaattatgto	ttgtggatca	catgatgcgt	aaatttgat	gaaggctctc	83160
cagaaagaaa	aatgcacaga	cctattttaat	atatttccct	taaatacaca	tacctatcc	83220
ctggtttaatt	aaataagcct	ttcgggttgag	aaatatgcca	attttaccgc	ttagctcatg	83280
tattcttttc	tttctttctt	tctttttttt	ctattctcat	cagttaaaca	gagccctgca	83340
ttttcttttc	agaacaattc	aatgtaagga	agtagtattt	tgagggtatt	aagggtttta	83400
tttgttttag	attgaattca	tgggctgggc	gcagtggttc	acgctgttaa	tcccagcact	83460
ttggaagget	gagacaggca	gatcactcgt	aaggagtctg	agaccagctg	ggccaacatg	83520
gtgatactcc	gtctctacta	aaaatacaca	aaaaattagc	cgggctggt	gggtgcgccc	83580
tgtaattcca	gtacttaga	aagcagaggg	aggagaatcg	cttgaaccca	ggaggcagag	83640
gttgagctga	attgagattg	tgtctttgca	ctccagcatg	ggttacagag	tgagactcca	83700
tctcgaaaaa	tataaataag	tataaataa	aattaggctc	tttctatttt	attgcagaca	83760
acgtaaaaat	atagagaaaac	acaaaaattt	ttctttgatg	ataccgcgca	gaaaaataac	83820
atagttaatt	catgcctcaa	acaattcatt	aagccaagtt	ctccagtctg	tatttaacca	83880
gagaaacaga	ctagaaatat	ttcttcatat	ccaaatagtt	aagattttga	ttactttttt	83940
tgtttatttc	taattttta	tggagagaaa	aataattttg	atgtcataaa	atatatttaa	84000
gtaaggtaaa	atataattac	attttactga	gttattatat	attaattttg	acaaatacat	84060
ttgagtgcba	tcttggtttt	tataattaaca	ggtttatata	tttttcagaa	aatttgctct	84120
tttcatggga	ttattttgtg	attatctagt	actttcaata	acaaaatggg	attaatggtt	84180
tccatgaaat	atgtttctat	ttcaataaac	ctttatgcaat	aggttaaaaa	gaatttcaat	84240
acacacatac	acacacacac	atataaatat	tcttttccat	ctccatcttt	cttaaatctt	84300
gtgatttatt	ttcttttgta	tttgattaga	gaaattttca	tgtagttttt	acattttatta	84360
tgtggattat	aaactgaata	attgtatata	ttaaatgtat	ttctctataa	aagactagtg	84420
aatgatactt	cttttcagtat	agtttcttgg	cctacaatcc	atataatctta	taattgatag	84480
attttttttc	ctattttatct	gaagctccca	gtgttgaaat	taaaaacatt	acttagtctt	84540
attttttttt	agtaacattc	tacatttttt	ctcaccactt	tttaagattt	tggaaatatt	84600
tctatttacc	attggatttt	acaaaatttc	tcctgatttg	ttgagacatg	tattatttta	84660
caataattct	gcattgggaa	agcttgagtc	ttggatttgt	gggagctgtg	ccttaagggc	84720
ctcaattgaa	tttcacattt	aatggtagag	tagagatttc	aaagcttggt	gttgatttca	84780
aagcaagtat	gagtatocat	cttattatgg	tatttcccag	aaggctcata	aataaaattg	84840
tccaccgaga	tttctttcca	aaaggaataa	aaaggaggca	taattaaaaa	catataacat	84900
taccacaggg	tcagactatt	tagctattct	ctaatttggt	cacattttaca	tctgttttta	84960
tccctttttc	aaattgattc	cttgaaagca	atattagtac	ccacagagag	tctcatcagc	85020
gotgagaata	gaaggacttc	aaatagcttc	attctacttg	ttacacttct	acaaatgtag	85080
tttttggttt	cacagcattt	atgggtgttc	catcataaag	ttggctcaaa	cagatcttaa	85140
aattgatata	aatattcact	aatttttata	actgctgcta	atataattcat	actgtaattt	85200
atttgacca	agtccaggat	cttagagtca	acattgttaa	atttcatctt	attagattca	85260
gcttagcaca	tcaagagtctc	tttgaabgct	gaactgcctc	aatgcagatt	ccttattatc	85320
atctctctga	tcattccaat	tgtgaatttg	taactgcact	cccttaaatc	attaaactgt	85380
tcaatgcac	aagttagtaa	tgaagcaggc	ctgagaataa	agtcatgcgt	ctgataatta	85440
gatatgggta	tttaattgaaa	ttaaaaactg	ataaaaccata	taactcatca	actcctctat	85500
cttgtccatg	agaactccag	atgggtcatt	gtcaaacatt	aataattgaa	atccaaatat	85560
agttgggtct	cagttgggtt	agatacatct	gggctgaact	acatttgtcat	aagccaacca	85620
taaaatcatt	aaattttttc	ctcataattc	ttatgcacac	tgaaatgttt	catactgata	85680
atagcttctc	ctotttaggga	ttggaattat	gccagggaat	aaagttgaag	tcatttaata	85740
atcatttgta	tcataatttt	ctttcatgga	atataatagtt	taagtgtagt	acttcttgct	85800
tatgtactta	tagatagaaa	gaaaagaaat	ttgattgtag	agatagaaaa	aacattaaaa	85860
aggggttaag	gagcatccca	gaaataaaat	actctattga	cttgagtggt	attttgctac	85920
atgtgatgat	ttttggaaa	tacctccaac	actaggaat	gactaagact	tggagtcctt	85980
caacactcc	ccctccaaat	agtgtgctc	aattttctct	cccttgata	tatgtggac	86040
ttagtgtctc	acttcgaaa	aatagatatg	gotgaagtta	acagtgtgtg	agtagataat	86100
tgatatgggt	tggctctgtg	tccccacaca	catctcatgt	tgaattgtaa	ttcccaatgt	86160
tgaggggagt	gattggatca	tagaggtgga	tctccccctt	gotgttttca	tgatagttag	86220
tgaggtctca	tgagacctgg	ttgtttaaaa	gtgtgtagea	ctttccccct	tgtctctctg	86280
ctctctctgc	ctgccatggt	aagatgtgct	tgcctccccct	tcaccttcca	ccatgattgt	86340
aaatttccca	aggcctccca	gccatgcttc	ctgtacaggg	tgtggaactg	tgagtcattt	86400
taacctcttt	tcttcataaaa	ttatccagtc	ctaggtagtt	ctttctagta	gtgtgagaac	86460
acactaatac	atgggtattgt	ggcttctctc	attctcagat	tagcagtgct	ggagaaagct	86520

```

gccattttatc aactcatgga aaggccatg tggtaaggac ctgaggcctc ctgacaaacag 86580
ccatgtgtgt cagtaatggt agaagcagat cctccttccc agccaagcct tctgatcact 86640
gtagcctggg ccatgatcct gattgcaaca caagaagaca gctcgtattca caactactta 86700
tataagccat tttgagattt ctgaccgata gaaactgtaa gataataaag gttagtgtgt 86760
ttaagtaaat atgttttttg ggtattttgt tacaatgcaa taaataacta atatagtatg 86820
tgtagatga cattattttt atctagtgtt ttaattcaga tattggaata atttattaat 86880
tagggaaaaca tacattcata aacacacata cacatttaat tttgagtgc aaaaaatatg 86940
agtctcggca acttcgaaaa cttaagaatg cttccaacag ccttactttg tatatacaat 87000
aagacaaata tttgggtttt ttgagtccct attttttatg tgtttaaaag aaatttcaga 87060
attaagaaat gggtcagat atgaatggaa cttacaggta catctcggag caggtatcca 87120
gccagtactt gtgcattttg ctgtattttc ccgggttgca ggataaaaaa catttctaca 87180
ctggtacgtg atttcatctc cagtctctgt ttaattcctt aaagggtgagt agtcaccatt 87240
tggaaatataa ggatttatcc atgatttttc tgaaaagaaa aagggtatat ggataatgca 87300
gaaaataagta tccgttaaaa ttaatcattt atataaacat ttaaaagtgg gtgttattta 87360
tttgtcctta gcataatata aaatggcatt aaaatgaaca catcatagta tcccttctgg 87420
tatatcactt atttttccct tcaactatatt ctcatctgac atatttgtac ctctgggct 87480
cttaatccct tcttctccaa agtcatccca taactcatga ttttccataa ctggmaatgt 87540
tctcatcaca tataacttca attcttactt taactttcct tctatttctt ggtttctgtg 87600
gttctcataa ggattgttta caaatattca gtgtttcttt cttctggaca attgatagga 87660
ctgcgcaacc cttctctttt gaagtaactg tggccatgtg attgcgtagg agactataat 87720
aaaagtggaa gtaatatctt ccactttaga gagaagtgtt aaaagccatt gtgtgaattt 87780
ttatgttctc tttcccaaag ataccgcgat taagaagga catgaaaaaa aatgatgttt 87840
ctgtcacttg attottacaa ttaatacaat gagtaaatgc ccttctgalc tacattgaca 87900
gtgaacatga atgaaaataa acttcagtc taaatatctt aacattgaga taactgatta 87960
catttttctt actataatag gataaaaatag cagagggttt ggaaaaacct ttcgttaag 88020
ggccagataa aatgtctctg ctgcaacaac tcaactctgc cattatagta caaaagtaat 88080
gaaaaacaat acataaacaa atgaacttgg ctgtgtttca ataaaaactt gtttacacaa 88140
agggggcaag ttgtattttt cctgcagcct atagtttgco atcctttggc ccagtgtatc 88200
ttaacttata aggcaccttc tcaactcctt ccattaaact tgcatactct caatatgga 88260
tccatttgca aaattcgttt taagataaaa tactatgcct ttaagtatt gtgaaaaaac 88320
tatatgacca cttctattgg agtcatattt tattttggac taaaaagctg tggcaaacat 88380
tcagcattgc ttgaaatcca tttatatacc cccaatttat ttactatttg atttccatg 88440
gtaaatgalc catagtctcc tctcttttct caagccact tgbatctata ctgatttaag tctttagttt 88500
aacagataat aagtctccat tcacacaaaa caattgagac cagcagtagt gaggttccta 88560
tacttcttcc cagcactcct caacattatc tgbatctata ctgatttaag tctttagttt 88620
agtcttcagt ggtaaagtgt tgctttcaaa ttcagggttag cctctttctt accttatcaa ccacactctt 88680
cctgtatttt aaaccattgt ttattccttc cctctttctt accttatcaa ccacactctt 88740
aaattgatat ggaagctttt ccaatttcca gtcccttcc aaaccccttt gttcaagttt 88800
agctaattga ctacatttct cctcccttcc cgtctcacat ttattcttta actcactact acctagtttc 88860
aattgctgtc tccacttttc ttgctctgat aaagcttacc aatgagccca atgtccaat 88920
tgacctctat ttgtttgcca ttgctctgat gtcactggta catattatgg acttcttaat 89040
tcagaaatgc ttgtcatttc acataattca taaaactctg taatatattga ctctgttgat tacatacttt 89100
tatttattga actgaacaga atabatttat gttctctctg ttctctttgt ctttgtctaa 89160
ttggtgtctt cctattacct cttattattt tcocttactt tatatttttt gcttctcttc 89220
gtgatgtctt ctttttatat ctattttttg gacctgcata cttgtcacat ctcatctcct 89280
ttgtacttta cttaattttt ctatactacc accattcctt tctcataagt tgtatattag 89340
gccatttttc tacttcttct ctactactacc attcattata tatttctctt totcaatacc 89400
tcaaacataa aattttataa agtttttaatt attcattata cgttctgaca gaataagctt 89460
atacttccac tgtgtccatt cagctcttaa gtttatactt agcaataatt atatgagaaa 89520
taatatatct ctatagctaa caggabaata tatttagatt taaagcttta ctattttaaa attttactat 89580
caatatgtat gtgacttaat atacaagttt tgttgacact aacttcaaat aagtcctaaa 89640
tttatgtaaa aatatgtctt ttctgtcact atcttctct ctatcatatt ttcatatacc 89700
tgtattcctt ttttcttttt atcttcaatt atttttctct atgatatagc tcaatttaat 89760
cattaaagtt cagtttatgt atcttcaatt gctatgagat gcaaaaaaca agagttaac taagaaatca 89820
accaattttt gaagtcaaaa tttgttaatt aagaatagaa agacttctgg tgattatgct 89880
ataaaataat atggaacaa tttgttaatt ctttaatttcc taactcata atctttttta 89940
caagcagtag acataaatcc tgttattaaa acattgcccg aacctgtacc tttatccaaa acaatacttg 90000
aaatacatca ttttttctta ctattggaaa caaccattgg tcaattgaag ttagaatact 90060
agactatcca aattcaaggt tagcactota tgctttgaac caaatctgt acaggggaaga 90120
gatagattcg gatcaaaagat agctttcctt tagcagttct tctgaccttt gattgtttct 90180
ataaataact ttctgttaca gattgtcctt actggacaca gagaccaaag ttttgacaat 90240

```

39/64

tcacotttaa	atcagtcctc	tgacatgtgt	gtgccataga	ccagattgaa	gaaaattaaa	90300
gtatttataa	tttaagtaga	ttatttccact	ttaataattat	cttattatct	aattccaaac	90360
ttcttataga	tttagaagca	acaaagagag	tttgaagtta	cctgatttca	gagaaaatga	90420
tgtgtataga	ttttgaattc	atcttatatc	agcaagtaga	tccttgcttt	gtaccaagaa	90480
aatagtcata	tttatgtctat	attagttggc	atcacaagag	tggaattctt	ttattaagaa	90540
agacttctct	atatctaata	agcgtaaagt	atatttcaat	aaaataaaaac	gtggtagagag	90600
agtgtatgct	taactaattt	gggataaatc	ctcttttatt	tatatcgatt	attagtgaac	90660
tgtcttctga	aaaggagtag	ccaatcccag	tgcttctctt	tggtatctct	tttccataag	90720
aaagcaggac	ctgcaagcat	agtattgaat	attcagggtt	tacttgtact	tgtgactgag	90780
aaatggaaaa	aaattataaa	agaaaaatgt	tttataaatg	tagagtcttt	gaggggtgtg	90840
tgtgtgtgtg	tgtgtgtgtg	tgaatcaatt	agtgttcaag	agaagcaaga	atagaaaagc	90900
agtaatacat	ttgggaaaaa	cagatggatc	tctcattgtg	aaaacaaaata	tgtgctaagg	90960
aaaggtttta	agtaggtatc	aaagtgaaga	agtaaaagag	acgaaaaaat	cagatgaacta	91020
caatgaggta	gtaatgctac	agagtcacat	attcaataaa	aactaaattc	ccagagtctt	91080
attttgaatt	cattgaaagc	tggaatgatg	gtttattgca	atgtttatct	tcaatacaca	91140
gcaaggtcct	gatgtaaaat	aagtggttta	taagttacat	tttgattact	gcattggataa	91200
attcactata	gatttgagag	gggtctctga	aataatatac	ttcaggtaga	agttaatgac	91260
aaaggacttg	tgcatgcact	tccttttgct	aggaactacg	aatgccatga	agacaaatag	91320
ttggaccccc	cacaccatta	ggcacaacatg	gactgtatgt	gggttattac	tgtctcatgt	91380
tcatttaattt	ctttctaaaa	tattctctta	acagtgccta	aaagttagaga	tcaogcaatt	91440
gtgaagaaaa	atatgttttc	caaggagaca	cttbtgggct	caaaccaaaa	tttttttagt	91500
gtatataaatt	aacccaaaat	taactattct	tttgtaaaaa	aggattacta	aagcacagtt	91560
taaacadgtg	tttatgaatc	atgggattta	aagttcagag	ggctcttaag	agttcaactc	91620
ttctttctct	cacagtaggg	cagtagtaacc	cttttagatt	tctggaccat	atgtggtaac	91680
actgttctct	gtttcactaa	ttgcagcaga	cctcatcaaa	agcaaaccca	cttattttat	91740
aaatgtttga	aaatatctca	aaactgttat	caccacacta	tagctgtagc	ttcttactgt	91800
acgtcttatg	gcataatttc	ttaaaagtcc	acaactgtcc	atattctctc	ttcttggcca	91860
tgatagtttg	aaactttccc	gtttaaaaatg	aagtaggtta	agtagaacac	tctattccag	91920
atatattttt	tggtgggcaa	agagcacagt	tgagatgaac	tctttggctc	tgtgtaacct	91980
ccctccataa	tgaaagtgtg	gaggtttttt	tttttttttt	tggttaatttt	ccaggaccat	92040
catcacogtt	gagtcatact	gggcctgttg	tttaacaaaa	tattcacttc	cttcaactta	92100
attccattgt	cagttgagag	tttcttcacc	tggtattaat	acaagttact	tttaaagtat	92160
tttaaaatat	tcatataatt	taaaataaatt	ctgggcatta	gtggagcaat	ctacttgttt	92220
gagaatttga	tgttactgag	aatttaggaag	tctattatag	tctcactctc	gatccagaca	92280
tggtttttga	tgatagacca	atgacttaat	aagctactga	actttttctgg	cctgttttat	92340
gtctgttttc	agagtgtgtg	tatcgtaoga	agtgtactca	aaatgaacct	tgaacacaga	92400
aaatgctata	tgttttttat	aattagtttat	ttacataaat	tagcactcta	cttttgattta	92460
aaataagtgg	atttattaaa	agaatttaatt	aaaatatgtg	ataaatttat	aaagatccag	92520
aaaataaagg	taacattacc	ttcacatgaa	ggcaacggac	gcoatccaga	ttcagtgcac	92580
acagcatctc	ctctttcact	gtattcataa	cccagtttac	atttatattg	aaatcgttca	92640
ttctccttat	aaataatctt	ctgagatata	ggagatccat	ttataacatc	tggggatttg	92700
catgaaattt	ctaaataaaa	gggatttaaat	tccaaaatgt	ttattgcaaa	ttaaaaggact	92760
gtgaccagga	ctaaattata	tgaaaacaga	aattgtgttt	ccatcaggta	aatcagtcac	92820
ccaaacaaaa	gttctgtttt	gacttgaccg	cttaataaat	gatttatctg	aagaaaagtt	92880
aaattctgat	taaaattatg	cttctgattt	tatttagttt	caggataaat	tagccttctt	92940
gaaataaata	gtgaccagta	acattcatca	actgtataaa	taaaattgat	cataaatata	93000
gttttattgt	gatgttttca	ctgaatgacc	tgcaaaaaat	aacacatctt	ctagttattg	93060
ataagacagg	aattatcaac	aggacttttt	gtcaaaagaca	ttgatttaac	tcattgtcat	93120
tacatctctg	aaaagttaact	gacctgtttt	tgtgtcatca	ctatttagcc	aagatttctt	93180
cagaaaaaaa	aaaaatggcc	atcatctttt	atacctttta	tacccacttc	tctcaaacat	93240
ttttacctgg	gattgtgcca	atcataagta	gtttcccaaa	ctctgttctc	ccactttcta	93300
atccattttc	cttgtgtata	gottaatgac	ctctcaggta	gacacatcgt	aactccactt	93360
gaaatccttc	attgattccc	aaatcaatct	gaataaaaga	cgcgttcttc	agcatggtgc	93420
atgcagcacc	tcagcactat	gtattggccc	accttctatt	tatcactgac	tctgtcccta	93480
cttgcatcct	agactaagg	gcctaggaac	aatggacaag	aatcagtggt	gcttcatgct	93540
ccttaagcc	tcactgccc	hccacttccc	tttccctgaa	ctctggtatg	cttttgctct	93600
cattttcact	tacaaaatct	cgtttttttt	ctttaagact	taatcgtagg	catcagccat	93660
tccaggaagt	tttccactaac	cacaggaatc	tagttgttaag	gatgtaaatt	ccatccatgt	93720
acttctaaag	tacataatat	ttgctatgct	gaataaaaaa	attagattta	acataaagaa	93780
ctattgttgt	tacaaaagtgt	tcttaagaag	agaaattctt	ttatctgtat	ctaagatata	93840
acagacttta	atagtaaaaa	taatttagat	attttagata	atattaaaaa	ataaatatgc	93900
cagaaacttc	tgccaaaaca	ttatttggtaa	aatgaacttg	aactatggta	ctactaaaca	93960

aatcaaccac	gatgtttatc	acagaagcca	aaatotttga	ttggtcatga	tgacacaggtt	94020
ggcagtatta	tgactaaaaa	aatcctggct	tacagttttac	tataaaactt	tttttaagag	94080
gcaacaattt	atttagtgga	ttctgttcaa	ttcagcaaca	tttatagtaa	acttgacagta	94140
caaataataa	ataggtctgc	ttcctaaaag	tggtatttcaa	aaacgaatgt	catttotaatg	94200
tatctcttga	aatacataat	gaatcttttg	ctttcaaaaat	aaaaacaaat	gtctatttcca	94260
gaggtcttac	agcttgacgc	agaaatactt	agcattctct	ttcaacctaa	gagacaacta	94320
caatggagtt	atgggttaaag	oatggactct	gggtgcagat	aacctacatt	taaatcctaa	94380
cttgactctt	tatgocatga	taatccaggg	catgtgattt	aacttctttg	caccagtctc	94440
ttccattata	aaatgaaagt	gatgagtaag	taaatcatgg	agtttttttga	aagttaaaaat	94500
gaaatgatgc	atgcaaagaa	cttagctcaa	ttacaggcag	atagtaagtg	ctcaataaac	94560
attagctatt	gttaatatbg	ctgatattcc	ttagaatgaa	cgatgtttta	aatgtatatt	94620
tacattttaa	aagctaaaaa	tactaaaaaa	gtaagtgtat	cttaccacaa	cacttttggtt	94680
tctcttttact	ccaaaaacca	togtctgaac	aatgcatttc	ttcatctctc	tcaatcttgtt	94740
agcctaggtt	acatacaaac	cgtactgctt	gtccaaaaatg	gtattcccca	tctgggttcca	94800
ttgcactact	gacaattttt	ccattctctg	gtgctgtcac	tggtlaaacac	ttcacaactg	94860
aagaaaatac	atgtaatggt	ttctaattgga	attttaaaaag	tttatgttga	aaaatatgtg	94920
tatgtataaa	atcatctcca	ggataagatt	ggaggaaatt	acttaaatga	tttttagaag	94980
catttgatgt	acctgtttgc	tagagatact	ttctctaaag	aaacaagcaa	atggaaatgtt	95040
tattcttgat	ttttttctat	gggagtggaac	aatgaaaaatt	actactttca	atgctagctt	95100
gtattttttgt	agtaacaaac	tagtattttt	aaataartaa	gaaatataaa	gcttgagata	95160
attaatatca	ttttcattta	tgccttagaa	taataataca	ctgtgttctc	aaaagatgta	95220
aaagcaaac	ttatgacatt	aacttcaata	gagaaatcat	cgttaatttt	ccatctctct	95280
cgacctaaag	gtttaasata	atttgagtag	ttcttttgat	totacttaat	attttccaat	95340
ttctctaaag	ttgtgggtcaa	actttattgt	actatagaat	gactcaggat	gcttggttaa	95400
ataaaaaattt	tagggctatc	ttctgtcatg	ctcaccccaa	agatactgat	tcagtaggtc	95460
atfttttttagt	aaccaagat	tttagttttt	aacaagcatc	ccaggtgatt	tcaatgtaga	95520
tgttccctag	accattaatc	ttcttctctc	aattttcata	gatgaaaaaa	tottccatta	95580
ttttctglag	ttgacagttt	ttgaatgatt	atcacggttc	ttctgtatct	ctctccactt	95640
gccactcaact	gtggaattag	gaaatactac	tctggttgat	ctcttttatt	ttcataatga	95700
ctagagattt	ggattattag	ctcaaaacat	gaaaacagaa	ctacattttt	ctcattttca	95760
ctgttttgctt	tacagaccag	tgagaaataa	cagagctcgc	ccttagttta	ttctcttttt	95820
cagtaaaagg	aagtccacag	gcaacctccc	ttagtgggag	gtctcaatca	cgttctccac	95880
ttcagctgtt	accatagatc	cctgcatttg	gggtggttact	gggtgagttc	ttcttccatta	95940
ataaaggcaa	aattctgggtc	tttattttagc	taatgatgct	tatatgcgtt	tctagtcatt	96000
agaatccaaa	aggaataaaa	aatcagtttt	agattccctta	atgtcttaata	cttcaattat	96060
tatatcagat	caggctgcat	tctgtttttg	cttttgaaac	accaagaatg	tagtaataaa	96120
aagactagat	tcccactcta	caattgtatga	gaaaaaaaaa	cattaaataa	aaatatttta	96180
tagagacttt	aagatatttt	aatgtaagac	ttttttttaa	tcttagatat	ttatttcaat	96240
atacttgtaa	atacatttta	tgtctacobb	cacatatagg	aatatcattg	gtccatccat	96300
ctgtgtcaca	ttcacggtaa	ttaatctcac	ctagcaattg	atacctgaaa	accsaasaaat	96360
aacagaaagt	tgacataatg	tgtgttttaca	tgcagtttta	aactcagatgc	cattctgagc	96420
gtccagaaac	tccatattba	ggaaaaatgaa	cagcatatgc	attttcttgt	ttcttggttc	96480
ttgttttggtt	cttcttctct	cttcttctct	cttcttctct	tgtcttagat	ttcttaangt	96540
tctctagaaac	attaatcttc	ttctcttaat	tttcatagat	gaaaaatctc	ttaacctctc	96600
tctcccttta	tctttctctc	cttcttggtg	catggactga	aaataatcat	aatccttggt	96660
tcacgacaaa	atcattattg	tttcatacaa	agtattctta	tttttccattg	aattatctaa	96720
ttagctaaat	tcaataatat	agtaagctcc	atgaactatc	eccaaaaacaa	aagctaaaaa	96780
taccatagta	accaacgact	aaacttatgt	tccctctctc	tccagtctta	gacgtatttt	96840
ctgtcttcca	tgattctgat	attttctgaa	caccctagg	ttttctacata	ataaagatag	96900
tgccagccaa	aagttgttag	tgtgtgattt	actttcagca	cttgcctcca	tctctccatc	96960
tctatcgtag	agattttttc	ctgagaatac	ccagttagtc	aaatctgctc	atccaaagcca	97020
tctaattgtg	aacttaagta	attttagtaa	cccatcaagc	ctgcccctttg	aactcaaaaa	97080
atgctctact	tgaatatgag	ttccctggga	catgtgcata	atgtgcatac	attgctagag	97140
gcttcagatc	tatacatttt	tatctcttta	gccaagtcaa	gtgctgaact	taaagagagg	97200
acacaagcct	gtgataaaag	aaatattttca	gaggtgagga	aggttagcaaa	ttaaaaaatt	97260
cagccccag	atattataac	ctattttggtt	atgtgtgata	agatcagcag	taatgattga	97320
agggctaaaa	atgtattttga	aaaacctccc	tcaggttagtg	actaaggaga	gaataaattc	97380
ataagaaatt	atacttattt	ggtatctact	atatctcaag	gtctcttcta	agggctgcag	97440
atgtgtgtct	tattttattt	tcttgccaat	ccatgatgca	cataaaatgt	gtctgttttg	97500
taggagagga	aatggtagtg	aagagatata	tttttaataa	cccataaatg	tttaagtgtga	97560
gagttttgaa	agggcaggtt	actccagtgga	ctaagcttta	aactattata	ttttatttgt	97620
tcaaatgaag	gaaaaaatgg	ggaaataata	atgttatttc	atttgtaata	tttggttaca	97680

41/64

tttatatttta	tgaagtatac	gattatagtg	atctaatoct	ggttttccca	tacataaatt	97740
tttctccaaa	ataatttttc	atctagcaga	gaataagggg	gataaaataa	cactgaggat	97800
atacagtgat	gatttttgga	atgaaaaccc	agtagttggg	tagaaggaa	agagtcaatg	97860
attctgaaag	agtagtattt	ttaatccatg	tggtaagaat	aatttgaga	cctgggacat	97920
taagtaacct	tagttgtta	taaaacttat	aagcagggtg	aagtcttgct	ttccttaaat	97980
tttataaaa	ctgtcaaaac	agttaccata	caatataaat	lggttacaat	tccatttggt	98040
cctgacacat	tgaactccca	tgatactctg	cacaaaatag	aatgtcgtga	agacttggtg	98100
ggtgaatact	tatatatgtg	catactgttt	tcccactctc	ccataattat	actctalcag	98160
agaagtata	cttcatttaa	atttttcaat	gttaaggaga	taatatggta	tccagattta	98220
attatttcca	tcatagttta	acttttcagg	acttgtgtat	tactttttta	aatgctcata	98280
gaaaaataa	ataaccttaa	aastatataa	agtagtagag	ttcctattta	ctatcttaat	98340
tataaaacct	tttttgatg	gactacatac	ccctcattac	atgtatcac	agcttttaca	98400
ccatattcaa	acacatttcc	tcctgttaagg	gtaaaagtac	caaaaggagt	atctccagga	98460
tgtccacagg	gcctttctaa	aacgaaaaaa	aaagtattga	attagttatg	aatagcaagg	98520
aatatatttt	atgtaggagt	gggggaacaa	gtatatttga	tattatataa	gaagacagat	98580
tgaatgtta	gaaaattaaa	catagcaaa	ccattatttc	ataattgaac	ttaaactata	98640
tgccttgctt	tttaattttg	gaggatgacc	accccttttt	gaaaatgatg	atghattggc	98700
tgggcacggg	ggctcacggc	tgtaatccca	gcacttttgg	aggctgaggg	gggtggatca	98760
cgaggccagg	agttccgagc	cagcctgccc	agcattgggtg	aaaacccatc	tctactaaaa	98820
atacaaaaat	tagccggggc	tgggtggcac	tgcctatagt	cccagctact	cggaagtgtg	98880
aggcaggaga	attgcttgaa	ccaggggagg	agaggttgca	gtgagccgaa	atagccgcac	98940
tgcactccag	ccagggcgata	gagggagact	ccatctcaaa	attgcccac	tgcactgcag	99000
cctaggtgac	agagccagac	tccatctcaa	aacaaaaaaa	aaagattalg	tattattttg	99060
tatttgactg	gcaatagtga	tataattcag	gcataattgc	tacaatatta	aatctttaag	99120
attttttcac	ctagtttttc	taaaattcac	aaatgtatta	agtacttact	ctgacatttc	99180
cttaattggat	taagagcaac	ccattctccc	ttcctgcata	ccattattac	atttccaaga	99240
gatctatata	cagggcggca	tttatagata	gcctgggtgc	cttctggata	tgtttggtca	99300
gaccaggaac	ctgtcagaat	ttctgttatt	cttcttggag	gaagtccatt	gcaatctaca	99360
aacaataaaa	acaaaaata	tgcataaagt	gtctatttaa	atgtacagta	tatttaggta	99420
attgttgctt	ttaaaaatgc	ctagacagtc	acaggtctat	ctaaaattct	ctctctctct	99480
ctctctctcc	taaccccata	tctatggagt	aaacatacat	ttcatgcatt	tagtgttaact	99540
atacatttca	cottataaaa	tttgtatcta	cataatttba	taagaatggt	cactgtggaa	99600
aaacacctaa	aaaactttgc	aaagcaatag	atatattttg	ttatattact	cttaattgct	99660
ggagagcatt	ctactattct	tccatttaatt	tgggaatat	ttattgagca	ctattctaag	99720
ttataaagaa	aaaacaatga	agaaacaaac	tatctgttct	caaagcattt	ccattctatt	99780
aggggaagca	gttatttaagt	aatcaagag	atgtataata	tgcattacag	gtagaaaaat	99840
tatatattaca	aaaattagca	tgataagtta	atacagaatt	atacaggcac	tccaaataag	99900
atagaatagg	atggaaaaga	acaatgtttc	tactccaaat	tggaaacaaca	acaaattgtg	99960
tgtgcatgtg	tatgtttcaaa	ggtaagtgtg	gggagcaaa	aggattaaat	gaacaaaaaca	100020
caagtaggaa	ggacotgttt	caagtaata	tagggtctct	ggccattttt	tacctgggtta	100080
tgtttgtcag	ctctggatat	ggattgaaga	tcaggcctct	atttagtctg	aatgggaagaa	100140
tggttaatgag	gtaagaaaga	accaaacata	aggaggctat	atctagcatg	aagaattctg	100200
aaactttgoc	aaatcaggtt	gctttgctag	agtcagggtg	gcttcatcag	ggaagactga	100260
ctttcccggt	gtctcataga	aaaaaagctc	caataagaaa	atggatctga	ctcaaataca	100320
caactagtat	tctcatcaaa	acatgccata	tttgaaagtc	actctggatg	atattttaaga	100380
gcagatgtca	aaacagcaga	aaagctgtat	acatatatat	attattttata	tataataaaa	100440
gotctttatat	atatgttcac	ttttctgctg	tttcattttat	atatgagcat	ttaagattat	100500
atatatatata	gaacagagtc	aaaacagcag	aaaagcaaac	atatatatata	atggctttta	100560
ttatatatat	atcatatgct	cacatacata	atatatatat	gttggcttct	tctatctcaa	100620
aagtotaata	tatgtacaca	catatatagt	atatatatat	acacatatatt	atattttatgt	100680
atatatatat	gtatatgtat	atactctgtg	tgtgtgtgtg	tgtgtgtgtg	tgtgtgtgtg	100740
tgtgtattag	tcttttgaga	tagaagaac	caaccagatt	cttgacttta	aaaacccaag	100800
agggtttaaat	ctttgagact	agaaaccaga	aatgggactg	actcaaaota	aaagtgttac	100860
ccaggtccct	ctgagttaaa	tttttgagtg	gctcaagaaa	gagcaaaaca	tcttgttgat	100920
gagagtaagt	tatataaaact	tttgtcatta	catgtttttg	ttbaaaaaata	cgatttttgaa	100980
taaaaattaa	aagatcacaca	aaaaagcaaa	aacaactgtg	aacaaaaaga	gaaaataaat	101040
attcagtaga	actagacact	cagatttcaga	tgttagaatt	agtgttaggt	ctttataaca	101100
gctatttttag	gaacattaaa	ggaactatag	aaaatataga	aatgaaaaat	taaaaaagat	101160
attcaaaaata	aaattgactc	ataaatcatg	tgcattctta	aaattggatc	aaaaatcaga	101220
ataaacaact	tgtcagatgg	ttttaagaat	caaatggaca	cagcacataa	caaaacttatt	101280
aaacttagag	gaagtttta	gtaaaaataa	ccaaaaggaa	atatagaaag	acaaaagtgt	101340
ataaacaaca	acaaacaaaa	cagagtataa	aaaaatgtgt	ggtgtagagt	caagttataa	101400

42/64

aacatgttta	attggaattc	taacaataga	gaagaaaatg	aacataggca	atatttgaag	101460
aaacaatagc	tcaaagggtt	ccaaaattga	tgaagaaaat	cagctcacaa	aatcaaaatt	101520
tctaaaaaac	cccasaatgc	tgtataccaa	gaaaaactat	actgatactc	tgctgaaaaac	101530
caaaagataaa	ggcaaaatct	taaaagcaga	ttgtattagt	ccattttttgc	acagctatga	101640
agaaatactc	aagactgggt	aatttataaa	gaaaagagat	ataattgact	cacaattcca	101700
catggttggg	gaggcctcag	gaaagttaca	gtcatggtgg	aaggggaagg	aaagacctct	101750
tcacatgatg	gcaagagaga	agtgcacaca	ggggaatgc	cagatgctta	taaaaccatc	101820
aaacttcacg	agaactcatt	cactatcacg	agaatagcat	aggagaaact	gccccatgat	101880
ccaagcacgt	cccactgggt	ccttccctca	acacacaggg	attalgggtga	ttacaattta	101940
agatgagatt	tgggttaggg	cacagagcct	aaccatatta	ttctgcccc	tgccctttccc	102000
aaatctcatg	tcctcacatt	tcaaaacata	atcatgcctt	cccaacagtc	cccccaagtc	102060
ttaactcaat	acagcattaa	ccctaaagtc	catgtccaaa	gtctcatctg	agacaaggca	102120
agtcctcttc	acataatgag	ttgtaaaatc	aaaagaaaat	tagtcatctt	caagatacaa	102180
tgggaatata	ggcatttggg	aaatgctccc	atcccaaatg	ggatgaattg	gctaaaaaaa	102240
agggaccaaa	ggctccatga	aagtcagaaa	tccaataggg	aagtcattaa	aactcaaaag	102300
tccaaaacag	tcccccttga	ttccatgtct	cacattcagg	tcacactgat	gcaagagggtg	102360
agctcccaaa	gccttgggca	gaactgcccc	aatgggtttg	caagggtatgg	ccccctgccc	102420
tggctacttt	cactgctggg	attgagctct	tgtggctttt	ccaggccaaa	gggtcaacct	102480
gtcagtgaat	ctaccattct	gggatcttga	ggatctgtgg	ccctcttctc	acagctccat	102540
taggtagtag	cccactggga	cctctgtgtg	ggggctccaa	tcctacattt	cccttgctca	102600
ttgcccagtg	agaggttctc	catgaggggt	cctcccttgc	agcacacctc	tgccctggaca	102660
tctaagcaat	tatatacatt	ttctgaatct	aggtggagggt	tttgtattct	gtgtacccac	102720
aggaccaaca	ccatgtggaa	gctgccaagg	cttagggcct	tcatttatctg	aagcaatggc	102780
ccaagctgta	tggttggcccc	ttttagacat	ggctgcagct	gggtgcagct	ggatgcaagc	102840
caccaactcc	tcagactgca	tcagacagtg	gggcccaggc	ctgcaaaaacc	atttttccct	102900
ccgaggcaac	caggcctgtg	atgggagagg	ctgccttaaa	gatcactaac	atcccttggg	102960
gacatttttc	ccttgctcatg	gtgatttaaca	tttggtccct	cattcccttac	acagattttct	103020
ccagtggygt	tgcatTTTTT	ccaaagaaaat	tgggttttta	tttctattgc	atcatcagge	103080
tgcaaatTTT	ccaaaactttt	atgctctgct	tcctttttta	acataagttc	caatttccga	103140
ccaactttct	caaaagttcaa	agttccacag	atctctaggg	aaggggcaaa	atgttgccaa	103200
tctctttgct	aaaacacagt	tagagtgcct	tttgatccag	ctcccaataa	gttccctgtc	103260
cccactctgag	accacotcag	cctggacttc	atattccaga	tcactatcag	catttttggtc	103320
taaagcattc	aacagttctc	taggaagttc	caagctttcc	cacatcttcc	tgctctcttt	103380
tgagacotcc	aaactgttcc	aacctctgoc	cattaccag	ttccaaagtc	acttccacat	103440
tttgagggtat	ctttataata	gtgcctact	accttgggtac	caattttactg	tattagtcca	103500
ttttgactg	ctataaagaa	ttacctgaga	ctgggtagtt	cataaaaaaa	gaagtttaaa	103560
ctgattcata	ctttcacatg	gttggggagg	cttcaggaaa	cttacaatca	tagtgggaagg	103620
tgaagaagaa	gagaggatct	tcttcatatg	gtagcaggag	agagaagtgc	aagttgggga	103680
aatgccagat	gcttaaacca	ttaaatctca	taagaactca	ctcactatca	tgagaacagc	103740
atgggacaaa	caacccccat	gatccagtca	cctccactg	agttccctcc	ttgacatgtg	103800
atgattatgg	agattataat	ttaagatgag	atltgggttg	ggacacagag	ccaaaccata	103860
tcacagacag	aggaacacatt	tttttccag	gagaatagta	aaaataacag	ccaagtctgt	103920
ggaagttaa	actgaagtct	gaatatatat	gtcttagcat	tactaaagtg	ctgaaaatta	103980
aaagtcagca	gagaactcra	ttaatggtga	aaatatactt	caaaaatgaa	agcaaataga	104040
aacacattct	taagcaaaaca	aaagcagaaa	gaattcaaca	agagcagact	caactataga	104100
aaaatactaa	aaaagttctc	tgggtcgaag	gaaactgate	taaaatataa	gcaaagaagt	104160
acaaaaagga	ataagcagaa	ctgaagaaaa	taaatagaag	agtaaatata	aaagctattg	104220
aaacatgata	aaccttatgc	tatgtatatt	ttactcaaat	aaaaaagagc	cttgactggt	104280
ttaatcaata	gacctgtttt	aatagtgttt	ttataaaatt	caagagtata	atatgaacaa	104340
atagtagcaa	aagtgtcagg	aaaaggtaaa	gaaaataaaa	gtgttgat	gttttcccca	104400
tagtcttgat	gtggtaaaaa	tattaattta	gaataaattg	taataattta	agcatgtttt	104460
gttgtaattg	ctaagtttag	cactaaacca	ataatattga	gatacataaa	ataactagaa	104520
tacatgatgt	aatgagatag	tcaagactat	ttgattaaaa	taagagaagg	caggaaaaaga	104580
agagagaaaa	atlgaggcaa	aagtaagtag	caatatgcta	gacttaaaat	gaactgtatc	104640
agtaattaca	ttaaatataa	atggattcat	caccatacta	aacatacaaa	gattgtctga	104700
ctggataaaa	gcataaaaga	aaactcaaat	atatgatgat	tacttttaat	aaaattgtac	104760
atataaaattg	agagtaaatg	ataaaaacca	atatgctaga	aaagtatcaa	ccaaagtaag	104820
aatgatatta	atgtattaat	atcaagcaaa	tgataatttt	agttagaaa	tattattaga	104880
taaaaagaga	gtcatttcat	attaataaaa	aggctacttc	aacagaaaga	tgtaataatt	104940
gcaaatgtgt	ctgaacaatg	tttgcctgag	ctggctcata	ctgactcata	ggagccaatt	105000
atacacatct	tttgcataata	caatgtctcc	tgatgacacg	ttggtaactt	gaaattgacc	105060
atattgtgag	aattttacacc	atgaactca	gcaaatttta	caaatcatgg	ttgttccctt	105120

43/54

tcctttttaa	aaatagttgg	ttgtttttaca	tttaccagca	tgccctctttg	cataaaacta	105180
tttaatacat	ttcaaaatat	aacagaaata	aaagaagtaa	gcaatccacc	atcatagttt	105240
gagatttaag	cacactgttt	ccaatatcca	atagaaaaa	aataaaaaa	taaggatata	105300
caagatatata	gcaacatttat	taaccaaatt	aagttttttt	tatttaataaa	acactgtctt	105360
caacaattgc	aagatgcata	ttcattccaa	gcaaatctct	accaatctca	aaaaattaaa	105420
gccactctaa	gtatactccc	tgaccactag	acatttgctaa	cagaaaaata	gtggaaaatt	105480
cacaaaattt	ttgaagttaa	gcaacccctt	tttttttttt	ttttttttga	gacggagtct	105540
cgctctgtcc	cccatgctgg	agtgcoccat	ctcagctcac	cacaacctcc	actcctgggt	105600
tcacgcatt	ctcctgcctc	agccatctga	gtagctggaa	ctacagggtg	ccgccaccat	105660
gcccggctat	tttttgggtt	ttttttctct	gtatttttag	tagaaacggg	gtttcacctg	105720
gttagccagg	atgggtctcaa	ttccttgacc	tggcctccc	aaaagtgate	cgccacacct	105780
ggcctcccaa	agtgtctgaga	ttacaggcgt	gagccaccgc	acttggcaag	caacacttat	105840
aaataactca	tgagtttaag	aaaaatataa	tataaatgag	aatatgattt	gaaataaaca	105900
ataatggaaa	tatatgttaa	aatttgtggg	ctgatgctga	agcactgatt	agagagaaaa	105960
aaatataact	cgaatgaatt	agaaataaaa	aactgttggg	aatcaattat	ccaaatttct	106020
aattcaagaa	actagtaaaa	cattaaatga	aatctaaaga	aaatagaaaa	cagcaataaa	106080
tagtgaatgat	cacataaaatc	acccctccaa	ttcaagggtga	caactaaagt	atttaaaact	106140
aggataccca	attctgttgt	tacggggcat	ggatgtgacc	tatactggca	tcaactttca	106200
tccttcatca	gcaaaattat	cctgggtggg	gttaagatat	tagaagctga	gtttcagtgc	106260
ctgaaatctc	catcaagctg	ttcttgtgca	tactgccttt	atccttattc	tgtattttcc	106320
ttcaagccaa	gtaaccttgg	caatgggtaa	gtctatcgta	ctgtgtaaac	ttggactacc	106380
tcaaattgaa	actcactctg	gcaggccttg	aattaaaaatc	cactggggcc	gggtgagggtg	106440
gctcacgcct	atattcccag	cactttggga	ggctgagatg	ggtggatcac	ctgaggctcag	106500
gagttcogaga	ctagcccagc	aaacatgtcg	aaaccccgct	tctactaaaa	atacaaaatt	106560
agccaaactgt	tgtggcacat	gcctgtaata	ccagctacgt	gggggcgtga	ggcaggagaa	106620
tctcttgaa	ctggagggcg	gagattgcag	taacccaaga	tcacgccatt	gcactccagc	106680
ctgggcaaca	agagcaaagc	tctgtctcaa	aaaaatataa	taataataaa	taaaaaataa	106740
aaccacactgg	aaatgaaatg	ggataaaatt	gaatccttac	tttatattgca	cagacacatg	106800
cacacaaatg	ccaggtagac	taaagagtta	ggtttaaaaa	aatttaaaat	aaatacatat	106860
atgtttcatt	cttttataat	tttttaatta	tctgctatat	atgatgatat	gtcattttta	106920
cttactatta	tttttagtgc	atctatctat	aattatattt	attttataaa	tatatattat	106980
aaaaagtatg	aataaatatc	aaaaaaggaa	ggcttaattgc	ataaagcaat	ttgcaaacag	107040
aacataatata	cattaaaaat	ttgttaatta	aaaatttatat	ttgtgaaaaa	atcatatata	107100
caaaatgtgg	agaaaaattta	actgaaaaat	tattcttaac	acaaacactt	cttgcagtta	107160
caaaagcaact	aaacactatc	taagaaaaaa	tgtttagagta	ggatagatca	tttactttaa	107220
aacaggcatt	aactgtacca	ttaccaataa	ttaaaagaga	taaaaaattta	sagaaaaatt	107280
ttttttgacc	aaatttaaca	caaaaatgta	aaggagatga	taatcaattt	tgttgaaaaa	107340
ttaggttaata	taaatattat	tattaaataa	aactgaaata	taaatgacta	ttacttcact	107400
aaaaagcaac	ttagcaataa	agaatcttaa	aagtactcat	acgtaagttg	acaaataatt	107460
tcaatttttt	aaaagtaaca	aataataatt	aaagattttg	tgaatatatt	aggtacagag	107520
tgtttattcc	agcattttta	ataatggata	taatttaga	atttatgeaa	attgtcaaat	107580
tatgtacac	ccatctgaat	taaaaattgt	ggtttgggta	atatttaatt	atgtgtcataa	107640
aattttataat	agtaagaagg	aaagtacgta	tatatattct	gttatagtga	gatacattag	107700
gtcagggggc	agaaaaactaa	cctgtgggccc	aaatccaatc	gctgcttgtt	ttgtaaataa	107760
aatttttagta	gaacacagct	atgctcatat	agttatatat	tgtctatgac	tccttttatg	107820
ttacaataga	agagctgagt	agcgagacat	tatggctcac	gaagtctaaa	atatttattg	107880
tctggctatt	tcacaaaaaa	tttgagtgcc	ttgggattca	ttatttcaga	ttaatcttat	107940
cacttaggac	accttcacaa	taaaaaccagg	tggcagccca	tgggtggctca	cacctgtaat	108000
cccaacattt	tggggaggctg	aggtggggaga	atccccctga	gcccaggagt	ctgagaccac	108060
cctgggcaat	atagcaagat	cccatctcta	caaaaaatta	aagaaacaaa	ttagttaccc	108120
atgggtggc	acacttgttg	tcccagctat	gtgagaggct	gggacaggag	ggtctcttga	108180
gcccaggagt	ttaaggatgc	agtgaactat	gatcatgtca	cgcactcca	gocgagagac	108240
aggggtgagac	cctgtcccaa	aaggggaaaa	aaacaggaaa	acatatgttt	tgaataaat	108300
actttcatag	aggcatttag	aaagctgacg	gcagactaaa	gaattaccat	aacatattct	108360
ggtataatca	gaacccagaa	aggaaaacag	gcagoccaatt	ttttcttga	ctgtggggcat	108420
tcaccatttg	gggaagacac	aagcttgctt	tttgatagcc	ttattaggct	aaagcaacaa	108480
aatttcaaagt	tggaaacctta	aatgaattca	cccacaggat	aagggagaac	tggaaagtaa	108540
ccacactctt	cttacaggaa	cccagctttg	aattgcttag	agcaccagg	aattttaaag	108600
cacaaatttg	gcttaaggta	gtctcacact	gaaagttctt	ctagccacco	agaaaagata	108660
actttgaact	ctaataatgag	gaagattttt	ttcttaagca	ccaaattatt	attacaaatg	108720
tcaaagacat	tatacgggag	aaaaagcacc	tagttaccat	aaacttdata	aggaacaaaa	108780
tagatatttg	atattggaat	aaatatatac	agactataat	caacaatact	aattctgttg	108840

tttaaatgta	agagaaaagt	ttgactaatg	atatctgagg	aaagaaatta	taacaaagta	108900
gtagcagatt	ttaaaaagaa	ccaaatataa	tttctaaaaa	tgaaaaaacc	catttttaato	108950
atcaatggac	agcttaatag	cagataaacac	agttgtaaaa	agaattcgtg	gacaggaggg	109020
caggtcaaaa	gaaataatac	aggatgcaac	atggagacac	acatgtgtgg	aaaatacaca	109080
agatgagcta	agagtcaatg	aggatagaaa	agccagagca	atgttggaag	agaatttttaa	109140
aaaatgaatg	gaacatacca	attaatatat	ccaagaatta	aaaaattcca	agcagtaaaa	109200
aaacacacct	atatgcatac	taaggaatat	gcagaaaaac	aaagagaaaa	tatcttaacc	109250
ttgttagaga	aaaatattaa	tttaaaaagca	gtaatggtta	gatttacaaa	gactttotcaa	109320
lagcaatagc	agaogccacc	aggtattaat	cacttccatt	ttcaggaaga	aataactatc	109380
tatatagaat	tctatatata	gaaataattt	tttgagaata	aagttttgat	tcataaaatt	109440
tatttttattt	tatttttttga	caagatctct	attgcccagg	ctggagtgcg	gtgggtgtgat	109500
tttagctcgc	tgcgaccttg	acccccctggg	ctcaagtggg	cccttgccctc	agccccccaa	109560
gtagctgtga	ctacagtcac	aaactacctc	ttctcagctaa	tttttgtatt	ttttgttagag	109620
acgagggtttt	gcogttttgc	ccaggctggg	ctcaaacctcc	tgggtctcaag	caatccactc	109680
accttagcct	cccaaatgac	tgggattgca	ggagtgcgac	accgtgcccg	ggctgatttaa	109740
taaaatttga	gagaatttgc	cactataaat	acacatttaag	gagagaaaaa	agatatattt	109800
cagaaaaactg	aaactgatcc	taaatataag	gtcttaggat	gaaagaagaa	atgaaaaaca	109860
aagaaaaatgg	taaatgttca	agtaaatata	aatgaatact	gactataaaa	taataaaaaat	109920
attacottac	atgggttttaa	atacaaacat	gtatgtgtat	acacccatat	acataaaaaa	109980
catgacaata	gtaggtaaac	tgtgagaagg	attaataaaa	ttaatgtctt	ttaagttctt	110040
cacagtgtcc	agaaaaacag	aaaggattta	atgagctgtg	acagttttct	taataagtcg	110100
tcttgcttaa	gtcagcattc	ccagttattg	agtcaaacct	atctaaatgt	tgggtgagaaa	110160
atatgtttgcc	agatacactc	ccaatcagtt	gactttaaac	aagctgatca	ttctaggtaa	110220
tctagatagg	ccagatcaaa	tcatttgaaa	ggctctgaaa	atagggctga	ggctcctctg	110280
aaaaagagag	ggaaattctgt	gyaaagcagc	ttccttttct	gtgagttcca	tccgtctctg	110340
aactcttccct	ttctgactac	ctgcctgtg	gatttcagac	ttgettattc	catgctcaca	110400
attccttgag	gcaattttatt	taaaaaacaa	aacaaaacaa	aacaaacaaa	acaaaaacct	110460
tttttaagta	ggttagatagg	agatttggtat	gtcaatcaat	taattgactg	atagataggt	110520
aatcttctac	ttctacttaa	gcttccccga	ttgaatcctg	agtgataaat	tattattaga	110580
ctttagtaag	ttaagaaggc	atatgctatg	ctctgaatac	atgcaacctc	cccacaacct	110640
ccaatttata	tgttttaacc	taatttaocaa	tcttagatga	ttaggaggtg	gggacactgg	110700
gaagtgaatta	ggtcgtgaag	gtggagctgt	catgatttgg	gatgtgtgcc	tttatagaag	110760
aggcaccaca	gagctgcctt	gtccctttca	tcattggagg	acacagccaa	aaggcactgt	110820
ctatgaacca	gagagcagac	ctcaccaaac	actgaatctg	ctggactact	cttgctgtta	110880
gactttctag	cattcagaag	tgtaaagaaat	acattcctgt	tgtttataag	ctaggcagtt	110940
aataatattt	tgtttgtagca	gcccaaagaa	aaaagtttta	gaagtgccca	ttaacatggt	111000
ggaacaaatc	ctattgaaaa	catttttgcaa	tatttcataa	gaaagaaaaa	accatataaa	111060
atttatattt	acaaaaataat	gtgaaagttr	ttatgggcac	taattttccc	ttgacctttt	111120
tgcuaatttg	tattagtga	ctcatataat	atgtgattcc	acattgcact	atttcgatgt	111180
ttataattta	agtaaacata	ttctactcca	ctagatgggt	ctaatactct	atcatacaaa	111240
cacaatcccc	ggcccccttc	gcacaaaagg	aaaactgatt	aattacaagg	tgatatgttt	111300
gtttttcaot	ttcaaaaattt	agatccattt	galgatgttc	aggttattgg	aaaaaataaa	111360
taagtaaaagt	aatccattaa	cacaaaaaaa	gttttagccg	ctcacttcc	agtgagaagt	111420
aaatgctttc	cottctgggt	attattatat	ttccaggtga	tacgtttgtg	ccccaaattc	111480
ttgatttcca	aatatagtgc	attgctttta	acaaccagat	gtagaaaaaa	aggatacact	111540
tcttccacaa	aatcttccct	ccaacttctc	acaatattta	ctctgtgaat	atgtttacta	111600
tatataaaga	attatcatat	tgattacctt	ttctcttcaa	atagtaactta	aaattctggt	111660
gctttttcca	tcagtgttaa	atggcatctt	ttgattctgc	ttgtaagaaa	aagatatgac	111720
cgccccctgt	ctattttccc	ttgctcctac	taccatcttc	aaaaatcttag	ttcagatcat	111780
catctgtcac	tttggtcatg	aaacttgcc	gctaaactagc	ctccagtcct	ctactctcct	111840
gttacttcag	tctattcaca	gagtgacaag	tgattcttgc	aaatctgggc	atgtcattcc	111900
tgtgattaaa	attcttctat	gacttcaact	tttacttata	cagcattgct	aactccttcc	111960
cttggttttgg	gaacccccctt	tctggctctt	gcactttct	cggatctcat	catgttaaat	112020
ctcccatgta	tttactgtgc	aaagtcacgc	tgattttatt	gtttatatatt	tgttgagcat	112080
ttcaaacctta	ttttttctct	agatccctta	caoggtttat	ttctcctct	tagaataatt	112140
ttacgacaga	tttctgatga	ctggctttgt	ctcatcttcc	aggcctctac	tcaaatgttc	112200
tgtcctcaaa	gtgatccact	cattctagtc	cccaagacca	agccacacta	atgtctctac	112260
atactaccat	ccccatctct	attttctctt	aggccctact	ttacctcctt	cacaaaattt	112320
ttcacaatgc	tataactatt	tttggttcatt	aggttttcta	tctatctccc	cacatcaaaa	112380
tgtaagctcc	ccacaattga	agaacaatgt	tttctcatgt	togtggagaa	attttcatta	112440
atgtctaggt	cttctcactt	cagatacact	ttctgtctg	cttttgttct	aaccattatt	112500
gtattgagta	ttatttgagat	aggagatggg	acttggacac	tggaccaaat	tgaggattat	112560

ccaaaacagg	tctgagtgga	agccccccc	tgtaaagacac	acagaccagt	gtgctatgac	112620
agttttaccat	taccatggca	acacccagaa	gttacaggcc	ctttccacag	caatgaccca	112680
acaaccggaa	gttaccatcc	tcctcctggc	aatttcagca	ttaactaccc	cttaattttcc	112740
atataattaa	aagtgcataat	aaatatgagt	gcagaactgc	ctctgagctg	ctaactgtggg	112800
cacactgcct	atgggtagcc	ctgotttagca	aggagaggtg	cctctgagge	tgctatataac	112860
tgccacttca	acaaaaattg	ctgtttaaca	ccacaggctc	acccttgaat	tctttactgg	112920
acaaaaacaa	gaaccttccc	aggctaagac	ccaatttggg	ggcttgctgt	cctacatcat	112980
tatcaactca	tgccatagca	aaagtattta	aggtaatgat	tcactgcact	gagtttcta	113040
aataattagg	tatatcttgt	gacataaact	ttatttgcc	gaattgacta	acaatcgaat	113100
gttcaagctc	agttgaacca	ccttcaagta	gacacacaa	ggttattttg	goccaaagtag	113160
tcaaaactctc	agcatgtatg	tacaacgggc	ttattaaata	ggatgcatac	aaattgaaa	113220
gcacagaaac	atttttttga	gatgtgattt	atcttaaaac	taaaagaaat	agccatctca	113280
ttttttctcat	tctagattaa	tgagtagact	acgccatcat	atctaagtat	ttgagtttaa	113340
acaatgaata	cttcatctta	cgtttacaag	tcatttaatt	gccagttaat	tttgtttaca	113400
aaacactaca	ttggtgaagc	tttaattcat	ttggctttat	tttacaattt	aaaattagtt	113460
ttagtctgga	tgacgtgggt	catgcttata	atccacagac	tttgacatgc	caagtoaaga	113520
ggatcaatag	accccaggag	ttcaagacca	gctggggcaa	cgtgggtgaa	cctgtctct	113580
acaaaaaatt	ttaaaaatta	cctgagcagg	ccggggcggg	tggtctcatgc	ctgtaatccc	113640
agcacttttg	gagggcaagg	ccggcagatc	accagatcac	gaggtcagga	gatccagacc	113700
atcctgacta	acactaacac	ggtgaaaact	cgtctctact	acaaatacaa	aaaaatagcc	113760
gggtctgggtg	gtgggtgcct	gtagtccag	ctactcggga	ggctgaggca	ggagaatggc	113820
gtgaacccgg	gagggcggagc	ttgcagtgag	ccgagatagc	gacactgcac	tccagcctgg	113880
gogacagagc	aagactccat	ctcaaaaaaa	aaaaaaaaaa	aaaaattacc	tgagcaagggt	113940
ggctgtaact	cctgctactt	ggyatgctta	ggtgggagga	ctgcttgagg	ccaggaggtc	114000
gagggctgag	tgagccatga	ttgcaccagt	acgtctcagc	ctgggtgaca	aagtgtatcc	114060
ctgtctcaaa	aaagtaagaa	taatactaaa	caaaatcaag	ttttttttta	gcccataaat	114120
taagagtgtg	aatacgttta	actactggta	aagagttagga	atgtttttac	tataatttga	114180
ggaaaaatagt	tatataattt	tggtcaaaagc	taaaaatcaa	tattacttaa	tatttttaata	114240
atcttaattt	acctaatttt	ttcaactttca	aattttaagg	gggcattatt	gacatacaaa	114300
caccaagcta	attacttatt	attgacatac	aaacataaga	ctaattactt	attttcaatg	114360
tcaatatato	ttttaactgt	tagttgaaaa	gtgtttttat	tcaaatgaaa	taaatcatga	114420
taaaattata	tatttgggaa	atccttaate	aaatttgbgc	tagattgttt	tggttagacta	114480
aagttgggtct	ctttgttcaa	ttattctatt	tttctaaaat	tattttgtgc	ataaaaaaca	114540
gtagatattia	tttttttaatt	agcctacttc	taaacttagt	aggtatcaga	atatattata	114600
aagcaaaagt	acaaaatcaa	tttggaaaaa	aetaaagcaa	atgaacaaaa	cagaaatagc	114660
aaaaatagg	atthtgcatt	aaatttcttt	cttatctctc	cactgatcta	tagtaatact	114720
atttattcaa	taatcctttg	gctttgggtat	acacagggga	tatatattcc	aggactccca	114780
cacaggccaa	aatctgcaca	tacttaaaat	ctacatttgg	ctctctggaa	accgcattga	114840
cgaaaagtca	gttttttcta	tgottaagtt	ttgcaaccca	ccaatactgt	atthtttgacc	114900
caggttttagt	tgaaacaaat	tcacatagta	agcagacccc	tgaagttcaa	gcacatattg	114960
gtcaagggtc	aattctatat	gcatactatc	gatatgatct	aattagcttt	tcaaaataag	115020
aatatattcaa	attattttat	aaataacatg	agaattaaaga	tcatttccaga	agtaacatat	115080
atacctttgt	aaacagagta	aagaattggt	taaagaaaca	aactctagag	acaaagcaga	115140
atagagatta	tgteacactt	aataggcatt	tgagaagaa	aaagaaaaaa	gaaaagaaaa	115200
aaatttagct	aggtgtggga	ggctgaggca	ggaggattgc	ttgagcccag	gtgttgggaag	115260
ctgcagtga	ctatgatcgc	accactgcac	tccagcgtgg	gcactccagc	ctcaggcaac	115320
aaagcgagat	cctgtctcaa	acacaaacaa	caaacaacaa	aacaacttaa	cagtgaataag	115380
agcaagaaga	gaattccaga	accataaaaa	gcagatagga	gaatagacga	tagtcacatg	115440
aagttggata	gaataacaag	tatgtcataa	ttagagataa	aacaagatac	tatcagaaca	115500
tggttgtaaa	ttccacaact	ttcttgaaat	gtgtatttga	atagctaatt	tctaattgcca	115560
gttattgttc	cagtcacaaa	aaacgaactc	agccacaaag	agacagtaca	attaggaccc	115620
tgaaaataga	gaaaaaaaaa	aaaaaacgca	acacacattg	taccaagtat	tactaagtag	115680
tacttgrtga	agttaaagt	atggaaaaat	gaatgagcga	aagaacagat	gagtaacaa	115740
gaaactatct	ggagaccttt	ccattatato	gttagattat	ggacagcctg	tggaaaaaagc	115800
gtagtagaca	gttagtacta	gaaaaataaa	gagaagacaa	ggtgataact	gttttagtgca	115860
cttaaaactc	tggtgcaaga	acccaggaaa	ctctaaccatt	tgtaattcca	ttgtacatct	115920
gacchatgtg	tcctaagctt	aaatttatgt	tacagttcag	gagttttctga	aagaatattg	115980
ctttttctct	ttctttctct	ctttctctct	tttttttttt	tttttttttt	agatggaatc	116040
tcctctctgc	goccaaagctg	aagggcaatg	gcctgactct	agctcactgc	aacctccggc	116100
tcctctgatc	aagcaattct	cctgcctcag	cctcctgagt	agctgagatt	acagtcacgc	116160
gccaccagc	ctggctaatt	tttgtatttt	tagtagagat	gggtgttcac	catttttggtc	116220
aggctgggtct	cgaactcctg	acatgggtgat	ccaccacact	gggcctccca	aagtgttggg	116280

46/64

attacaggtg	tgagccacca	tgcccgccct	ggaagaataa	tcacttttct	atctattaca	116340
tttccagtta	acaaggttta	tgaaaaactt	ggctaagtta	aaatgtcaga	agaaataaaa	116400
gtgtttctgc	aaatgttttt	tttttccott	ttatbtgttc	attttttgat	gttcagttac	116460
tttatttctc	ctgagctatc	tttttatgac	tccttataat	tttaagctaa	aatgcaatac	116520
ttttttgtca	attacatcat	cccttttcca	tgtactatgg	ttttgtgaag	aaatgggtaa	116580
agtacacgtt	agtttaactga	gcacgggata	gatttgggtg	cagaatctca	aaggccatgg	116640
caggtggggg	atgggtgtgtg	tggggaggag	gagaaggcat	aactgggaag	aatgaaaagt	116700
ggcaaaagac	tcgagaataa	acaatcgagg	attaagcaaa	taaaagtggg	tcaatgtaga	116760
ctgggtcaga	tcttagasac	caaaggccac	acatgaagaa	cattttaccaa	tctgtttttg	116820
aacttatatt	tgggaaactta	cttctaccta	agaataattt	tagtttagcaa	tacttagata	116880
tttcattttt	agtttaaaatt	atatgtaggc	aaaagagtag	catatgcatt	cccaggatat	116940
gcctaaattt	aaaataagca	aagcttgcc	ggcagacgt	ctcaggctcg	tgccatttct	117000
gtgggcattt	tctctacccc	ttctcttata	tgcactacta	tagcacttca	accagcagat	117060
ctgtcctacc	tgggaaaaacc	ccatcttcca	gaatcacttt	gttctattct	tatcctcatc	117120
aacatccatt	tctacccctc	cccgccact	gaaattgttt	cagggaagtt	gtcagatgat	117180
aataattcaa	agtaaaattat	gaataatact	aaatttaact	atcctaaaa	atgtattcag	117240
tgtatttgtc	attccatgta	aatgacagat	tgggtgaaat	tatagtaata	ttaatatcaa	117300
caggtaaagt	atftttaggag	gagatgagat	attgaagcca	attgggccat	cgcacaattt	117360
aaatcacacc	atatagataa	atacacatac	tactatctct	gaaaatatgg	gggtttgggg	117420
gagcaaaagg	gaattcttat	ttatcacact	gaaattcaaa	catacaattt	aggattttag	117480
accactatc	tcttttctct	gactgtaatg	gaatccatca	atctctgato	tataaagctc	117540
tctgggacct	gaaataacgt	ttctgpcact	taaatctcca	ggattaaaaa	acatgtctcc	117600
caaacaacac	agccagtatt	tacttgaca	tgtttcagta	gagttttaat	ttattcactt	117660
taatcatctt	ggaatttctg	ggctgtggcc	taatttcata	tagtacacaa	ttgttagacc	117720
ctaaatctaa	aaaatctgct	tggctcataa	atattcaaaa	ccttggtcat	actatatttc	117780
aaaaaggtga	aattaggtgg	tacgattgag	aaactgttat	tttaaaactt	gtcctgtaaa	117840
tctgacccaa	ttcttagtag	cctgcagtga	ccccctgagc	cagactgtta	aaacaaggag	117900
gcaatttaacg	ttcctacaca	attggaaatg	ttattgtaga	caatatattg	catttagaaag	117960
gttctatgta	gtacccaata	tattasaaaa	agaaaacaaa	tagaaagctg	aaattacaaa	118020
ttattctctg	tggtctataat	tctttcttag	taattgaatag	tgtttttttt	gaagaaagt	118080
cactcttaac	agagcagaag	taatgctaaa	atgttatgct	gttgaataaa	gcagattgtg	118140
atagtattca	aactatcttc	tcaatttggg	attcagttat	caatgtggaa	aatataaaca	118200
gaagcaaaata	ttgaaatata	tgtgagtatt	tttcatgato	aaagctactc	tgtaagtaa	118260
aaatttttta	gatattggtag	attaatagaa	ctgatggaca	tctcgaaacta	gttttagtttc	118320
agagagtatt	tgggaaacaa	ggaataaatt	aggagtctga	tatccactga	aaattcatgt	118380
agtttttttc	cattggcttt	tgcattacat	gtgcttttat	gaaaattatg	aggctggcct	118440
aagcattgct	ttaaatacaa	agttgtgctt	tatcttttag	gaaataatca	gattttatct	118500
attttcacca	caacatata	agtgcctgat	ttcaattcac	cagtagaac	tgataccaca	118560
tttaaacaca	cattgatgaa	aaataaaata	aaagtgaac	aagttagcaa	taatcaatta	118620
tgtaaaataag	atgttttaaat	cactattggt	taattatcac	ataaaccttg	atgtactcta	118680
ttttaataat	atttcaaaatt	caacttttta	ataacttaaa	ctgtttatta	aacttgccat	118740
tgatttcttg	ttttaagat	tagaaataaa	acaaatctcc	cttatatgac	aaatgggtatc	118800
tatgtaaaac	tggaagcaaac	agtatgtagg	tatgaaacgt	tagaaacatt	cccataaatt	118860
tagtaagaaa	agacagaaat	atttacacaa	agaaacagaa	aaagatgtct	tttacaatag	118920
gtaatatattg	cattgttctg	gaactgtttg	taaatacaaa	aaggtttcat	tttaaaatac	118980
taattataat	atttatatgt	acaaggaaat	aattgttttc	ttcattttaa	aagtggctac	119040
atataaagtt	tacaagccaa	agaacaagca	ataacattag	aaaatataac	tgaaaataat	119100
tcaacctttc	aaaagggtatt	aaacatatct	gaattttttt	taaaattaca	aagtgtataa	119160
ctataagaat	atatctgctt	ttattttcta	gatttgaaga	ctgaacaga	gattttgtatt	119220
attttgcta	attcttcagt	tcttagagga	tatgtaatgg	tcactcaatc	aaaatttctt	119280
tactaagtga	aaagattttta	gaaattatga	ataatattga	attcattcag	tttaaaaaatg	119340
tttaccaaat	atctatcaca	taactgggtta	octatcaaaa	actaggaaag	caaacctcct	119400
ccaagaataa	gctttttta	ctatcaagaa	gcagtgtat	aattaaattt	tattatgaat	119460
ccagaaaattg	tttactctgag	gtcagaaaaa	aactcctaca	ttcatattca	ctactccaaa	119520
agactgctct	tcaagaatat	atgttatata	caactacagg	aaaaaaatct	ctattgaaca	119580
acttaactgt	tacaaatatt	gtatattcaa	ttgggtttca	aatttatata	atatttttat	119640
tctgataata	caagtaatac	ttgtctacaa	gaattctaat	gtcatgacaa	tatcagttgt	119700
aaatgataaa	tgaattttta	tttaggaaga	gttaaaatca	tatttgaat	aaatctaato	119760
atbatgattt	gatggctttt	attgactatg	tatatctaca	tccttcttaa	tgtttccaca	119820
taatacattt	tggttatact	cctaagcaaa	aaagtaaaat	acattttatg	ataaattaca	119880
gggaaatgat	tattccagat	catagttttt	cagaaatgtt	tattaaaaca	ttttattcta	119940
tttttatatta	aatataatta	tgatgaatat	ttagatatac	cattcaaaata	aggttcttacc	120000

atcttttttaa	ctcaacaatg	tcaaaagcca	ctcaattgtc	aagttacaga	atacttaago	120060
acatttttcta	aatcaaattt	ttattactcc	tgtgaaaagc	atcatnagca	aatgttttcat	120120
aatacagttt	tcagaaaaga	gtctctttta	atctttacctt	ctgctacaca	aatagcccat	120180
aacataaggg	aaataatctt	tgtctagaagt	ctcattttttt	ggatctttta	agaggacatt	120240
taccagctaa	ctctgttcac	aacgtccagt	tctctctctc	caagaattgt	gattagtgcg	120300
ggaaagaact	tgtctcaaaa	ggaagttgaa	actagatgct	cgcctatca	gaaacttttg	120360
caaagtaaat	aaaaaatcaa	ccacaagcca	caagcccaga	aatgccagaa	gttaaaoccca	120420
attctcactg	cactcccact	aaatgttaat	gctgtgacgg	gctcttggac	tttttctttat	120480
taagctaggg	aaattctcog	ttggaaaatg	ttcatgttct	tggatgtgct	aaatcagcag	120540
ctggcgatat	ctctctggatt	tcataaaacc	ttcaattatt	caaaactctat	tggggtctat	120600
tgtgtataaa	cttcagaaca	ggaaataaga	gaaactttta	aagaatcac	atacaaaaac	120660
ttgggttagg	caatgttttc	acsaatcagca	gtgtacaaac	gtgtacaaac	tttgccaaga	120720
atgcagtgtc	tgatgaattt	gggggtctgc	ttttctagca	atztatgaaa	ttagttttct	120780
aaatactttt	tgtatatgtg	tatgaagcaa	ctggctcact	ctcatttgac	gtaaataggt	120840
ttaataatcc	aaaaatcaac	aaattgaaat	gctgattttt	aaaactttgt	attgtagtgt	120900
aataatgtata	aggaaaacat	aaatcatatg	ctggatattg	agaaggtaaa	gatacctgtg	120960
aaaccaccac	caaggtcaaa	acactgaaca	ttattacatc	ccagaaaacc	ccagtactcc	121020
ttttcagtc	atacgctctc	caacccctctc	ccacacacaga	gaccacgatt	aatgaaaaag	121080
ctgatcttca	agaacatgga	atatatttgt	ctggcttttg	tactttgtat	ccattcacaac	121140
aagcagttta	ttcttatgtt	tagagttttt	caccaaaaat	tgtgttttga	ccattcacaac	121200
acattgttag	atgtagttaac	agatagttca	ttcttattgc	gatttaatac	ttcacttttt	121260
gaatagttca	catttttattt	atctgtgtgc	ctgttagtga	gcatttgagc	agatttttagt	121320
ttggagctgg	tatgaatagt	gctgctatgg	gccttatatt	atgaggtttt	tggtaaacac	121380
aatccacatt	tctggttaagt	gcatacttgg	tagtgaaaaca	ctgggacata	atttatgttt	121440
aggtgttaatg	gataaaaatta	gacaattttc	caaattggatt	ataacacttg	acatcacttg	121500
acattttctat	cagcagtgct	caagtgtctc	cataccctca	gagatacttg	gtaatttttaa	121560
tccttgtaat	tttagctttt	ctggtaaacac	aaagcaataa	ttctccgtgg	ttataaatatg	121620
aattttctctg	atgactaatt	gaaatgtgag	agatccctga	ttcccttga	aggacatgca	121680
acaggtgtgc	ggcttgccag	ttaggctgcc	ctgcagctca	aaaccccttac	ggggaggggg	121740
agcacacaga	tgcaccgggtg	cgggaaccgg	agtgagcgtc	ttcgggtctc	ggcctcacag	121800
cagcatctag	gggtgggtgt	ctgcgatttc	cgaagcccaa	gtgggctgat	gttacagtgt	121860
gctcccttag	ctttgccatc	tgc aaatggg	ttatgtgtta	atcagctcaa	caaaccctct	121920
tccttatctc	atgggtagtg	ggacagtga	atagccctct	atatccccag	ctgttgccca	121980
gtgtcccaaa	agaatcggat	cacacggggg	ctcgagggat	gagggcaact	ttttatttag	122040
tgggtggggg	ggctgtcagc	aagatggagt	gggaaggtga	ccttcgccc	gtgtcaggcc	122100
tcccagtggc	cagactcttc	tcaccccgct	cctggccaaa	ctccctcgg	agtcagatg	122160
tccctctctc	ctttctctgc	tgtgtcatcc	tgcacatgca	ggcctgtttg	tgggcttgcc	122220
tctcgtctc	ctcacttgta	ggtctcttct	ggagcttgga	gtttgggatt	tatatggggg	122280
tacgacagcg	gggcatggcg	ggccaaaagg	caactttttg	ggtgtgaaac	ctgaaatgcc	122340
tgtcctcatt	tagggccaca	ggtcttcagg	cttgaggggtg	gggcttttgc	ttggggacca	122400
ccctctctcta	ccagctattt	ccctgtctcc	tgcctttaac	atgaagttga	gaaactttcc	122460
tgtggtaact	ggctatttag	ataccctctt	tggtaaaggt	tctattcaaa	tcctttgcat	122520
atctttttct	tattgagttg	tttgtctttg	acttatbtga	gtgtaggaac	tgtttatata	122580
taattactta	tatattctag	atatgaaaat	aatcttatta	atatgtatta	taaatacctt	122640
cttccagctc	gtgggttttc	tttctatcca	gtattacatg	tcttttataa	taataaaaaag	122700
aattccttaa	ttttaaaata	gagcaaat	tcaatttttt	tctatgacta	gtgcattatg	122760
tgtcctattt	aatgaaagct	tgcctagtcc	tgaacacaaa	tgtttttctt	ctaaaagaat	122820
tattttatct	ttccacattta	agacctttag	aacaactgta	attgtctttt	gtgtatagca	122880
taataaaaaag	ctccagatgc	atttttaaaa	tagagatata	caattgttat	agcattatct	122940
aaogaaagta	tcattctttc	ctctgtactg	acatgctttc	acctttgtca	taagtcagggt	123000
gctggatatg	tgtgggtcta	tatcaccag	ctctctctac	tgtaatagtt	tattttttaa	123060
acttttctaa	agtgtaaaat	tctgggaact	ttggctttct	agttatcttt	taaattgatt	123120
totttttttaa	tttctatctc	taaataatta	cactgtttta	aaatttgatg	agtctttctt	123180
tatggcccat	tatagtcaaa	attctaccta	tgtcagtagg	tcaagtttgt	aatttgttaa	123240
aatcttttgc	atttttatta	tgtttttgtc	tgtattatcc	atcagatatt	gaaaggggtg	123300
attacatctc	ccattataaa	tgtggatttg	tgtatttccc	tgtttaatgc	tgtgaatctt	123360
tatatatttt	agggtatga	tgatgcttgc	atacgtattt	agaattgtga	tatccttctt	123420
ttgcattggg	cattttctca	tattaaatgg	cccacccctaa	ctctaatttt	gcttccaatg	123480
tgaattttac	atttttattt	atcttttatt	ttatttttgt	aataaaaaata	taaggaataa	123540
gagtttagac	tagtcaattg	ttctgagaaa	aataagaaat	aaaatagcat	ggatataatga	123600
ataatcaagc	aaattcgaat	tctgaactat	catctctgaag	tttaatttga	tttaactgat	123660
aacacatatg	ttgacatact	agatcattta	aaactctctc	ttattccttc	cttagtttta	123720

tctgttttgag	tatgaatoca	aacatttttac	ctgggggctta	aattttccaat	agtgggtttct	123780
attotaatag	caatattatc	acttgagag	tattccagaa	acttactaag	attaatatta	123840
ttgagtgtta	attatatacc	aggcacagat	ctaagcacat	ttattcaata	cttaatgcaa	123900
cacaatgaaa	tgggagacta	ttactctttc	aaaggtatag	atgactgaac	tgaaccacag	123960
aacatttttag	caactccctt	aaggtcacaa	gacattgctg	gagccaggta	tcaaateccag	124020
tggctctgtgt	ttaaaaatag	tgtttaaaaa	tatagtaaaa	tattcacata	tgtactotag	124080
tgtatgcttc	acattttatt	attttacaat	tatgcataata	ctgtaaaagt	attgaaggta	124140
cacacacaca	tatatatgtt	tgttgataat	ttaaagtaca	tacaggaatg	attttgctat	124200
acaaatcttc	acctaatttg	caattgttga	atgtaaaaatg	ccactctact	atccaagtag	124260
aaataatcct	cttgaattaa	tttcaacaaa	tatcttttcag	atgtattatt	tttactattt	124320
tttcttttato	ctactctttt	tcaaagactg	atggctaaag	tcaattgagt	gtttttgttt	124380
cccttttttcc	atcaatactt	ttcaaaaacta	caaaaagtcta	ttataaagaa	attcagaaca	124440
taagaaaatt	agcaacatat	tatgccttaa	actcataaaa	ttattatgta	gtattagatt	124500
accattatgaa	agaccagata	gtaaatagtt	aactattaat	actaagatta	aacatgaaat	124560
ggatccaatt	tattttcaat	attcatgttg	gcacattctc	agcaaataca	tactatgtat	124620
atltggacat	taaaaaattta	gaagagtaag	gatataaatt	tgtattagag	aaaaatccat	124680
atltaaaaaaa	ttagaaatag	ttaatatcta	tgttaagtaa	caaatgactg	ttatgattaa	124740
aattttcgaa	ggaagtgttac	aagaaagaga	aattactgaa	cactgggttt	gatcagggat	124800
gatttttaaga	acacttggat	atbacactgt	agtttaaggg	aagagtacca	ctgagagctgt	124860
gaagaatagg	aaagtgtggg	gactaatcta	gaattaatga	gaagactcac	attggagcag	124920
tggttttgca	caaggaaatt	gtggaagaag	taaaaggagc	ttttaaagag	gaatgggttg	124980
aattccagat	caaaaacttg	caaatatttt	tacaggcaat	aaagaatcct	tgatagatct	125040
aattgaggaa	gaaatgtaag	tcatgcatta	tttaagtaat	gggtgctttg	cggttgtatt	125100
aaaatagatg	gaggaaaaag	gactcagaga	aatgacaaat	taaataaatt	actgaatgaa	125160
ttcataatag	aactattaca	cagcatctca	atgtaaaaga	aaagggtaaa	aactaatatt	125220
tataacagag	cttgattttt	ctatgaagct	aatgaagtct	aagcttcagg	gctcctaatt	125280
tgaacagaca	ccatcaagga	cctgagctgg	cccttaataa	cgtttctgca	tggctcatota	125340
tttttgtaaa	aaattgaaga	gaattaatct	cttaattgca	agagaatgaa	cggctgtctc	125400
tcttattcta	tgttgatttc	cccttcattg	catttccact	gattcagttg	acattacagt	125460
ttcaggcatt	tgaaggatgc	aagaaaaagt	tacacataga	atgctattag	tttgagattt	125520
atgtgggtata	ttttacagtc	tcaattaaat	ataatttgat	aactgatggg	cctccaagtg	125580
taagaatggc	ttccaggaa	actcctacca	ccctgtgccc	aaatcaattt	gcatacatac	125640
acaaaaacttc	agtgtctgaa	gacagcacat	atgaatatgc	ccgacaccag	aagtctatgt	125700
gtagtgaagg	agaaacaaga	ttaaaaagta	taaagactat	gatcagctgt	gtaaaaattt	125760
aagtggatga	ttccattctc	attgattctt	ctcctagtaa	aaatgaaaaa	ttgctcaagt	125820
cattcacaa	atattggcat	caataacaat	accataaaat	ttacaacgca	cctttgaaat	125880
gaagacattg	aggtcaaaact	agttttcaat	gtttcaattt	aaagaacatt	taatatattt	125940
tatatcatta	gaactctttt	aatgtcctga	aaccttggag	cttatttatgt	cagggaaatc	126000
tgcaggatt	ttttccgaaa	tttgatgaca	atcttaaaaa	tgttttagaca	taagtgttga	126060
acttgaatg	acttcaaaata	tttccacata	acaagaaaca	aattttaaate	aaacatacta	126120
aaagaaagac	tgaattattt	tttctatttt	atgtacactg	aaaatatttat	aaaatgggtg	126180
catatgaagg	aaaagtcaaa	aaagtattca	acaaaaacgt	agaatttcaa	ggtaacaaaag	126240
actttatcac	acaatgacta	tacctaactat	attttgtgtt	tctatgatat	ttcatttgttg	126300
tttttaatttg	catttcccta	atagtatttg	atgttgagta	tttttttcat	gaacctgcta	126360
gttatttgta	tgttttcttt	tgagaatgt	ctgatcagtt	cctttgcccc	tttttaasatt	126420
atgttatttg	ttttcttgct	attgagttgt	ttagagttcc	ttatatattt	tggacatttaa	126480
ctccttatca	agtgtatggg	ttacaatgt	ttctctccat	tccataggct	ttctcttcat	126540
tctgttattt	gtttccatag	ctgtacagaa	gtctctttagt	ttgatgaaat	cccatttgtc	126600
tattttcact	tttgttgct	gtgttttcag	agcactaaa	aaaataaaaa	taaaaaataaa	126660
ttgcaatatt	gtggagattt	taactcattt	cttctagtaa	ttttacagtt	ttttgtcttt	126720
aatccatttt	gagtgatatt	ttgtatctag	tgtaaagataa	agatccaaat	taatccttct	126780
gcatacagat	acccaatttt	cccaatacaa	tttgttgatg	agtctgtcct	ttcttcattg	126840
tgtgttcttg	gcacottttat	tgaanaatcaa	ttggccgtaa	atgcatgggt	ttatttctgg	126900
gctttctatc	ttgtttcgtt	gataaatatg	ttgttttcta	tgccagcacc	atgtgtgttt	126960
gattacaata	aaattttgaa	atcaaggagt	atgaaggagt	atgatgcctc	cacctttatt	127020
ttttctatct	aaaattgttt	tgattatttg	ggaacttttg	tgtttccata	tgaattactc	127080
tgggcttgct	atatabgggtg	cttattgtgt	tgaggtacat	ttcttctata	cttagtcggg	127140
tggaaatttt	atcatgaaaa	gatattgaat	tttgtcagat	agtttttctg	tatttattga	127200
gatgatcacc	tgggtttttgt	ccttcattct	gttataattgg	tatatcagac	gtactgattt	127260
gcataatgtg	caacatcctt	gcaccccaga	gataaaatccc	acttgatoat	gggtgatgat	127320
tctttcaatg	tgttgggtgaa	ttcagtttgc	taatatattg	ttgaggggtt	togtgcctat	127380
gtgatgagag	atactgggct	gtaattttca	tttcttctag	tgtctttggc	tgggttttggg	127440

atcaaaaataa	tattgacttc	atagaatgat	gltagaagta	cttcttccac	ttcaattctt	127500
taaaaaagtt	taagaaaagt	cgatattagt	tcttctttaa	agtttggtag	aatttagctg	127560
taaaaaccata	cagcttttgg	cttttctttg	acaggaaact	tttttttgatt	caatcatttt	127620
atltgttatt	gatctattca	gatttctatt	atttaaatgat	tcaggcttgg	tagattgtat	127680
atgtctaggt	tgcattgtga	tgtgtcttga	tatgttgtat	gtgtatgcac	gtagaaattt	127740
atacatttct	tctagggtta	ccaaattatt	ggtgtatgat	tcttcacatg	tgtctcacia	127800
cttttttatt	ctgtggtatc	aattgttagg	tctctctttt	catttatgat	tttattttat	127860
tcattctctt	ttttaaatgt	agotaaatat	tattatcttt	tcaaaaaatc	aactttttca	127920
ttgatttttt	ctgactattt	tatttttctg	ctctgttctt	tgttattttc	ttctttttgc	127980
taggtttgaa	ctttgttctt	ctctcagttc	cttgaaattt	acatagttca	tttgagatct	128040
tttttttaata	tagacatttg	ttgtttatata	ttttctatga	agaactttcc	acttataact	128100
tttttctctg	catccctgga	gttttgcaat	gtagtttttt	cattttttatc	ctgtattttt	128160
tatttttctt	ttgatttctt	ctctgacaca	ttgttgaaaga	gcattggtgat	taattctcac	128220
atatttctaa	atttttctatg	atttctcttg	ttattgattt	ctagtttcat	gttactgtga	128280
ttggaaaaga	ttgttatgat	ttcaattccc	ttaaaacctc	acttattttc	tggcctaacg	128340
taogattctat	cctggaggat	gttctctaacg	tgtttgaaaa	gaatgtgcac	tctgttctctg	128400
ttgggttagaa	tctttgggtat	atatctgttg	ggtctatttg	gtctaaagtg	taattcaagt	128460
ccatttttatt	ttttattgat	tttctgtctc	gatgttttgt	tcattgtttga	aaatggggtt	128520
ttgaagtctt	ttgtctatgt	tatgtttcat	tctatctttc	ccttcagatt	gcttagccat	128580
tctctgtttt	gacccaagaa	tactagctgg	tggcatttgt	gactgcagca	tttaccocaa	128640
gatgactttt	cattgaaata	tcttgggtgt	actattattt	ttacattgct	ctagtatata	128700
aactttggaa	acaaaagacg	tcattctatt	tatagattc	tgtttttagt	agtgatattt	128760
togttttacaa	aatatggtaa	tctctgatca	ctgaaaaatg	caaactctag	aaaaagtagt	128820
attctctacat	gttaagttta	catagttctc	gaacagatgt	tggctgaaga	ttcatttgat	128880
gaatctgatt	gttctcaaat	agatgattct	gatgtctatc	ctgttttagaa	ataactccaa	128940
gaaaactttc	tatttttatt	tcacattgaa	aatcagtcac	atttgcttca	acctcaagaa	129000
ctttgtttat	gtaaaatcaa	gtgaatgttg	gcagcaagct	ttactttttt	ttcttaaatg	129060
ggaaaagagt	taataactgc	tttatatatt	taggtgtctc	gatgttgagt	gcataatata	129120
ttacaattgt	tatattatct	tgatgaattg	accactttat	cattacacag	tgacttctct	129180
tgtttctttt	tacactttac	tacttaagtg	ctattttgtc	tgatacaagt	gaagtacct	129240
ctgtctctct	ctgattttca	ttttgcttgg	agtatctttt	tctatctccag	cagtctctgt	129300
gtgtctctaa	aggtgaattg	agtttcttgt	taacatagta	tacttggatc	ttgttattgt	129360
ttttaaaaaa	tattcatctc	gccactcttg	atctttgaat	tacagaagtt	aattcattta	129420
catttaaggt	aattattgat	aagttagggac	ttgtactgtc	tactttgtaa	tttgtttttt	129480
ggctttctat	ttctgccttc	ctctcttgtc	gtctttattt	gtgggttgat	aattttctct	129540
ggtggtattc	tttttaactc	ttcttttttg	ttcttttgca	tcaactatag	gtttctgctt	129600
tgtggttagt	taccatgagg	aatacataaa	acatcttaaa	catttaaatc	aatttaacat	129660
tttaaatcac	ttcatcagtc	tcactagtca	cattttcaaat	actcaatagc	cacatatagg	129720
taatggctat	tacagagcat	tttcatcctc	atagaaattt	tcataagata	gtgctaagtg	129780
atatggtagt	ccaaatcagg	tgcccatatt	gtcagaaaa	aggatggaaa	ggaaatgagt	129840
attttccata	tggtgatctt	gatatatatt	caaaagagca	ggatattaaa	catcatgaat	129900
tattataaat	aaaactacta	gttacatctg	atttgtaaac	caatttaatt	tttttttttt	129960
aagacagagt	ctcgtctgtt	caccocaggt	ggagtgcagt	ggtgtctatc	tggtctcactg	130020
caacctctgc	ctccagttt	ccagtgatcc	tctgtctctc	gcctcccccag	tagctgggat	130080
cacaggcgca	caccaccact	tccggtgat	ttttttgtat	tttttggttag	agacggggtt	130140
tcactgtggt	gcccagctg	gtctcaaat	cctgagctca	agcaatccac	ctgcctcagc	130200
ctoccaaatt	gctgggatta	caggcatgag	ccactgcacc	cggccaattt	atttttsata	130260
atcacaaata	taagtgttat	aattcacatg	tgaagattca	gtcatcaatt	actcagctctg	130320
tgtttttatt	ttttcagttg	tcattggttg	ggctttttctg	tctgtacctc	cacacaacca	130380
ccagcacttt	gaaagtatag	ctagtacaaa	ttaaagcaca	acacaaatta	aagttaaaaa	130440
aaagaagaga	attgtgcaga	gtccattgtc	ctttctctaa	tttaattcaaa	tcatgatcag	130500
cttgtctatt	tctttcactt	ttctgtattt	gaaatcaaat	tttctctccc	ttactgactc	130560
agacatatat	tgttctctct	tctctcccaa	aaaagagttt	taaaatctctg	aaaagtgtcc	130620
ttgttatatt	tcttttttaa	ttgcaggaaa	aaaataatgc	cccaataacc	ttatgtgctt	130680
atatgcattg	cctaagataa	aggtcacctt	tatgatttat	tttagaacat	tttttcattg	130740
catgaagaag	ccctaacatt	caaagtctcc	tttcccactt	agtactttta	cttcttttcta	130800
aaaggacact	gctagcacaa	ttcaataatt	tggacaaaaag	tgaagaatga	tgacttttaga	130860
ttttgttttaa	tttttagttg	aagggaagtga	aaacacacat	gatctctacat	ttatatttat	130920
tgcaattatt	ttattaggtg	cattattaaa	gctagattgc	aagctcttca	aataatttaa	130980
ccatctgaag	gtaaaaggaaa	aaaaaatacc	atatctcttg	caacttctctc	agtcactata	131040
aatcgcattg	aaaatctttt	aaaatcttca	gagaaaaattg	attttctctcc	cttcaactata	131100
ccagctgctt	cttttaattgt	tctctttccc	aggttcccag	gcatttatcc	cagggtacaa	131160

50/64

cacacacacac	aactgcaaat	ttctgtcttt	taaatggcat	attagaatc	tgtgagcaaa	131220
gtcacttttt	tgccccagca	ctggcaatgc	atcaactttc	caagctctac	tgactcaatt	131280
tttaattgcta	tgtaattgatt	aatttatatg	tgccaggtgc	tgtattaaat	gcattatcta	131340
atttaattcca	ctcaaaaact	ttataatata	cttttatcat	tgccgttttc	tgccatggga	131400
atctgaattc	cagagaggtt	aaaatgactt	gcttaagtta	gtagtgaact	tgagatttga	131460
tccctggctg	tctgggtcct	caattgagca	tgtaacaaat	agtctcgtg	cctttttgac	131520
tccaagtgtg	ttttattcca	aagctttgtt	atcaattttg	gttttggaca	gagggaaactc	131580
ttagagctga	tattctccag	tctctaata	agattcctag	agacataatt	taatacgttg	131640
tgtaattgatc	atacttaagt	agagtgtatt	tgctttctgt	aagtttaatt	tccaagatat	131700
ctaacaaatt	atgtactgct	acatatcaga	tagaagtaat	catttcttgg	gaaaaataaaa	131760
accagtctta	cctatgatgt	ataattagta	aatgactgaa	agtagatggg	taattgtcat	131820
ttatttagttg	taagttaata	atttataacc	cagtttaatat	aactaattag	attagcttat	131880
acatatcatt	taaatgaaat	tcaaatccaa	aatgatgcct	gagaattcat	atatgtttac	131940
attttgatag	ttattatgct	atctctatct	ccccccagca	aaaaatctat	tccttaaccc	132000
taatttaattt	ttaaatcaac	agcaaaaaaa	aaaatgtaaa	aattaatctg	ggtacatgac	132060
caacttttag	tagatttgat	aaaatatttt	attgatatat	cagaaaacaa	cataattact	132120
gctagttcca	ttgttaagtt	tttaattctaa	taagaaatcc	tattttattaa	tcatttaaca	132180
ttacattact	aataatattc	atatttaatt	tcactctcaa	atttaacaaaa	cagcatttga	132240
ttgtaaaaga	gaaacttttt	tccattagat	attcccaggg	aataaagttc	cactcacaaa	132300
gtattcctca	aaagtgtatt	taaagtaatc	tttaaggtaa	tcccaaatcc	tcaatagcac	132360
ataaaagcat	gcatttttta	aaagttaatc	ataaaccaaa	aaagatgaag	taaaactatta	132420
attccctggg	agatttctta	atgggtataca	agtgtttbatt	tttctctgtc	aggtgaatta	132480
ttagaaataa	atttgaatgc	caaggtgatg	aagattccct	ttgattacat	atgaaaacct	132540
tctttaaaaa	ttactcacag	ataaaaaatt	atgggttccag	atgggttccag	tgccagggta	132600
ttatatacaa	aaatgggttaa	actgctaaat	aaaatatgca	attctagggtg	tottattttgt	132660
aatcccttagt	cctgtttcag	cagttgtcca	aggtcagggt	aattgtaatg	atcacttttg	132720
tagaacacaa	tggttaaggat	gactttttgt	tggtgttgtt	taagatggag	cctccctctg	132780
tcacccaggg	tggtagttag	tggtgtgatc	tcagctccct	ggaacctctg	cctccctggg	132840
tcaaaacaatt	ctctcgtctc	agcctcccca	gtagctggaa	ttacaggcat	ggccaccac	132900
agcctcgcta	acttttgtat	tttcagtaga	gacgggtgtt	ccacatgttg	accaggttag	132960
tctcaaaactt	ctgacctcaa	gtgatccacc	caactcggcc	ccccaaagtg	ctgggattac	133020
aggcataagc	cactgtgccc	agctgagggg	gactattttt	ataatggcat	cttaaaatga	133080
ttaaactatt	taaaattaaa	aggtcattaa	tagtgtgaaa	aatttccact	gaagtaattt	133140
ccacttctac	agttagattt	gtaatagatg	ccttctttgt	tottaaaaat	gagttgtata	133200
cattaaatat	gtacagtttt	atgtgttaat	catacatcaa	taaaaatgatt	tgaaaaacaa	133260
tgttcaagat	cagttgaatc	ctattcttaa	gggaataatg	gtagtgaacta	gttgttgtaa	133320
accctcgact	accagtatct	aactaatagc	caacacaaata	tggtgttcag	ggctagttgg	133380
agccagatag	aagcatttct	ctggcccttg	tggtatttta	agattgaact	acataatgac	133440
cttcataaca	tggaatgaaa	tggtatcctg	attctttgca	catagaactg	gctgcaaaaga	133500
aaagctgagt	tagattacac	agcaggggaa	taaaagaaaag	agaaaaagta	cctcttactt	133560
tcatttgaat	gtaactgtga	aaatggatgt	atgtaattat	ggctaaaata	cgcttaggaa	133620
gggaattttc	aaaatgagaa	tacatttgca	agccacacaga	tgctatgaat	ttttatgttt	133680
caagacattta	caaattgttg	tccaagaatg	ttatcctaatt	tcccaaaactc	ccaattgcac	133740
ataaaggcag	gtatttttcc	acagccctgc	aaaattgctt	aatataaaaac	ttttacgtta	133800
ctgttaaatgt	aagtgaaaaa	gcataatata	ttcttggttt	gatcaactca	gacatttttg	133860
gaagaatggg	ttatgactat	gatattaatt	tatttaattac	tcacataactt	cctagctatt	133920
tgctatttga	tttgtctctc	actgtttttc	taaaactatt	atcttgacac	atccctbggt	133980
cagctcctta	atcatttagt	ccttttcttt	tccttttatt	ttctttcttt	ccttctttct	134040
ttctttcttt	tttttttttt	tttttttttt	tttgacacgg	tttccgtctt	gttgcccgag	134100
ttggagttag	gtggcatgat	cttgggtcat	tacaacctct	gctccctggg	ttcaagttag	134160
tctcctgcct	cagctcctcc	agtagctagg	attacaggca	tgccaccacca	cgccagctta	134220
atcttctgatt	tttgatagag	acaggggttc	tcctatgttg	ttaggttggt	ctcgaactcc	134280
cgatctcagg	tgatccaccc	acctcggcat	cccaagtggt	tggtgattaca	agcgtgagcc	134340
actgtgcccg	goccatgtcc	ttttcaacgt	attagtttcc	caggggtgct	atcaaaaaat	134400
accactaaact	gggtgggttaa	aaatacattt	tatcactttc	tggtgggttag	aaatatgaag	134460
tcaaggtgtc	agcagggcca	cgctacctcc	agagatgcca	gagaagaatc	cttctagcat	134520
aaggtgattg	ctgtcaattc	ttgttaattcc	tcggctttcca	gttgcatcac	tctaatatct	134580
gcattcatca	tcacatagac	tttttcattg	cgtgtctctc	tgcttctgtg	tgtaaatctc	134640
cctctctctt	ctcataaaat	caccaaataca	gtatgacctg	atgttaactt	gattatatct	134700
gcaaaagactc	tatttccaaa	taagtcacat	tcataattag	tggtgggttag	ggtagttagc	134760
acatatctggc	aaccacatat	acttatgttt	ggtgggcatt	gattgtgtgg	agaaaaagta	134820
agtataatca	tcgacttaga	gaacttaaaag	tagaacaag	aggcacatat	aaatatgcca	134880

51/64

ataagtgcag	aactgagtag	aaaagaaata	caggtaaatgg	aaggagaaaag	cogtcaagct	134940
agagaagaca	ctcaaaactgg	atcttgataa	aattagtaag	tgctcgacag	gccagctttg	135000
tgaatttctg	ctctgctatt	ttttctcttg	gtgggaaggt	tttaabcatg	aagtgtattt	135060
ctttaataga	tataaaatat	tcatatttta	atctctgttt	gtgtaaccc	tttaataaac	135120
tttttatttt	agtatagttt	tcaattttata	gaactgttga	aaatagaata	cagagaatcc	135180
tgaataacctc	atatagaact	tcccttatca	ttaatatctt	atattactat	ggtagatttg	135240
tcacaacaaa	tgaagcaata	ttgccacatt	ataattcatt	aaaattcatg	gtttacaatt	135300
atcttcttat	ttttacaaa	atcttctgtc	tgtgocacga	tccattggg	gatatcacct	135360
atcttagtc	catgtctct	gtggctctac	tagactgaca	gtttcttaca	cttacctgt	135420
ttccttgaaa	aatttgagga	gaactgggtta	ggtatttgaa	ataacatctc	tcagttggag	135480
ttggtctgaa	gttttctca	tgattaaata	aggggttatgg	gtttttggag	gaagatcact	135540
cacatgaagt	gtcattttca	ttacatccca	tcaagggttac	atgataccaa	catacatcac	135600
tgattatggt	aacctgaatc	acttggctgg	agtaggtttt	gtcaggttta	tacagtgttt	135660
atcttaactta	tttccctatt	tccataccgt	gtttattttg	aagagcatta	ctaagcacac	135720
cttatattca	aggggttagga	cattaagctt	cactcctttg	aaaggggaat	actacatata	135780
ttctttgtaa	ttcttttagtg	ctggaaactt	gtttcttccc	tccattta	ttatgcattc	135840
aactatttat	gtatataaat	atggactcat	ggatgtttag	tttacctttt	gggtttatgat	135900
ccaaaactat	attatttatt	ttgtctttca	aattattcca	gattaggcca	ttgggagacc	135960
tttcagattg	actcttgat	gtttttgaca	tgaccccatc	atcttatttt	tttcagtgct	136020
ttcttatttc	tgacactaca	ggataaatca	gtttcatctt	gtatattccc	tgctcagtc	136080
ctagaatcag	ccctttctgc	aagtaacaa	ccctttctgc	ttgtttccgt	ctattggagg	136140
atagttctag	aaacgaagat	ctgggtgctg	agtggttttg	ttgtttgtc	ggtactgagg	136200
tgttatttct	cataggtcct	ctcagcaaat	aatagagcta	ggaaahgtac	ctatgtatc	136260
taatotatgc	atgcacatat	ttataataat	ttccatttgt	acctatccat	atattatagc	136320
agcatgagtt	cagactagtg	ctctgactc	taacccagtg	ctacagggtt	tattctagat	136380
ttctcctgt	ttgatgtaac	ctccctctc	aacagtgaga	agctggctcc	tacctgttaa	136440
catctattta	cttttgttta	atcacagtag	acatgtatag	aattttgaga	attattcatc	136500
cacacccaca	tgagacataa	ctttgccagc	tagaatagta	cttactgact	gttccctttg	136560
ccttcagact	tacagtttcc	aataatcctc	aaagttactt	agataagcaa	cttttccctt	136620
cttctttaag	tgaggtgata	acatacattt	aatagagtta	atctttataa	totgaattcc	136680
acccagagat	ccatcatctt	ctcactgtct	tatttttaaa	tttgatata	tcaatattta	136740
ctctttgtgc	tatgaagttt	tataaaattt	tgctgaaagc	gtaatgtccc	atattcacca	136800
ctatagtaac	atattgtact	gccagcttat	agagttgata	aattacaaat	aagagaaata	136860
gaatattttc	ctttaccttc	atctttttct	ctcccaacat	tattttcttt	atgtagggtcc	136920
agttttctga	cctagatcat	cttccctctg	cctgaaabaa	atcttttaac	atttcatgca	136980
ggtctactgg	tgatgaattc	cttctgtttt	taattttctc	ttcatttttg	taggataatt	137040
ttcttgata	tagaatttca	tggtgataga	tcattctttc	aatacttggt	gtattttact	137100
ccactctgtt	cttgcctttg	taattttctg	tgtacttctt	atccttgatt	ctctaattgg	137160
taaggtgttt	ttttctctg	gattctttta	gattttcttc	ttgtttgtc	tttgggtttc	137220
ttaaatttga	ataaaatatt	aggagtactt	tttcagttat	tattctgggt	ggtgttgtct	137280
aatcttctg	gaactgtggt	ttgggtctgt	cgtaattttt	tcaatgtttc	tggtgtttag	137340
taattcaaat	ttcttctctg	tccctctctt	gtttttcttt	cttctaata	tcaaatata	137400
catagtcaat	ccagttgaat	tttttccaga	gttcttaaa	gttctgact	gagctttttt	137460
tgttttctct	tactttatat	ttttctctct	aaatttaagt	ttggaaagtt	tctattgacc	137520
tctctacagg	ctcagtgatg	ctttccttag	cctattccgg	tctactgatg	agcttaccta	137580
aagtaatctc	cgtttctggt	acagtggttt	tggttctctg	cactttcttt	atattctttc	137640
tcaaaatttc	tattttctgt	tacatttatc	atctgttctt	gcattgttgt	tattttttcc	137700
actagaacct	ttacatatatt	aattatagtt	atcttttaaat	attctgtctg	ataagtccaa	137760
gacttgtgtc	atataagtg	ggtaagtggt	gttctgatat	ttgtttctc	tcttcaaa	137820
gtcttttttg	ttctcttttg	gtgtactctg	taattttttg	tcaaacacca	aacatgttat	137880
atcagatcat	aggaactgag	gtaaatagag	ttctactgtg	aagatttatg	ttctgattag	137940
aaactgaatt	ttattttaatg	cttgcctgag	ctatggatat	caaagaattc	atattcctct	138000
agtgtccttg	actttctctc	cttgactttg	ggcattctca	agtatttttt	tctcaagagt	138060
ctgtgtcttg	cagttctttc	atctgttaac	aacaagagct	ctgttgattt	gatggtaagg	138120
tgtttagggg	gggggtgttt	tgttaactat	caatttaaat	taattgttgg	gtggggggct	138180
gtatattttg	cctgtgatct	tcacaagtg	ttttctctat	atcttttttg	ttttgttttg	138240
tttttaatta	ttcttcccaa	ggtgagacag	aaagagttaga	agaggctgga	gtgataagaa	138300
tacctctctc	catggctctg	ggacaatgct	ctgttaagtt	ttctctcttg	agagttggga	138360
tttggttatg	gaaaggttct	tggcatattt	cacaaggatt	actcttccaa	ttctctatgc	138420
cagaagaagg	tgtttctttg	ttcttctatt	tgagaacctg	gtgctataat	tgagggtaaa	138480
gcatacaaaa	gtgtgtgtat	actaggggtt	gtgggtctct	gttaagtctg	tggacctggg	138540
agttttctcat	tctcattcta	ttccacactt	agtctctaga	aattttgtcaa	aattatcatt	138600

taattctttat	tagttttatgg	ottcagctac	ttttgcttga	aataagcaga	cctgggctgt	138660
gactctctga	atfttacttct	ccagatttca	gggtgggtgg	ttgcoctgcaa	aatcaattct	138720
ttgttgggct	caagaaaagt	cactgatttc	taatttatcc	atcttttcc	tggtgtaaga	138780
ataggagtgc	ctgcttctta	gattttgaca	tatgagagct	gaaagtcctt	tatattattg	138840
acatgaatgt	ctcagtttgc	caaatgcatg	ggtatctctc	ttgggttata	gtcatcatga	138900
tctttgtctt	tggcatctaa	aaaagctaga	ggaaggcatg	acagaatggt	ccaaacctaa	138960
tatgcttgcc	tagcttgcac	aattgaagca	atgttttcaga	ccaggagaag	aaatagtgtt	139020
tggctctctc	acagaagagt	taataaagt	aggggctcta	tcccagggtta	cttccaagtt	139080
taacagtcct	gacaagacag	tataagccac	tgaagactac	agaggcttag	ataagaaagg	139140
gtcatgttct	caaaactgaca	tagaaatgac	aaaatgtggc	cctgggtatgt	tgtcttaaac	139200
attgcaagtg	ctttttaaaa	ataaccctct	aaaggaaaaac	caagtcatgc	taatatgtcta	139260
atgacaaatc	atcagtggat	ttattgacaa	atcatcaata	aattctagga	caatattgtc	139320
aaattttattg	gcaaatcatc	aataaattct	agaacaatat	aaactcttga	tgcatgttca	139380
gattctgttta	caatgatgat	ttttgataat	ggcttctact	gagaaaaactg	cctatgtatc	139440
acattgcata	ccatcctagc	acaactgaca	aaaacaggct	gactttgaa	atagccaaaa	139500
tccaaggcat	catccaagg	acottgttgg	gaactatbtg	gaccataatt	caaagaaatt	139560
gtaaagatga	gctgttgatt	catcagccat	taagtacaaa	aaaggagcct	caacacttga	139620
ctgattgttt	tggatattgc	agatagcaca	taccacaatt	aaaaatttga	ctacagcctc	139680
tagactaatc	aaacagacta	ccagcttaat	atctacagct	catggctttg	aaatcaagcc	139740
aaatattagt	aactcaagyc	ctgaagctca	tatctccttc	agactccatg	acattacaaa	139800
tgtttctagc	cacagggttg	attgaaacct	atggcaaaag	accatgagta	ctcctcagcc	139860
tctaggattc	atactcaagg	actttctcct	gctacagaga	aatgctccta	ccattttctc	139920
tacagatttta	gattatcgca	cctcaaaaaa	tgtcgttact	ccttagcaga	gcccccaaat	139980
agaagctaga	actggtcctt	gagaccttag	ccaggctacc	aattccacct	ttacacaaaag	140040
atatcattggc	tgtctataaa	atagtctgca	tacagagaaa	acaaaatcag	tgcaaaagaag	140100
cagccttcca	acataataat	agattgcca	taatttatgt	ogttgattgc	tcttcggaat	140160
gagttgcaca	tcaaatgggt	ttcctagaca	tcccaatatt	aacaaattta	cctttacaca	140220
gacttctggg	ccaacactaa	tagcctgaas	atatacgtac	ccaggactgt	ggttggtgtga	140280
tagcatagga	aacacctggc	ccactaggaa	tgcatgagtc	ttggagtggg	gaatgataaa	140340
atlttgagaa	gggaacagat	cctcccttc	tttbaataac	agtattgtta	aatatatgtg	140400
ccatctctct	tttctttttt	tttgtgccta	ccatgcacctc	tgaagatata	tagaattttt	140460
tagatgcttt	tttaaacttc	aatatgtgaa	aggaaagatt	atattgttca	acgttaaggat	140520
aattgagcag	acatgaactt	ggacattgac	tttgccctcaa	gtgggttttac	acacccccgc	140580
ttctgcccc	atggactgct	catgaaaata	atattggtgac	ttgtttccct	gtgaaactca	140640
ccatcctgga	gaaagaacat	tcagtctgtc	tcagtcccaa	gagggaaatgt	aaacttttgat	140700
tggttggggt	taaactaccc	aactctgaga	gatggatggg	aggggtgagaa	ctcataaata	140760
atlttgctct	ttgtctattac	acatatgtaa	aaataactctt	aaataactctt	ttacaaaatct	140820
tttgggcaat	gtcttgtgat	ataaatccctg	tacaaatttg	gatatgttac	attccactgg	140880
atccagcttg	tgggtttctca	ctgatgctcc	attctcagaa	aatactgtgt	aacctctctc	140940
actcccagac	atactgtgaa	accactatg	agtttgtgtc	aatcagagct	aaattactta	141000
cacttaaatga	gtgccccag	gggatgagag	aaaattatga	atggttttgga	ggctcatttc	141060
cttctctctc	tttttttttt	tttttttttt	tttttttttt	ttgttagtata	gcaaggatct	141120
ggcccagctt	gagccaatct	ggggagaaaac	aagggtctttg	gctgacatca	gcattcttgt	141180
cattcaaaagt	ctttccaagt	gcacttaactt	tgcagacctt	ggctgtaagt	atgcctagtc	141240
cctgggtattg	ctcctgagat	tcttgaaaac	atltttttatt	aattaaatta	tgcacttcta	141300
tattcatctc	aagctaactt	aaatatttgt	aacaagaaga	taggacatat	tctctttttt	141360
tgtgattctc	atltccacat	ccatcctgta	caggtaggct	tctgcttgat	ggaatatttg	141420
taatgggtcca	catagacatt	caatgttttg	cctgtactgt	gaaatgagtg	ttcagggtat	141480
tgcttgggaat	caggtttttaa	gtcttaactg	aagaccgaat	gtcttttagta	gttgatgac	141540
tcttcagatt	ttctatttct	cctttaatca	gttttctcaa	cttctaattt	ttctagaaat	141600
ttgcttatct	catatgcatt	ttcaaatata	ttggcatttaa	tttgttcata	attgtctcat	141660
tggttttaac	ttaatattat	ttaatcttgt	ctgttctctt	tttagttctc	cttaattctta	141720
atcttatctg	aggttttaact	atltttattag	taattttcaaa	aaaatcaatt	cttggaattcg	141780
ttagttaact	aggttttttca	atltttattat	ttttttcttt	attattttccc	tccctccact	141840
cttggtggat	ttatatcatt	tttatatttt	taatttccatg	agatagctgt	ttagctcatt	141900
gatttttaaca	ctattttttt	ctaatgtaag	aatttttaggc	tatccattta	tctctatag	141960
ttcttttaac	ttaacactct	attatgatac	atagtattta	agttattctc	atltttccaaa	142020
ttttgctbaa	tttctcttagt	gctttttctt	gtgattcagc	agttgtatgc	tttttcttgt	142080
atlttacaagt	atagtttttat	tctagtcata	ttttgttatt	attccttaac	tgtgtcatca	142140
tctcatgaag	ttactgttgt	agcaactatt	tgaataatttt	aaaaactaac	ttgatgactt	142200
ggcacactat	cacttttcat	aaatattcta	tatgtgcata	aaaatgcata	ttcttgaatt	142260
gttatgggtac	actattttgat	atatattatt	acttttaggtt	tagtaatggt	gttgataaaa	142320

ttctctaaat	tgttttctgtt	ttataaaaaat	ttattttatto	tactaaccac	taagagaggt	142380
atgataaaat	aacacagaat	gttgatagat	ttgtcaatat	ctctttgttag	atgtgtgaat	142440
tatttcacto	tctttttctcc	ctcctctttt	tctttgtctc	tctctccct	cctttcttct	142500
ttctccctcc	tcctgtctcc	tatgtttctta	gatagataaa	attgtaaaa	tggtacagat	142560
tgagaaggga	acatttttaac	attatgcact	gatcctcttt	aatttaataa	cattttgtta	142620
tctagtggat	tttttttagtt	taatttgaca	attttatctt	ttcactgcag	agtttagccc	142680
aattagtgc	attgtgattt	tcaattgttt	taatcatttt	cctgtcatct	tacaattatt	142740
tcctctttta	cactttttac	ttttctcctt	taatgacttt	ttttttatcg	ttcctattcc	142800
atttttcatt	tttattttta	ttgttttaaa	catttatctta	aaatgcactt	aattgtataa	142860
aataaatcca	tattttcaatg	acccttcaaa	caataagaaa	ttataatact	tgtctgttta	142920
tgactttccc	aatttacaatg	atcttatttt	ttcgtattct	aatcctgccc	tttcttttaa	142980
caccactaac	taaaaaattat	gattattta	ttttaaggaa	ataatattta	cttaaattta	143040
cctcaaaaat	gtctctttga	ctatccctct	gttgctattt	atgaaagcac	aacttctaga	143100
agcttctttc	tttcttttct	ctttcttttt	ttttttatat	gggtttcttg	ctctgtcacc	143160
caggctggca	tgacgtggca	tgataatggc	tgactacaat	ctcaaatct	tggtgtcagg	143220
gtgttggaac	tgtttgttcc	ccagtgtctc	aaagaaatag	cattcgaaca	taaacctaat	143280
tctctcagca	aggcagtttt	tactttctgc	agaaaggggtg	ctctctgcag	atatacaagg	143340
ggatcctctt	gcctcagcct	ccctagtagn	tggaacttca	ggcattcctc	atcacacttg	143400
gctaattttt	tcttattttt	tgtagatgct	gcctctcctc	atgttactca	ggctagtctt	143460
gaattcctgg	cctcaagcga	tottccttct	tcctcctccc	aaagtgtctg	gattaaaggg	143520
atgagccgcc	acacctgtct	aaaagcttct	tttaacaaagt	ctgtgtttta	taattattag	143580
cttttttata	caaaattttt	cttcaagag	agttttctctg	agtactccat	tggaagctga	143640
tttttatatt	ctcttgacaa	tgtgaagaga	ctatttcaat	atctcatagc	ttccatcttg	143700
gcttaaaagg	cttcttacag	tgtagcagtc	ttgttttctg	tggtgagctt	tctttttctt	143760
ctgttctctt	taggatcttc	tcttctgtct	tagtgttctt	catttttact	aatgtatgct	143820
taggtatgca	tttctgttta	cttgtttaca	accttctctg	actcattgct	tcttatctat	143880
tttttatatt	ttctgaaaa	tctcagaca	tgatctcctc	aaatgttttc	tcttttcttt	143940
tatatattct	ttttctggga	ctcagaggta	tacgataccc	tcgcttatag	cctctgtttc	144000
tctttcatgt	gattttgtct	gttttatatt	tggggctatg	tcttcagatt	tatatatttc	144060
tttttatatt	tgtgctgtat	aaatttacta	tctaattgtg	gtgtcattgt	aaatttttag	144120
gtctcacttt	ttctgactcc	cactcttgaa	gacaaggctc	tctgtgtgtt	cagtgtatctg	144180
tgtttgtcaa	ttcacatttt	cttctatgtt	gggaacatat	gaacatatga	gggctattta	144240
tttttcataa	gaaagaggaa	attttcatct	ggttctgcga	ggttccagaa	gtcagcagtg	144300
agccatgcaa	catttttagat	agctccaagc	atcccactaa	ctaaagtgga	agtaataaaa	144360
acactcagaa	tctcagtgcc	ttaaaatgag	tttttatattg	tttttatatg	taaaaacaca	144420
aatgcataaa	atataataat	atacaaaaata	ttgcattttg	tgtgtataat	atacaacata	144480
ttgtgtttgt	tgtacataata	tacaaaaata	caaataabtt	taaacagatt	ttgggttaga	144540
cataattttta	tagaacactc	tttaatatatt	gttttattct	tttctcactc	atgtctcttg	144600
tttttaaggg	cccccatgg	actgacagta	catgtttttc	tcaccttgag	atcaatatga	144660
gatctcagtc	tgagatctag	gctatctgaa	cgctatcagt	cacgaagaga	aaggaagaaa	144720
tctggtaaat	tgtaactgtt	ttcttaaagc	ttctgattag	agatcatata	aatcaataca	144780
actctcattt	aattgtctta	agaggggtcc	atgggtgtat	ttagtatcaa	aactatgaa	144840
tacagtctta	ctgttagtct	caaatactct	catttccattg	tttctatttt	ttgttaggtt	144900
taacattttat	tctgagtttc	caaccttaca	ttcaatttca	tacttaattt	ttcaattttc	144960
ttcaaatctt	agttttgttt	ctaagtggat	ttattttttg	cgcgaatct	ttccaaatgt	145020
ggctctctctg	ttattgagat	cttaattttg	attcatcttt	tttctccctg	tatttcatca	145080
tcaaattttt	aggataagct	gtgtttggac	tctattcttt	gatttctctg	acattcataa	145140
athtattttct	tttatactaa	aatgtcaact	tgactaaata	taaaaagtat	tgagtccac	145200
ttcttttttt	taaggacttt	ataaatatta	ttgactcat	ttttagtctg	tgattacgtg	145260
caagagtcct	tcagattttt	ctcctttctg	tgactttctc	tgaataccta	tagggtagct	145320
tttaactttgt	aaccaatttt	aatttaattt	cattttacatt	gttaaaaatca	caaaataaga	145380
tatactggtt	taccaagtca	ggtaaacaccg	agatatagaa	aagaaaaat	cagttagtatt	145440
tatataccct	ctccttaagc	tagttttttc	cttttttaaa	tataaatatt	tattgcttac	145500
aacacagtta	gagaaaatgt	ggaaaatgta	tctctaggat	gaattactat	tttaaatgta	145560
aatacaacca	tgtaagtaac	atgcagatta	agaaacacta	caagagttagt	agcattccag	145620
aagtctctgc	atgccccctt	ccattagctt	gagtaaccgt	taacttgact	actaacagct	145680
aaaatagttt	tgcttatctt	ttttttgaat	aaaaaaacaa	gaagtttttt	gcmaaattta	145740
aatacacata	gtcagaaata	taaatgggat	ataatattgt	ttatatattt	tattaatgaa	145800
agcattgtat	acagatagtg	tagcatcaca	caaaaaggta	tgtgtatatt	cttaataata	145860
atatttgaat	taaattttgt	gagctatgtg	aagggaggct	aaatttttat	atctgcaggt	145920
atcaacgggt	tgaacttatgt	gaaatcgttg	gcatttgagaa	agatttggag	aaaccagaaa	145980
ttttgtatat	tgctaattgaa	aacgaacatt	ggtacaatta	ctttaaagaa	ctctgtagcg	146040

gaatctacca	aatttgaaaa	tatccacatg	ttgcagttctg	tcagttcttat	tcctaggttat	146100
atacttaaaaa	aatttataga	catgttcacc	gacagacatg	atatgtatta	aaattccaat	146160
atctcttaacg	atggaattgg	tgccctttcta	agaagagatc	caaaaagagtc	ttctttctttt	146220
caatctctctc	ctctccccct	ttctctttct	ctctctctct	cactctttcc	ccaccacatg	146280
aggatattac	aagagagcag	ccatctgtga	acctaaaaga	aggcactcac	caaaaaccag	146340
accattctga	catcttgatc	ttagacttca	aaccttcaga	actgtgagaa	ttaaatgttt	146400
gttattttaag	ccacacaatt	tttgggtatc	tatttttagca	gcccaaattg	tcaaggaaaa	146460
taattacctc	aaactacaat	gcattattac	cactcaccca	caaagaaaaa	aaaaaagcta	146520
aaatgaaaaa	aatcacatca	taagggctcc	agccccaggc	ccatgacctc	attacctccc	146580
aaagggccccc	tgtgctaaag	taattccatt	gcagggtagg	ctttcaacat	gaatttcgtg	146640
ggacacaaatc	atacagtcac	tagcacttat	ttaacagtgt	tatatctctc	tacagctttt	146700
cttctatgtt	catatataaa	gatatacaga	tgattttttt	ctactttatc	ttcatttgtt	146760
atftaacatt	taatcatgca	aataattatt	tatacatgt	ataaggactt	actgtaaaaa	146820
aaacctacct	ctgcttaaga	aatggaatgt	tatctttgca	gaattcttga	tctatctttg	146880
aaattcaata	ttttcaaaag	aattgttttt	tgcttttatt	taacctcat	tttaaatfta	146940
ttatttaattt	ttcattaatt	cggtctccaga	agcagttagt	tgagataatc	atactcttta	147000
gttcaaaaagc	accttagttg	tttcaattta	ttttcatatc	ctctcttata	gccactccct	147060
ctctgattttt	cttttctctc	tactaaactc	caaacacatt	aaaatatttg	atgcataaac	147120
atltgtgtgc	atgttctctc	aaaacatatt	tttcaatttt	tcatagaat	tatttttctt	147180
acacatctta	tactaggtct	taaatttttt	attctgtatt	atatttttaa	tacctatcgt	147240
gtttatatat	atatattgct	gcattagtttt	cataatgtac	accaatcaca	gatgactttt	147300
ctatccccctc	agtgcacatc	acttttaact	ctccaacttc	ttttatctcc	aacaataatg	147360
caatgcacatc	ctttgtacat	gtgtctttat	gggtgaltgt	gaagacatct	cggtgtatag	147420
cttttgagct	gtattctttt	tccaaaaagt	ttatgtatcc	taaatacgt	ttataccaa	147480
ctaattgctc	tctggaatgt	ctacatcagt	ctataattaca	atacagtata	caaaggctct	147540
tatatcttta	tatctcacta	ttgtttttaa	atttgtatat	ctctagttac	taactctagg	147600
aaacattttct	ttttaaaact	cagatgggta	ttagctttta	tttcttttct	gtaaaaattc	147660
tcttcataatc	cttttctatg	agaagccata	cttttaaatt	attgatataa	ttgatatgca	147720
tacattttct	atatatttct	tactttattct	caactaaccc	ctaattgatt	ttatataattg	147780
taaaagtcag	atlttcccaa	tctgtcattg	gtttgggttg	tttaacttta	cagttgttct	147840
tttcttcaga	aaaggcattg	atlttgtaag	tttattttgt	atccagcaat	ctttatgcac	147900
tctatgcact	cttttttttt	ttttctctgt	accaagtctc	gccctatcac	caggctggag	147960
tgacgtgaag	agatctccgc	taactgcaac	ctctgcctcc	tgggttcagg	cgattcttct	148020
gccttagcct	cctgagtagc	tgggattgca	ggtgtgcacc	accatgccc	gchatttttt	148080
gtatttttag	tagacacggg	gtttcaccat	gttggccagg	atgggtcact	tctcttgacc	148140
tctgtatccg	ccgcctcgg	cttcccaaa	tgtgtggatt	accagcgtga	gccactacac	148200
ctggccttca	tgcctctttt	tattattgtt	aatagtttgt	caatgaattc	agctcctcca	148260
gtgtttttct	tagttttatt	gttctagatt	gttttcttag	aatacaatat	gctgtcttaa	148320
ccatataaata	aaggattctc	ttcagaaaaa	aacagttaaat	ttttgaattt	ttaaaaatata	148380
ttttctattta	tcatatattg	attacataat	tgttttttcc	tcatactcag	taacagcaat	148440
tatgctata	ttgtatttgt	cttttatatc	tataattaga	tctctaattc	gctttattta	148500
tcatttttaa	gaattccatg	ttgattctct	caagtttttc	tttcatgtcc	taaaaatata	148560
aacaggcata	aatgtgtgtg	tgtgtgtgag	tgtgtccatg	gtgggggttt	atgtatgtgt	148620
atatgcacac	aatgtgtgta	atgtgtcttt	tatttctgta	tttgttttgt	ttctctcttt	148680
tatctttttc	tgagctctgt	gaacttaact	ttcatttctg	gtcttataat	tggtttatgt	148740
tttcttttaag	tcttttgaac	tcaagaagat	ttgattagaa	actatatttt	gggttttggt	148800
aattgttcta	gtggattttt	taacctctct	tatttcttta	tattgtcttt	ttcttactta	148860
tttaattttt	aatctacag	tatgtcatcc	atgtctgttt	ctttctgatt	cttacttatt	148920
ttgaatggga	tgcacatata	tagtttaaat	atctgttgaa	ataaaattaa	aggtgagaga	148980
tgtgagctaa	agcagtgaac	acttaggaca	tatctctatc	atctttgttt	tgtcatctcc	149040
ttggtaataa	tctccactct	ttattttact	ttctcatgtc	tgtgtgagcag	aaaatctttg	149100
gagttttctat	ttccacagta	aagtctctat	ctccagggtg	ctgtgacatt	tttgaatct	149160
attaattttat	tttctgctgg	ctttgattag	ctgtcaccaa	gggtattggg	gtgtatgtac	149220
tctcatcttg	actgattttc	gaanaagatg	catatatatg	tggcttctta	ttcagccttt	149280
ctacactctc	caatcttgct	ttataaaac	tgtattgtat	tcacatcttc	catgtaagat	149340
atcttttgatc	ctttcagagc	tgtgctatat	atltttgaaga	acctctgcac	tattttaaaat	149400
atctgttaagt	gtttgcactt	actcttgaca	ctttttccca	ttttggtccc	aataaatttt	149460
ttctttttatt	tggagtttgt	gattttaaah	gtggttgtct	cctgggtccc	atgatgacac	149520
agcagtcocat	atltctttta	tacttggtgg	ttgtttcagt	tggcaataca	gaaggagatg	149580
aataaaaattg	caaaagtga	gaatgtcaa	ttcatgcagt	taaaaatgat	gtaaaagttaa	149640
tatattaaaa	ttaggtaaaa	tattgggtaa	aatctttttt	ctttgttcaa	aacagagctc	149700
cacctgtttg	ctcagcctgg	agtgcagttg	tgtgatctca	gttcaactgca	acctctgact	149760

55/64

```

cctggggttca agccattctc ctacctcagc cccctagtag ctgagattac aggcattgga 149820
caccacattg gctaattttt gtattttotag cagagacaag ttttcaccat gttggccagg 149880
atgggtctcaa actcctgacc tcaagcgatc caccacttc ggccctccaa agtgctggga 149940
ttacaggcat gagccaccgt tccagcctgg ttaaaatatt ttttaattgct tatctttgaa 150000
agtctgctat tattgtgaaa ttgatttttc tatgggatca gatggactga tgctttgtgg 150060
tgggtgtgta atcactgcag aagaaaattt ggggaactgaa cctggaatgt tagtccatgc 150120
caattatttg aaaatttagca tccaaaaaagc aataaaattt gttgagaaaa attgaaagtt 150180
attacactac ctagtttttac taggaaaaga ttctggcatt gggccaatga tgactgataa 150240
ttattoatag cactattgaa gagattgatg tattttacta ggaatttttc aggtgtgagt 150300
gatagaaatt cagctctctt aagcaaaaag ataacttatt gattccctatg actgggtact 150360
ctaggagtgg tgcttgcttt agtcatagcc agatccagaa gattaaaaat aaatcttgtg 150420
ttgctgcaaa gtttaggtat ttctggacca ttcacaatat ggacagacat agcccttagt 150480
tagaaatcta gcagaacaag aattttttgtc tctgatact catacatgaa atattccttg 150540
tcaccattgc ccatactctt tgaaccacat tagattatat gcccattgaa gtatatagaa 150600
aggggtagta gaatgccacc atgatac                                     150626

```

<210> 10
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Forward promoter primer for CFH gene

<400> 10
 agaatcgtgg tctctgtgtg tgg 23

<210> 11
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Reverse promoter primer for CFH gene

<400> 11
 agcagctggg gatatactct gg 22

<210> 12
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Forward promoter primer for CFH gene

<400> 12
 tcaaatgaga gtgagccagt tgc 23

<210> 13
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Reverse promoter primer for CFH gene

<400> 13
 ctgttcacaa cgtccagttc tcc 23

56/64

<210> 14
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 1 primer for CFH gene

<400> 14
gtgggagtgc agtgagaatt gg 22

<210> 15
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 1 primer for CFH gene

<400> 15
aactcaacaa tgtcaaaagc c 21

<210> 16
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 2 primer for CFH gene

<400> 16
gatagacctg tgactgtcta ggc 33

<210> 17
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 2 primer for CFH gene

<400> 17
ggcaatagtg atataattca ggc 23

<210> 18
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 3 primer for CFH gene

<400> 18
acctcagcct cccaaagtgc 20

<210> 19
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 3 primer for CFH gene

57/54

<400> 19
tgcatactgt tttcccactc tcc 23

<210> 20
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 4 primer for CFH gene

<400> 20
aaggaggagg agaaggagga agg 23

<210> 21
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 4 primer for CFH gene

<400> 21
caggctgcat tcgttttttg 20

<210> 22
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 5 primer for CFH gene

<400> 22
ccactcccat agaaaagaat cagg 24

<210> 23
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 5 primer for CFH gene

<400> 23
acttcttttg accagtctct tcc 23

<210> 24
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 6 primer for CFH gene

<400> 24
gataaatcat ttattaagcg g 21

<210> 25
<211> 22
<212> DNA
<213> Artificial Sequence

58/64

<220>
<223> Reverse exon 6 primer for CFH gene

<400> 25
gaaccttgaa cacagaaaat gc 22

<310> 26
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 7 primer for CFH gene

<400> 26
ggatgacttt ggagaagaag g 21

<210> 27
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 7 primer for CFH gene

<400> 27
tatgagtttc ggcaacttcg 20

<210> 28
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 8 primer for CFH gene

<400> 28
tcattcttcatt taacaaagac c 21

<210> 29
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 8 primer for CFH gene

<400> 29
agatctattt tggtcacttt gc 22

<210> 30
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 9 primer for CFH gene

<400> 30
ctttgttagt aacttttagt cy 22

<210> 31

59/64

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 9 primer for CFH gene

<400> 31
ttatacacag ttgaaaacc 20

<210> 32
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 10 primer for CFH gene

<400> 32
ggcaactctg agcttatctt cc 22

<210> 33
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 10 primer for CFH gene

<400> 33
agagtaggaa aagcctgaat gg 22

<210> 34
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 11 primer for CFH gene

<400> 34
catagattat ttttgtacgg 20

<210> 35
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 11 primer for CFH gene

<400> 35
caaaactccc ttcttttccc 20

<210> 36
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 12 primer for CFH gene

60/64

<400> 36
atctgatgcc cctctgtatg acc 23

<210> 37
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 12 primer for CFH gene

<400> 37
attcagtact caatacatgt cc 22

<210> 38
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 13 primer for CFH gene

<400> 38
caccattctt gattgtttag g 21

<210> 39
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 13 primer for CFH gene

<400> 39
gaatctccat agtaataagg 20

<210> 40
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 14 primer for CFH gene

<400> 40
caatgtgttg atggagagtg g 21

<210> 41
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 14 primer for CFH gene

<400> 41
attgaattat aagcaatatg c 21

<210> 42
<211> 22
<212> DNA
<213> Artificial Sequence

61/64

<220>
<223> Forward exon 15 primer for CFH gene

<400> 42
catttcagcg acagaataca gg 22

<210> 43
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 15 primer for CFH gene

<400> 43
gtgtgtgtgt gtgtgtgtgc 20

<210> 44
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward intron 15 primer for CFH gene

<400> 44
aaggcaggaa agtgtcctta tgc 23

<210> 45
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse intron 15 primer for CFH gene

<400> 45
gtcaaattac tgaaaatcac c 21

<210> 46
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 16 primer for CFH gene

<400> 46
aactgttaca cagctgaaaa g 21

<210> 47
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 16 primer for CFH gene

<400> 47
gtggtgattg attaattgtgc 20

<210> 48

52/64

<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 17 primer for CFH gene

<400> 48
ggtggaggaa tatatctttg c 21

<210> 49
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 17 primer for CFH gene

<400> 49
atagaataga ttcaatcatg c 21

<210> 50
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 18 primer for CFH gene

<400> 50
cgatagacag acagacacca gaagg 25

<210> 51
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 18 primer for CFH gene

<400> 51
cagctataat ttcccacagc agtcc 25

<210> 52
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 19 primer for CFH gene

<400> 52
gtgtaatctc aattgctacg gctacc 26

<210> 53
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 19 primer for CFH gene

53/64

<400> 53
caagtagctg ggacttcaga tgc 23

<210> 54
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 20 primer for CFH gene

<400> 54
tagtttcacg tcttttcctc 20

<210> 55
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 20 primer for CFH gene

<400> 55
gaattttaag caccatcagt c 21

<210> 56
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 21 primer for CFH gene

<400> 56
ccaggactca tttctttcac c 21

<210> 57
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 21 primer for CFH gene

<400> 57
ctttctgaca gaaatatttg g 21

<210> 58
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 22 primer for CFH gene

<400> 58
tgatgtttct acatagttgg 20

<210> 59
<211> 25
<212> DNA
<213> Artificial Sequence

64/64

<220>

<223> Reverse exon 22 primer for CFH gene

<400> 59

ggagtaaaac aatacataaa aaatg

25